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Abstract 
Cancer cells preferentially metabolise glucose via aerobic glycolysis (the 
Warburg effect), which is less energy efficient in terms of ATP production 
compared to oxidative phosphorylation (OXPHOS). Mitochondrial DNA 
(mtDNA) encodes proteins of the electron transfer chain and is crucial for 
functional OXPHOS. MtDNA exists as multiple copies in cells and, often in 
cancer, there is co-existence of mutant and wild-type mtDNA. There is evidence 
for mitochondria to contribute towards the tumor biology of multiple myeloma 
(MM) and glioblastoma multiforme (GBM). The mtDNA from both these cancer 
types were explored to determine its role in tumor biology.  
 
Sequencing of MM cells and tumor samples using the Ion Torrent next 
generation sequencer identified Cytochrome C Oxidase and ATP 6 to contain 
critical variants that are capable of disrupting protein function. Gene expression 
analysis determined that glycolysis is essential to maintaining MM cell 
proliferation. Without glycolysis, there was up-regulation in the expression of 
tumor survival genes, which was only effective in MM cells that had sufficient 
mtDNA copy numbers above the mtDNA set point. 
 
Sequencing of GBM cell lines, tumor and normal patient samples suggested that 
there is a predisposition of GBM tumors to acquire a set of GBM-specific 
mtDNA variants during tumor development. Conserved mtDNA regions, such as 
Cytochrome C Oxidase I, tend to be least susceptible to mutations. The presence 
of variants in these conserved regions carry more detrimental effects at the 
protein-level than at other mtDNA regions. Differentiation of GBM cells 
decreased the tumor phenotype, as assessed by gene expression analysis.  
 
Altogether, this thesis provides support for the importance of mtDNA in tumor 
biology. The implications are that the variants identified could be used to screen 
MM and GBM tumors in a clinical diagnostic lab for the treatment of both these 
cancer types.  
	  	   26	  
Abbreviations 
Acetyl-CoA  Acetyl-Coenzyme A 
ADP   Adenosine Diphosphate 
ANOVA  Analysis of Variance 
ATP    Adenosine Triphosphate 
CASP   Caspase 
COX   Cytochrome C Oxidase 
CYT B  Cytochrome B 
DAD   Defender Against Death 
ddC   Dideoxycytidine 
2-DG   2-Deoxyglucose 
DMEM  Dulbecco’s Modified Eagle Medium 
DNA   Deoxyribonucleic Acid 
EGF   Epidermal Growth Factor 
ELISA   Enzyme-Linked Immunosorbent Assay 
EMBL   The European Molecular Biology Laboratoy 
EMP   Embden-Meyerhof-Parnas 
ETC   Electron Transfer Chain 
FACS   Fluorescent-Activated Cell Sorting 
FADH   Flavin Adenine Dinucleotide 
FBS   Fetal Bovine Serum 
FCCP   Trifluorocarbonylcyanide Phenylhydrazone 
FGF   Fibroblast Growth Factor 
GBM    Glioblastoma Multiforme 
GITC   Guandine Isothiocyanate 
	  	   27	  
GuCl   Guandine Hydrochloride 
GSH    Glutathione 
HIF   Hypoxia-Inducible Factor 
HRM   High-Resolution Melt 
HSP   Heavy-Strand Promoter 
IMP   Insulin-like Growth Factor 2 mRNA Binding Protein 2 
IL6   Interleukin 6 
ISP   Ion Sphere Particles 
IUPAC  International Union of Pure and Applied Chemistry 
JAK   Janus-Activated Kinase 
LB   Luria-Bertani 
LSP   Light-Strand Promoter 
MAPK   Mitogen-Activated Protein Kinase 
MCL1   Myeloid Cell Leukemia 1 
MgCl2   Magnesium Chloride 
MMRF  Multiple Myeloma Research Foundation 
MtDNA   Mitochondrial DNA 
MTERF  Mitochondrial Specific Termination Factor 
MTSSB  Mitochondrial Single-Stranded Binding Protein 
NADH   Nicotinamide Adenine Dinucleotide 
NaOH   Sodium Hydroxide 
NCBI   National Center for Biotechnology Institute 
ND   NADH Dehydrogenase 
NEAA   Non-Essential Amino Acids 
NRF   Nuclear Respiratory Factor 
	  	   28	  
NSC   Neural Stem Cells 
OXPHOS   Oxidative Phosphorylation 
PBS   Phosphate-Buffered Saline 
PCR   Polymerase Chain Reaction 
PDB   Protein Data Bank 
PEP   Phosphoenolpyruvate 
PGC1α Peroxisome-Proliferator-Activated Receptor Gamma Co-
activator-1-Alpha 
PGM Personal Genome Machine 
PKM2 Protein Kinase M2 
POLG Polymerase Gamma 
PPARδ Peroxisome-Proliferator-Activated Receptor Gamma 
RCSB Research Collaboratory for Structural Bioinformatics 
RITOLS RNA-Incorporated Throughout the Lagging Strand 
RNA Ribonucleic Acid 
ROS Reactive Oxygen Species 
rRNA   Ribosomal RNA 
SOC   Super Optimal Broth with Catabolite Repression 
SEM   Standard Error of the Mean 
SIRT3   Sirtuin 3 
SNP   Single Nucleotide Polymorphism 
STAT3  Signal Transducer and Activator of Transcription 3 
TE   Tris-EDTA 
TFAM   Mitochondrial Transcription Factor A 
TFB1M  Mitochondrial Transcription Factor B1 
	  	   29	  
TFB2M  Mitochondrial Transcription Factor B2 
tRNA   Transfer RNA 
TWINKLE  Progressive External Opthalmoplegia 1  
UV   Ultraviolet  
WHO   World Health Organisation 
XBP1   X-Box Binding Protein 1 
X-GAL  5-Bromo-4-Chloro-3-Indolyl β-D-Galactopyranoside 
	  	   30	  
 
 
 
 
 
 
Chapter 1: General introduction 
	  	   31	  
1.1. Mitochondrial DNA and its role in energy production 
The mitochondrial genome (mtDNA) is a small double-stranded genome that 
resides exclusively within the mitochondrial matrix. It is a 16.6kb circular 
genome and encodes 13 polypeptides that are critical for functionality of the 
electron transfer chain (ETC) (Figure 1.1), alongside 22 tRNAs and 12s and 16s 
rRNAs. The ETC is largely responsible for the production of ATP via oxidative 
phosphorylation (OXPHOS).  
 
Figure 1.1. The human mitochondrial genome. Genes that encode subunits for 
each of the different complexes of the electron transfer chain are annotated 
according to colour. The mitochondrial genome encodes 13 polypeptides that 
participate in OXPHOS, and also contain genes encoding for 22 tRNAs and 12S 
and 16S rRNAs, which function in protein translation of mitochondrial genes. 
There is also a triple-stranded non-coding D-loop region, where the promoters 
for light and heavy strand synthesis are housed.  
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As a consequence of its small genome size, mitochondria rely on the import of 
nuclear-encoded subunits to complete the assembly of the ETC protein 
complexes. Complex II is the only protein of the ETC that is exclusively 
assembled from nuclear-encoded factors. These observations emphasize the 
necessity of communication between the nucleus and mitochondria in 
maintaining ETC function1,2.  
 
MtDNA biogenesis, transcription and replication all require the activities of 
nuclear-encoded mitochondrial factors, which must be imported into the 
mitochondrion. These nuclear genes are either translated by ribosomes in the 
cytosol3, or co-translated during the import process into the mitochondrion4. 
Either way, these precursor proteins all contain a mitochondrial targeting signal, 
usually located on the N-terminus5. These signals are removed upon successful 
translocation into the organelle, and depending on the specificity of their target 
sequence, proteins will be directed to one of the four major intracellular 
compartments: the matrix, the inner membrane6, outer membrane7 or 
intermembrane space8. In most cases, proteins are folded into their native 
conformation after translocation into the mitochondrion, as unfolded proteins are 
more able to efficiently pass through the translocase complexes that span across 
the inner (TIM) or outer (TOM) mitochondrial membrane9. The translocation 
process of these polypeptides is reliant on a supply of ATP10.  
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1.2. Maintenance of mtDNA and its mode of replication 
Peroxisome-proliferator-activated receptor gamma co-activator-1-alpha (PGC1α) 
is widely considered as the key regulator of mitochondrial biogenesis. For 
example, the ectopic expression of PGC1α in myotubes enhances the expression 
of key mitochondrial transcription factors, such as the nuclear respiratory factor 
(NRF) and mitochondrial transcription factor A (TFAM) genes11. In addition, 
SIRT3, a target of PGC1α, which localizes to the mitochondria, can also be 
considered as the key regulator in mitochondrial biogenesis since SIRT3 
mediates the effects of PGC1α by maintaining mitochondrial biogenesis and 
reactive oxygen species (ROS) production12. PGC1α expression is controlled by 
peroxisome-activated receptor δ (PPARδ)13 and, once translated, PGC1α 
activates nuclear respiratory factors 1 and 2 (NRF1 and NRF2), which stimulate 
the expression of a range of nuclear genes to promote mitochondrial transcription 
and replication. The NRFs regulate the expression of mitochondrial transcription 
factors A (TFAM), B1 (TFB1M) and B2 (TFB2M) by binding to their promoter 
regions14.  
 
TFAM functions together with TFB2M to synthesise an RNA-DNA hybrid 
primer that can be used by the mitochondrial DNA polymerase complex, 
polymerase gamma (POLG), during mtDNA replication15,16. The POLG complex 
requires activity from subunits polymerase gamma A (POLGA) and B (POLGB) 
to exert its full function. POLGA carries catalytic capabilities, whereas POLGB 
is an accessory subunit supporting the synthesis of a nascent mtDNA strand by 
assisting in DNA binding and maintaining processivity of the polymerase17 
(Figure 1.2).  
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Figure 1.2. MtDNA replication. The nuclear-encoded replication factors work 
together to ensure efficient replication of mtDNA. The mtDNA specific helicase, 
TWINKLE, unwinds DNA at the origin of replication located on the heavy 
strand. The mitochondrial-specific DNA polymerase (POLG) complex utilizes the 
catalytic (POLGA) subunit, together with the two supporting subunits (POLGB), 
to synthesise a complementary mtDNA strand in the 5’ → 3’ direction. The 
mitochondrial single-stranded binding (MTSSB) proteins prevent the premature 
re-annealing of mtDNA single strands. 
 
POLG also possesses 3’ → 5’ exonuclease activity and works closely with the 
mtDNA-specific helicase, TWINKLE, to separate double-stranded mtDNA into 
single-stranded mtDNA18. During this process, the mitochondrial single-stranded 
binding protein (MTSSB) is recruited to prevent the premature re-annealing of 
the two separated mtDNA strands prior to the complete synthesis of a nascent 
complementary strand from the mtDNA template. Mitochondrial specific 
termination factor (MTERF) mediates control on attenuating further 
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transcriptional activity of mtDNA19. Altogether, the combined functions of these 
nuclear-encoded factors are essential for efficient replication of mtDNA. 
Although TWINKLE has been associated primarily with unwinding of the 
double-stranded mtDNA during replication, structural analysis performed on 
TFAM has further suggested that it also possesses the capability to separate 
double-stranded mtDNA regions for transcription to take place20. 
 
Several models for the replication of mtDNA have been proposed. The strand 
asynchronous method proposed that the initiation of mtDNA replication occurred 
at the promoter of the heavy strand, and upon successful replication of two-thirds 
of the mitochondrial genome, synthesis from the light strand promoter 
subsequently followed21. However, the theory was later challenged by others, 
based on the identification of double-stranded mtDNA regions during the 
replication process22.  
 
The strand-coupled replication mechanism was then proposed, which is similar 
to the process of nuclear DNA replication23. It was thought that, during strand-
synchronous mtDNA replication, double-stranded intermediates are produced, 
which comprise hybrid RNA-DNA regions. This led to the development of the 
RNA incorporated throughout the lagging strand (RITOLS) theory, which 
suggested that RNA intermediates formed part of the lagging strand during 
mtDNA replication24. However, based on the evidence to date, it is possible for 
mtDNA replication to occur via a combination of these mechanisms, with the 
strand-synchronous method predominating during periods of mtDNA 
replenishment after exposure to mtDNA stress25. 
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1.3. Overview of tumor biology 
Tumor development refers to the transformation of normal cells into cancer cells 
via the accumulation of genetic and cellular changes, which result in the loss of 
responsiveness of these cells to growth regulatory signals26. Tumor growth 
normally occurs as a result of a net increase in the rates of cellular proliferation 
compared to the rates of apoptosis. Results from a colorectal cancer study 
provide evidence to support this, whereby rates of apoptosis and proliferation are 
both increased during development of the cancer, with cell proliferation having a 
greater influence on these cells than apoptosis27. However, there are some 
exceptions as with the case of lung cancer where it was suggested that tumor 
volume is associated with an increase in the rate of apoptosis and a decrease in 
the rate of proliferation, leading to the development of necrotic tissue28.  
 
According to Hanahan and Weinberg, a malignant tumor has several 
characteristics. Apart from the acquired independence to proliferative and anti-
proliferative signals, cells also have the ability to undergo self-renewal and 
metastasis and can maintain their growth through de novo angiogenesis for 
supplies of oxygen and nutrients to the tumor29. 
 
When a cell undergoes division, there are 4 phases through which it must 
proceed. These are the G1 (cell growth), S (DNA synthesis), G2 (second cell 
growth) and M (mitotic) phases. In normal cells, there are a number of 
checkpoints within the cell cycle that function to protect the nuclear genome 
from DNA damage. The first checkpoint occurs prior to DNA synthesis during 
the initial growth of the cell in the G1 phase, which assesses for the presence of 
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sufficient nutrients, growth factors and the absence of DNA damage30. The 
second checkpoint functions between mitosis and DNA synthesis to check for the 
completion of DNA replication31, and another exerts control over the assembly 
of the spindle to ensure chromosomes are properly attached before cell division. 
After these checkpoints, the cell cycle is repeated32,33 or the cell undergoes 
differentiation by leaving the cell cycle at the G0 resting phase34. However, 
dysregulation of these cell cycle checkpoints is thought to be a common cause of 
the onset of cancer development35,36.  
 
It has been demonstrated that the gene encoding for p53, the protein that 
regulates progression of the cell cycle at the G1 phase, is often mutated in 
cancer37,38. Loss of function of this critical protein means that incompletely 
replicated or damaged DNA can progress through the cell cycle to be passed onto 
progenitor cells. Consequently, these cells will have characteristics of increased 
genomic instability, which would result in the gain of DNA sequence mutations, 
thereby potentially initiating the tumorigenic phenotype39.  
 
Changes to tumor biology can be caused by the dysfunction to various genes 
involved in mitochondrial biogenesis. For example, signal transduction via the 
PGC1α pathway has been reported to be up-regulated in type I endometrial 
cancer, compared to normal endometrial tissue40. Therefore, regulation of the 
PGC1α molecule may be critical for the control of tumor development in some 
cancers. The role of SIRT3 has also been examined in oral squamous cell 
carcinoma cell lines, and was discovered to be highly expressed, which correlates 
with up-regulation in the expression of PGC1α levels41. 
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From some studies, it has been suggested that mitochondria can influence 
progression of the cell cycle. For example, loss of the nuclear-encoded complex 
IV subunit, cytochrome c oxidase Va (CoVa) in Drosophila melanogaster, not 
only decreased ATP production by 60% of original levels, but also inhibited 
progression of the cell cycle at the G1 phase. This occurred via the activation of 
MAPK and p53 activity, which decreased levels of cyclin E required for cell 
cycle progression42. Since this discovery, mitochondria have been proposed to 
act via other signaling pathways. These could be stimulated by the increase in 
reactive oxygen species leading to the up-regulation of p27 levels, which can 
modulate progression of the cell cycle by inhibiting activity of the cyclin E-
CDK2 complex43. 
 
Mitochondria are also capable of secreting the protein survivin into the cytosolic 
compartment in an attempt to prevent the onset of apoptosis44. Defects in the 
genes that regulate mtDNA replication have been suggested as possible initiators 
of tumor development, since POLG is mutated in 63% of breast cancer cases45. 
Furthermore, the oncogenic protein, c-Myc, responsible for the control of cell 
size and in the rates of proliferation and apoptosis, is reported to directly regulate 
TFAM by binding to its promoter region, which could affect mitochondrial 
transcription46. 
 
1.4. Heteroplasmy and mtDNA 
Due to the limited presence of efficient proof-reading mechanisms during 
mtDNA replication, mtDNA is highly susceptible to the development of 
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mutations. Multiple mtDNA copies exist within a single mitochondrion, with 
more metabolically demanding tissues possessing greater numbers of mtDNA 
copy. In normal and cancer patients, a proportion of these mtDNA copies acquire 
mutations that exist alongside wild-type copies. This is known as heteroplasmy 
and is especially common in the pathogenesis of various diseases47,48. The 
presence of mtDNA variants in normal individuals is not unusual, as previous 
studies have demonstrated via a mathematical modeling approach that random 
mutations may arise in the absence of selective advantage or tumorigenic 
influences49,50. Such studies have also put forward the possibility that some 
homoplasmic mutations may have been acquired within mtDNA in this manner.  
 
In the last few years, it has been increasingly accepted that normal cells naturally 
harbour heteroplasmic mutations51. However, in these cases, heteroplasmy tends 
to be reported at higher frequencies in the control regions of mtDNA than in the 
coding regions52. Sequence variants in the control D-loop region usually do not 
cause any detrimental effects, unless it resides in a region that is crucial for the 
binding of mitochondrial transcription and replication factors53. The diverse 
variability in the D-loop mtDNA sequences between individuals, explains why 
sequencing of the D-loop region alone, is commonly performed to determine the 
different mtDNA haplotypes that define normal individuals of varying ethnic 
backgrounds54-56.   
 
Heteroplasmy in the coding regions of mtDNA is commonly thought to 
compromise the ability of the ETC to function, and therefore energy production 
required to maintain and support cellular metabolism. The concept of having a 
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critical threshold level for mtDNA mutations was first suggested by Howell in 
1983, who hypothesized that beyond a certain proportion of mutant mtDNA 
copies, energy production via the electron transport chain declines to the point 
where cellular metabolism is also compromised57. Although, cybrid fusion 
experiments have supported the concept that mutant mtDNA enhances 
tumorigenicity of cancers, for example, in prostate cancer58, contradicting 
evidence remains for the involvement of mtDNA in tumor development59. 
 
1.5. Mitochondrial energetics 
The key processes of mitochondrial energetics, which cover the pathways of 
glycolysis, the citric acid cycle and OXPHOS, are briefly described to outline the 
metabolic events taking place within normal cells (Figure 1.3). The processes of 
lactic acid fermentation and a discussion of the Warburg effect are also presented 
to explain the altered form of metabolism that is preferred by cancer cells.  
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Figure 1.3. Overview of the key processes of mitochondrial energetics. 
Glycolysis takes place in the cytosol. The product pyruvate is imported into the 
mitochondrial matrix, where it is converted to acetyl coenzyme A (acetyl-coA). 
Acetyl-co A initiates the citric acid cycle to supply reducing factors NADH and 
FADH2 to the mitochondrial electron transfer chain, located on the inner 
mitochondrial membrane. ATP is generated from complex V of the electron 
transfer chain. 
 
1.5.1.Glycolysis 
Glycolysis (Embden-Meyerhof-Parnas (EMP) pathway) is a catabolic pathway 
commonly used in eukaryotes. During glycolysis, glucose enters cells in its 
unphosphorylated form since glucose 6-phosphate carries a negative charge that 
prevents its facilitated transport through the cell membrane60. Phosphorylation of 
glucose within the cell assists in its metabolism, as the presence of a phosphate 
	  	   42	  
group causes instability of the glucose molecule60. In mammals, there are four 
types of hexokinases (I to IV), with only the subtype IV carrying substrate 
specificity for glucose61. Catalysis by hexokinase represents an irreversible 
reaction, responsible for the initial step of converting glucose to glucose-6-
phosphate in the presence of ATP (Figure 1.4).  
 
A series of reactions follow to produce fructose 1,6-bisphosphate, which 
undergoes a cleavage reaction via a class I aldolase to form two triose sugars: 
glyceraldehyde 3-phosphate and dihydroxyacetone phosphate62. Glyceraldehyde 
3-phosphate can be further metabolised in the glycolytic pathway, which means 
that dihydroxyacetone phosphate must be converted to this isoform in order to be 
fully oxidized to pyruvate62. At this point, there are two molecules of 
glyceraldehyde 3-phosphate. The enzymatic steps that follow produce 4 ATP and 
2 molecules of nicotinamide adenine dinucleotide (NADH). Therefore, 
glycolysis produces a net synthesis of 2 ATP molecules for each glucose 
molecule metabolized. The 2 NADH reducing factors generated can be used to 
donate electrons during OXPHOS to help establish a proton gradient across the 
mitochondrial inner membrane for ATP production.  The overall reaction of 
glycolysis can be summarized in the following formula and in Figure 1.4, where 
all the metabolic intermediates from the pathway are shown: 
Glucose + 2Pi + 2ADP + 2NAD+ → 2pyruvate + 2ATP + 2NADH + 2H+ + 
2H2O    60 
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Figure 1.4. Summary of the glycolysis pathway. Glucose is metabolised to 
produce 2 molecules of pyruvate. Pyruvate can then be used as a substrate for 
the citric acid cycle upon conversion to acetyl coenzyme A in the presence of 
sufficient oxygen. In the absence of oxygen, pyruvate undergoes fermentation to 
produce lactate. 
 
1.5.2. Lactic acid fermentation 
Under low oxygen concentration, normal cells attempt to regenerate NAD+ to be 
used as an electron acceptor in the glycolysis pathway. This occurs via the 
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catalysis of pyruvate into lactate via lactate dehydrogenase A, which is 
dependent on NADH produced during glycolysis. In cancer development, the 
receptor tyrosine kinase, FGFR1, is often over-expressed63. Its role is in the 
phosphorylation of lactate dehydrogenase A at tyrosine residues 10 and 83 of the 
protein structure64. This augments the catalytic ability of the enzyme and 
increases its binding capabilities to NADH. The reaction for the generation of 
lactate is represented in the formula below and is summarized in Figure 1.5: 
Glucose + 2Pi + 2ADP → 2lactate + 2ATP + 2H2O 
 
Figure 1.5: Lactic acid fermentation. Under conditions of limiting oxygen 
concentrations, pyruvate is converted into lactate via the enzyme lactate 
dehydrogenase A, which re-generates NAD+ and stimulates further cycles of 
glycolysis to produce low levels of ATP. In cancer development, the over-
expression of FGFR1 attaches phosphate groups to lactate dehydrogenase A at 2 
positions on tyrosine 10 and 83 to increase the efficiency of catalysis. 
 
In the presence of sufficient oxygen tension, there is a preference for normal 
cells to undergo further metabolism via the citric acid cycle rather than through 
lactic acid fermentation. 
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1.5.3. Citric acid cycle 
Pyruvate is transported into the matrix of the mitochondrion, where it is 
subjected to the catalytic actions of pyruvate dehydrogenase to decarboxylate 
pyruvate to produce acetyl coenzyme A (acetyl Co-A) that can be used as a 
substrate for initiating reactions of the citric acid cycle65. Decarboxylation of 
acetyl-CoA results in the release of CO2 as a product of the reaction. The first 
step of the citric acid cycle involves the combination of acetyl Co-A with 
oxaloacetate, a four-carbon molecule, to generate citrate and waste product 
coenzyme A (CoA) (Figure 1.6)66.  
 
Completion of the citric acid cycle produces a number of reducing molecules 
including NADH and FADH2 that are used during OXPHOS. The only reactions 
that are irreversible within the citric acid cycle are those catalysed by citrate 
synthase, isocitrate dehydrogenase and α-ketoglutarate dehydrogenase67. The 
reactions that summarise the citric acid cycle are represented according to the 
following formula: 
2Pyruvate + 2ADP + 2Pi + 2FAD + 8NAD+ → 6CO2 + 2ATP + 2FADH2 + 
8NADH 
 
All intermediates produced upon completion of the citric acid cycle are shown in 
Figure 1.6. 
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Figure 1.6. The citric acid cycle. Oxidation of acetyl-Coenzyme A (acetyl-CoA) 
results in the production of reducing factors NADH and FADH2 that can be used 
as high energy electron donors during the process of OXPHOS via the electron 
transfer chain.  
 
The intermediate, citrate, has been suggested as a potential therapy for cancer68. 
It can be administered orally to cancer patients, and functions by inhibiting the 
actions of phosphofructokinase69, thereby blocking glycolysis. It is thought that, 
by inhibiting glycolysis, mitochondria will be forced to utilize other substrates, 
such as amino acids in place of glucose for their metabolic requirements70. The 
intermediates formed from the metabolism of amino acids could be used to 
stimulate the citric acid cycle, which would generate energy via OXPHOS71.  
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Pyruvate dehydrogenase activity induced by the oncogene BRAFV600E is 
frequently mutated in various cancers inclusive of melanoma. Recently, pyruvate 
dehydrogenase was thought to contribute to the onset of senescence in tumor 
cells72. It was proposed that activation of the enzyme increases the metabolism of 
pyruvate in the citric acid cycle to enhance respiration, which results in the 
increased production of reactive oxygen species72. This finding suggests that the 
over-activation of certain enzymes responsible for catalysis during the citric acid 
cycle could be detrimental to cancer cells.  
 
On the other hand, recently, it was reported that gene expression levels of 
aconitase, a different enzyme of the citric acid cycle, which catalyses the 
conversion of citrate to isocitrate, is up-regulated under conditions of hypoxia, as 
observed in prostate cancer cells73. This contradicts the situation with pyruvate 
dehydrogenase, as up-regulation of aconitase, in this case, appears to support the 
growth of these tumor cells. Together, these results suggest that changes to the 
expression of different citric acid cycle enzymes can exert different effects upon 
the tumorigenicity of cancer cells. 
 
1.5.4. Oxidative phosphorylation 
The electron transfer chain is situated on the mitochondrial inner membrane and 
comprises 5 protein complexes (Figure 1.7). Complex II comprises entirely of 
nuclear-encoded subunits, whereas Complexes I, III, IV and V are assembled 
through a combination of nuclear-encoded and mtDNA- encoded subunits74. 
NADH is used as an electron donor to Complexes I, III and IV of the 
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mitochondrial electron transfer chain, whereas FADH2 supplies electrons to 
Complexes II, III and IV75. 
 
 
Figure 1.7. Schematic diagram of the mitochondrial electron transfer chain 
(ETC). The sequential transfer of electrons across the 5 protein complexes 
reduces a molecule of oxygen to generate water at Complex IV within the 
mitochondrial matrix. During this process, an electrochemical gradient is 
formed across the mitochondrial inner membrane through the accumulation of 
protons in the intermembrane space. The electrochemical gradient is then used 
by Complex V to generate ATP from ADP and inorganic phosphate.    
 
The sequential transfer of electrons from one complex to another, results in the 
translocation of protons into the intermembrane space from the mitochondrial 
matrix. However, Complex II, succinate dehydrogenase, which oxidizes FADH2 
does not directly contribute to the generation of the proton gradient76. The 
electrochemical gradient is maintained as protons are unable to diffuse freely 
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across the mitochondrial membrane, relying instead on specific proton channels, 
otherwise known as the ATP synthase protein complex (Complex V). The ATP 
synthase utilizes this electrochemical gradient to produce ATP from ADP and 
inorganic phosphates77. However, excessive accumulation of the proton gradient 
may prevent further activity of the ETC, since this would stimulate inhibition of 
any further proton translocations as well as inhibit the oxidation of NADH75.   
 
The coupling between activities of the ETC and the production of ATP via ATP 
synthase is referred to as OXPHOS. Proper functioning of the citric acid cycle 
and OXPHOS is important in, for example, the development of mouse ovarian 
follicles78. Decreased ability of any protein complex to function, impacts on the 
overall ability of the ETC to produce ATP. The first nuclear-encoded mutation 
identified in Complex I corresponded with the diagnosis of Leigh syndrome79. 
Since then, other Complex I disorders have been reported, which include 
Parkinson’s disease caused by the presence of excessive oxidative stress, thereby 
resulting in the misassembly of Complex I80.  
 
On the other hand, deficiency of Complex II has been associated with patients 
diagnosed with late-onset optic atrophy and ataxia81. Complex III disorders are 
thought to give rise to mitochondria myopathy82,83, and Complex IV defects to 
the progression of leukodystrophy84. Mis-assembly of one protein complex may 
impact upon the respiratory activity of another, a situation that arises in 25% of 
OXPHOS deficiencies85. This is exemplified by the requirement for Complex III 
to be fully assembled for the stability of Complex I, regardless of whether 
Complex III is functional or not86. 
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Glycolysis and the citric acid cycle collectively generate a total of 10 NADH and 
2 FADH2 reducing molecules. The whole process of glucose metabolism can 
therefore be illustrated using the following equation: 
Glucose + 6O2 + 38 ADP + 38Pi → 6CO2 + 6H2O + 38ATP 
 
1.5.4.1. Protein modeling analysis of the ETC proteins  
Currently, the molecular structures of human mitochondrial proteins have not yet 
been determined; as such protein structures from species closely related to 
human (sharing protein homology of over 70%) were used to identify the 
location of specific mutations. These proteins were identified through the Protein 
Data Bank (PDB) database, and the structures were downloaded from The 
Research Collaboratory for Structural Bioinformatics (RCSB) PDB database to 
be examined on the Swiss-PDB viewer (v.4.1.0) software. Only protein 
complexes III and IV of the human ETC were examined, since the bovine protein 
counterparts for these complexes were the only structures available that were 
over 70% homologous to the human protein complexes.  
 
Before inferences can be drawn from these protein models, on the effect of any 
non-synonymous mutations, it was necessary to understand the interactions 
between different protein subunits and how these work together to create a 
working protein complex.  
 
1.5.4.1.1. Cytochrome bc1 complex 
The cytochrome bc1 complex represents Complex III of the mitochondrial 
respiratory chain (Figure 1.8). Its main function is in the electron transfer 
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processes from the hydrophobic carrier ubiquinol to cytochrome c, during which 
there is a redox reaction that is initiated from the oxidation of hydroquinones 
(QH2) to quinones (Q). This is followed by the reduction of cytochrome c 87. 
 
 
Figure 1.8 Diagram of the Complex III monomer, cytochrome bc1. The locations 
of the redox prosthetic groups in cytochrome b (heme bL and bH) and in 
cytochrome c1 (heme c1) are shown. The main processes of the Q cycle are also 
represented, in addition to the net movement of the protons during catalysis.  
 
Interaction between cytochromes b and c1 forms the cytochrome bc1 core 
complex. However, completion of the structure requires the presence of the 
Rieske iron-sulfur protein, which spans cytochrome b and c1 thereby connecting 
the 2 monomers88. The iron-sulfur cluster resides within the mobile C-terminus 
globular domain of the Rieske iron-sulfur protein89. Stabilisation of this redox 
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prosthetic group occurs only after the protein has formed a complete complex 
with cytochrome bc189. Formation of the cytochrome bc1 complex is made 
possible as the c-terminal helix of cytochrome c1 interacts with the fifth 
cytochrome b helix. The flexibility of the Fe/S protein head domain permits 
interaction with the cytochrome bc1 complex87, which is essential as the 
frequency at which the head domain moves controls the rates of catalysis90. 
 
The Q cycle is responsible for carrying out the functions of cytochrome bc1 
complex. Two catalytic sites exist that allow for oxidation of ubihydroquinone  
(QH2) and reduction of ubiquinone to ubiquinol (Qi). The Qo site and Qi site 
reside opposite one another on the positive and negative side of the inner 
membrane, respectively91. Although the two catalytic centers Qi and Qo are 
located apart from one another, they are actively coupled to each other88.  
 
During two consecutive oxidation reactions of QH2 at the Qo site, two electrons 
are lost.  One electron is transferred to the Qi site to re-generate ubihydroquinone 
(QH2), which is then released from the enzyme complex92. The other electron is 
shuttled to the 2Fe2S cluster found in the Fe-S protein. This second electron is 
transferred from the Fe-S protein to cytochrome c1 during catalysis by movement 
of the head domain, from which it is further transferred to the hydrophobic 
carrier, cytochrome c, and shuttled to cytochrome c oxidase (Complex IV). 
During the Q cycle, by-products of superoxides can be formed from the 
oxidation of ubiquinol, as a result of electron leakage93. Nonetheless, the primary 
function of the Q cycle is in the generation of a membrane potential across the 
mitochondrial inner membrane. The net yield of 2 protons per catalytic cycle 
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contributes towards a proton gradient87, which is important for the production of 
ATP via ATP synthase (Complex V)92.  
 
1.5.4.1.2. Cytochrome c oxidase complex 
Cytochrome c oxidase (COX) I-III together form the catalytic core of Complex 
IV94 (Figure 1.9). Within the hydrophobic core of COX I, there are two heme A 
cofactors (a and a3) 95. The flow of electrons begins from the hydrophobic carrier 
cytochrome c, which transfers electrons to the CuA centre in the COX II subunit, 
and subsequently to the heme a site. From here, electrons are shuttled to the 
heme a3-CuB bimetallic centre, where oxygen binds and becomes reduced to 
water96. 
	  
Figure 1.9 Cytochrome c oxidase (Complex IV) of the mitochondrial ETC. Three 
subunits (COX I, II and III) comprise the catalytic core of Complex IV, with the 
two heme A cofactors, the copper centres and the reduction of oxygen to water. 
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COX II is highly hydrophilic compared to COX I and III97, and is structurally the 
smallest of all the subunits that comprise the catalytic core of cytochrome c 
oxidase98. On the other hand, COX III is absent of any prosthetic groups, with its 
structure being defined by the presence of seven membrane-spanning alpha 
helices. 
 
Assembly of Complex IV occurs in a successive manner, initiating from COX I 
followed closely by recruitment of accessory factors such as heme groups, and 
subsequently by other subunits99. As a result, defects arising early during this 
process are thought to have a cumulative effect on the overall assembly, and 
thereby functionality of the protein complex95. Following the complete assembly 
of Complex IV, there appears to be no interaction between COX II and III, as 
they interact only through the transmembrane region of COX I 100. 
 
Quality control regarding assembly of the proteins occurs throughout protein 
biosynthesis, at both the subunit level and also when the complex is fully 
formed94. However, since there is thought to be a mutation threshold level, some 
defects in the mitochondrial respiratory chain are permitted, as non-mutated 
counterparts are believed to compensate for activity in the mutant proteins95.  
 
All subunits of Complex IV together with cytochrome B represent the mtDNA-
encoded proteins that are most conserved throughout evolution. COX I is the 
most conserved region (47.2%) amongst the 13 mtDNA-encoded polypeptides, 
when comparing the human amino acid sequences to the yeast protein 
counterpart. This was followed by cytochrome B (32.4% protein homology) and 
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the remaining Complex IV subunits COX III (30.8% protein homology) and 
COX II (28.6% protein homology)101. Reasons for protein conservation for these 
mtDNA regions can be attributed to their roles as key components of the ETC. 
In summary, cytochrome B has the important role of catalysing the transfer of 
electrons from the hydrophobic carrier ubiquinol to cytochrome c, which is 
coupled to the translocation of protons across the inner membrane of the 
mitochondrion. Within the cytochrome bc1 complex, there are prosthetic groups 
and redox centres that collectively maintain activity of the Q cycle102. Complex 
IV catalyses the final stages of the ETC by reducing molecular oxygen to water, 
and as such, mutations to the complex subunits are more likely to be less 
tolerable. For example, the region within COX II that is involved with the 
shuttling of electrons from cytochrome c to the CuA center has been reported to 
be very highly conserved102. Consequently, mtDNA variants detected within 
these regions have a greater chance of being predicted to cause protein 
impairment. 
 
1.6. Warburg effect 
Frequently, in tumor biology, there is a metabolic switch from respiration via 
OXPHOS to the preferential use of glycolysis, even in the presence of sufficient 
oxygen concentration103. This process results in the Warburg effect (Figure 
1.10). Although glycolysis yields fewer molecules of ATP per molecule of 
glucose, the generation of lactate regenerates and permits the recycling of 
reducing factors, such as NADH, that assist in the continual cycling of 
glycolysis. This results in the rapid generation of low levels of ATP, which 
supports the high levels of proliferation characteristic of these tumor cells104.  
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Figure 1.10. The Warburg effect. Normal cells undergo anaerobic glycolysis and 
subsequently utilize pyruvate, the product of glycolysis, in different ways 
depending on the concentration of oxygen. In the presence of sufficient oxygen 
concentration, pyruvate undergoes complete oxidization to CO2 during the 
process of OXPHOS. In the presence of limiting oxygen concentration, pyruvate 
is converted to lactate in order for glycolysis to continue. Metabolism via this 
pathway yields fewer molecules of ATP compared to conditions of high oxygen 
concentration, but is the preferred mode of metabolism in both cancer and highly 
proliferative cells regardless of the oxygen concentration available (Warburg 
effect). 
 
During development and in the event of tissue repair, rapidly proliferating 
embryonic stem cells have also been demonstrated to undergo metabolism via 
aerobic glycolysis105. There are several reasons for cancer cells to respire through 
aerobic glycolysis. The first is that the production of lactate reduces the local pH 
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levels, which may deter normal cells from migrating into the region thereby 
encouraging metastasis of the tumor106. Reduced oxygen availability might also 
be a factor in preventing the establishment of normal cells, since cancer cells are 
more readily able to adapt to these unfavorable conditions. Additionally, the 
secretion of lactate suppresses the host immune response by inhibiting the 
maturation of monocytes to form dendritic cells, which have a role in the 
initiation of specific T-cell immune response107. Lactate also prevents the release 
of cytokines from these dendritic cells as well as from the cytotoxic T 
lymphocytes, which are otherwise important for preventing the further growth of 
tumor cells108.  
 
However, aerobic glycolysis is not universally applicable to all cancer cells, as 
there are exceptions where tumor cells retain the preferential use of OXPHOS109, 
for example, in the THP-1 leukemia cell line110. Nonetheless, elevated expression 
of factors, such as hypoxia-inducible factor (HIF) and c-Myc, are commonly 
observed in cancer cells, and has been demonstrated to correlate with increases in 
the expression of lactate dehydrogenase A111,112.  
 
The balance between the activities of lactate dehydrogenase and pyruvate 
dehydrogenase dictates whether glycolysis or OXPHOS is used as the 
predominate method for cellular respiration113. However, it has been suggested 
that p32, a surface marker on cancer cells, may participate in the switch between 
glycolysis and OXPHOS114. The down-regulation of p32 was reported to 
promote OXPHOS over glycolysis, whereas its up-regulation was shown to 
promote the opposite114. 
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1.7. Other effects of mitochondrial dysfunction in cancer 
Apart from changes to mitochondrial energy metabolism, cancer cells also have 
abnormal iron metabolism. Iron is an essential component required for the heme 
and non-heme cofactors present in the protein complexes of the ETC115 (also 
refer to section 1.5.4.1.1), and is also critical for the function of ribonucleotide 
reductase responsible for the synthesis of deoxyribonucleotides116,117. This means 
that dysfunction or decreased levels of iron would negatively impact on the 
energy production in the mitochondria. On the other hand, mitochondrial 
diseases such as, Alzheimer’s or Parkinson’s disease, can be characterized based 
on their over-accumulation of iron118. However, much work remains to be 
determined in understanding the exact location and degree of iron accumulation 
that causes pathogenesis in these diseases118.  
 
Another effect of cancer on mitochondrial biology can be illustrated by the over 
expression of human microRNA, MiR-25, in ovarian and colon cancer cells. 
MiR-25 is believed to down-regulate levels of the mitochondrial calcium 
uniporter (MCU) and therefore decrease the uptake of mitochondrial calcium 
ions119. The consequence of this results in cancer cell survival, thereby providing 
another role for mitochondria in the control of tumor biology.   
 
1.8. MtDNA variants in cancer 
The release of ROS by-products, caused by leakage of electrons during the 
sequential transfer across protein complexes of the ETC, can damage mtDNA by 
inducing oxidative base lesions, since mtDNA resides close to the ETC120. ROS 
production in cancer cells has the potential to be detrimental, since enhanced 
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ROS release combined with impaired mitochondrial antioxidant capacity in these 
cells, disrupt the integrity of mtDNA121. On the contrary, low levels of ROS 
production in normal cells, is believed to be important in mediating cell 
proliferation and in the control of cell signaling response122. 
 
MtDNA sequence variants have been reported in various cancer types as 
potential contributors towards the onset of cancer (Table 1.1). Those thought to 
have roles in breast cancer include variants at positions 12308bp123, 9055bp 
(G→A), 10398bp (A→G) and 16519bp (T→C)124. On the contrary, mtDNA 
variants predicted to reduce the risk of breast cancer have also been proposed, 
which include those at positions 3197bp (T→C) and 13708bp (G→A). These 
have been suggested to stabilize the protein structures where these mutations 
reside124.  
 
Differences in mtDNA haplotypes of individuals also have an influence on the 
susceptibility of developing cancer, an association which has been shown with 
several cancer types including, prostate cancer125 as well as breast cancer123,124. 
MtDNA haplotypes refer to inherited changes in the mtDNA sequence of 
individuals that allow for the determination of their maternal ancestry, and 
therefore identify these individuals as originating from a particular ethnic 
background or region126. For Chinese people belonging to sub-haplogroups D, 
D4a and D5, it is thought that their mitochondrial genome increases their risk to 
oesophageal cancer127. Furthermore, in a separate study, it was reported that 
within the D-loop, the presence of the 150bp (C→T) variant positively associated 
with the probability of developing human papillomavirus infection and cervical  
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Table 1.1. MtDNA variants reported in colorectal, breast and thyroid cancer 
Cancer Reported variants MtDNA region 
T1651C tRNAVal 
G2758A, T2352C, A2706G, A2768G, T2885C, T2914G, 3107delG 16s rRNA 
C3316T/A, A3759G ND1 
A4769G, G5178T ND2 
G6260A, G7028A, T7055C/G, 7335insC, G7256A, T7146A COX I 
C7498T tRNASer 
C7521T tRNAAsp 
G8206A, G8251A COX II 
A8618G, T8784C, A8860G, G9055A ATP 6 
A10398G, C10400T ND3 
T11641C ND4 
C12633A ND5 
G16233A, G16266A, G16294A, T16309G, A16325G, C16390T D-loop 
C
ol
or
ec
ta
l12
8  
9-bp Ins5892C, 8269-9bp del Non-coding 
G85A, T194C/T, C195T/C, C199T, C204T, A207G, C295T, 2-bp 
Ins303C, T210C/T, Ins311C, C16069T, C16114T/C, G16145A/G, 
T16189C, A16293G, T16519C 
D-loop 
G709A, T710C, C1243T/C, A1555G 12s rRNA 
G1719A, G2706A, T3197C 16s rRNA 
T3394C, G3849A/G ND1 
T4216C, A4295G, T4323C/T tRNAIso 
T4336C tRNAGln 
C4499T/C, A4529T, G4580A, G4665A/G, A4917G, A5240T, 
G5460A ND2 
C7028T COX I 
G8251A, A8498G/A, G8994A, G9055A ATP 6 
T9885A/T COX III 
T10034C tRNAGly 
A10398G ND3 
A11768G/A ND4 
A12308G tRNALeu 
T12636C, A12642G, C12852T/C, G13263A, G13368A, T13397A, 
T13398A, T13674G/T, G13708A ND5 
T14470C ND6 
C14766T tRNAGlu 
A15607G, A15655G/A, C15700T, G15755T/G, T15783C, A15824G CYT B 
B
re
as
t12
4,
12
9  
A15924G/A tRNAThr 
Ins3571C, 3331del242bp, T3949C, G3392A, T4222C, G4148A ND1 
G5185A, G4720A, G4975A, G4831A ND2 
A8836G, A8836G, G8839A ATP6 
G10537A ND4L 
11084delCA, 11038delA, 10885delT, G11403A, G12056A, 
G11475A, T11613C ND4 
T12797C, G13414A, A13870T, Ins13235T, T13271C, G13042A ND5 
Th
yr
oi
d1
30
 
T15209C, T15674C, T15843C, T15813G CYT B 
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cancer, independently of mtDNA copy number within a population of Chinese 
women131. It was thought that the C150T variant promoted increased 
mitochondrial replication or increased ATP production, which was beneficial for 
tumor cell survival132. 
 
Statistics for colon cancer estimate that defective mtDNA could be responsible 
for up to 70% of cases133, whereas for gastric cancer, predictions were in the 
range of 5 to 37%. In samples representative of head and neck cancer, a total of 9 
mtDNA base substitutions were observed, together with one base insertion across 
the entire genome134. Identification of these mtDNA rearrangements can be 
determined using non-invasive techniques on patients, for example through the 
analysis of saliva samples135. Likewise, bladder cancer mtDNA variants can also 
be identified using urinary patient samples135. 
 
Aside from mtDNA variants arising as a result of sequence base substitutions, 
deletions are also commonly observed in cancers. Large-scale deletions, such as 
the 4977bp deletion located between mtDNA positions 8470bp and 13477bp 
disrupts the activity of multiple mtDNA genes that are important for OXPHOS 
within the ETC. In this context, genes that are disrupted include both ATPase 6 
and ATPase 8 subunits of Complex V, Cytochrome C Oxidase III (COX III) of 
Complex IV and several of the Complex I subunits136. This deletion has been 
associated with lung136, thyroid137, breast138, oral139 and gastric cancer140 and is 
thought to be a relatively common mutation amongst cases of tumor 
development. 
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Overall, there is evidence to suggest that mtDNA variants could lead to the onset 
of cancer. However, there remain a few exceptions. For example, it has been 
demonstrated that, with the progression of head and neck squamous cell cancer, 
mtDNA variants become established at a much later stage of tumor development 
with levels of mutation reported between 21 – 51%, primarily within the D-loop 
region141. There was also the preferential establishment of coding region variants 
within ATPase 6, NADH Dehydrogenase 2 and 5 (ND2 and ND5), Cytochrome 
B (CYT B) and COX III142. Together, this suggests that in some cases, mtDNA 
variants arise as a consequence of tumor development. Furthermore, the 
development of these mtDNA variants was thought to occur independently of 
mtDNA copy number in human cancer cells143.  
 
The mtDNA of Glioblastoma multiforme (GBM) and multiple myeloma cells 
were examined to determine whether these cancers share the presence of known 
mtDNA variants identified within other cancer types. The purpose of this was to 
investigate whether certain mtDNA variants predispose cells to develop cancer. 
This could explain why cancer cells preferentially switch their metabolism to 
glycolysis during tumor establishment. Multiple myeloma and GBM were 
chosen for this analysis, as there is an increasing interest in the involvement of 
mitochondria for both cancers. 
 
1.9. Multiple myeloma and mitochondria 
Multiple myeloma is a type of bone marrow cancer affecting plasma cells. It 
represents one of the more common haematological disorders, and is frequently 
preceded by a premalignant stage known as, monoclonal gammopathy of 
	  	   63	  
unknown significance (MGUS). Although MGUS is asymptomatic, it is 
relatively common, affecting more than 3% of individuals over 50144, with 
numbers rising to 8% in those over the age of 80144. However, the risk of MGUS 
progression into fully malignant multiple myeloma is very low, estimated at 1% 
per year after diagnosis145. In the UK alone, over 4,000 new cases of multiple 
myeloma arise per year, which is in addition to the current estimate of 
approximately 20,000 to 30,000 individuals already suffering from the effects of 
this cancer146. Many of the symptoms displayed by affected patients appear to be 
non-specific146 and amongst these, approximately 80% of cases involve 
degradation of the bone147. 
 
Development of myeloma involves a multi-step process. Transformation towards 
a malignant cell type is normally initiated from a combination of altered genetic 
and environmental events that accumulate and cause change in the functionality 
of a plasma cell148. The resultant myeloma cell invades cavities in the bone, and 
secretes monoclonal proteins that are abnormal forms of immunoglobulin. These 
proteins eventually crowd out the functional immunoglobulins secreted by the 
normal plasma cells, resulting in the onset of symptoms, such as reduced 
immunity, leading to infection in the affected patient149. Proliferation rates for 
multiple myeloma cells tend to be dependent on the stage of advancement, with 
newly transformed cells having a slower rate of proliferation than those at a later 
of stage of progression150.  
 
Currently, there are no effective treatments that exist for the complete 
elimination of multiple myeloma. Instead, therapy aims to prolong the survival of 
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affected patients151. One of the key features of multiple myeloma is its ability to 
undergo recurrent relapse, such that with each relapse period, the biology of the 
cancer changes from its original state of diagnosis. Alterations could include 
differences in the way the cancer responds to chemotherapy or differences in 
their behavior in vivo, with one study in particular demonstrating changes to the 
nuclear genomic DNA sequence variants depending on the stage of tumor 
progression152.    
 
A number of antioxidant systems reside within the mitochondria, and one type of 
defence mechanism relies on the import of cytoplasmic glutathione (GSH) into 
the organelle153. The import of GSH maintains the mitochondrial redox state to 
prevent the onset of dysfunction and cell death154. Since mitochondrial function 
is often perturbed in cancer, an anti-tumor drug, Imexon, has been developed for 
use as a potential therapy to selectively eliminate cancer cells whose dysfunction 
originates in the mitochondria. Imexon functions by sequestering molecules, 
such as cysteine, that are essential for the production of GSH155. Physically, 
Imexon exerts changes to the ultrastructural arrangement of mitochondria. 
Moreover, it has been reported to increase cellular susceptibility to ROS damage 
and imbalance of the membrane potential that spans across the inner 
mitochondrial membrane155. Although cellular cytotoxic response of Imexon has 
been compared across a range of multiple myeloma cell lines, which include the 
RPMI 8226, U266, NCI-H929 and NB-4 cells, it has been demonstrated that 
differences exist between each in terms of their sensitivity to the drug. Despite 
this, all cell lines investigated were able to show reduced ability to survive in the 
presence of the drug155.  
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Other mechanisms that have evolved within the mitochondrion to counteract 
ROS accumulation include enlargement in the overall size of the mitochondrion, 
which is thought to increase mitochondrial internal surface area to dilute the 
effects of ROS155. Aside from alterations to mitochondria as a whole, Imexon 
was discovered to specifically target mtDNA, whilst leaving nuclear DNA intact 
at low dosages155. However, to date, not many studies exist that focus on mtDNA 
and any changes that may be induced in the genome during tumor development. 
 
1.10. GBM and mitochondria 
Glioblastoma multiforme (GBM) is a cancer of the brain that originates from 
abnormal proliferation of glial cells. GBM can arise in one of two ways; de novo 
initiation of the disease is referred to as its primary state, whereas GBM that 
arises as a result of de-differentiation of a less aggressive tumor is known as a 
secondary tumor. GBM is the most common malignant tumor, estimated to affect 
80% of adults diagnosed with primary brain cancer156. Prognosis for affected 
patients remains poor, as GBM is a category IV brain tumor, classified as the 
most severe of its kind according to the World Health Organisation (WHO) 
standards157. Median survival rates for these patients are around 12 months158, 
and in 90% of cases the tumor re-establishes itself even after treatment with 
intense combination therapy159. As such, current treatment of GBM focuses 
largely on pallative care160. 
 
Necrosis of local brain tissue is often observed in GBM161 and, at the genomic 
level, there has been reported genomic instability of these tumor cells, making it 
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difficult to define the underlying cause of the tumor157. Investigations conducted 
into the microenvironment of glioma cells provided evidence for functional 
differences between cells located at the periphery of the sphere and those within 
its centre 162, supporting the concept of heterogenicity for these cell types. GBM 
is also known to acquire mutations during the course of its tumor 
development163. 
 
One study attempting to define the cause of tumor establishment in GBM was 
able to show that expression of protein kinase M2 (PKM2) was positively 
correlated with the grade of GBM. PKM2 participates in the glycolytic pathway 
converting phosphoenolpyruvate (PEP) to pyruvate by catalyzing the transfer of 
a phosphate group from PEP to a molecule of ADP164, and functions to restrict 
the production of pyruvate in order to divert resources towards stimulating 
proliferation via the generation of macromolecules165. It was also determined that 
GBM cells are highly reliant on OXPHOS, as disruption to this process 
negatively impacted upon clonal expansion of the GBM cells166. This was 
identified via examination of insulin-like growth factor 2 mRNA binding protein 
2 (IMP2), which normally delivers mitochondrial mRNAs to their protein 
complexes for assembly166. 
 
Alantolactone is a sesquiterpene lactone found in the roots of inula helenium 
L.167. Its anti-cancer properties for GBM cells has demonstrated potential 
towards the development of future therapies to treat this malignant disease168. It 
was discovered that, in the presence of this compound, cell proliferation was 
prevented and apoptosis was stimulated in GBM cells, an effect that reported 
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time and dose dependence. The mechanism of apoptosis was determined to occur 
via depletion of glutathione (GSH) and the increase in ROS, as well as loss of the 
mitochondrial membrane potential, which is similar to the effects that can be 
induced by Imexon for the selective elimination of these cancer cells168.  
 
1.11. Conclusion 
Transformation of normal cells into the malignant phenotype involves the 
dysregulation of many collaborating factors at the nuclear and mitochondrial 
level. MtDNA is unique to the mitochondrion, and has an important role in 
controlling the metabolism of cells. In cancer, the processes that govern 
mitochondrial energetics are believed to be compromised according to the 
Warburg effect, which states that there is the preferential utilization of glycolysis 
regardless of the availability of oxygen. The phenotypic changes that arise as a 
consequence of these metabolic changes are thought to provide cancer cells with 
adaptability to establish a tumor in regions that are considered sub-optimal for 
the growth of normal cells.  
 
There is some support for the concept that mitochondria could have a role in the 
initiation of tumor development for some cancer types. MtDNA variants have 
been identified in a number of cancers and amongst these, several have been 
thought to promote or prohibit cancer development, depending on the specific 
variant involved. Given that targeting of the mitochondria has been suggested as 
a potential form of treatment against GBM and multiple myeloma, it would be 
feasible to examine the contribution of the mitochondrial genome to the 
development of these cancers.  
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1.12. Hypothesis 
MtDNA has a role in the initiation of tumor development in GBM and multiple 
myeloma, with mtDNA variants disrupting the functional ability of the ETC 
protein complexes. In this respect, it was hypothesized that variants would 
prevent the proper assembly of protein complexes that comprise the ETC, or 
would carry impairment in their ability to shuttle electrons between the protein 
complexes, or disrupt the translocation of protons across the inner mitochondrial 
membrane. Failure to establish the electrochemical gradient required for the 
production of ATP via Complex V, would compromise ATP production and 
force cancer cells to use glycolysis as their primary source of metabolism, 
thereby following the Warburg effect.  
 
1.13.   Aims and objectives 
2. To identify novel mtDNA variants that could be responsible for 
initiating multiple myeloma.  
To do this, next generation sequencing will be used, and the variants identified 
will be analysed by bioinformatics and other in silico tools to predict the severity 
of the variants identified and their likelihood of causing protein impairment 
(Chapter 3). 
 
3. To determine the importance of mtDNA in maintaining the tumorigenic 
phenotypes of multiple myeloma cells.  
Multiple myeloma cells will be depleted of their mtDNA in culture and analyses 
will be conducted to determine the changes in the expression profiles for genes 
involved with mitochondrial biogenesis, transcription and replication, as well as 
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genes associated with its tumor biology. Metabolic assays will be performed to 
measure the oxygen consumption of these cancer cells. ATP and lactate assay 
measurements will also be taken to define any changes to the tumor phenotype of 
these cells after induced depletion of mtDNA (Chapter 4). 
 
4. The outcomes from Aim 1 and 2 will be tested in another model, using 
GBM cells. Therefore, the aim is to identify mtDNA variants that could 
be responsible for initiating GBM and to determine whether certain 
tumor types harbour specific mtDNA variants. 
 
GBM cells and patient tumor samples will undergo next generation sequencing 
to determine whether the mtDNA variants are the same or different to those 
identified from sequencing of the multiple myeloma cells. GBM tumor variants 
will be compared with mtDNA variants identified from the sequencing of normal 
brain biopsy samples, and GBM cell line variants will be compared with the non-
tumorigenic human neural stem cells. To determine the importance of mtDNA in 
the establishment of a tumor, GBM cells will be depleted of their mtDNA in 
culture and transplanted into immunedeficient mice for the recovery of mtDNA 
copy number to examine whether the presence of mtDNA is required for the 
establishment of a tumor in vivo (Chapter 5).  
 
4.  To determine the contribution of mtDNA to the tumorigenic phenotype 
of GBM cells. 
MtDNA depletion will be performed and cells subsequently analysed for changes 
in the expression levels of key genes involved with mitochondrial biogenesis, 
	  	   70	  
transcription and replication. GBM cells differentiated into astrocytes and 
neurons will also be analysed for changes to the expression levels of these genes 
to determine whether the tumorigenecity of GBM cells is lost upon 
differentiation into mature cell types (Chapter 6).  
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Chapter 2: General methods 
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For chemical compositions of laboratory reagents, refer to Appendix (i).  
 
2.1. Cell culture  
All culturing was performed under sterile conditions in the Top-Safe 1.2 (Class 
II) Bio-cabinet (LAF Technologies Pty Ltd., Victoria, Australia). Generally, the 
procedure for passaging of the cells was as follows: 
 
2.1.1. Passaging of adherent cultures 
Media was aspirated and rinsed with Dulbecco’s Phosphate-Buffered Saline 
(PBS) in the absence of Ca2+ and Mg2+. TrypLE Express (Gibco, Carlsbad, CA, 
USA) was used as a cell dissociation agent and cells were incubated for 3 
minutes at 37°C. To inactivate TrypLE activity, cell culture media containing all 
the essential supplements to fully support cell growth (complete media) was 
added to the culture at a ratio of 1:3 (TrypLE:media), and transferred to a 15ml 
conical tube (BD Biosciences, Franklin Lakes, NJ USA)*. Cells were centrifuged 
for 3 minutes at 14,000rpm (Eppendorf centrifuge 5702; Eppendorf AG, 
Hamburg, Germany). The supernatant was aspirated and cells were resuspended 
in 1-2ml complete media in preparation for the cell count.  
 
* Until this point, the procedure outline has been specific to passaging for 
adherent cultures. The steps after this are shared with the protocol for non-
adherent cells.  
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2.1.2. Passaging of non-adherent (suspension) cells 
Cells in suspension were transferred to a 15ml conical tube (BD Biosciences). 
The culture flask was rinsed with PBS and subsequently transferred into the 
15ml conical flask containing the cell suspension. Cells were centrifuged for 3 
minutes at 14,000rpm, after which the supernatant was aspirated and the cells 
resuspended in 1ml TrypLE Express for incubation at 37°C for 3 minutes. All 
remaining steps of the procedure follow the same protocol as above (section 
2.1.1). 
  
All cells were counted using a haemocytometer counting chamber of 0.1mm 
depth by 0.0025mm2 (Improved Neubauer with bright-line; Blau Brand, 
Wertheim, Germany) as cultures were passaged, using a glass coverslip of 
0.40mm. Cell viability was assessed using the trypan blue exclusion assay 
(Sigma, St Louis, MO) at a 1:1 cell to trypan blue ratio. The calculation for total 
cell numbers were as follows, based on viable cell counts: 
 
i) Average cell count per grid on hemocytometer X dilution factor of cells    
=   value 1 
ii)  Value 1  X  104     =   value 2 
iii) Value 2 X  cell resuspension volume (ml)  =  total number of cells in culture 
 
The percentage viability of cells was calculated using the following formula: 
= [1.00 – (number of blue, nonviable cells / total number of cells) X 100] 
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All cells were visualized using the Primo Vert inverted microscope (Carl Zeiss 
Microimaging, Gottingen, Germany) and all cell lines were maintained under 
conditions of 37°C with 5% CO2. Details for the maintenance of each cell line 
used are outlined below. 
 
2.1.3. Human foreskin cell line, BJ fibroblasts 
BJ fibroblasts (American Type Culture Collection, number CRL-2522, 
Manassas, VA, USA) were maintained as a monolayer culture in 1x Dulbecco’s 
Modified Eagle Medium (DMEM) high glucose, containing 10% Fetal Bovine 
Serum (FBS), 2mM GlutaMAX, 0.1mM non-essential amino acids (NEAA), 
1mM sodium pyruvate and 25U of penicillin/streptomycin (all from Gibco). 
Fibroblasts were passaged every 3 to 4 days, with cultures seeded at 8 x 104 
cells/cm2 at the beginning of each passage cycle.  
 
2.1.4. Human hepatocarcinoma cell line, HepG2 
HepG2 cells were cultured as a monolayer in DMEM media supplemented with 
10% FBS, 2mM GlutaMAX and 25U of penicillin/streptomycin (All from 
Gibco). Cells were passaged every 3 days and seeded at a density of 8 x 104 
cells/cm2. 
 
2.1.5. Human multiple myeloma, U266 cells 
Human multiple myeloma U266 cells169 were cultured as a single cell suspension 
in RPMI 1640 media, supplemented with 10% fetal bovine serum (FBS), 2mM 
GlutaMAX and 1mM sodium pyruvate (all from Gibco). Cells were subcultured 
at a density of 8 x 104 cells/cm2 and passaged every 3 to 4 days. 
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2.1.6. Human glioblastoma multiforme, HSR-GBM1 / GBM L1 / GBM L2 
cells 
Human glioblastoma multiforme (GBM) cell, HSR-GBM1, GBM L1 and GBM 
L2 were cultured as neurospheres in DMEM/F12 media supplemented with 2% 
StemPro neural supplement (Gibco, Carlsbad, CA, USA), 20ng/ml basic 
fibroblast growth factor (bFGF) and 20ng/ml epidermal growth factor (EGF; 
both Millipore, Billerica, MA). Cells were passaged every 3-4 days using 
TrypLE Express (Gibco).  
 
2.1.7. Human glioblastoma multiforme, NO7-152 cells 
NO7-152 cells represent another type of GBM cells. These adherent cells are 
cultured as a monolayer and required media composed of DMEM high glucose, 
4% non-essential amino acids (NEAA), 2mM GlutaMAX and 20% FBS (all 
from Gibco). Cells were passaged in the presence of TrypLE Express. 
 
2.1.8. Human glioblastoma multiforme, GBM 4 / CSC-020 / CSC-014 cells 
Additional GBM cells, GBM 4, CSC-020 and CSC-014 were cultured in 
knockout DMEM/F12 media supplemented with 2% StemPro neural supplement, 
EGF and bFGF (both at concentrations 20ng/ml) with added 2mM GlutaMAX 
(all from Gibco). The GBM4 cells were maintained as an adherent culture, 
whereas CSC-020 and CSC-014 were maintained as neurospheres similar to the 
HSR-GBM1, GBM L1 and L2 cell lines. Passage of the GBM 4, CSC-020 and 
CSC-014 cells was performed every 3-4 days in the presence of TrypLE Express 
(Gibco). 
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2.1.9. Depletion and replenishment of mtDNA in U266 and HSR-GBM1 cells 
U266 cells underwent mtDNA depletion using 10µM of 2’,3’-dideoxycytidine 
(ddC), in the presence of 50µM of uridine (both from Sigma, St Louis, MO), 
which were supplemented to the culture media. Supplies of both factors were 
replenished daily through half media changes for up to 30 days, with the cells 
undergoing a complete media change after 3 or 4 days. Collected samples for 
analysis were rinsed with PBS (Gibco) prior to storage of the cell pellet at -80°C. 
 
For replenishment of mtDNA, U266 cells were cultured in complete RPMI 160 
media in the absence of ddC and uridine. HSR-GBM1 cells were cultured in 
conditioned media during mtDNA replenishment after a period of mtDNA 
depletion. Conditioned media was collected from HSR-GBM1 cells that had 
been cultured for 2 days in fresh culture media supplemented with growth 
factors, and stored at -20°C until use.  
 
2.1.10. Inhibition of glycolysis using 2-deoxyglucose 
U266 cells were depleted of their mtDNA in culture and allowed to recover in 
complete media together with the presence of 5mM 2-deoxyglucose.  
 
2.2. Isolation of plasma cells 
Bone marrow mononuclear cells were isolated from the bone marrow of patients 
diagnosed with relapse and/or refractory stage multiple myeloma. Isolation was 
performed using Ficoll-Paque Plus (Amersham Biosciences, Rydalmere, 
Australia) followed by treatment with red blood cell lysis buffer (154.98mM 
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ammonium chloride, 126.61mM EDTA, 9.99mM potassium bicarbonate). Cells 
were then cultured for 24 hours in complete U266 media after which, plasma 
cells were magnetically separated using the CD138 microbeads kit (Miltenyi 
Biotec, North Ryde, Australia). 
 
2.3. Fluorescent-activated cell sorting (FACS) on U266 cells 
U266 cells were subjected to FACS based on their expression of the cell surface 
marker CD45. Cells were harvested and resuspended in 100µL FACS buffer 
consisting of PBS supplemented with 5% FBS. Cells were then labeled using the 
mouse anti-human CD45 antibody conjugated to FITC (BD Biosciences) by 
adding antibodies at a 1:100 dilution and incubating the mixture at 4°C in the 
dark for 15 minutes. Cells were then washed three times with FACS buffer and 
centrifuged for 5 minutes each at 300g. The supernatant was aspirated and the 
cell pellet was re-suspended in 100µL FACS buffer, for analysis on the 
FACSAria Cell Sorter (BD Biosciences). CD45 positive and negative fractions 
were collected into two sterile 15ml polypropylene conical tubes (BD 
Biosciences), and cultured in U266 media as necessary. 
 
2.4. DNA extraction 
Extraction of DNA was performed on either cell samples stored at -80°C at a 
density of 2x106, or on 25mg of tissue samples. The procedure was undertaken 
using the DNeasy Blood & Tissue kit (Qiagen).  
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2.4.1. DNA extraction from cells 
Cell pellets were thawed and resuspended in a volume of 200µl of PBS (Gibco), 
after which 20µL of proteinase K (stock 20mg/ml) was added. 4µL of RNase A 
(stock concentration 100mg/ml) was added and the sample left to incubate for 2 
minutes at room temperature♦, before adding 200µL of lysis Buffer AL. This 
was mixed by pulse-vortexing for 15 seconds (Gallenkamp Spinmix vortex 
shaker, Gallenkamp, Sussex, UK). The mixture was incubated for 10 minutes at 
56°C using the Dri-Block DB-2A heating block (Techne, Staffordshire, UK), 
after which 200µL of 100% ethanol was added and mixed by pulse-vortexing for 
15 seconds.  
 
♦ Until this point, the procedure outlined was specific to the DNA extraction 
procedure for cultured cells.  
 
The sample was then applied to the silica gel membrane of a DNeasy mini spin 
column and centrifuged for 1 minute at 8000rpm (Heraeus Biofuge Pico, Kendro, 
Germany). The flow-through containing debris was discarded and the spin 
column retaining DNA was placed in a new 2ml collection tube. 500µL of Buffer 
AW1 wash buffer was added and centrifuged for 1 minute at 8000rpm. The 
collection tube containing flow-through was again discarded and the column 
placed in a new collection tube. 500µl of Buffer AW2, a wash buffer containing 
ethanol, was then applied as a second wash step. This was centrifuged for 3 
minutes at 13,000rpm to dry the membrane. The collection tube was replaced 
with a fresh collection tube and the column was centrifuged for 1 minute at 
13,000rpm to remove any residual ethanol traces, before eluting DNA under 
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centrifugation at 13,000rpm for 1 minute in 30µL of sterile water. Products were 
stored at -20°C.  
 
2.4.2. DNA extraction from tissues 
25mg of frozen tissue was cut using a sterile scalpel under sterile conditions, and 
stored in 100µL of Buffer ATL. The sample was pulse-homogenized using the 
Pro 200 tissue homogenizer (Pro Scientific Inc., Oxford CT, USA) for several 
seconds each time, until the tissue aggregates could no longer be observed. 80µL 
of Buffer ATL was added to the tissue lysate, followed by 20µL of proteinase K 
(stock 20mg/ml). This was mixed by pulse-vortexing (Gallenkamp Spinmix 
vortex shaker) for 15 seconds before overnight incubation of the sample at 56°C 
on a heat block (Techne). After incubation, 4µL of RNase A (stock 100mg/ml) 
was added and mixed by vortexing. The sample was left to incubate at room 
temperature for 2 minutes, then vortexed before continuing with the DNA 
extraction procedure outlined above, as for cultured cells.  
 
2.5. RNA extraction 
RNA was extracted from either cell samples stored under conditions of -80°C at 
a density of 2x106 or from tissue samples. The protocol for the RNeasy mini kit 
(Qiagen) was followed.  
 
2.5.1. RNA extraction from cultured cells 
For cultured cells, 350µl of Buffer RLT containing denaturing guanidine 
isothiocyanate (GITC) was added to a thawed cell pellet for lysis and instant 
inactivation of RNases that may degrade and disrupt the integrity of the RNA 
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sample. This was pulse-vortexed for 15 seconds (Gallenkamp Spinmix vortex 
shaker)Δ.  
 
Δ the procedure outlined until this step was specific to RNA extraction for 
cultured cells. Methodology after this was shared with the RNA extraction 
procedure for tissue samples.  
 
Cell homogenization was performed using the QIAshredder (Qiagen) by 
applying the lysate to the column. This was centrifuged at 13,000rpm for 2 
minutes and 1 volume of 70% ethanol was then added and mixed by pipetting. 
The sample was transferred to an RNeasy spin column and centrifuged briefly 
for 15 seconds at 13,000rpm. The flow-through was discarded and 350µl of 
Buffer RW1 was applied to the spin column to selectively isolate RNA of 
>200bp. This was centrifuged for 15 seconds at 13,000rpm to wash the column 
membrane, and the resulting flow-through was discarded.  
 
To perform the on-column DNase digestion step, 10µl of DNase I solution 
(2.727 Kunitz units/µl) was carefully mixed with 70µl of Buffer RDD. This was 
added to the column membrane and left for 15 minutes at room temperature for 
on-column DNA digestion, before further addition of 350µl Buffer RW1 to the 
spin column. The column was centrifuged at 13,000rpm for 15 seconds, the flow-
through was discarded and 500µL Buffer RPE, a mild washing buffer, was added 
to the spin column. This was centrifuged for 15 seconds at 13,000rpm. The flow-
through was discarded afterwards and another 500µL of Buffer RPE was applied 
to the membrane, and centrifuged for 2 minutes at 13,000rpm. To ensure no 
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carry-over of ethanol, the column was centrifuged for an additional minute at 
13,000rpm, before eluting RNA under centrifugation at 13,000rpm for 1 minute 
using 30µL of RNase-free water.  RNA was stored at -80°C. 
 
2.5.2. RNA extraction from tissue samples 
30mg of frozen tissue was cut under sterile conditions using a clean scalpel. 
Tissue was homogenised using the Pro 200 tissue homogenizer (Pro Scientific 
Inc.) in 600µL Buffer RLT containing beta-mercaptoethanol (Sigma) diluted in a 
ratio of 1:100 (6µL). Homogenisation was conducted for no longer than 10 
seconds each time, until the tissue was completely lysed. The lysate was 
transferred into a QIAshredder, and centrifuged for 2 minutes at 13,000rpm, 
continuing with the steps as outlined above for RNA extraction in cultured cells.   
 
2.6. Spectrophotometry 
Quantification of DNA and RNA templates was performed using the NanoDrop 
1000 spectrophotometer (Thermo Scientific, Wilmington, USA). Prior to its use, 
the instrument was calibrated with sterile water to provide a blank reading. The 
NanoDrop 1000 (version 3.7) was used as the analytical software for this 
instrument.  
 
For the 260/280nm absorbance ratio, a value of 1.8 was considered good quality 
for DNA and a value of around 2.0 was considered good quality for RNA. 
Values from 1.8 to 2.2 for the 260/230nm absorbance ratio were considered 
acceptable for further use.  
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2.7. Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
For synthesis of cDNA, a two-step reverse transcriptase (RT) PCR was 
performed. 1µg RNA template was added to 540ng Oligo (dT)18 primer (Bioline) 
made to a final volume of 20µl with sterile water. The reaction was incubated at 
70°C for 5 minutes, using the PTC-200 Peltier Thermal Cycler (Global Medical 
Instrumentation, Minnesota, USA), and allowed to cool to 4°C before addition of 
further components to the RNA-primer mix, which involves addition of 5µl of 5x 
reaction buffer, 10mM dNTPs, 40U of RiboSafe RNase inhibitor and 200U of 
enzyme BioScriptTM (all from Bioline) to a final reaction volume of 30µl in 
sterile water. The sample underwent thermal cycling at 42°C for 60 minutes and 
70°C for 10 minutes with products held at 4°C at the end of the reaction. cDNA 
was stored at -20°C. 
 
2.8. Polymerase Chain Reaction (PCR)  
50ng of template was used for each PCR reaction, in the presence of the 
following: 1X NH4 Reaction Buffer, 1.5mM Magnesium Chloride (MgCl2), 
1mM dNTPs, 2.5U of BioTaq DNA polymerase (all from Bioline) and 25µM 
each of the forward and reverse primer. The total reaction volume was made up 
to 50µL by the addition of sterile water.  
 
Cycling conditions for conventional PCR using the PTC-200 Peltier Thermal 
Cycler (Global Medical Instrumentation) were as follows: 95°C for 5 minutes, 
then 35 cycles of 94°C for 30 seconds, specific primer annealing temperature for 
30 seconds (Refer to individual chapter methods for primer details) and 72°C for 
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30 seconds. Final extension of the products was performed at 72°C for 10 
minutes with end products held at 4°C.  
 
The formula used for calculation of the optimal annealing temperature of primers 
was based on the GC content of the short primer sequence, taking into account 
nucleotide length of the primer: 
 
Tm = %GC x 0.41 + 64.9 – (600 / n)              170 
 
2.8.1. Agarose gel electrophoresis 
DNA products were mixed with 6X Loading Dye in a ratio of 5:1, and loaded 
onto wells of a 1.5%Φ agarose (Bioline) gel made with 1X Tris-acetate-
ethylenediamine tetraacetic acid (TAE) buffer, and stained with SYBR Safe 
(Invitrogen) for product visualisation under UV radiation. Agarose gels were 
moulded using a gel tray and comb set (Plaztek Scientific, Melbourne, 
Australia). Gel electrophoresis was performed under conditions of 100V for 50 
minutes using the PowerPac 300 voltage power supply (Bio-Rad, New South 
Wales, Australia) in the presence of 1X TAE running buffer.  
 
Φ A 1.5% agarose gel was prepared for products anticipated to be between 400-
1000bp in size. Fragments below 400bp, were resolved on a 2% agarose gel and, 
for products of long range PCR, producing >8kb DNA fragments, a 0.7% 
agarose gel was prepared.  
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2.8.2. Gel documentation and analysis 
DNA products following gel electrophoresis were observed under UV 
illumination, using the MiniBIS Pro (DNR Bio-Imaging Systems, Jerusalem, 
Israel) with images acquired through GelCapture (version 7.0.15), DNR’s 
acquisition and analyses software. UV exposure of the products was set at 0.7 
with settings for the gain and brightness adjusted as needed.  
 
2.9. PCR product purification 
2.9.1. Direct purification of PCR products 
PCR products between 100bp to 10kb in size were purified using the QIAquick 
PCR purification kit (Qiagen), only if the product appeared to be specifically 
generated from amplification for the gene of interest as assessed by agarose gel 
electrophoresis. The protocol was as follows: Buffer PBI containing pH indicator 
was added at a ratio of 5:1 to the volume of PCR product that was required for 
purification. In cases where the pH was found to be sub-optimal, 10µL of 3M 
sodium acetate (pH 5.2) salt was added to adjust pH conditions. The mixture was 
applied to a QIAquick spin column and centrifuged for 1 minute at 13,000rpm. 
The flow-through was discarded and 750µL of wash buffer (Buffer PE) 
containing ethanol was added and left to stand at room temperature for 5 minutes 
before centrifugation for 1 minute at 13,000rpm. The flow-through was 
discarded and the column was again centrifuged for 1 minute at 13,000rpm, 
before the final elution phase, which was performed in 30µL of sterile water. 
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2.9.2.  Purification of PCR products from agarose gel following 
electrophoresis 
PCR products between 70bp up to 10kb were purified following gel 
electrophoresis using the QIAquick Gel Extraction Kit (Qiagen). In brief, 600µl 
of solubilisation buffer (Buffer QG) was added directly to the excised gel slice 
stored in a 1.5ml Eppendorf tube. This was incubated at 56°C for 10 minutes 
until the gel slice had been completely dissolved in buffer. If the product for 
purification was less than 400bp or above 4kb in size, 200µL of isopropanol was 
added to the buffer-gel mix. The contents of the tube was transferred to a 
QIAquick spin column and centrifuged for 1 minute at 13,000rpm. The flow-
through was discarded and 750µl of wash Buffer PE was applied to the column, 
which was allowed to incubate at room temperature for 5 minutes before 
centrifugation for 1 minute at 13,000rpm. The empty column was again 
centrifuged at 13,000rpm for 1 minute, before eluting the DNA in 30µL sterile 
water. 
 
2.10. Long range PCR  
Long range PCR was used to amplify the whole mitochondrial genome in two 
overlapping fragments:  
Long 1: forward primer: 5’-GACGGGCTCACATCACCCCATAA-3’, reverse 
primer: 5’-GCGTACGGCCAGGGCTATTGGT-3’.  
Long 2: forward primer: 5’-GCCACAACTAACCTCCTCGGACTCCT-3’, 
reverse primer: 5’-GGTGGCTGGCACGAAATTGACC-3’.  
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Reactions were performed using the PTC-200 Peltier Thermal Cycler (Global 
Medical Instrumentation). 50ng genomic DNA template was used in the presence 
of 1X High Fidelity PCR Buffer, 0.2mM each of dNTPs, 2mM MgSO4, 0.2µM 
each of the forward and reverse primer, and 1.0 unit of Platinum Taq High 
Fidelity DNA Polymerase in a total volume of 50µL sterilized water.  
 
Conditions for the amplification reaction were as follows: 94°C for 2 minutes, 
then 35 cycles of: 94°C for 15 seconds, 63°C for 30 seconds, 68°C for 8 minutes 
45 seconds∇, followed by a final extension phase of 68°C for 10 minutes, with 
products kept at 4°C until further use.  
∇ Platinum Taq High Fidelity DNA Polymerase has processivity of extending 
1kb of sequence for every 1 minute of the extension time.   
 
Purification of long PCR fragments followed the QIAquick PCR purification kit 
protocol, as described in section 2.9.1.  
 
2.11. Real time PCR (qPCR) 
For the generation of real-time PCR standards, products of 150-450bp underwent 
(1.5%) agarose (Bioline) gel electrophoresis with SYBR Safe (Invitrogen) and 
were extracted from the gel following the manufacturer’s instructions for the 
QIAquick Gel Extraction Kit (Qiagen). Spectrophotometric analysis (section 2.6) 
was performed to assess the approximate concentration and quality of the sample 
prior to use for real-time PCR. High quality samples were diluted to a final 
starting concentration of 1ng/µl, from which ten-fold serial dilutions (1x10-2 – 
1x10-8ng/µL) were generated to produce a correlation coefficient (efficiency; R2) 
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value that is informative of how well the template has been converted to the 
amplified product during the exponential phase of each cycle, which was 
generally in the range of 0.86 (mtDNA copy number) to 0.98 (POLGB).  
 
Standards were run in duplicate and samples in triplicate, together with water-
only negative controls (in triplicate per run). Samples for each gene of interest 
were assessed twice on independent run cycles to minimize inter-experimental 
variability. For each reaction, 20ng template/standard, 5µM of both forward and 
reverse primers all in 1x SensiMixTM SYBR (Bioline) was used in a total reaction 
volume of 10µL. Cycling of the reactions utilized the 72-well Rotor Gene (RG)-
3000 instrument (Corbett Research, Cambridge, UK). Data were collected and 
analysed using software Rotor Gene 6.  
  
Collection of data was performed as previously described171. Briefly, acquisition 
of data was obtained from the FAM/SYBR channel during the extension step. 
After cycling of the samples and standards, melt analysis was performed with 
ramping ranging from 47°C to 99°C at 1°C increments to measure product 
dissociation. To eliminate interfering fluorescence from primer dimers, a second 
acquisition step was added, set to the temperature at which the specific product 
starts to denature.  
 
The standard conditions for all genes consisted of 45 cycles of the following: 
95°C for 15 seconds, specific annealing temperature (Table 4.1) for 15 seconds, 
72°C for 15 seconds and the appropriate temperature for second acquisition for 
15 seconds.  
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2.11.1. Analysis of mtDNA copy number  
MtDNA copy number per cell was determined by calculating the ratio of mtDNA 
to nuclear DNA, divided by 2, as there are two copies of the nuclear genome. 
Normalisation for copy number analysis was performed against endogenous β-
globin levels. 
 
2.11.2. Gene expression analysis 
Calculations for relative gene expression were performed using the Pfaffl 
method172 on cDNA. The formula for the Pfaffl equation: 
 
Expression ratio = (Etarget)ΔCt target (control-treated) 
                       (Eref) ΔCt ref (control-treated) 
 
 
Where E represents the efficiency of the run, and ΔCt represents the change in Ct 
value. The Ct value is the value where the threshold level intersects with the 
amplification curves generated from the real-time PCR run. The threshold level 
was manually set at 0.1 on the Rotor Gene 6 software, which was set within the 
exponential phase of the amplification, above the background level of 
fluorescence detection. β-actin was used as a reference gene against which 
expression of the gene of interest was measured. For quality control, only 
reactions of high efficiency values (above 0.88) were considered acceptable. 
 
2.12. ATP production 
Fresh cells were harvested, resuspended in complete culture media and 
quantified using a hemocytometer. ATP measurements were performed using the 
ATPLite assay kit (Perkin Elmer, Zaventem, Belgium). Standard dilutions of 
	  	   89	  
ATP from 10-3mM to 10-6.5mM at 0.5mM intervals were prepared from a stock 
of known concentration (10mM) provided with the assay kit. Standards were run 
as duplicates on a white 96-well plate (Nunc, Roskilde, Denmark). 
 
All test samples were seeded at 50,000 cells per well, and were run in triplicate 
alongside negative controls. 50µL of cell lysis buffer was added to each of the 
wells. The plate was mixed by mechanical shaking at 700rpm for 5 minutes 
(room temperature). Substrate buffer containing luciferase and D-luciferin was 
added to all wells and the plate was again mixed for 5 minutes at 700rpm. The 
samples were dark adapted by covering the plate with foil for 15 minutes, 
following which luminescence was quantified on the FLUOstar Optima plate 
reader (BMG Labtech, Ortenberg, Germany; v. 2.20). Data analysis for the 
concentration of ATP within the samples was performed using the MARS data 
analysis software v.1.10, based on data extrapolated from the standard curve 
generated within the software program.  
 
2.13. Lactate production 
A sample of culture media was obtained from cell cultures 24 hours after a 
complete media change with and without ddC. A colorimetric system was used 
to measure quantitatively lactate content, as provided by the Lactate Assay Kit II 
(BioVision, San Francisco, CA, USA).  
 
The protocol was as follows: a sample of 2µL collected media was used for each 
well of a clear 96-well plate (Nunc) made to total volume of 50µL with Lactate 
Assay Buffer. Samples and a negative control were all prepared in triplicate sets 
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on the plate, whereas standards ranging from 0 to 10nmol generated at dilutions 
of 2nmol intervals were plated in duplicate. For each well, the following reagents 
were added: 46µL of Lactate Assay Buffer, 2µL of Lactate Substrate Mix and 
2µL of Lactate Enzyme Mix, so that all wells contained a total volume of 100µL. 
The negative control also contained the reaction mix but in the absence of the 
enzyme. The plate was subjected to shaking at 700rpm for 5 minutes followed by 
incubation in the dark for 30 minutes at room temperature.  
 
Absorbance was measured on the FLUOstar Optima plate reader (BMG Labtech) 
under 450nm wavelength. Data collection and analysis based on extrapolation 
from a standard curve were performed as for the ATP assay above. The 
calculation of lactate concentration is represented by the formula: 
 
                 Amount of lactic acid derived from the linear regression 
Lactate concentration =                  curve (nmol/µL)___________________                                         
                                                   Total volume of the sample originally within the culture (µL) 
 
 
2.14. Respirometry assessment on cells to determine their OXPHOS 
capacity 
Real-time measurements of oxygen capacity within cells were performed using 
the Oxygraph-2K high-resolution respirometry system (Oroboros Oxygraph-2K, 
Innsbruck, Austria) in conjunction with the integrated DatLab (v3.1) analysis 
software. Prior to the experiment, the two polarographic oxygen sensors from 
chambers A and B (2cm3 each) were calibrated in 1X Hanks balanced salt 
solution (HBSS) (Gibco) to normal atmospheric oxygen concentrations (oxygen 
saturation levels) and to conditions of zero oxygen levels using a 5% solution of 
sodium hydrosulfite (Na2S2O4; Sigma) in 1x HBSS.  
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After calibration, both instrument chambers were rinsed thoroughly using several 
washes of 100% ethanol, 70% ethanol, water and 1X HBSS. The chambers were 
then filled with another aliquot of 1X HBSS, which was allowed to warm to 
37°C, whilst continuously stirred at 750rpm. Once both chambers reached 
atmospheric oxygen concentration, the chamber stoppers were lowered to create 
a closed chamber containing exactly 2ml of 1X HBSS. 
 
Cells were harvested fresh and quantified using a haemocytometer, 2x106 cells of 
which were rinsed with PBS before being resuspended in 30µL of 1x HBSS 
(Gibco). Using a glass syringe, 2x106 cells were transferred each into the closed 
instrument chambers (A and B). A basal measurement of oxygen respiration was 
taken. Oxygen consumption rates were expressed as specific oxygen (O2) flux 
per cell (pmol O2 per million cells (Mil) per second(s))173. Oligomycin (5mg/ml) 
was then added to block complex V (ATP synthase) activity and determine the 
rate of uncoupled respiration that arises as a result of proton leak from the 
electron transfer chain. Maximal respiratory capacity was assessed using 
carbonyl cyanide p-(trifluoromethyoxy)-(phenylhydrazone) (FCCP) (Sigma), 
following titration of the inhibitor at various concentrations between 10-100nM. 
Lastly, 5mM of antimycin A, an inhibitor to Complex III, was used to determine 
background levels of respiration that arise from non-mitochondrial sources. In 
between the addition of cells and each of the inhibitors, there was a waiting 
interval of 5 to 10 minutes to ensure complete equilibration before each step.   
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2.15. DNA cloning  
Conventional PCR reactions were set up to amplify the region of interest in 
preparation for insertion into a plasmid vector. PCR products were gel purified 
and ligations into the pCR2.1 vector (Invitrogen) were performed immediately 
after PCR using reagents supplied with the TA Cloning Kit (Invitrogen): 1x 
ligation buffer, 50ng of pCR2.1 vector, 4 Weiss Units of T4 DNA ligase together 
with a 1:1 vector:insert ratio for the PCR product, to a final volume of 10µl with 
sterile ddH2O. The formula below was used to calculate the amount of PCR 
product required for the ligation reaction with the pCR2.1 vector: 
X  =  Y x 50 
               3900 
Where X represents the amount (µL) of PCR product of Y (bp) that is required 
for a ligation at a 1:1 vector:insert molar ratio. The value 50 represents the 
concentration (ng) of the pCR 2.1 vector, and the value 3900 represents the total 
size of the pCR 2.1 vector. 
 
Ligations were incubated at 12.5°C overnight, and were confirmed by gel 
electrophoresis with M13 primers (Forward: 5’→3’ CTGGCCGTCGTTTTAC; 
Reverse: 5’→3’ GTCATAGCTGTTTCCTG) designed to span the insert region. 
For long-term storage, the ligation product was kept at -20°C conditions. 
 
Once the ligation efficiency had been confirmed, 50µl of 20mg/ml 5-bromo-4-
chloro-3-indolyl β-D-galactopyranoside (X-GAL) solution (Bioline) was added 
and evenly spread across Luria-Bertani (LB) agar plates containing 100µg/ml 
ampicillin (Sigma-Aldrich).  
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DH5α competent bacterial (E. coli) cells from the TA Cloning Kit (Invitrogen) 
were thawed on ice for 5 minutes and 2µl of ligation product was added directly 
to this. The mixture was left to incubate for 30 minutes on ice, then the cells 
were heat-shocked at 42°C for 30 seconds, and transferred immediately back 
onto ice. 250µl of room temperature S.O.C media was added to the cells, and the 
bacteria were incubated at 37°C for 1 hour with shaking at 225rpm in tubes that 
were permissive to O2 exchange. 50µl of transformed bacteria was then plated 
onto LB ampicillin plates that had been previously coated with X-gal. Plates 
were inverted and left for overnight incubation at 37°C. 
 
White colonies were selected and screened by PCR using M13 primers. Products 
of the anticipated molecular size were excised from the gel and purified prior to 
capillary sequencing. Sequences were checked for the presence of the gene 
region of interest, and also for orientation of the insert. Colonies of interest were 
expanded further overnight at 37°C with shaking at 220rpm, in 5ml LB broth 
containing 100µg/ml ampicillin (Sigma-Aldrich).  
 
2.15.1. Plasmid purification 
Plasmids were purified using the QIAprep Spin Miniprep Kit (Qiagen). 1.5ml of 
bacterial culture expanded in LB broth overnight (section 2.15) was transferred 
to a 1.5ml Eppendorf tube and centrifuged for 15 minutes at 8000rpm. The 
resulting bacterial pellet was resuspended in 300µl of Buffer P1 (resuspension 
buffer) containing 100µg/ml RNase A. 300µl of lysis buffer (Buffer P2) and 
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mixed thoroughly by inverting the tube 6 times. The mixture was then incubated 
at room temperature for 5 minutes.  
 
300µl of Buffer P3 containing potassium acetate was added and mixed by 
inversion 6 times. The tube was then subjected to incubation on ice for 5 minutes 
and centrifuged at 13,000rpm for 10 minutes. The supernatant containing 
plasmid DNA was carefully extracted and applied to a QIAprep spin column. 
This was then centrifuged for 1 minute at 13,000rpm, and the flow-through was 
discarded.  
 
The column was washed with 500µl of Buffer PB containing isopropanol and 
guanidine hydrochloride (GuCl). The column was centrifuged for 1 minute at 
13,000rpm and the resultant flow-through discarded. 750µl Buffer PE containing 
ethanol and Tris-Cl was applied to the spin column and centrifuged for 1 minute 
at 13,000rpm. The flow-through was discarded and the empty column was 
centrifuged to dry the membrane. Elution was performed in 30µl using sterile 
water by centrifuging for 1 minute at 13,000rpm.  
 
2.16. High resolution melt (HRM) analysis 
All primers used for HRM curve analysis generated an amplicon size of no more 
than 250bp. For each primer pair specific to the gene of interest, an optimization 
step was performed using gradient PCR on the MultiGeneTM Gradient Thermal 
Cycler (Labnet International) to determine the optimal annealing temperature at 
which primers will bind to and therefore amplify the template DNA. All HRM 
reactions were conducted in triplicate on a 96-well plate, with 10ng/µl template 
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DNA, 2.5µM of forward and reverse primers, 1x HRM master mix containing 
LCGreen Plus+ (TrendBio) and sterile water to a final volume of 10µl. 20µl of 
mineral oil (Sigma) was added to each sample well to prevent evaporation of the 
sample, and a plastic seal was then applied over the plate after which the plate 
was centrifuged for 1 minute at 1000rpm.  
 
The PCR protocol for primer optimization was as follows: 95°C for 2 minutes, 
45 cycles of 94°C for 30 seconds and 60-72°C for 30 seconds, followed by 1 
cycle at 94°C for 30 seconds (to allow for heteroduplex formation), and lastly the 
final products were held at 25°C before further processing. The 12 temperatures 
that were tested during optimization included 60°C, 60.7°C, 61.3°C, 62.9°C, 
64.7°C, 66.4°C, 67.2°C, 68.7°C, 70.1°C, 71.3°C, 71.6°C and 72°C. 
 
The plate containing the amplified products was analysed using the LightScanner 
(Idaho Technologies, Salt Lake City, Utah) with data collection performed 
within the LightScanner Instrument & Analysis software with Call-IT 2.0 
(V.2.0.0.1331). The starting temperature for the melt analysis was set to 70°C 
with the range ending at 96°C with increases at 0.1°C increments. Upon 
completion of the run, 7µl of the sample from the optimization run was taken out 
from the wells to represent each of the different temperatures (60-72°C) and 
analysed by gel electrophoresis on a 2.5% 1x TAE agarose gel (at voltage 100V) 
to determine the optimal primer binding temperature. Once identified, the above 
method was applied to test samples but instead of using a specific annealing 
temperature for the PCR protocol, with the same settings being applied to the 
LightScanner instrument.   
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2.17. Capillary sequencing 
Samples up to 1000bp in length were analysed with the 16-capillary 3130xl 
Genetic Analyser fitted with a 80cm array (Applied biosystems). The amount of 
template used for sequencing depended on fragment size: 10ng for products 
between 100-200bp, 25ng for those between 200-500bp and 50ng for fragments 
500-1000bp. Template was added to 3.2µM of either the forward or reverse 
primer, and the total volume was made up to 16µl with sterile water.  
 
Processing of the samples was conducted at The Gandel Charitable Trust 
Sequencing Centre (Monash Institute of Medical Research, Clayton), using the 
BigDye Terminator v3.1 Cycle Sequencing kit, which uses dideoxy terminators 
tagged with one of four different fluorescent dyes to generate products of 
different length that can be separated according to size by electrokinetic 
injection. The procedure is as follows:  
 
For each reaction 1µl of BigDye v3.1 was added, together with 3.5µl of 5x BDT 
buffer to 15.5µl of sequencing template, as prepared above. The total reaction 
volume of 20µl was then subjected to the following cycle sequencing conditions: 
96°C for 1 minute, 25 cycles of 96°C for 10 seconds, 50°C for 5 seconds and 
60°C for 4 minutes. Products were then held at 4°C until the purification stage.  
 
Purifying extension products were performed using ethanol/sodium acetate 
precipitation. Firstly, an ethanol/sodium acetate mix was prepared by adding 2µl 
of sodium acetate (pH4.6) to 50µl of 95% ethanol. The 20µl sequencing reaction 
from the thermal cycler was added to the 52µl ethanol/sodium acetate mix. This 
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was vortexed briefly and left to precipitate for 15 to 30 minutes at room 
temperature. The mix was then centrifuged at 13,000rpm for 20 to 30 minutes, 
and the supernatant carefully aspirated until all ethanol had been removed. 250µl 
of 70% ethanol was then added, vortexed and centrifuged for 10 to 15 minutes at 
13,000rpm. Again, the supernatant was aspirated to remove all traces of ethanol, 
and the tubes were left to dry on a heat block set at 90°C for 2 to 5 minutes. The 
sample pellet was stored at 4°C and protected from light until electrophoresis 
was performed.  
 
For electrophoresis, the purified sample pellet was resuspended in 22µl of 
deionised formamide to maintain single-stranded DNA. This was vortexed and 
centrifuged briefly before heating to 90°C for 2 minutes, after which the sample 
was transferred immediately onto ice. The sample was then loaded on to a 96-
well plate, before placing it into the 16-capillary 3130xl Genetic Analyser. Data 
were analysed using the Foundation Data Collection software version 3.0, and 
parameters suitable for the polymer type (POP-7) were also set using this 
software.  
 
The digital data were visualized in the form of trace sequence files using the 
software, 4Peaks, version 1.7.2 (Neefix laboratories).  
 
2.18. Next generation sequencing 
Procedures describing the library preparation are covered in sections 2.18.1 
through to 2.18.7. Sections 2.18.8 onwards describe the procedures for 
performing automated emulsion PCR, recovery and enrichment of the amplified 
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DNA in preparation for sequencing on the Ion Torrent Personal Genome 
Machine (PGM).  
 
2.18.1 Quantification of double-stranded DNA 
Overlapping products from long PCR covering the entire mitochondrial genome 
were quantified using the Qubit 2.0 Fluorometer. For each sample, 1 or 2µL of 
DNA were mixed with the Qubit Working solution (prepared by diluting the 
Qubit reagent 1:200 in Qubit buffer) and made to a total volume of 200µL, 
vortexed and then incubated for 2 minutes at room temperature in the dark. The 
Qubit instrument was calibrated beforehand using the set of standards provided 
with the Qubit assay kit to produce a linear regression graph plotting 
fluorescence against concentration. The standards were prepared by adding 10µL 
of each standard to 190µL of Qubit Working Solution. The concentration of the 
test samples was then measured taking into account the volume of the sample 
and fluorescence emitted. The formula for calculating the concentration is: 
 
Sample concentration (µg/mL) = QF value   x   (200/x) 
 
Where the QF value refers to the fluorescence value retrieved after assessment 
using the Qubit fluorometer, and the value x refers to the amount of sample (in 
µL) added to the Qubit Working Solution. 
 
After quantification, both products were then pooled at equimolar concentrations 
to ensure even coverage of the mtDNA.  
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2.18.2.  Fragmentation of the amplicons from long PCR 
Firstly, the pooled long PCR products were made up to a volume of 130µL in 
low TE Buffer and transferred to a Covaris microtube. Fragmentation was 
performed using the Covaris Adaptive Focused Acoustics (AFATM) S220 system, 
within a full de-ionised water tank degassed at 4°C (Figure 2.1). The Covaris 
was operated via the Covaris Sonolab 7 software, and treatment parameters were 
as follows for the generation of 200bp fragments, as recommended by the 
manufacturer:  
 
peak power (W) = 175.0, duty factor = 10% and cycles per burst = 100, treatment 
time (seconds) = 60 and number of cycles = 3.  
 
The duty factor (or duty cycle) refers to the percentage time the transducer 
transmits acoustic energy. Peak power (or intensity) refers to the amplitude of the 
waves and correlates with acoustic power. Cycles per burst represent the number 
of energy waves in a single burst.  
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Figure 2.1. Physical shearing of genomic DNA to produce random sized 
fragments.  
 
 
2.18.3. End repair of the fragmented DNA and sample purification 
After fragmentation, the blunt-ended DNA is end-repaired to generate blunt-
ended DNA possessing 5’ phosphate and 3’ hydroxyl groups (Figure 2.2). 
 
 
Figure 2.2. End repair of blunt-ended DNA molecules  
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For the end repair procedure, 79µL (approximately 100ng) of the sheared DNA 
was transferred into a 1.5ml LoBind Tube, and 1X End Repair Buffer and 1µL of 
End Repair Enzyme was added and mixed with the sample, giving a total 
reaction volume of 100µL. This was incubated for 20 minutes at room 
temperature, and purification of the end-repaired DNA was performed using the 
Agencourt AMPure XP Kit in preparation for the ligation of Ion adapters to the 
DNA, which will be used to amplify the DNA. 
 
Agencourt AMPure XP Reagent beads (Beckman Coulter, Inc, NSW, Australia) 
were added at a ratio of 1.8 to the sample volume of 100µL (total volume at this 
stage = 280µL) (Figure 2.3). The bead suspension and DNA were mixed by 
pipetting 5 times, followed by pulse centrifugation and incubation for 5 minutes 
at room temperature. After this, the sample was again pulse centrifuged and 
placed in a DynaMag-2 magnetic rack (Life Technologies) for 3 minutes until 
the magnetic bead suspension has been separated from its solution. The 
supernatant was removed and discarded, following which the magnetic reagent 
beads were resuspended in 500µL of fresh 70% ethanol for the first wash 
procedure, without removing the sample tube from the DynaMag-2 magnetic 
rack. The samples were incubated for 30 seconds, and then rotated twice in the 
rack to mobilise the reagent beads. Once the solution clears, the supernatant was 
again removed and the wash step was repeated a second time with 70% ethanol. 
For removal of residual ethanol, the sample tubes were pulse-centrifuged and 
loaded onto the DynaMag-2 magnetic rack before removing the supernatant.  
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Figure 2.3. DNA purification using the Agencourt AMPure XP kit. Image taken 
from:https://www.beckmancoulter.com/wsrportal/wsr/research-and-
discovery/products-and-services/nucleic-acid-sample-preparation/agencourt-
ampure-xp-pcr-purification/index.htm 
Accessed 19/09/2013. 
 
The reagent beads were air-dried at room temperature for up to 5 minutes, and 
then the sample tubes were removed from the rack in preparation for the elution 
step. 25µL of low TE was added to the samples, and mixed by pipetting 5 times. 
The sample was then vortexed for 10 seconds, pulse centrifuged and placed in 
the magnetic rack for 1 minute. The supernatant containing the eluted DNA was 
then collected into a new 0.2ml PCR Tube. 
 
	  	   103	  
2.18.4. Ligation of adapters, nick translation and DNA sample purification 
Adaptor ligation is performed by nick translation, which allows for one adaptor 
(P1) to ligate to the 5’ end of all DNA molecules and another adaptor to ligate to 
the 3’ end (Figure 2.4, Table 2.1).  
 
Table 2.1. Sequences of the Ion ligation adaptors 
 
Adaptor Terminal 
end 
Sequence 
P1  5’ CCACTACGCCTCCGCTTTCCTCTCTATGGGCAGTCGGTGAT 
 3’ T*T*GGTGATGCGGAGGCGAAAGGAGAGATACCCGTCAGCCA
CTA 
A 5’ TTCCATCTCATCCCTGCGTGTCTCCGACTCAG 
 3’ T*T*AAGGTAGAGTAGGGACGCACAGAGGCTGAGTC 
 
 
 
 
Figure 2.4. Nick translation for the ligation of sequencing adaptors. Adaptors 
were ligated to either end of the DNA molecules before amplification of the DNA 
templates. 
 
	  	   104	  
The reaction setup for ligation of the adapters used the following reagents added 
to the eluted (25µL) end-repaired and purified DNA in a 0.2ml PCR tube: 1X 
Ligase Buffer, 2µL of Ion P1 Adapter, 2µL Ion Xpress Barcode X(◊), 2µL dNTP 
mix, 2µL DNA Ligase and 8µL of Nick Repair Polymerase to a total reaction 
volume of 100µL by addition of nuclease-free water. The samples were mixed 
and loaded into a thermal cycler programmed to run using the following 
conditions: Hold for 15 minutes at 25°C (for nick translation), hold for 5 minutes 
at 72°C (heat-activation of the polymerase) and hold at 4°C. The reaction was 
immediately transferred into a 1.5ml LoBind Tube for purification of the 
adapter-ligated and nick repaired DNA. 
 
(◊) X represents any of the 1-16 different barcodes chosen available with the kit.  
 
For the purification procedure in preparation for creating a 200 base-read library, 
Agencourt AMPure XP Reagent was added at a volume 1.4x (140µL) to the 
sample volume (total volume at this stage = 240µL). The remainder of the 
protocol is the same as mentioned previously under section 2.18.3, with the 
exception that the elution step was performed in 20µL of low TE buffer. The 
supernatant containing the eluted DNA is collected and transferred to a 0.2µL 
PCR tube in preparation for the next step. 
 
2.18.5. Size-selection of the unamplified library 
Size-selection of the DNA library was used to select DNA fragments of the 
desired length for an unbiased amplification of the libraries. Size-selection was 
performed using a 2% E-Gel SizeSelect Agarose Gel system (Life 
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Technologies). 20µL of the purified samples were loaded onto alternate wells to 
avoid cross-contamination of DNA libraries. The 50bp reference DNA ladder 
(1µg/µL) provided with the kit was diluted 1:40 in low TE buffer. 250ng (10µL) 
of this was loaded onto the gel. Empty wells at the top of the gel were loaded 
with 25µL of deionized water. All collection wells at the bottom of the gel were 
loaded with 25µL of deionised water, with the exception of the middle lane, used 
for electrophoresis of the DNA reference ladder, which was loaded with 5-10µL 
of deionised water. Electrophoresis settings for the “Run Time to Reference 
Line” were set for 11 to 14.5 minutes, monitored regularly and stopped when the 
band of interest reached the reference line. Once this was achieved, the collection 
wells at the bottom of the gel were refilled to 25µL with sterile water. 
Electrophoresis time for the “Run Time from Reference Line to Collection Well” 
was set for 1 to 2 minutes. Towards the end of the run, occasionally the band of 
interest can be seen to migrate into the collection well, which can then be 
collected using a pipette. If the DNA band of interest has migrated past the 
collection well point, the ‘Reverse E-Gel’ program was run to reverse migrate 
the band into the collection well.  
 
2.18.6. Amplification of the 200 base-read DNA libraries and purification 
25µL of the size-selected unamplified library was used in combination with the 
following reagents to allow for amplification of the 200 base-read purified DNA 
libraries: 100µL of Platinum PCR SuperMix High Fidelity mastermix and 5µL of 
Library Amplification Primer Mix (All from Invitrogen), giving a total reaction 
volume of 130µL. The Platinum PCR SuperMix High Fidelity is composed of a 
mixture of recombinant Taq DNA polymerase, magnesium, dNTPs and salts. 
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The reaction mix (130µL) was transferred in equal volumes between two 0.2ml 
PCR tubes (65µL per 0.2ml PCR tube) and placed into a thermal cycler for 
amplification under the following conditions: Hold at 95°C for 5 minutes (a 
minimum time of 2 minutes is required for denaturation of the template and 
activation of the polymerase); 6 cycles of 95°C for 15 seconds, 58°C for 15 
seconds and 70°C for 1 minute; products were then held at 4°C at the end of the 
reaction.  
 
The DNA libraries were purified by addition of Agencourt AMPure XP Reagent 
at a volume of 1.5x the sample volume. The remainder of the protocol is the 
same as for section 2.18.3, with the exception that the elution step was performed 
in 20µL of low TE buffer. The supernatant containing the DNA was transferred 
to a new 0.2ml PCR Tube. 
 
2.18.7. Quantification of the DNA libraries  
A 1µL sample of the DNA library underwent analysis on the Agilent 2100 
Bioanalyzer using the Agilent High Sensitivity DNA Kit (Agilent Technologies, 
Santa Clara, CA). First, the gel-dye mix was prepared. High Sensitivity DNA 
dye concentrate (stored in the dark) and High Sensitivity DNA gel matrix 
reagents were equilibrated for 30 minutes at room temperature. The dye 
concentrate was mixed by vortexing for 10 seconds followed by pulse 
centrifugation. 15µL of this was transferred into the gel matrix solution. The 
mixture was vortexed for 10 seconds, and the complete contents were transferred 
to a spin column. This was centrifuged at 6000rpm for 10 minutes at room 
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temperature. The spin filter was discarded and the gel-dye mix was kept in the 
dark (stored at 4°C for a maximum of 6 weeks). 
 
A High Sensitivity DNA chip was set up on the chip priming station. 9µL of the 
room temperature gel-dye mix was loaded at the bottom of a single well marked 
with a circularised ‘G’ (markings are pre-labelled on the chip). The DNA chip 
was loaded onto the chip priming station and subjected to pressure by closing the 
chip priming station. After pressurisation, the chip priming station is opened and, 
9µL of the gel-dye mix was then pipetted into the remaining three ‘G’ wells. 5µL 
of the High Sensitivity DNA marker was pipetted into the well marked with a 
ladder, in addition to the 11 sample wells. 1µL of High Sensitivity DNA ladder 
was loaded onto the chip, alongside 1µL of each sample (wells 1 to 11). In the 
case of empty wells, 1µL of marker was used instead. The chip was positioned 
horizontally in the holder of the IKA vortex mixer (Model MS3) to ensure 
minimal disruption to the chip during vortexing. The chip was vortexed for 60 
seconds at 2400rpm, after which, the Agilent 2100 Bioanalyzer was set up and 
the chip placed into the instrument chip holder. The run was initiated using the 
Agilent 2100 expert software.  
 
Electropherogram results were analysed, with fragment size indicated by the 
elution time and sample integrity indicated by the presence of well-defined 
peaks. Quantification of DNA concentration was possible through comparisons 
performed against the internal standards.  
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Once DNA libraries had passed this quality check process, the DNA libraries 
were diluted to 9pM, which was determined through optimisation to provide the 
highest amount of DNA per bead without generating polyclonal beads.  
  
2.18.8. Emulsion PCR on the Ion OneTouch instrument 
Before preparing the amplification solutions for the emulsion PCR step, the Ion 
OneTouch was set up by attaching one Ion OneTouch Reagent Tube containing 
Ion OneTouch Oil to the left side of the instrument, and another Reagent Tube 
containing Ion OneTouch Recovery solution to the right side. Two OneTouch 
Recovery Tubes were then installed into the front slots of the instrument to later 
collect the Ion Sphere Particles (ISPs) containing amplified DNA template.  
 
To prepare the emulsion PCR (amplification) mix, the following reagents were 
added to a 1.5mL Eppendorf LoBind Tube: 280µL Nuclease-free water, 500µL 
Ion OneTouch 2X Reagent Mix, 100µL Ion OneTouch Enzyme Mix and 20µL of 
DNA library diluted to 9pM. This was mixed by pipetting before adding 100µL 
of Ion OneTouch ISPs (total volume of 1mL). The Ion OneTouch Reaction Filter 
was assembled by attaching a Reaction Tube and a 15mL conical tube to the 
Filter. 1mL of the amplification mix was loaded slowly into the sample port on 
the Filter. Following which, an additional 1.5mL of Ion OneTouch Reaction Oil 
was slowly added through the same sample port on the Reaction Filter. The filled 
Ion OneTouch Reaction Filter was fitted on to the Ion OneTouch instrument to 
begin the emulsion PCR reaction (Figure 2.5). 
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Figure 2.5. Emulsion PCR procedure illustrating the amplification of DNA 
template on the ISPs. 
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2.18.9. Recovery of the template-positive ISPs 
Upon completing the run, both Recovery Tubes loaded at the front of the 
instrument, which contain the ISPs with amplified DNA template were carefully 
removed. Without disturbing the pellet of template-positive ISPs, all but 50µL of 
the Ion OneTouch Recovery Solution was discarded from each Recovery Tube. 
The pellets from each Recovery Tube were resuspended in the remaining 50µL 
by pipetting, and both suspensions were transferred to a fresh 1.5mL LoBind 
Tube. 1mL of Ion OneTouch Wash Solution was added to the template-positive 
ISPs, and the tube centrifuged for 2.5 minutes at 15,500 x g. The supernatant was 
discarded, leaving behind a volume of 100µL, which was vortexed to resuspend 
the ISPs.  
 
2.18.10. Enrich the template-positive ISPs 
‘Melt-Off’ Solution was prepared by combining 865µL of nuclease-free water, 
125µL of 1M NaOH and 10µL of 10% Tween-20 (diluted in water) to produce a 
final concentration of 125mM NaOH with 0.1% Tween-20. 130µL of MyOne 
Dynabeads Wash Solution was pipetted into a fresh 1.5mL LoBind Tube. 13µL 
of Dynabeads MyOne Streptavidin C1 Beads was added to the Wash Solution 
and mixed by pipetting. The tube was loaded into a DynaMag-2 magnetic rack 
and incubated for 2 minutes to separate and discard the supernatant. Dynabeads 
were re-suspended with 130µL of Wash Solution and mixed by pipetting.  
 
100µL of the re-suspended ISPs containing amplified DNA was transferred into 
the first well of an 8-well strip. 130µL of re-suspended Dynabeads was added to 
well 2, 300µL of Ion OneTouch Wash Solution was added to wells 3 to 5, wells 
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6 and 8 were left empty, and finally 300µL of previously prepared ‘Melt-Off’ 
Solution was loaded into well 7. The 8-well strip was fitted onto the Ion 
OneTouch Tray on the instrument. The Ion OneTouch Enrichment System was 
prepared by placing a new tip over the Tip Loader and placing an opened sterile 
0.2mL PCR tube under the Tip Arm. To begin the automated enrichment 
process, ‘start’ was selected on the Ion OneTouch instrument. At the end of the 
run, the PCR tube containing the enriched ISPs was removed in preparation for 
the rinsing step. 
 
2.18.11. Rinsing of the enriched ISPs   
The enriched ISPs were centrifuged for 1.5 minutes at 15,500 x g. To ensure 
there is the absence of Dynabeads MyOne Streptavidin C1 Beads in the enriched 
ISP mix, the tube was loaded in to the DynaMag-2 magnetic rack for 4 minutes 
to separate the beads from the ISPs and to transfer the solution to a new tube 
before repeating the centrifugation step. ISPs were washed by discarding all but 
leaving 10µL of supernatant in the tube, followed by the addition of 200µL of 
Ion OneTouch Wash Solution, which was mixed by pipetting. The tube was 
centrifuged for 1.5 minutes at 15,500 x g and again the supernatant was 
discarded, leaving behind 10µL volume. 90µL of Wash Solution was added and 
mixed with the ISPs by pipetting. 
 
2.18.12. Preparation of the enriched ISPs for sequencing 
To prepare the enriched ISPs for sequencing, the sequencing primer is first 
annealed to the enriched beads. For barcoded samples to be multiplexed and run 
on a 316 chip, the total volume of the sample was transferred to a PCR tube. 
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Control ISPs are resuspended by vortexing and briefly centrifuged, before an 
aliquot of 5µL was transferred to the tube containing the enriched ISPs. A further 
100µL of annealing buffer was added to the tube and mixed by pipetting. The 
tube was then subjected to centrifugation for 1.5 minutes at 15,500 x g, before 
removing the top supernatant and leaving behind a volume of 15µl containing the 
ISPs. 12µl of sequencing primer was then added and the pellets resuspended by 
pipetting. The tube was placed in a thermocycler at 95°C for 2 minutes followed 
by 37°C for 2 minutes. Immediately after, 3µl of sequencing polymerase was 
added, and the tube incubated at room temperature for 5 minutes. 
 
The enriched ISPs were loaded onto the Ion Torrent sequencing chip, and the 
number of sequencing cycles was set to 125 cycles on the instrument for a 200bp 
sequencing run.  
 
2.19. Detection of mtDNA variants 
Detection of variants, insertions and deletions of the genomic sequences was 
performed using CLC Genomics Workbench (v5.5.1). Reads were filtered to be 
above a 0.05 quality threshold level, (which accepts a base if its Phred quality 
score is above 15) and those below a read length of 15 nucleotides were 
excluded. The parameters applied when mapping the sequence to a reference 
genome (human mitochondrial Cambridge Reference Sequence; NC_012920.1) 
included setting a mismatch cost of 2, and an insertion and deletion cost of 3. 
This meant that the individual score for a particular read, for example one that 
contained a single mismatch together with a single nucleotide deletion, would 
have a cost score of minus 5. If the read length in this scenario were 100bp, a 
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total cost of 5 would give the overall read a final percentage value of 95% 
identity. Applying these cost values then influenced whether the reads were 
considered acceptable for mapping, as only those reads containing at least 80% 
identity to the reference sequence were accepted into the final mapping.  
 
For detection of single nucleotide polymorphisms (SNPs), further parameters 
were applied in addition to the above. The window length, which extends quality 
assessment to the neighbouring bases either side of the potential SNP position, 
was set to 7. The maximum number of gaps and mismatches allowed within this 
window length was set to 5, with the minimum quality of the potential SNP and 
its surrounding bases set to 15; and quality assessment of which is based on 
Phred score algorithms. The minimum coverage permitted for SNP detection was 
set to at least 5 reads, and the minimum variant frequency was set to 3%. All 
sequences were then filtered to remove duplicate reads that would otherwise 
over-estimate the variant frequencies. Finally, for a variant to be considered true, 
each was manually assessed to reside on both a forward and reverse read strand. 
 
2.20. Predictive in silico analysis  
SNPs&GO (University of Bologna) is a web-based application used to predict 
whether a non-synonymous amino acid change causes disease using reliability 
index values. Results obtained are based on a combination of factors, inclusive of 
gene ontology, annotations and evolutionary information retrieved from the 
Swiss-Prot protein database 174. MutPred (v.1.2; Buck Institute, Indiana 
University), on the other hand, is another in silico predictive tool, which 
calculates whether a non-synonymous amino acid substitution induces a 
	  	   114	  
detrimental effect on protein function. It lists the top 5 features that are affected 
by the substitution and ranks these based on their probabilities for doing so 175. 
Previous studies have used both SNPs&GO and MutPred as the preferred 
analytical tools for protein in silico analysis176,177. 
 
2.21. Determining changes to the amino acid sequence 
The single letter abbreviated codes used to describe amino acid change in the 
coding regions of mtDNA are based on the International Union of Pure and 
Applied Chemistry (IUPAC) codes for mitochondrial-specific amino acids.  
 
2.22. Determining susceptibility rates of the mtDNA regions to mutation 
To calculate the mutation rate for each of the mtDNA regions carrying variants, 
the number of mtDNA variants detected in each gene region was divided by the 
size of its corresponding mtDNA region (bp). This approach normalizes the 
different sizes of the mtDNA regions to allow for more effective comparison of 
base substitution rates across the mtDNA. To calculate the total mutation rate for 
the coding and non-coding mtDNA regions, the total number of mtDNA variants 
in each group was divided by, the total length of the corresponding coding or 
non-coding region (10,328bp and 6241bp, respectively). Throughout this thesis, 
the coding region is defined as a gene region on the mtDNA that encodes for a 
protein on the ETC. Likewise, the definition of a non-coding region in this thesis 
is a region that does not encode for a protein contributing directly to the ETC. 
This means that the ribosomal and transfer RNAs are categorized within the non-
coding region alongside the regulatory D-loop in this thesis. Calculated values 
for mutation rates are all displayed to 3 significant figures. 
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2.23. Structural analysis of proteins 
SwissPDB viewer was used to visualize the locations of non-synonymous protein 
mutations. The protein structures used in this study were of bovine origin, and the 
PDB files for these are as follows: COX I: 1OCC_A, COX II: 1OCC_B, COX III: 
1V54_C, CYT B: 1BGY_C, CYT C1: 1BGY_D, Rieske protein: 1BGY_E. 
 
2.24. Phylogenetic analysis 
Alignment of multiple (>3) sequences was performed using the Clustal Omega 
tool (EMBL-EBI), with outputs saved in the PHYLIP format. Phylogenetic 
analysis was performed using sequential commands from the PHYLIP software 
(v.3.69). First, the program ‘dnadist’ was used to calculate pair-wise distances for 
all sequences, and to generate a distance matrix from this. Using these results, the 
program ‘neighbor’ was run to infer those distances calculated from dnadist, and 
to draw a phylogenetic tree via a neighbor-joining method that utilizes the F84 
evolutionary model. Evolutionary models comprise a series of mathematical 
algorithms that attempt to take into account multiple substitutions of nucleotide 
bases at a single position of the sequence, and also bias from transition and 
transversion events. The F84 model uses two separate parameters to assess for 
differences in rates of change for both transition and transversion events, with 
rates exhibiting variability from one nucleotide base to another. ‘Drawgram’ was 
then used to produce a rooted tree for visual display of the outcomes. 
 
2.25. Statistical analysis 
Graphical output and statistical analysis were performed using the Prism 5 
software package version 5.0d (GraphPad Software, Inc., San Deigo, CA). For 
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analyses performed on more than 2 samples, a one-way ANOVA test was used 
followed by correction using the Bonferroni post-hoc test. Significance was 
considered when p<0.05. All data are represented as mean ± standard error of the 
mean (SEM).   
	  	   117	  
 
 
 
 
 
 
Chapter 3: Identification of MtDNA 
Variants in Patients Diagnosed with 
Multiple Myeloma 
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3.1. Introduction 
The human genome was first sequenced over 10 years ago as part of the Human 
Genome Project, in an international collaboration involving 20 different research 
groups178. The main advantage of using next generation sequencing technology is 
primarily in the production of large volumes of data, with the genome being 
sequenced numerous times to generate a consensus template through assembly of 
short sequence reads. Coverage, defined as the number of times a particular 
nucleotide is sequenced by overlapping short fragments179, ensures accurate 
assembly of the genome. With the launch of various next generation sequencers, 
comparative studies have been performed on the different platforms180,181, with 
certain sequencers having characteristics that make them suitable for use in 
particular applications. Variability exists in terms of the length of the short 
sequence reads that could be used in the sequencing reactions, distribution of 
coverage for the genome and quality of the results obtained after the sequencing 
run.  
 
In clinical practice, next generation sequencing technologies have already been 
implemented for a variety of solid cancers. Current projects include the Cancer 
Genome Atlas project, which anticipates genome-wide analysis of over 20 
different cancer types. Sequencing data for several tumor types inclusive of 
glioblastoma multiforme182 and melanoma183 amongst others have been released 
in the last few years. In terms of cancers of haematological origin, acute myeloid 
leukemia184,185 and chronic lymphocytic leukemia186 have undergone whole 
genome sequencing, examining the effect of disease on the DNA sequence of 
nuclear genes. This same technique was also applied to multiple myeloma, in a 
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study involving 38 recruited individuals187. With support from the Multiple 
Myeloma Research Foundation (MMRF), the CoMMpass, is a large-scale study 
currently in progress, which aims to recruit 1,000 multiple myeloma patients 
within the next 5 years, in an effort to develop personalized treatments for 
patients [www.themmrf.org]. 
 
To date, whole genome sequencing has been performed to determine sequence 
changes in the nuclear genome during the development of multiple myeloma at 4 
stages, including diagnosis, first and second relapse phases and also during end-
stage secondary plasma cell leukemia152. Findings of variants distinct to the 
different stages were able to identify potential variants that may be causative to 
the progression of tumor development at that particular stage. However, there are 
currently no studies that have explored the possibility of mtDNA in the initiation 
of multiple myeloma. 
 
Over 100 multiple myeloma cell lines have so far been established188. One of the 
earliest and the best characterized is the U266 cell line, founded in 1968169. It 
was originally derived from the bone marrow of a patient diagnosed with IgEλ 
secreting multiple myeloma. These U266 cells are reportedly characteristic of 
plasma cells not only in their morphology, but are also representative of these 
cells in their relapse, refractory or terminal phase of multiple myeloma169. Since 
their establishment, the cell line has undergone extensive cytogenetic and 
functional characterization189. Additionally, its immunoprofile has been well-
defined188,190. For this reason, U266 cells were chosen as a model for multiple 
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myeloma in this Chapter, to determine whether there is a role for mtDNA in 
these tumor cells.  
 
Previous publications have sequenced bacterial genomes using the Ion Torrent191 
and have demonstrated uniform coverage for reads across the genomes 
regardless of the proportion of GC content. MtDNA was evolutionarily derived 
from a bacterial genome, and due to their small genome size (16.6kb), the Ion 
Torrent was considered most suitable for the sequencing of mtDNA. 
Furthermore, the Ion Torrent benefits from high throughput (80-100Mb/h) and a 
short sequencing time of approximately 3 hours. However, it has been reported 
that the Ion Torrent is not sensitive enough in distinguishing sequence calls of 
any length within homopolymer regions181, and that a second validation 
technique should be adopted192.  
 
Various approaches used by other studies to address this problem have included 
ignoring variants that appear within these homopolymer regions193,194. For 
studies that were unwilling to compromise with the lower sensitivity achieved 
from this approach, they resequenced these homopolymer regions numerous 
times and/or using different next generation sequencers to verify these 
variants195,196. However, for most research groups this is financially demanding. 
The approach chosen to overcome the possibility of reporting sequencing errors 
in this thesis, involved the use of high resolution melt (HRM) analysis to verify 
calls to support results retrieved from the Ion Torrent sequencer. This was 
because capillary sequencing was not sensitive enough to detect low-level 
variants below the 10% detection threshold197.  
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3.2. Aims and hypothesis 
The overall aim of this chapter was to determine whether changes to the mtDNA 
sequence could be responsible for initiating tumor development in patients 
characteristic of the relapse and/or refractory phase of multiple myeloma. Results 
were compared to an in vitro model of multiple myeloma to determine whether 
the outcomes were comparable.  
 
It was hypothesized that the variants most likely to be responsible for the 
development of multiple myeloma would have high levels of mutation, and 
would likely alter critical mtDNA regions to promote mitochondrial respiration 
via glycolysis. Different multiple myeloma tumors were hypothesized to have 
mutations that are variable to one another, which would reflect differences 
between individual patients and their severity for multiple myeloma progression. 
However, these tumors were also anticipated to share a common set of cancer 
mutations that define multiple myeloma within their mtDNA sequence. 
Furthermore, it was probable that the majority of variants detected using an in 
vitro system could differ from those identified in patient tumor samples, 
primarily because of the presence of additional factors within an in vivo 
environment that could increase the tumorigenicity of these cancer cells. 
Nonetheless, it was anticipated that there may also be a small subset of common 
cancer mutations shared between cultured multiple myeloma cells and those 
obtained from patient tumors.  
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3.3. Preliminary experiments  
To prepare templates that could be used for sequencing of the whole 
mitochondrial genome using the Ion Torrent sequencing platform, long PCR was 
used. This ensures that the sequence amplified is purely representative of 
mtDNA. Moreover, other studies have used long PCR for whole genome 
sequencing of mtDNA198-201. Primers in this study were published previously202. 
The first of the two overlapping primer sets spanned from tRNA phenylalanine 
to the ATP6 region (for fragment A), and the second from the ATP6 to the 12S 
rRNA region (for fragment B). These were of product sizes 8382bp and 8704bp, 
respectively. However, optimisation of the PCR conditions was required.  
 
3.3.1. Optimisation of the long PCR  
Several enzyme systems were tested. These included the Platinum Pfx DNA 
Polymerase (Invitrogen), the Pfx50 DNA Polymerase (Invitrogen) and the 
Platinum Taq DNA Polymerase (Invitrogen). Each of these enzymes were tested 
with or without PCRX Enhancer Solution (Invitrogen), which facilitates 
amplification of difficult templates that are rich in GC content by lowering the 
melting temperature of the DNA (Figure 3.1). Conditions for each of the 
reactions are listed below, with all made to a total volume of 50µL with sterile 
water: 
 
(1) Platinum Pfx DNA Polymerase system: 
1X Pfx Amplification Buffer, (1X PCRX Enhancer Solution), 15mM dNTP Mix, 
1mM MgSO4, 2.5 units of Platinum Pfx DNA Polymerase enzyme and 15µM 
each of the forward and reverse primers. 
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(2) Pfx50 DNA Polymerase system: 
1X Pfx50 PCR Mix (containing 1.2mM MgSO4), (1X PCRX Enhancer Solution), 
15mM dNTP Mix, 5 units of Pfx50 DNA Polymerase and 15µM each of the 
forward and reverse primers. 
 
(3) Platinum Taq DNA Polymerase High Fidelity system: 
1X High Fidelity PCR Buffer, (1X PCRX Enhancer Solution), 10mM dNTP Mix, 
2mM MgSO4, 2.5 units of Platinum Taq High Fidelity enzyme and 15µM each 
of the forward and reverse primers.  
 
Cycling conditions for all enzyme systems were as follows: 94°C for 2 minutes, 
35 cycles of 94°C 15 seconds, 63°C for 30 seconds# and 68°C for 8 minutes 45 
seconds, with final extension of the products performed at 68°C for 10 minutes. 
Products were held at 4°C at the end of the reaction.  
 
# If 1X PCRX Enhancer Solution was added, the annealing temperature was 
reduced to 61°C. 
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Figure 3.1. Long PCR optimisation. Amplification of one long PCR fragment 
was attempted using the Platinum Pfx DNA Polymerase, Pfx50 DNA Polymerase 
and Platinum Taq DNA Polymerase High Fidelity enzyme systems on human 
fibroblast (BJ) DNA. Each enzyme was tested in the presence and absence of 1X 
PCRX Enhancer Solution, which lowers the primer annealing temperature for 
low quality and/or GC-rich templates. Products were resolved by electrophoresis 
on a 0.7% agarose gel. 
 
Results demonstrated that only the Platinum Taq DNA Polymerase High Fidelity 
enzyme system, without the presence of 1X PCRX Enhancer Solution, produced 
the amplicon of interest. To verify this, the reaction was repeated alongside the 
primers used to produce the second long PCR fragment (Figure 3.2). 
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 Figure 3.2. Long PCR amplification 
of human mtDNA. The Platinum Taq 
DNA Polymerase High Fidelity 
enzyme amplified two overlapping 
fragments (A and B) each of sizes 
8382bp and 8704bp, respectively. 
PCR products were resolved on a 
0.7% agarose gel.  
 
 
 
 
Results confirmed that the Platinum Taq DNA Polymerase High Fidelity enzyme 
system is suitable for the generation of long PCR fragments for sequencing on 
the Ion Torrent platform.  
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3.3.2. Optimisation of the Ion Torrent sequencing workflow 
As part of the library preparation for next generation sequencing, DNA is 
sheared so that the randomly sized short fragments can be assembled to generate 
a consensus sequence. This can be done either mechanically or enzymatically. 
Both these methods were investigated to determine the optimal workflow for 
generating DNA libraries suitable for next generation sequencing analyses.  
 
Recombinant plasmids containing either the wild-type or mutant insert for the 
Mitochondrial Encephalomyopathy, Lactic Acidosis, Stroke-like episodes 
(MELAS) mutation (A3243G), were sheared mechanically using the Covaris 
S220 system, or enzymatically using the Ion Xpress Plus Fragment Library Kit. 
Results were analysed on an E-gel to investigate the size distribution of 
fragments after both types of shearing (Figure 3.3). 
 
Figure 3.3. Mechanical and enzymatic shearing of plasmid DNA libraries. (A) 
Covaris S220 system, (B) Ion Xpress Plus Fragment Library Kit. Plasmids 
containing the wild-type or mutant insert for the MELAS A3243G mutation were 
loaded in duplicate onto an E-gel system for electrophoresis. Sheared DNA of 
approximately 200bp is ideal for further processing and for sequencing on the 
Ion Torrent. 
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Results revealed that enzymatic shearing produced distinct DNA bands on the E-
gel, which suggested that this method of shearing introduced an element of bias 
(Figure 3.3B). It is likely that the restriction enzymes cleaved DNA at specific 
sequence sites, which would not be ideal for sequencing as this would result in 
uneven coverage of the genome (Figure 3.4). On the other hand, the DNA smear 
produced from mechanical shearing indicated the presence of randomly sized 
fragments, the majority of which were of the ideal size (200bp) and therefore 
suitable for further processing and sequencing on the Ion Torrent (Figure 3.3A).  
 
 
Figure 3.4. Sequence coverage of enzymatically sheared MELAS plasmid DNA. 
The image was taken from the Integrative Genomics Viewer (IGV) software 
(Broad Institute).  
 
Automated and manual protocols for library preparation were also compared to 
identify the method that would minimise variability between sequencing runs on 
the Ion Torrent sequencer (Table 3.1). The Ion OneTouch system requires only 
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the manual loading of the DNA library and amplification master mix onto the 
instrument, as clonal amplification of template on the Ion Sphere Particles and 
sample recovery is automatically performed.  
 
To perform this comparative test, mtDNA amplified from HSR-GBM1 cells was 
mechanically sheared and separated into six portions, three of which would be 
examined for reproducibility using the Ion OneTouch system, and the other three 
for the same using the manual preparation method. 
 
The percentage level of mutation identified from libraries prepared using the 
manual method were more variable amongst the triplicate data sets, and had 
higher SEM values compared to those obtained from the Ion OneTouch system 
for each of the variants identified (Table 3.1). Greater variability in the manual 
preparation of sequencing libraries meant that the Ion OneTouch workflow was 
more consistent in between experimental sequence runs during the triplicate test.  
 
Based on these preliminary experiments, it was determined that a combination of 
using the Covaris and the Ion OneTouch system, would provide the most 
appropriate workflow for generating high quality results from the Ion Torrent.  	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Table 3.1. Comparison of the automated and manual protocols for minimizing experimental variability. Labels 1, 2 and 3 indicate a 
triplicate data set.  
   Percentage change in variant (%)  
   Ion OneTouch (automated) Manual preparation  
 Reference 
Position 
Variant 
change 
HSR-GBM1 
[1] 
HSR-GBM1 
[2] 
HSR-GBM1 
[3] 
SEM HSR-
GBM1 
[1] 
HSR-
GBM1 
[2] 
HSR-
GBM1 
[3] 
SEM Gene region 
16218 C→T 15.7 21.2 17.6 1.61 15.9 26 19.2 2.97 D loop - Hypervariable segment 1, 7S 
DNA, membrane attachment site 
1386 T→C 20.5 20.2 16.4 1.32 9.7 18.2 18.6 2.9 12s ribosomal RNA (rRNA) 
Non-
coding 
region 
2702 G→A 4.4 4.2 3.5 0.27 5.9 5 4 0.54 16s ribosomal RNA (rRNA) 
Coding 
region 
6999 G→A 11 9.9 9.4 0.47 3 10.6 10.9 2.58 Cytochrome C Oxidase I: COX I 	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3.3.3. Ion Torrent sequencing on control DNA samples. 
Using the optimized sequencing workflow, mtDNA from two control DNA 
samples were sequenced, which included two human fibroblast cell lines. One is 
known to contain the MELAS mutation and the other is a commercially available 
(BJ) cell line. By sequencing the MELAS fibroblast cell line it becomes possible 
to confirm the sensitivity of the Ion Torrent in being able to detect a known 
(A3243G) mutation that is characteristic of mitochondrial disease. On the other 
hand, sequencing the BJ cell line would reveal the baseline levels of mutations in 
a normal cell type that could be used as a reference sample for High-Resolution 
Melt (HRM) analysis, during comparisons to cancer DNA samples.  
 
 
The MELAS mutation is classified pathogenic due to misincorporation of amino 
acids in mutant tRNA leucine structures that can impair proper protein 
translation203. Sequencing results positively detected the characteristic A3243G 
MELAS mutation at a level of 20.9% in the tRNA leucine 1 region (Table 3.2), 
which was an observation consistent with other studies204. The variant was 
confirmed at low levels using capillary sequencing (Figure 3.5), which is 
believed to have a minimum threshold level of 10% for mutation detection197. 
Since the additional variants listed in Table 3.2 have not been reported to be 
associated with MELAS disease, it may be that the mutations have arisen as 
natural variation during cell culture.   
Figure 3.5. Capillary sequencing 
of the fibroblast cell line 
containing the MELAS A3243G 
mutation. 
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Table 3.2. Ion Torrent sequencing on the human fibroblast cell line containing the MELAS A3243G mutation. 
       MutPred 
 Reference Position 
Variant 
change 
Percentage 
change in 
variant (%) 
Gene region 
Amino 
Acid 
Change 
SNPs&GO 
Probability of 
deleterious 
mutation 
Top 5 predicted features caused by amino acid mutation 
16186 C→T 5.9 D loop - Hypervariable segment 1, 7S DNA, membrane attachment site     
1661 A→G 57.4 tRNA valine     
1722 A→T 8.8     
2224 C→T 30.8     
2228 A→T 25     
2960 T→G 98.6 
16s ribosomal RNA (rRNA) 
    N
on
-c
od
in
g 
re
gi
on
 
3243 A→G 20.9 tRNA leucine 1     
9568 T→C 42.3 Cytochrome C Oxidase III: COXIII I121T 
Neutral RI 1, 
Uniprot 
P00414 
0.749 
Gain of glycosylation at I121 (P = 0.0049) 
Gain of disorder (P = 0.0059) 
Loss of catalytic residue at P123 (P = 0.0396) 
Loss of stability (P = 0.1428) 
Gain of phosphorylation at T119 (P = 0.1623) 
10550 A→G 3.3 NADH Dehydrogenase 4L: ND4L Syn (M)    
11467 A→G 30.4 NADH Dehydrogenase 4: ND4 Syn (L)    
15264 C→T 7.1 P173L 
Disease, RI 
4, Uniprot 
P00156 
0.361 
Loss of relative solvent accessibility (P = 0.0793) 
Loss of solvent accessibility (P = 0.089) 
Gain of methylation at R177 (P = 0.1226) 
Loss of glycosylation at S172 (P = 0.1763) 
Loss of disorder (P = 0.2084) 
15267 C→G 6.4 T174S 
Disease, RI 
3, Uniprot 
P00156 
0.866 
Gain of glycosylation at T174 (P = 0.0587) 
Gain of disorder (P = 0.0665) 
Loss of catalytic residue at T174 (P = 0.1513) 
Loss of methylation at R177 (P = 0.2045) 
Loss of sheet (P = 0.3635) 
C
od
in
g 
re
gi
on
 
15812 G→A 16.4 
Cytochrome B: CYT B 
V356M 
Neutral RI 6, 
Uniprot 
P00156 
0.502 
Loss of catalytic residue at V356 (P = 0.0473) 
Loss of stability (P = 0.4396) 
Loss of glycosylation at T361 (P = 0.4462) 
Loss of helix (P = 0.4763) 
Loss of sheet (P = 0.6423) 
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Sequencing of the BJ fibroblast mtDNA revealed the presence of only two 
mutations within the cytochrome B region (Table 3.3). These two variants 
appeared at low levels, and were also identified present in the other MELAS 
fibroblast cell line (Table 3.3). From this, it is possible to speculate that perhaps 
this region is especially susceptible to the development of mutations in the case 
of non-tumorigenic cells.  
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Table 3.3. Ion Torrent sequencing of the BJ skin fibroblast cell line. 
	  
       Mutpred 
Reference 
Position Reference Variant 
Percentage 
change in 
variant (%) 
Gene region 
Amino 
Acid 
Change 
SNPs&GO 
Probability of 
deleterious 
mutation 
Top 5 predicted features caused by 
amino acid mutation 
15264 C C/T 9.8 Cytochrome B: CYTB P 173 L 
Disease, RI 4, 
Uniprot P00156 0.361 
Loss of relative solvent accessibility 
(P = 0.0793) 
Loss of solvent accessibility (P = 
0.089) 
Gain of methylation at R177 (P = 
0.1226) 
Loss of glycosylation at S172 (P = 
0.1763) 
Loss of disorder (P = 0.2084) 
15267 C C/G 9.6 Cytochrome B: CYTB T 174 S 
Disease, RI 3, 
Uniprot P00156 0.866 
Gain of glycosylation at T174 (P = 
0.0587) 
Gain of disorder (P = 0.0665) 
Loss of catalytic residue at T174 (P = 
0.1513) 
Loss of methylation at R177 (P = 
0.2045) 
Loss of sheet (P = 0.3635) 
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3.3.4. Determining the sensitivity of variant detection on the Ion Torrent 
sequencer and HRM system 
The sensitivity limits on both the Ion Torrent and HRM system were tested to 
determine the lowest possible mutation level that could be accurately detected in 
both systems. To do this, a PCR amplicon of 223bp containing the MELAS 
mutation was cloned into the pCR2.1 bacterial cloning vector, as outlined in 
sections 2.15 and 2.15.1. Bacterial clones containing plasmids with the wild-type 
and mutant mtDNA sequence were identified and confirmed by capillary 
sequencing (Figure 3.6).  
 
Figure 3.6 Confirmation of MELAS wild-type and mutant inserts in recombinant 
plasmids. 
 
Purified wild-type and mutant plasmids were mixed at specific ratios to generate 
dilutions of plasmid DNA at varying mutational loads. These wild-type/mutant 
plasmid dilutions were analysed by Ion Torrent and HRM.  
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Figure 3.7. HRM analysis of plasmid DNA mixed at specific mutational loads.  
 
HRM analysis revealed that the change in fluorescence detection was 
proportional to the sequence difference between the two heteroduplex strands of 
the MELAS wild-type/mutant DNA (Figure 3.7). The 100% wild type and 100% 
mutant DNA did not result in a noticeable change in fluorescence levels unlike 
the 40%, 50% and 60% mutational loads, which would have required less energy 
input to separate the double-stranded heteroduplex DNA. It was possible to 
determine from this analysis that even mutations at the 1% level could be seen 
from the HRM results.  
 
Similar tests on the Ion Torrent were performed. Results demonstrated little 
difference between the expected mutation load and actual levels of mutation 
detected (Table 3.4). From these results, the 3% mutation level was chosen as 
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the lowest threshold level, above which variants could be accurately identified 
without detection of background sequencing errors.  
 
Table 3.4. Determining the sensitivity levels on the Ion Torrent. 
 
HRM is therefore more sensitive than Ion Torrent in the detection of mutations, 
which supports the use of HRM as a validation tool to confirm the outcomes 
identified from the Ion Torrent sequencer.   
Anticipated percentage 
mutation (%) 
Percentage mutation detected on 
the Ion Torrent (%) 
 
Detectable on the HRM 
0 0.04 Yes 
1 0.5 Yes 
3 1 Yes 
10 7.4 Yes 
100 100 Yes 
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3.4. Methods 
Methods used are described in the following sections: 2.1.5, 2.1.9, 2.2 to 2.4.1, 
2.6, 2.8.1 to 2.9.1, 2.10, and 2.16 to 2.22. Additional methods are provided 
below: 
 
3.4.1. HRM primers for the multiple myeloma mtDNA variants 
Primers were designed for each of the mtDNA variants detected from the Ion 
Torrent sequencing of multiple myeloma cells and tumors. The primers used for 
HRM all generated a product of between 100-250bp (Table 3.5), and all had an 
optimal annealing temperature of 55°C.  
 
3.4.2. Ethics statement 
Plasma cells were obtained from patients who had provided full written consent. 
All patients were diagnosed with multiple myeloma in the relapse and/or 
refractory stage. Patient consent and the clinical procedures for obtaining the 
cells were approved by The Alfred Health Human Ethics Committee 
(Melbourne, Australia).   
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Table 3.5: Primers used for multiple myeloma variant screening on the HRM 
 
Variant 
Position 
 (bp) 
Forward primer (5’→3’) Reverse primer (5’→3’) Product 
size 
(bp) 
557 CATCCTACCCAGCACACACA TGATGTGAGCCCGTCTAAAC 134 
659 TGTAGCTTACCTCCTCAAAG TCGTGGTGATTTAGAGGGTG 160 
976 CACACGATTAACCCAAGTCA CAGTTTGGGTCTTAGCTATTG 168 
1082 CTCCAGTTGACACAAAATAG TCTGGCGAGCAGTTTTGTTG 161 
1152  CACTATGCTTAGCCTAAACC GAGGTTGATCGGGGTTTATC 151 
1389 CAAGGTGTAGCCCATGAGGT CTGTTCAACTAAGCACTCTAC 132 
1589 CCTCAAGTATACTTCAAAGGAC AGAGCGGTCAAGTTAAGTTG 177 
1717 CTTAACTTGACCGCTCTGAG TTCCCTTGCGGTACTATATC 144 
2553 GAACTCGGCAAATCTTACCC ATTATGCTACCTTTGCACGG 131 
3208 GAGAAATAAGGCCTACTTCAC GTTGGCCATGGGTATGTTGTT 184 
3391, 
3417 
CTACTCCTCATTGTACCCAT TATGGCGTCAGCGAAGGGTT 140 
5432, 
5438 
CTACCTACGCCTAATCTACT TAGGAGTAGCGTGGTAAGGG 135 
5752 CAGCTAAGCACCCTAATCAAC 
 
TCTAAAGACAGGGGTTAGGC 
 
161 
6352 CAGGTTGAACAGTCTACCCT AAGAGGGGCGTTTGGTATTG 180 
6774 CATTTGGATACATAGGTATGGTC AGTGTGGCGAGTCAGCTAAA 180 
7718 CATGATCACGCCCTCATAAT AGGATAGTTCAGACGGTTTC 133 
8010, 
8018 
GGACTAATCTTCAACTCCTAC TAAGCCTAATGTGGGGACAG 167 
8252 CTCTGAAATCTGTGGAGCAAAC CTAAGTTAGCTTTACAGTGGG 131 
8759 CACCACCCAACAATGACTAA AGATAGTTGGGTGGTTGGTG 168 
8821 TTGCCACAACTAACCTCCTC GTGCCTTGTGGTAAGAAGTG 162 
9111 CTCATGCACCTAATTGGAAG TCGTGCAGGTAGAGGCTTA 163 
9216, 
9226 
CCAAGCCTACGTTTTCACAC AGCGTTATGGAGTGGAAGTG 
 
179 
10657 TCGCTGTTCATTATAGCTACTCTC GTACGTAGTCTAGGCCATATG 156 
11220 CTTGGCTATCATCACCCGAT CCTAGGGTGTTGTGAGTGTA 128 
11445 TACCTCTTTACGGACTCCAC AGGCTATGTGTTTTGTCAGG 155 
11674, 
11675 
CTGCCTACGACAAACAGAC GGCAGAATAGTAATGAGGAT
G 
160 
12847 CCTTCTTGCTCATCAGTTGA GTTGTGGGTCTCATGAGTTG 146 
14772 CAACCACGACCAATGATATG GAGTGAGCCGAAGTTTCATC 163 
15264, 
15267 
GAGGCCAAATATCATTCTGAG GTTGTTTGATCCCGTTTCGTG 218 
16186 CCACCATGAATATTGTACGGTA TGGCTTTGGAGTTGCAGTTG 147 
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3.5. Results 
 
3.5.1. Detection of mtDNA variants in multiple myeloma tumors  
Five independent tumor samples were analysed by next generation sequencing. A 
3% threshold criteria was applied for the detection of mutations, and from this, 16 
heteroplasmic variants were identified (Table 3.6). Half of these identified 
variants have not previously been reported before in MitoMap (557bp, 659bp, 
1082bp, 1152bp, 2553bp, 12847bp, 14772bp and 15264bp). 8 variants were 
present in each of the non-coding and coding regions of mtDNA. All variants 
identified, except for those at positions 15264bp and 15267bp, were unique to 
each of the tumor samples. Where there were similarities in the location of these 
variants, there were also differences in their levels of mutation. Levels ranged 
from 3.1% (D loop; 16186bp) to 43.9% (12s rRNA; 1152bp) in the non-coding 
region, and for the coding region, values were between 3.1% (CYT B 14772bp) 
to 28.7% (ND5 12847bp). Variants within the coding regions of mtDNA induced 
both synonymous and non-synonymous amino acid changes in the corresponding 
protein sequence. CYT B nucleotide positions at 15264bp and 15267bp appeared 
as a potential hotspot region for variants. At least 3 of the 5 tumor samples 
analysed possessed a variant at a frequency above 3% at each of these positions.  
 
3.5.2. Verification of variants and screening of additional tumors using 
HRM 
The same tumor samples from Table 3.6 underwent validation using the HRM, 
which confirmed the presence of these variants (Table 3.7). For these 5 tumor 
samples, HRM analysis also revealed the presence of additional variants. These 
are likely to represent variants between levels of 1% and 3%, which were  
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Table 3.6. MtDNA variants detected from multiple myeloma tumors. Results were filtered to exclude presence of duplicate reads. All 
variants listed represent those detected above the 3% mutation threshold level.  
  Percentage change in variant (%)    Mutpred 
Reference 
Position 
Variant 
change 
S228 S219 S140 S139 S241 Gene region Amino 
Acid 
Change 
SNPs&GO Probability 
of 
deleterious 
mutation 
Top 5 predicted features caused by amino 
acid mutation # 
16186 C→T     3.1 D-Loop - Hypervariable segment 1, 
7S DNA, membrane attachment site 
    
557* C→T    3.3  D-Loop - Major H-strand promoter     
659* T→C  20.4    12s rRNA     
1082* A→G    36.5  12s rRNA     
1152* A→G  43.9    12s rRNA     
1389 G→A    8  12s rRNA     
1717 T→C    5.3  16s rRNA     
2553* G→A 25.2     16s rRNA     
5432 A→G     4.7 NADH Dehydrogenase: ND2 Syn (K) - -  
5438 C→T   5.4   NADH Dehydrogenase: ND2 Syn (T) - -  
7718 A→C  3.9    Cytochrome C Oxidase: COX II T 45 P Disease, RI 0, 
Uniprot P00403 
0.668 Loss of stability (P = 0.0296) 
Gain of glycosylation at T45 (P = 0.0341) 
Gain of helix (P = 0.0496) 
9111 T→C  3.6    ATP Synthase 6: ATP6 Syn (I) - -  
12847* G→A 28.7     NADH Dehydrogenase: ND5 A 171 T Neutral, RI 1, 
Uniprot P03915 
0.713  
14772* C→T    3.1  Cytochrome B: CYT B P 9 L Disease, RI 1, 
Uniprot P00156 
0.643 Loss of disorder (P = 0.0255) 
Loss of glycosylation at P9 (P = 0.0326) 
Loss of methylation at K12 (P = 0.0427) 
15264* C→T 5.2 6.3   5.4 Cytochrome B: CYT B P 173 L Disease, RI 4, 
Uniprot P00156 
0.361  
15267 C→G 7.3 8.7 3.5  6.8 Cytochrome B: CYT B T 174 S Disease, RI 3, 
Uniprot P00156 
0.866  
* Novel variants not reported in MitoMap # Only predictions of P<0.05 are shown.  
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 Non-coding region Coding region 
Gene region D-loop 12s rRNA 16s rRNA ND2 COX II ATP 6 ND5 CYT B 
Variant change C→T C→T T→C A→G A→G G→A T→C G→A A→G C→T A→C T→C G→A C→T C→T C→G 
Reference position 16186 557 659 1082 1152 1389 1717 2553 5432 5438 7718 9111 12847 14772 15264 15267 
S238                 
S171                 
S162                 
S156                 
S237                 
S235                 
S341                 
S254                 
S184                 
S335                 
S325                 
S228 #### ####    ####  ####    #### ####  #### #### 
S390                 
S327                 
S298                 
S334                 
S252                 
S354                 
S219           #### #### ####  #### #### 
S140   #### ####  ####  ####  ####      #### 
S139  #### #### ####  #### ####    ####  #### ####   
S241 ####       #### ####  ####    #### #### 
S307                 
S226                 
tu
m
or
 sa
m
pl
es
 (n
 =
 2
5)
 
S216                 
 94.44 61.90 69.57 82.61 100.00 72.22 90.91 53.33 96.00 80.00 96.00 84.00 95.65 96.00 Total 
(%)  5.56 38.10 30.43 17.39 - 27.87 9.09 46.67 4.00 20.00 4.00 16.00 4.35 4.00 
Significance **   * **  **  ** * ** * ** ** 
 
 
Key:  Variant present  Variant present - analysed jointly (either 1 present or both) * Variant present in >80% of samples 
  Variant absent  Variant absent - analysed jointly (either 1 absent or both) **  Variant present in >90% of samples 
  Sample not available #### Variant presence/absence confirmed with both Ion Torrent and HRM 
Table 3.7. Screening additional multiple myeloma tumors using HRM.  	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determined as the threshold levels of variant detection for the HRM and Ion 
Torrent, respectively. In addition to the variants reported from Table 3.6, a 
further 20 tumor samples were screened with HRM to identify the patterns of 
variants across a range of tumors representative of multiple myeloma (Table 
3.7). Based on the available material, seven tumor samples were screened to be 
positive for all variants (S237, S341, S254, S325, S327, S354, S226).  
 
Generally, more variants were detected in the non-coding than in the coding 
region. The nucleotide position most variable in its presence or absence of 
mutation was at 557bp, within the D-loop major H-strand promoter region. For 
the collection of samples screened, the total proportion of samples containing the 
presence of the screened variant was calculated (Table 3.7). Values were 
adjusted based on the actual number of samples screened, since not all tumor 
samples could be analysed across the complete range of variants, due to limited 
availability of material.  
 
Over 90% of the tumor samples shared the presence of particular variants located 
at positions 1152bp (12s rRNA), 1717bp (16s rRNA), 5432/5438bp (ND2), 
9111bp (ATP6), 14772bp (CYT B), 15264/15267bp (CYT B) and 16186bp (D-
loop). The D-loop variant at position 16186bp resided within the hypervariable 
segment 1 region of mtDNA, which is associated with natural sequence variation 
in diverse populations. The variant at position 2553bp within 16s rRNA 
displayed the most variability, with only 8/15 samples found to have the presence 
of this variant. This could be attributed to the reduced number of samples 
available for examining this particular variant during the screening procedure.  
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3.5.3. Susceptibility of mtDNA regions to the development of mutations 
The sizes of mtDNA gene regions can impact on the number of variants detected 
within these regions. As such, by normalizing the number of variants to the size 
of the affected mtDNA regions, it is possible to determine the susceptibility of 
different mtDNA genes to the development of mutations.  
 
The 12s rRNA region had the greatest number of variants above the 3% 
threshold criteria, compared to any other region investigated, based on the 
calculated susceptibility score of 4.20 x 10-3 (Table 3.8). 12s rRNA was 
discovered to be 7.60x more likely to acquire a mutation than the ND5 region (4 
variants occurring across the 954bp region of the 12s rRNA gene, compared to 1 
variant in the 1812bp region of ND5) (Table 3.9).  
 
CYT B was the second-highest scoring region that was susceptible to nucleotide 
change relative to the other mtDNA regions. CYT B was 4.77 fold more 
susceptible compared to ND5 to developing a variant above the 3% threshold 
level of mutation, which is also the second highest factor difference, below that 
of the 7.60 fold difference between the 12s rRNA and ND5 regions (Table 3.9). 
COX II and ATP6 were two regions that had an equal chance of undergoing a 
mutational change, which perhaps reflected the close proximity of these two 
genes in the mitochondrial genome. 
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Table 3.8. Susceptibility of mtDNA regions to the development of mutations. 
 
 Normalised data 
Reference 
Position 
Gene region Nucleotide positions 
for gene regions (bp) 
Size of 
gene region 
(bp) 
Number of variants 
detected in gene 
region 
Mutation rate in 
each gene region 
Mutation rate grouped 
for coding/non-coding 
regions 
557, 16186 D-Loop 1..576, 16024..16569 1122 2 0.00178 
659 
1082 
1152 
1389 
 
 
12s rRNA 
 
 
648..1601 
 
 
954 
 
 
4 
 
 
0.00420 
1717 
2553 N
on
-c
od
in
g 
re
gi
on
 
16s rRNA 1671..3229 1558 2 0.00128 
 
 
 
 
0.00128 
5432 
5438 
NADH 
Dehydrogenase: 
ND2 
 
4470..5511 
 
1042 
 
2 
 
0.00192 
7718 Cytochrome C 
Oxidase: COXII 
7586..8269 684 1 0.00146 
9111 ATP Synthase 6: 
ATP6 
8527..9207 681 1 0.00147 
 
12847 
NADH 
Dehydrogenase: 
ND5 
 
12337..14148 
 
1812 
 
1 
 
0.000552 
14772 
15264 
15267 
C
od
in
g 
re
gi
on
 
 
Cytochrome B: 
CYTB 
 
14747..15887 
 
1141 
 
3 
 
0.00263 
 
 
 
 
 
 
0.000775 
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Table 3.9. Fold change differences on the susceptibility of mtDNA regions to 
mutation.  
Gene region D loop  12s rRNA 16s rRNA ND2 COX II ATP6 ND5 CYT B 
D loop  0.43 1.39 0.93 1.22 1.21 3.23 0.68 
12s rRNA 2.35  3.27 2.18 2.87 2.85 7.60 1.59 
16s rRNA 0.72 0.31  0.67 0.88 0.87 2.32 0.49 
ND2 1.08 0.46 1.50  1.31 1.31 3.48 0.73 
COX II 0.82 0.35 1.14 0.76  1.00 2.65 0.56 
ATP6 0.82 0.35 1.15 0.77 1.00  2.66 0.56 
ND5 0.31 0.13 0.43 0.29 0.38 0.38  0.21 
CYT B 1.48 0.63 2.05 1.37 1.80 1.79 4.77  
 
Key 
if value >1 susceptibility of the region to variant changes is greater for the gene listed on the left 
if value <1 susceptibility of the region to variant changes is less for the gene listed on the left  
	  
 
3.5.4. Identification of variants during mtDNA replenishment in U266 cells 
Sequencing of the U266 cells (Table 3.10) identified variants that were different 
to the tumor sample variants  (Table 3.6). This confirmed that myeloma plasma 
cells cultured in vitro exhibit different biological properties than those grown in 
vivo, most likely due to myeloma cells in the body being able to interact with 
other stromal cells in the bone marrow microenvironment205. 4 novel variants 
were identified that had not previously been reported in MitoMap (9529bp, 
13058bp, 13985bp and 14159bp). Since there were no common variants detected 
between the tumors and the U266 cells, it was of interest to determine whether 
U266 variants remain the same or differ after a period of 7 and 14 days of 
mtDNA depletion, followed by recovery. This was examined using the Ion 
Torrent sequencer. 
  
Variants at 14155bp and 14160bp within the ND6 region displayed random 
change to their levels of mutation (Table 3.10), which would argue against the  
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Table 3.10.  Identification of variants during mtDNA replenishment in U266 cells. Cells were depleted of mtDNA for 7 or 14 days 
followed directly by recovery for 3 (R3), 7 (R7) or 14 days (R14).  
	   	   	   Percentage	  change	  in	  variant	  (%)	   	   	   	   Mutpred	  	   Reference	  Position	   Variant	   U266	  control	   U266	  day	  7	  R3	   U266	  day	  7	  R7	   U266	  day	  7	  R14	   U266	  day	  14	  R3	   U266	  day	  14	  R7	   U266	  day	  14	  R14	   Gene	  region	   Amino	  acid	  change	   SNPs&GO	   Probability	  of	  deleterious	  mutation	  
Top	  5	  predicted	  features	  caused	  by	  amino	  acid	  mutation#	  
16519	   T→C	   51.7	   55.0	   53.5	   52.4	   58.1	   54.2	   52.6	   D	  loop	  -­‐	  Membrane	  attachment	  site,	  7S	  DNA	   	   	   	   	  568	   C→T	   5.3	   	   	   	   	   	   	   D	  loop	  -­‐	  Hypervariable	  segment	  3	   	   	   	   	  Non-­ coding
	  
1243	   T→C	   40.5	   45.9	   42.3	   43.0	   43.6	   39.5	   40.2	   12s	  ribosomal	  RNA	   	   	   	   	  8994	   G→A	   53.6	   64.4	   66.1	   58.7	   67.6	   69.7	   54.5	   ATPase	  6	   Syn	  (L)	   -­‐	   	   	  9529*	   C→T	   	   	   	   4.8	   	   	   	   Cytochrome	  c	  oxidase	  III	   P108L	   Disease,	  RI	  2,	  Uniprot	  P00414	   0.676	   Loss	  of	  disorder	  (P	  =	  0.01)	  Loss	  of	  glycosylation	  at	  P108	  (P	  =	  0.05)	  12705	   C→T	   80.6	   78.1	   76.6	   76.0	   79.4	   78.0	   79.4	   Syn	  (I)	   	   	   	  13058*	   C→A	   	   	   	   	   	   	   3.1	   T241N	   Neutral,	  RI	  5,	  Uniprot	  P03915	   0.684	   Loss	  of	  glycosylation	  at	  T241	  (P	  =	  0.02)	  13981	   C→G	   	   	   	   	   	   	   3.5	   P549A	   Neutral,	  RI	  9,	  Uniprot	  P03915	   0.447	   Gain	  of	  helix	  (P	  =	  0.03)	  13984	   C→T	   	   	   	   	   	   	   3.5	   Syn	  (L)	   -­‐	   	   	  13985*	   T→C	   	   	   	   	   	   	   3.5	   NADH	  Dehydrogenase	  5	   L550P	   Neutral,	  RI	  1,	  Uniprot	  P03915	   0.457	   Gain	  of	  loop	  (P	  =	  0.001)	  Loss	  of	  helix	  (P	  =	  0.004)	  Gain	  of	  catalytic	  residue	  at	  P549	  (P	  =	  0.02)	  
Gain	  of	  glycosylation	  at	  L550	  (P	  =	  0.04)	  
Gain	  of	  relative	  solvent	  accessibility	  (P	  =	  
0.05)	  14155	   C→T	   3.7	   	   4.3	   4.9	   	   	   3.1	   Syn	  (G)	   -­‐	   	   	  14159*	   C→G	   	   	   5.4	   	   	   	   	   R172P	   Disease,	  RI	  3,	  Uniprot	  P03923	   0.423	   Loss	  of	  methylation	  at	  R172	  (P	  =	  0.03)	  
Co
d
in
g	  
re
gi
on
	  
14160	   G→C	   9.0	   3.7	   5.5	   4.1	   	   5.1	   	   NADH	  Dehydrogenase	  6	   R172G	   Neutral,	  RI	  2,	  Uniprot	  P03923	   0.442	   Loss	  of	  methylation	  at	  R172	  (P	  =	  0.03)	  
* Novel variants not reported in MitoMap # Only predictions of P<0.05 are shown. 
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presence of mechanisms that would either favor or selectively eliminate certain 
mtDNA variants during mtDNA depletion. Four out of the 13 variants detected 
were shared between all samples, which included two in the non-coding region 
of mtDNA (16519bp within D-loop and 1243bp within 12S rRNA) and two in 
the coding region (8994bp within ATP6 and 12705bp within ND5).  
 
For the D-loop variant at position 16519bp, prolonged depletion increased its 
percentage frequency relative to day 0 cells. The 7-day mtDNA depleted cells 
recovered for 3 days had a lower level of mutation (55%) than U266 cells that 
had been depleted for 14 days, and allowed to recover for the same length of 
time (58.1%). Comparing these different depletion/replenishment stages, 
prolonged depletion increased the levels of mutation for some the mtDNA 
variants, such as for the 12705bp C→T variant within the ND5 region. However, 
this is not always the case, as the variant at position 1243bp within 7-day 
depleted cells recovered for 3 days had higher levels of the variant than the 14-
day depleted cells also recovered for 3 days. Decreasing levels of mutation for 
the 1243bp variant was evident across the other depletion/replenishment stages. 
Noticeably, the variant at 8994bp had variable changes during the course of 
depletion and replenishment, but was the only variant that displayed the greatest 
changes to its levels of mutation. Changes to the other variants were only 
marginal in comparison.  
 
Loss of the 568bp C→T variant in U266 cells during mtDNA depletion 
emphasized that apart from changes in the levels of mutation during the 
progressive decline of mtDNA copy number, it is possible for some variants to 
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be lost entirely. Although this could occur via a selection mechanism, whereby 
the mtDNA copies that do not possess this variant could be preferentially 
replicated to decrease the overall mutation levels of the variant within the 
mitochondrial population. On the contrary, replenishment of mtDNA copy 
number for 14 days after 7 days of depletion, revealed the acquisition of an 
additional low level variant (4.8%) at position 9529bp, not previously reported 
for the control cells. As such, there are no selective forces to either favour or 
eliminate certain mtDNA variants during mtDNA depletion. 
 
Overall, the majority of variants were discovered in the 14-day depleted and 14-
day recovered cells, which acquired low levels of mutation during the course of 
extended mtDNA depletion.   
 
3.5.5. Susceptibility of depleted and recovered U266 cells to mutations 
ND6 was identified as the region most susceptible to mutation within the coding 
region (Table 3.11). For the non-coding regions, this was the D-loop, calculated 
to have a fold change 1.70 times greater than the 12s rRNA region (Table 3.12). 
Comparing ND6 to the D-loop region, ND6 was found to have a 3.21 fold greater 
probability of developing a mutation. Likewise, this fold change difference was 
observed to be greatest between ND6 and the 12s rRNA region, which reported a 
5.46 fold difference.	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Table 3.11. Susceptibility of depleted and recovered U266 cells to mutation.  
      Normalised data 
Reference 
Position Gene region 
Nucleotide 
positions for 
gene regions 
(bp) 
Size of 
gene 
region 
(bp) 
Number of 
variants 
detected in 
gene region 
Mutation rate in 
each gene region 
Mutation rate grouped for 
coding/non-coding regions 
16519…568 D loop 1..576, 16024..16569 1121 2 0.00178 
1243 N
on
-
co
di
ng
 
12s rRNA 648..1601 953 1 0.00105 
0.000481 
8994 ATPase 6 8527..9207 680 1 0.00147 
9529 Cytochrome C Oxidase III 9207..9990 783 1 0.00128 
12705, 13058, 
13981, 13984, 
13985 
NADH dehydrogenase 5 12337..14148 1811 5 0.00276 
14155, 14159, 
14160 
C
od
in
g 
re
gi
on
 
NADH dehydrogenase 6 14149..14673 524 3 0.00573 
0.000968 
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Table 3.12. Fold change differences for the susceptibility of depleted and 
recovered U266 cells to the development of mutations. 
Gene region D-loop 12s rRNA ATP 6 COX III ND5 ND6 
D-loop  1.70 1.21 1.40 0.65 0.31 
12s rRNA 0.59  0.71 0.82 0.38 0.18 
ATP 6 0.82 1.40  1.15 0.53 0.26 
COX III 0.72 1.22 0.87  0.46 0.22 
ND5 1.55 2.63 1.88 2.16  0.48 
ND6 3.21 5.46 3.89 4.48 2.07  	  
Key 
if value >1 susceptibility of the region to variant changes is greater for the gene listed on the left 
if value <1 susceptibility of the region to variant changes is less for the gene listed on the left  	  
	  
3.5.6. MtDNA variants in U266 sub-populations of CD45+ and CD45- cells 
U266 cells are heterogenous for the expression of CD45, a marker of 
malignancy. FACS sorted CD45+ and CD45- U266 cells were sequenced by Ion 
Torrent to determine whether variants found in these sub-populations were 
similar or different to those in the total population of U266 cells. From these 
results, it would be possible to determine whether the two CD45 sub-populations 
harbour characteristic mutations that could distinguish each based on sequence 
alone. Sequence variations could also be responsible for differences between the 
biological properties and cellular phenotypes of the two sub-populations206. The 
hypothesis was that the CD45- population would harbour more detrimental 
variants, as these cells have been reported as important indicators of tumor 
malignancy in multiple myeloma207.  
 
It was estimated that 43.66% of U266 cells after FACS were positive for the 
CD45 marker and 56.34% were negative (Figure 3.8). Whilst it is known that 
the proportion of CD45+/- cells undergo constant conversion into one another 
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dependent on the exposure of stimulants to the U266 cells208, the majority of the 
heterogeneous U266 cell population was identified negative for CD45, which 
supported the observation of others208.  	  
	  	  	  	  	  	   	  
Figure 3.8. Fluorescent-activated cell sorting (FACS) analysis on U266 cells. 
U266 cells are known to be heterogenous for expression of the surface marker 
CD45. (A) Before enrichment for CD45 (B) After enrichment for CD45, 43.66% 
of cells were detected positive of the surface marker. 
	  
Sequencing identified 23 variants, 13 of which had not been previously identified 
in MitoMap (976bp, 6352bp, 6774bp, 8010bp, 8018bp, 8759bp, 8928bp, 8934bp, 
9216bp, 9226bp, 11220bp, 11445bp and 11675bp). 20 variants were located 
within the coding regions of mtDNA (Table 3.13). The 3 variants within the 
non-coding regions resided in the 12s rRNA (976bp), 16s rRNA (3208bp) and 
5752bp (origin of light strand replication). The mutations levels ranged from 
12.3% to 53.7% (both in 12s rRNA) (Table 3.13). For the coding-region 
variants, 14 non-synonymous amino acids mutations were identified in total, 9 of 
B	  A	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Table 3.13. MtDNA variants in U266 sub-populations of CD45+ and CD45- cells. 
   Percentage change in variant (%)    MutPred 
 Reference Position Variant CD45+ CD45- Gene region 
Amino Acid 
Change SNPs&GO 
Probability of 
deleterious 
mutation 
Top 5 predicted features caused by amino 
acid mutation # 
976* A→C 53.7 12.3 12s rRNA     
3208 C→A 33.3  16s rRNA     N
on
-
co
di
ng
 
5752 A→G 30  Orign of L-strand replication     
3391 G→A 37.5 21.4 G 29 S Neutral, RI 0 0.895  
3417 C→A 29  
NADH Dehydrogenase: ND1, 
Uniprot P03886 Syn (P) -   
6352* T→G 23.6  L 150 W Disease, RI 2 0.797 
Loss of stability (P = 0.0384) 
Gain of catalytic residue at I147 (P = 0.257) 
Loss of helix (P = 0.4763) 
6774* C→G 22.7  
Cytochrome C Oxidase: COX 
I, Uniprot P00395 
H 291 D Disease, RI 8 0.844  
8010* T→G  33 V 142 G Disease, RI 1 0.531 Loss of stability (P = 0.002) 
8018* C→T  28.6 P 145 S Disease, RI 8 0.871  
8252 C→A 27.3  
Cytochrome C Oxidase: COX 
II, Uniprot P00403 
P 223 T Neutral, RI 9 0.327  
8759* T→G  33.3. F 78 C Disease, RI 4 0.837  
8821 T→C 20.2 12.7 S 99 P Disease, RI 6 0.819 Gain of glycosylation at T96 (P = 0.0461) 
8927 C→A 34.2 9.7 P 134 H Disease, RI 6 0.749 Loss of glycosylation at P134 (P = 0.029) 
8928* T→C 34.2 10 Syn (P) -   
8934* C→G 22.9 6.4 Syn (P) -   
8939 T→A 26.5 9.3 
ATP synthase 6: ATP6, 
Uniprot P00846 
I 138 N Disease, RI 3 0.793 Gain of disorder (P = 0.0401) 
9216* C→A  28.6 Q 4 K Neutral, RI 8 0.493 Gain of methylation at Q4 (P = 0.0048) 
9226* C→G 44 56.5 
Cytochrome C Oxidase: COX 
III, Uniprot P00414 A 7 G Neutral, RI 8 0.529  
10657 T→G 33.3  NADH Dehydrogenase: ND4L M 63 X(stop) Uniprot P03901   
11220* T→G  25.6 L 154 R Disease, RI 3 0.738 Gain of methylation at L154 (P = 0.0051) Loss of stability (P = 0.0279) 
11445* T→G 23.5 4.9 M 229 X(stop)    
11674 C→T  55.6 Syn (T) -   
C
od
in
g 
re
gi
on
 
11675* C→T 21.7  
NADH Dehydrogenase: ND4, 
Uniprot P03905 
P 306 S Neutral, RI 6 0.579  
* Novel variants not reported in MitoMap # Only predictions of P<0.05 are shown. 
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which were predicted to have the potential to impair protein function, with the 
remaining 5 predicted to induce neutral effects reported at mtDNA sites 3391bp 
(ND1), 8252bp (COX II), 11675bp (ND4), 9216bp and 9226bp (COX III).  
 
The COX II variant at 8018bp, predicted to cause protein dysfunction, occurred 
at a frequency almost three times higher in the CD45- cells than in its positive 
counterpart (Table 3.13). However, a selection of variants including the 8821bp 
mutation within the ATP6 region was detected at two-fold higher levels in the 
CD45+ than in the CD45- cells. Likewise, the 8927bp mutation also within 
ATP6, presented with approximately a four-fold increase in the CD45+ cells than 
in the CD45- cells. The variant at 8939bp exemplifies this further containing a 
percentage mutation at three-fold higher levels in the CD45+ compared to the 
CD45- cells, even though CD45- cells are responsible for maintaining the 
tumorigenic characteristics of multiple myeloma. 
 
Overall, 78.26% of variants were common to both sub-populations, with a few 
extra variants within the CD45- cells. At several sites, variants appeared 
exclusive for either the CD45+ or CD45– cells (Table 3.13). Those present only 
in the CD45+ sub-population included variants at sites 3208bp, 3417bp, 5752bp, 
6352bp, 6774bp, 8252bp, 10657bp and 11675bp. Those exclusive to the CD45- 
cells were found at positions 8010bp, 8018bp, 8759bp, 9216bp, 11220bp and 
11674bp. The variant located at position 8821bp within ATP6, was the only 
variant sharing less than a 10% difference in variant level between the CD45+ 
and CD45- samples.  
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Data retrieved from the Ion Torrent were subsequently validated using the HRM, 
which corresponded with the variants identified from next generation sequencing 
data (Table 3.14). Additional variants were also detected, which were likely to 
have mutation levels between the threshold levels of variant detection for the 
HRM (1%) and Ion Torrent (3%).  
 
Table 3.14. Confirmation of CD45+ and CD45- variants using HRM analysis. 
	  
   Cells  
 Reference 
Position 
Variant CD45+ CD45- Gene region 
976 A→C #### #### 12s rRNA 
3208 C→A ####  16s rRNA N
on
-
co
di
ng
 
re
gi
on
 
5752 A→G ####  Origin of light strand replication 
3391 G→A #### #### 
3417 C→A ####  
NADH Dehydrogenase: ND1 
6352 T→G ####  
6774 C→G #### #### Cytochrome C Oxidase: COX I 
8010 T→G #### #### 
8018 C→T #### #### 
8252 C→A ####  
Cytochrome C Oxidase: COX II 
8759 T→G #### #### 
8821 T→C #### #### 
8927 C→A #### #### 
8928 T→C #### #### 
8934 C→G #### #### 
8939 T→A #### #### 
ATP synthase 6: ATP6 
9216 C→A  #### 
9226 C→G #### #### Cytochrome C Oxidase: COX III 
10657 T→G ####  NADH Dehydrogenase: ND4L 
11220 T→G #### #### 
11445 T→G #### #### 
11674 C→T  #### 
 
C
od
in
g 
re
gi
on
 
11675 C→T ####  
NADH Dehydrogenase: ND4 
 
 Variant present 
 Variant absent 
 Variant present - analysed jointly (either 1 present or both) 
 Variant absent - analysed jointly (either 1 absent or both) 
 
 
 
Key: 
#### Variant presence/absence confirmed in both Ion Torrent and HRM 
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3.5.7. Susceptibility of CD45+ and CD45- cells to mutations 
After normalising the number of variants to the sizes of the gene regions for the 
CD45 cells, the origin of light strand replication was most susceptible to the 
development of a mutation (1 variant present within a 77bp region of mtDNA) 
(Table 3.15). However, since the susceptibility score for the origin of light strand 
replication may be over-estimated due to the presence of a single variant within a 
very short (77bp) region of mtDNA, it would be necessary to consider the 
importance of the second-most susceptible gene to the development of mutations.  
 
Table 3.15. Determining the susceptibility of CD45+ and CD45- cells to 
mutations. 
 Normalised data 
Reference 
Position 
(bp) 
Gene region Nucleotide 
positions for 
gene regions 
(bp) 
Size of 
gene 
region 
(bp) 
Number 
of 
variants 
detected  
Mutation 
rate in each 
gene 
region 
Mutation rate 
grouped for 
coding/non-
coding regions 
976 12s rRNA 648..1601 954 1 0.00105 
3208 16s rRNA 1671..3229 1558 1 0.000642 
5752 N
on
-
co
di
ng
 
re
gi
on
 
Origin of L-strand 
replication 
5721..5798 77 1 0.0130 
 
0.000481 
3391 
3417 
NADH 
Dehydrogenase: ND1 
3307..4262 955 2 0.00209 
6352 
6774 
Cytochrome C 
Oxidase: COX I 
5904..7445 1541 2 0.00130 
8010 
8018 
8252 
 
Cytochrome C 
Oxidase: COX II 
 
7586..8269 
 
684 
 
3 
 
0.00439 
8759 
8821 
8927 
8928 
8934 
8939 
 
 
 
ATP synthase 6: 
ATP6 
 
 
 
8527..9207 
 
 
 
681 
 
 
 
6 
 
 
 
0.00882 
9216 
9226 
Cytochrome C 
Oxidase: COX III 
9207..9990 783 2 0.00255 
10657 NADH 
Dehydrogenase: 
ND4L 
10470..10766 296 1 0.00338 
11220 
11445 
11674 
11675 
C
od
in
g 
re
gi
on
 
 
 
NADH 
Dehydrogenase: ND4 
 
 
10760..12137 
 
 
1377 
 
 
4 
 
 
0.00290 
 
 
 
 
 
 
 
 
 
 
0.00194 
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The region that was second most likely to acquire variants was ATP6, calculated 
to have a variant susceptibility value of 8.82 x 10-3. 16s rRNA was the least 
susceptible to the development of mutations in the CD45 cells (susceptibility 
value: 6.42 x 10-5). Comparatively, the origin of light strand replication was 1.47 
fold greater than the ATP6 region to the development of a mutation. However, 
the greatest fold change difference occurred between the origin of light strand 
replication and the 16s rRNA, which was calculated to be 20.23 (Table 3.16). 
	  
Table 3.16. Fold change differences for the of CD45+ and CD45- cells to 
mutation.  
Gene 
region 
12s 
rRNA 
16s 
rRNA 
OriL ND1 COX I COX 
II 
ATP6 COX 
III 
ND4L ND4 
12s 
rRNA 
 1.63 0.08 0.50 0.81 0.24 0.12 0.41 0.31 0.36 
16s 
rRNA 
0.61  0.05 0.31 0.49 0.15 0.07 0.25 0.19 0.22 
OriL 12.38 20.23  6.20 10.01 2.96 1.47 5.08 3.84 4.47 
ND1 2.00 3.26 0.16  1.61 0.48 0.24 0.82 0.62 0.72 
COX I 1.24 2.02 0.10 0.62  0.30 0.15 0.51 0.38 0.45 
COX II 4.19 6.84 0.34 2.10 3.38  0.50 1.72 1.30 1.51 
ATP6 8.41 13.75 0.68 4.21 6.80 2.01  3.45 2.61 3.04 
COX 
III 
2.43 3.98 0.20 1.22 1.97 0.58 0.29  0.76 0.88 
ND4L 3.22 5.26 0.26 1.61 2.60 0.77 0.38 1.32  1.16 
ND4 2.77 4.53 0.22 1.39 2.24 0.66 0.33 1.14 0.86  
 
Key 
if value >1 susceptibility of the region to variant changes is greater for the gene listed on the left 
if value <1 susceptibility of the region to variant changes is less for the gene listed on the left  	  	  
3.5.8. The influence of GC content on the development of mutations 
To determine whether the GC content of an mtDNA region influences its 
susceptibility to the development of mutations, each mtDNA region from the 
sequencing outcomes of the multiple myeloma tumors (Table 3.6), was 
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examined. For few variants, a correlation existed between the percentage GC and 
probability of mutation acquisition (Table 3.17). 
 
Table 3.17. Calculating the GC content of each mtDNA variant region. 
    Nucleotide count  
Gene region Nucleotide 
positions for gene 
regions (bp) 
Size of 
gene region 
(bp) 
Adenine 
(A)  
Thymine 
(T) 
Guanine 
(G) 
Cytosine 
(C ) 
% G/C 
content 
D-Loop 1..576, 
16024..16569 
1122 339 260 152 371 46.6 
12s rRNA 648..1601 954 315 205 181 253 45.5 N
on
-
co
di
ng
  
16s rRNA 1671..3229 1558 547 344 270 397 42.8 
NADH 
Dehydrogenase: 
ND2 
4470..5511 1042 326 268 99 349 43 
Cytochrome C 
Oxidase: COXII 
 7586..8269 684 196 172 102 214 46.2 
ATP Synthase 6: 
ATP6 
8527..9207 681 206 174 71 230 44.2 
NADH 
Dehydrogenase: 
ND5 
12337..14148 1812 551 447 192 622 44.9 C
od
in
g 
re
gi
on
 
Cytochrome B: 
CYTB 
 14747..15887 1141 326 287 137 291 46.3 
 
 
CYT B was calculated to have a probability score of 2.632 x 10-3, which was the 
second-highest most susceptible region for mutation. It was also ranked second 
in terms of its GC content (46.3%), below the D-loop (46.6%). Similarly, the 16s 
rRNA region was ranked 7th of all genes analysed for its susceptibility to 
mutation (1.284 x 10-3), wherein it also possessed the lowest GC content 
amongst all mtDNA regions assessed (42.8% GC). Finally, ATP6 was 
determined the 5th most susceptible region for mutation based on normalized data 
(1.4706 x 10-3), which almost corresponded with it possessing the 6th most GC 
rich region of all others examined (44.2%).  
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From Table 3.6. 50% of mutational events involved a pyrimidine-pyrimidine 
substitution, closely followed by purine-purine (37.5%) and lastly by purine-
pyrimidine transitions (12.5%). However, Table 3.9 did not appear to follow suit, 
as the majority (69.6%) of variants involved a purine (A or G) and a pyrimidine 
(T or C) substitution. In 26.1% of cases these variants were pyrimidine-
pyrimidine in nature, very rarely (8.7%) did these involve purine-purine 
substitutions. This suggests that there was no bias towards the variant introduced 
in place of a natural nucleotide base in mtDNA, thereby giving all residues an 
equal (33.3%) chance of being substituted during a mutational event.  
 
3.5.9.	  In silico and protein structure analysis	  
3.5.9.1. Multiple myeloma tumor sample variants 
The amino acid substitution caused by the variant at position 7718bp induced a 
change from threonine to proline (T45P) in the COX II region, which was 
predicted to impair protein function (Table 3.6). MutPred predicted a high 
probability (P <0.05) for the T45P mutation to disrupt the structure of COX II, in 
addition to the potential gains of glycosylation and local gain of helix structure 
(Table 3.6). The mutation resided on the end of a transmembrane-spanning helix 
(Figure 3.9) on the bovine COX II model, which shared 72% sequence identity 
with the human COX II structure. Although modeling was performed using the 
bovine protein structure, results from SNPs&GO and MutPred were based on its 
human counterpart.  
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Figure 3.9. Location of the T45P mutation using the bovine model of Complex 
IV. (A) Protein structure of the catalytic centre of Complex IV, which comprises 
of COX I, II and III in their entirety. (B) Inset of the COX II subunit containing 
the T45P mutation on the transmembrane helical region. In the bovine model, a 
methionine exists in place of the threonine that is found at position 45 of the 
human COX II protein. 
 
Although the variant at 9111bp of mtDNA resulted in a synonymous protein 
mutation, a base change at nucleotide position 14772bp appeared to induce a 
significant change (RI = 1) for sample S139 within the CYT B region (Table 
3.6). This proline to leucine mutation at position 9 of the protein sequence (P9L) 
was predicted at the 95% confidence level to cause loss of glycosylation, and 
consequently loss of methylation on lysine downstream at position 12 of the 
protein sequence (Table 3.6). The P9L mutation was modeled on the bovine 
protein structure, which shares 78% protein sequence identity to its human 
counterpart, and identified to reside within the loop region (Figure 3.10).  
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Figure 3.10. Location of the CYT B P9L mutation using the bovine model. (A) 
The catalytic core of the cytochrome BC1 complex. Events of the Q cycle are 
highlighted, which contribute towards the generation of an electrochemical 
gradient across the mitochondrial inner membrane. (B) The P9L mutation 
resides on a loop region of the bovine cytochrome B protein. (C) Magnified inset 
of the P9L mutation. 
 
Mutations at positions 15264bp and 15267bp also resulted in amino acid changes 
(P173L and T174S), which were predicted to impair protein function (RI = 4 and 
3 respectively) (Table 3.6). For these mutations, MutPred predictions on protein 
features were not considered significant (P>0.05). Both the P173L and T174S 
mutations were modeled on the bovine CYT B structure to reside on a helix 
structure within the mitochondrial inner membrane space (Figure 3.11). The 
presence of two adjacent mutations could disrupt helix-helix interactions that 
may be important in maintaining structure of the CYT B subunit. 
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Figure 3.11. Mapping of the CYT B mutations P173L and T174S. (A) The 
catalytic core of Complex III. (B) The P173L and T174S mutations arise within a 
membrane-spanning helix region of cytochrome B. The T174S mutation 
represents a loss of a conserved threonine amino acid, whereas for the P173L 
mutation, the proline residue was replaced by alanine in the bovine model of 
CYT B subunit. (C) Magnified image of the P173L and T174S mutations. 	  	  
3.5.9.2. CD45+ and CD45- sub-population variants 
For the variants in the CD45+ and CD45– cells, the leucine to tryptophan 
(L150W) mutation present at position 6352bp was located within the loop region 
of COX I (Table 3.13 and Figure 3.12). Substitution of histidine to aspartate 
(H291D), another COX I mutation, was located on a transmembrane helical 
region (Figure 3.12). These observations corresponded to the in silico 
predictions, since the reliability index for L150W shows a value of 2, which 
supports the hypothesis that mutations in the loop regions do not exert much 
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influence on the overall protein structure. Likewise, for H291D the reliability 
index was predicted to be 8, which matches the hypothesis that mutations in 
structural regions of the protein are more likely to be detrimental. 
 
 
Figure 3.12. Modelling of the COX I mutations L150W and H291D in a bovine 
model. (A) Representation of the whole catalytic core of Complex IV. (B) 
Locations of the L150W and H291D mutations on COX I, both of which involve 
loss of a conserved residue between the human and bovine species. (C) 
Magnified inset of the L150W and H291D mutations. 
 
Other mutations within the COX II and III regions were also mapped using the 
bovine protein structure. The V142G mutation lies within the 10-stranded beta 
barrel structure located at the C-terminal end of COX II, in the mitochondrial 
intermembrane space. Valine is often found within beta sheets, as it is a C-beta 
branched molecule (Figure 3.13). The V142G amino acid substitution was 
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predicted by MutPred to impair protein function and cause loss of stability to the 
protein structure (Table 3.13).  
	  
Figure 3.13. Mapping of the COX II variants within CD45+ and CD45- cells. 
(A) The P223T mutation found within the CD45+ cells, and the CD45- mutations 
V142G and P145S were located on the bovine COX II structure. The P223T 
mutation does not involve the loss of a conserved amino acid residue, as serine 
replaces the presence of a proline in the bovine model. However, both the V142G 
and P145S mutations involve the loss of a conserved residue. (B) Magnified view 
of the three COX II mutations. 
 
Also within COX II, the P145S mutation located downstream of V142G resided 
on the same beta sheet structure (Figure 3.13). The P145S mutation was 
predicted to induce protein dysfunction, with a reliability index of 8, greater than 
that for V142G (RI = 1) (Table 3.13). Finally, the P223T mutation in COX II 
was modeled to reside within the intermembrane space region on a helix 
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structure (Figure 3.13). Due to its location further from the core region of 
Complex IV, it was predicted with confidence that the P223T mutation exerted a 
neutral effect (RI value = 9) (Table 3.13).  
 
Two COX III mutations at positions 9216bp and 9226bp, causing amino acid 
mutations glutamine to lysine (Q4K) and alanine to glycine (A7G), were 
modeled on the bovine structure. Both were located on the loop regions close to 
the mitochondrial matrix (Figure 3.14), and were predicted with high confidence 
to be neutral mutations (RI values = 8) (Table 3.13). 	  
	  
Figure 3.14. Mapping of COX III variants within CD45+ and CD45- cells. (A) 
Location of the A7G and Q4K mutations relative to the catalytic core of Complex 
IV. (B) Magnified inset of the two COX III mutations. (C) Alternative view. 
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Synonymous amino acid changes were reported at several sites, 3417bp (ND1), 
8928bp and 8934bp (ATP6) and 11674bp (ND4) (Table 3.13). Where amino acid 
substitutions involved a transition to a stop codon (10657bp; ND4L and 11445bp; 
ND4), it was not possible to perform in silico predictions on protein function. 
However, premature stop codons would terminate mitochondrial protein 
synthesis.  
 
The 10657bp variant that induces a substitution from methionine to a stop codon 
at position 63 of the ND4L polypeptide chain will produce a premature protein 
chain that is truncated by 35 amino acids. The resultant polypeptide will consist 
of only 64.3% of the complete protein sequence. For the 11445bp variant in 
ND4, only the first 50% of the polypeptide chain will be synthesised, due to the 
mutation generating a stop codon that arises exactly half-way in the protein wild-
type sequence for ND4. Shortening of the polypeptide chain will prevent proper 
assembly of the protein complex, thereby disrupting its overall ability to function 
correctly. The earlier the termination of protein synthesis, the more deleterious 
the effect imposed upon the protein structure. 
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3.6. Discussion 
3.6.1. Multiple myeloma variants 
Variants at positions 16186bp209 (D-loop), 1389bp (12S rRNA)210, 3391bp 
(ND1)211, 5432bp (ND2)212, 8928bp213, 9111bp214 (both within ATP6) and 
11674bp215 (ND4) have been previously reported, based on the human 
mitochondrial genome database, MitoMap. However, none of these have been 
associated specifically with multiple myeloma. This suggests that the variants in 
this Chapter represent novel discoveries, and could potentially be specific disease-
causing variants.  
 
CpG dinuclotide regions have been thought to be more susceptible than other 
sequence regions to mutation216. However, only 12.5% of variants identified 
from the tumor samples in Table 3.6 were located within these regions (at 
1389bp and 12847bp), more than that observed within the U266 cells in Table 
3.10 (8.7% of variants at 8252bp and 9226bp). These relatively low values either 
suggest that the incorporation of mtDNA variants occurs randomly, or highlights 
the presence of other factors that could influence these variants to arise in certain 
regions of the mtDNA over others.  
 
3.6.2. Impact of variants located in the non-coding regions of mtDNA 
While the impact of amino acid substitutions can be predicted using a 
combination approach of in silico and protein modeling analysis, the impact of 
mutations affecting the non-coding regions of the mtDNA can also be predicted 
based on our understanding of the biological functions for these genes. 
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MtDNA replication is only possible following initiation at the origin of heavy 
(H) strand replication217. The H-strand initiates transcription of mtDNA from two 
promoters, HSP1 and 2, which differ in their sites of initiation and termination of 
transcription, with the latter located 90-100bp downstream of HSP1218. In basal 
conditions, HSP1 demonstrates higher activity than at the light strand promoter 
(LSP) region219. Under the control of the heavy strand promoter, transcription 
results in generation of the 12s and 16s rRNA, as well as 12 mtDNA-encoded 
genes and 14 tRNAs220. Whereas, under the influence of the light strand 
promoter, transcription results in the production of 1 mtDNA-encoded gene 
(ND6) in addition to 8 tRNAs219. Nevertheless, the light strand promoter, which 
functions independently of the H-strand promoter220, remains important for the 
synthesis of RNA primers. Once processed via cleavage reactions, these RNA 
primers are required for mtDNA replication217.  
 
Variants were identified within the H-strand promoter region (HSP1) at 557bp, 
(Table 3.6) and also within the origin of light strand replication (at 5752bp) 
(Table 3.13). The absence of a functional HSP1 site could severely reduce 
transcription for most of the mtDNA-encoded genes. On the other hand, 
disruption to the integrity of the origin of light strand replication, is likely to 
impair mtDNA replication, as in vivo mutagenesis studies suggest that this region 
is essential for maintaining mtDNA replication221. 
 
Variants have also been identified in the 12s and 16s rRNA regions (Tables 3.6 
and 3.13). Depending on the severity of these mutations, it is possible for 
mitochondrial transcription to be defective, as both 12s and 16s rRNA encode 
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mitochondrial ribosome subunits. Since there is absence of variant detection in 
any of the mtDNA tRNA gene regions, it is likely that the mitochondrial 
translational machinery remains functional in multiple myeloma.   
 
3.6.3. Replenishment of mtDNA and mtDNA variants 
Variants that arose as a result of replenishment of mtDNA copy number for 14 
days in U266 cells, after 14 days of mtDNA depletion, noticeably occurred 
within ND5. Previously, variants in the ND5 region have been reported to 
enhance tumorigenicity of cells222. Re-populated mtDNA copies in the 14-day 
recovered U266 cells, could exhibit more tumorigenic properties compared to 
control U266 cells. Although predictions from SNPs&GO have determined these 
variants individually exert a neutral effect on the ND5 protein, perhaps together 
the novel variants will be detrimental to Complex I function. This is likely to be 
the case, as mathematical modeling supports the concept that the accumulation of 
mutations promotes tumor establishment, demonstrating a positive correlation 
between the two variables223. 
  
Prolonged culture of the 14-day recovered U266 cells is likely to increase the 
frequency of mutation for the low level variants that accumulate within mtDNA. 
This is because, with each mtDNA replication cycle, the presence of a 
heteroplasmic variant is likely to be maintained and depending on the fidelity of 
the mitochondrial replication machinery, further variants could be introduced. 
However, one study reported that the average frequency of heteroplasmy remains 
the same even across different stages of colorectal tumors224. Since not all tumors 
behave in the same manner, it remains possible for mutation levels to increase 
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alongside the duration of culture. For example, variants in the recovered sample 
may have been originally present in U266 control cells, but did not reach above 
the 3% threshold detection level until it underwent induced stress in the presence 
of ddC. 
 
3.6.4. Additional considerations 
According to clinical studies, multiple myeloma patients possessing a higher 
ratio of CD45- than CD45+ plasma cells have lower survival rates, higher 
possibility of developing extra-medullary disease and display higher resistance to 
chemotherapy treatment207,225.  Moreover, in the 5T2MM murine model of 
systemic myelomatosis, in vivo transition of predominantly CD45+ 5T2MM cells 
into the CD45- counterparts, correlated with the development of more aggressive 
disease kinetics, neo-angiogenesis and the elaboration of angiogenic growth 
factors226,227. Furthermore, fractionated CD45- patient myeloma cells have 
greater engraftment capacity than CD45+ cells in a xenotransplantation mouse 
model228. In support of this, results from this Chapter have revealed that mtDNA 
variants are more abundant in the CD45- population than in CD45+ cells. 
 
However, separation of the U266 cells into CD45+ and CD45- cells may induce 
phenotypic and biological changes229. This could explain why variants in a 
heterogenous population of U266 cells were different to those detected in the 
sub-populations enriched for CD45+ and CD45-. Furthermore, there may be 
inter-dependence between the two CD45 sub-populations that preserve a defined 
set of variants. 
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3.6.5. Protein modeling analysis 
The results from the protein modeling analyses were examined in the biological 
context to confirm the biological reliability of these in silico results. The amino 
acid change from threonine to proline, caused by the variant at 7718bp within 
COX II, is likely to be biologically reliable in terms of its prediction on protein 
dysfunction (Figure 3.9). Threonine is a hydrophilic molecule due to possession 
of a hydroxyl group, and structurally can reside on either the interior or surface 
sides of a protein. Any substitution involving an amino acid change into proline, 
will impact on protein structure. Since the side chain in proline connects twice to 
the protein backbone, introduction of this imino acid induces rigidity to the local 
protein region. As a result, proline preferably resides on the protein surface. 
 
While variants present in loop regions are not likely to impact significantly on 
the overall protein conformation, flexible loop regions remain important for 
protein-ligand and protein-protein interactions essential for mediating 
biochemical signal transduction230. For the substitution involving proline to 
leucine (P9L) at 14772bp within CYT B (Figure 3.10), it is possible that further 
flexibility of the local region will be induced, as proline is lost in this case. In 
addition, the L150W protein mutation reported in COX I, assigned a RI value of 
2, is likely to be biologically reliable as the variant residing in the loop region is 
unlikely to initiate disease (Figure 3.12). 
 
The RI value of 8, given to the second COX I mutation H291D, appears to be 
acceptable as the location of the variant appears buried within the interior of 
COX I (Figure 3.12). Furthermore, the H291D mutation is biochemically 
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unfavourable. Although histidine and aspartate are both polar molecules, the 
latter is also negatively charged. While histidine can reside within the interior or 
the surface of a protein, aspartate displays preference to reside on the protein 
surface. If however, aspartate is present on the interior side, it often participates 
in the formation of salt-bridges with other positively charged residues to create 
hydrogen bonds that assist in maintaining protein stability231.  
 
Histidine at position 291 is also a copper B metal binding site (Uniprot P00395). 
Histidine is commonly found in enzyme reactive centers, as the imidazole ring 
present in histidine allows it to accept or donate protons near to physiological 
pH, making these amino acids ideal for enzyme catalysis reactions232. 
Substitution of histidine is likely to interfere with the iron present in heme a3, 
which functions to form a heterobimetallic site with the CuB centre233, since 
histidine 291 represents one of three histidine residues participating in the 
stabilization of the CuB centre234. Altogether, these observations suggest that loss 
of the conserved histidine at position 291 can disrupt functionality of the 
catalytic cycle. This will interfere with the transfer of electrons from the 
hydrophobic carrier ferrocytochrome C to the heme a3/CuB centre. 
 
The amino acid substitution V142G in COX II represents another mutation that 
is likely to biologically induce disease (Figure 3.13). Valine is limited in the 
conformations it can form, since there is the presence of two non-hydrogen side 
chains. While valine is unreactive, its hydrophobic property allows it to 
participate in interactions with other hydrophobic molecules, for example, 
lipids231. Glycine on the other hand, carries only hydrogen on its side chain. Its 
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small size means that presence of glycine will confer flexibility of the protein 
structure where it resides. The loss of rigidity in protein structure from a 
substitution involving valine to glycine, could interfere with stability of the beta 
barrel structure of COX II, a consequence which was reflected in the in silico 
predictions made in Table 3.13 (P = 0.002). 
 
With reference to the P145S mutation also in the COX II protein (Figure 3.13), 
the substitution event may be unfavorable due to serine primarily being found in 
functional centers, as its hydroxyl group is capable of hydrogen bonding with a 
range of polar molecules231. Both V142G and P145S were found to be present in 
both the CD45+ and CD45– cells. The combination of both is likely to severely 
reduce stability of the beta barrel structure. The final COX II mutation, P223T, 
was predicted to induce a neutral effect (Table 3.13), most likely due to its 
location being relatively distant from the main catalytic core center (Figure 
3.13). 
 
It is probable that the two mutations residing adjacent to each other on the helical 
segment of CYT B (Figure 3.11) exert a greater effect on protein function than 
the presence of a single mutation. The biochemical effect of a transition from 
proline to leucine has been discussed previously. On the other hand, a change 
from threonine to serine at position 174 on the protein sequence is considered a 
favourable substitution. Both residues are polar in nature, with the chemical 
difference between them being a hydrogen group in serine, whereby a methyl 
group is found at the same location in threonine. However, together these 
mutations may disrupt overall structure to CYT B.  Given that variants 15264 
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and 15267bp appear common across the myeloma tumors screened, their joint 
presence is likely detrimental to protein stability. 
 
Not surprisingly, all non-synonymous ATP6 mutations (F78C, P134H, I138N 
and S99P) were predicted to impair protein function. Due to its essential role in 
the production of ATP, loss of ATP6 function is likely to disrupt respiratory 
capacity of a cell, thereby promoting aerobic glycolysis. According to the 
Warburg theory, under these conditions, proliferation of the tumor cells will 
increase, therefore enhancing malignancy of the tumor.  
 
A study performed in the Chlamydomonas reinhardtii model have presented 
results to support the theory that suppression of ND4L polypeptide production 
impairs assembly of the entire Complex I protein structure235. Moreover, ND4 
participates in ubiquinone-binding236 as well as in the translocation of protons 
across the mitochondrial inner membrane237. Therefore, incomplete translation of 
both these gene regions, caused by the introduction of pre-mature stop codons in 
the mtDNA sequence, are likely to impose adverse implications. 
 
3.6.6. Contribution of mtDNA variants to tumor biology 
The development of multiple myeloma requires the collective influence of 
variants, which has been the case for disorders such as MELAS, whereby the 
G13513A mutation was found to be associated with the disease238 alongside the 
characteristic 3243bp mutation239. Acquisition of these cumulative mtDNA 
variants, leads to dysfunction of several of the protein complexes that are 
responsible for respiration via OXPHOS.  
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Inefficient energy production through OXPHOS could be a stimulant for the cells 
to switch metabolism towards glycolysis, even in the presence of sufficient 
oxygen concentration (the Warburg effect). However, if mtDNA variants only 
impair Complex I function, electrons are still able to enter the electron transfer 
chain through Complex II, which receives electrons from succinate and transfers 
these to FADH2 and the hydrophobic carrier coenzyme Q, for shuttling to 
Complex III240. Electron transfer initiating from Complex II yields fewer protons 
overall for use in the synthesis of ATP through Complex V, as Complex I would 
not be contributing to the generation of a proton gradient in this situation.  
 
3.7. Conclusion 
Different multiple myeloma tumors characteristic of patients in their relapse 
and/or refractory phase, are capable of exhibiting unique mutations that could 
enable each to behave in a different manner and to progress at variable rates 
during the course of tumor establishment. Cytochrome B was determined as a 
potential hotspot region for mutations, especially at nucleotide positions 15264bp 
and 15267bp. However, the 12S rRNA region was the most susceptible to 
development of mutations.  
 
Accumulation of mtDNA variants could induce cells to respire via aerobic 
glycolysis, therefore promoting the progression of multiple myeloma.  It is 
possible that the accumulation of these variants could simultaneously alter the 
ratio of CD45+ and CD45- cells to increase the CD45- malignant sub-population, 
thereby further encouraging malignancy. 
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Chapter 4: The Role of MtDNA in the 
Maintenance of Mitochondria and 
Multiple Myeloma 
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4.1. Introduction 
Multiple myeloma cells have the ability to migrate to the bone marrow, where 
they are able to interact with cells within the bone microenvironment, such as the 
stromal cells241. The interactions formed are able to stimulate signal transduction 
pathways that promote the proliferation and metastatic potential of these tumor 
cells. Some of the key factors involved with the tumor biology of multiple 
myeloma are represented in Figure 4.1. 
 
 
 
Figure 4.1. Key factors in the tumor biology of multiple myeloma. CASP8 and 
DAD1 are additional proteins that are important to the development of this 
cancer, but do not form interactions with the other tumorigenic proteins 
mentioned.  
 
Interleukin 6 (IL6) is an in vivo growth factor produced mainly by stromal cells 
in the bone marrow to promote the growth of multiple myeloma. It is capable of 
stimulating the Ras/MAPK cell proliferation pathway242, and is considered 
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critical, since proliferation is inhibited in the presence of anti-IL6 
antibodies243,244. However, IL6 is not consistently found to correlate with 
multiple myeloma147. Homodimerisation of gp130 is induced following binding 
of IL6 to its receptor, which initiates signalling via the RAS/MAPK and Janus-
activated kinase (JAK)/signal transducers and activators of transcription (STAT) 
pathway245. Fibroblast growth factor receptor 3 (FGFR3) is another molecule that 
utilises the RAS/MAPK pathway, and is responsible for the regulation of cellular 
proliferation246. Downstream of the IL6 signalling cascade, activation of the 
transcription factor STAT3, upon its phosphorylation, enhances the expression of 
survival-related genes241,247. 
 
X-box binding protein 1 (XBP1) functions upstream of IL6 and is capable of 
increasing gene expression levels and secretion of IL6, by interacting and 
binding to the IL6 promoter 248 at the NFkB site to control its gene expression 
levels249. IL6 does not influence expression of the survival factor MCL1250, 
despite a previous report suggesting otherwise251. Instead, MCL1 expression is 
thought to be regulated at the post-translational level, with one study suggesting 
that it is the interaction between deubiquitinase USP9X and MCL1 that allows 
for stabilisation of the survival protein252. This provides evidence that increases 
in MCL1 protein levels occur independently of the regulatory mechanisms 
during transcription252. However, others have suggested that STAT3 influences 
the expression of MCL1253,254, therefore indicating the presence of multiple 
regulatory mechanisms that control MCL1 expression.  
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Apart from ATP generation, mitochondria also have a role in the control of 
apoptosis, which is mediated via the intrinsic or extrinsic pathways. The intrinsic 
apoptosis pathway releases Cytochrome c from damaged mitochondria, which 
forms a complex with APAF-1 to generate an apoptosome255. The extrinsic 
pathway on the other hand, functions independently of mitochondria following 
the stimulation of a receptor-mediated signalling response. Different caspases 
have distinct roles during apoptosis; caspase 8 and 10 function as initiators of the 
extrinsic pathway, whereas caspase 9 is associated with the intrinsic 
mitochondrial-dependent pathway256. Caspase 8 is unique in that it can also 
mediate the effects of cell survival257,258. In addition, defender against death 1 
(DAD1) represents another factor participating in the control of cell survival259, 
which is believed to be highly conserved across a range of plant and animal 
species260. 
 
2’3’-dideoxycytidine (ddC) is a nucleoside analog that was previously used as an 
anti-retroviral drug for the treatment of human immunodeficiency virus (HIV)261. 
ddC prevents mtDNA replication by inhibiting activity of the mitochondrial 
POLG complex262. This is because the lack of a hydroxyl (-OH) group at the 3’ 
position of the carbon ring within a nucleotide base, which is normally present in 
deoxynucleotides prevents further addition of other nucleotides during DNA 
synthesis263. ddC is selective towards inhibiting replication of mtDNA, since it 
has been reported to exert no effect on the DNA polymerase α complex, which is 
the enzyme responsible for chromosomal DNA synthesis264. Moreover, it has 
been reported that in the presence of ddC, mtDNA replicates at a rate 50,000 fold 
slower than in its absence265.  
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Since the Warburg effect is characteristic to many cancer types, the use of 2-
deoxyglucose (2-DG) as a potential anti-cancer drug has gained interest in recent 
years266. 2-DG is a competitive analog of glucose and functions to inhibit 
glycolysis in its phosphorylated state, since 2-DG-6-phosphate is unable to be 
further metabolized by the body267. Clinical trials have so far determined that 
oral administration of 2-DG at doses of 250-300mg/kg of body weight is safe for 
GBM patients268. However, pre-clinical results from mouse models have 
determined that higher doses can induce cardiac toxicity, which has limited its 
use as a successful drug in the treatment of GBM, and potentially other cancers. 
Recently, there has been growing interest to suggest that combination therapy to 
include the use of 2-DG, together with mitochondrial inhibitors, such as 
antimycin A or oligomycin, could be a possible approach to induce apoptosis, 
which was tested in several breast cancer cell lines269. However, to date, this 
remains a controversial research area. Nonetheless, 2-DG is an effective inhibitor 
of glycolysis for in vitro studies. 
 
In this Chapter, multiple myeloma cells were depleted of their mtDNA using 
ddC, and allowed to re-populate in the presence and absence of 2-DG. Metabolic 
measurements were also taken to identify any changes to the production of ATP 
or lactate in these cancer cells during the process of mtDNA depletion.	  	  
4.2 Aims and hypothesis 
The aim was to assess the importance of mtDNA in the maintenance of cell 
proliferation in multiple myeloma cells, by examining mtDNA copy number 
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alongside expression analyses of mtDNA and nuclear-encoded genes that are 
involved in the processes of mitochondrial biogenesis, transcription and 
replication. Several key tumor biology genes associated with multiple myeloma 
were examined to determine the influence of mtDNA copy number on the 
malignant phenotype of these cells. The contribution of the glycolysis pathway 
towards maintaining the tumorigenic phenotype of these cancer cells was also 
investigated.   
 
It was anticipated that the expression of the mtDNA-encoded genes would 
decrease during mtDNA depletion, as other studies have reported this using 
ddC270. Although the use of other mtDNA depletion agents, including ethidium 
bromide, result in same outcome271, these have been reported to exert greater 
non-specific effects by altering cell metabolism, for example, by increasing 
superoxide and lactate production272. Here, it was hypothesised that the reduction 
of mtDNA copy number in multiple myeloma cells using ddC would increase the 
expression of genes involved with tumor development, and perhaps also genes 
involved with the maintenance of mtDNA. This was because other studies have 
reported mtDNA depletion to be capable of enhancing the malignant phenotype 
of prostate carcinoma273,274. Furthermore, it was hypothesized that by culturing 
cells under conditions that inhibit glycolytic activity, the tumorigenic properties 
of these cancer cells would be suppressed, as cells could be forced to utilize 
OXPHOS in the absence of glycolysis. 
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4.3. Preliminary experiments 
4.3.1. Standard curves for analyzing ATP and lactate production 
For quantification of ATP and lactate production in cells, dilutions of a known 
stock concentration (10mM) was performed for the generation of a standard 
curve from which it would be possible to extrapolate data from. For the ATP 
assay, the following standards were used: 10-4, 10-4.5, 10-5, 10-5.5, 10-6, 10-6.5. 
Results produced a standard curve with a linear regression fit of r2 = 0.98 
(Figure 4.2). 
 
Figure 4.2. Standard curve for measuring ATP production. (r2 = 0.98).  
 
A standard curve dilution was also performed for use with the lactate 
colorimetric assay. The following concentrations were used: 0nmol, 2nmol, 
4nmol, 6nmol, 8nmol and 10nmol. The linear regression fit gave an r2 value of 
0.97 (Figure 4.3). 
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Figure 4.3. Standard curve for measuring lactate production. (r2 =0.97).  
 
Standard curves were performed with each experimental run to ensure 
consistency of the dilutions and to obtain an accurate value for the production of 
lactate and/or ATP from cell cultures. 
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4.3.2. Measuring oxygen consumption rates using respirometry 
Respirometry measurements were taken to identify the preferential method 
through which glucose was metabolized in cells. The outcomes of this 
experiment were informative of how dependent the cells are on mitochondrial 
function, and therefore on mtDNA copy number. However, prior to the 
experiments, optimization had to be performed on various concentrations of the 
uncoupler drug Trifluorocarbonylcyanide Phenylhydrazone (FCCP) on the cell 
type of interest. The drug FCCP determines the maximal respiratory capacity in 
cells, and so the highest concentration that could be used, without inhibiting 
further respiration, had to be optimized (Figure 4.4). 
 
Figure 4.4. Determining the optimal concentration of Trifluorocarbonylcyanide 
Phenylhydrazone (FCCP) using respirometry.  
B	  
A	  
	  	   184	  
Optimisation was performed using U266 cells. The red line represents oxygen 
flux, and the blue represents total oxygen concentration within the closed 
chambers; both were measured as a function of time and detected by the 
polarographic oxygen sensors. Blue vertical lines represent the addition of events 
throughout the duration of the experiment, with labels signifying the following 
events: “Cells” – the addition of U266 cells into the closed chambers; “Oligo” – 
the addition of oligomycin into the closed system to determine the amount of 
proton leakage during respiration; “FCCP (nmol)” – the total concentration of 
FCCP within the cell chamber, ranging from 5nmol to 16nmol; “Ant A” – the 
addition of antimycin A to terminate mitochondrial oxygen consumption. Panels 
(A) and (B) are duplicate experiments to illustrate the reproducibility of the assay 
between the two independent cell chambers on the Oxygraph O2K instrument.  
 
Titration of the various FCCP concentrations ranged from 5nmol (lowest) and 
was increased at increments of 1 or 2nmol, up to the point at which maximal 
respiration can no longer be sustained after addition of further FCCP. A 
concentration of 14nmol FCCP was identified to be optimal for U266 cells, as 
16nmol was inhibitory for stimulating further respiration. The optimization was 
repeated in a similar manner for additional cell lines. 	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4.4. Methods 
The methods used in this Chapter are described in the following sections: 2.1.4 to 
2.1.6, 2.1.9 to 2.2, 2.4.1, 2.5.1, 2.6 to 2.8.2, 2.9.2 and 2.11 to 2.14.  
 
4.4.1. Real-time PCR primers for gene expression and mtDNA copy number 
analysis  
Primers used for determining gene expression changes in U266 cells during, and 
after, mtDNA depletion are displayed in Table 4.1. The primer sets used for 
determining mtDNA copy number are also shown.   
 
Table 4.1. Primers used to examine the expression of genes and mtDNA copy 
number. 
Gene Abbreviation Forward/ 
Reverse 
Sequence (5’->3’) Annealing 
temperature 
(°C) 
Product 
size 
(bp) 
F CAGTGATTATAGGCTTTCGCTC ATP synthase 
F0 subunit 6 
ATP6 
R GTGTTGTCGTGCAGGTAGAG 
56 
 
343 
F CAAAACCTAACTTGCGCAGA Beta actin β-actin 
R TTTTAGGATGGCAAGGGACT 
53 261 
F CAACTTCATCCACGTTCACC Beta globin β-globin 
R GAAGAGCCAAGGACAGGTAC 
56 268 
F CTGCTGGGGATGGCCACTGTG Caspase 8  CASP8 
R TCGCCTCGAGGACATCGCTCTC 
63 113 
F ATGACCCCAATACGCAAAACT Cytochrome B CYT B 
R GGGAGGACATAGCCTATGAA 
54 401  
F CTGCTTCCTAGTCCTGTATG Cytochrome C 
oxidase subunit 
II 
COXII 
R GTCGGTGTACTCGTAGGTTC 
56 235 
F CATCCTAGCGGTTTGCCTGA Defender 
against cell 
death 1 
DAD1 
R AGCAGAGCTAGCAGTAAGTG 
56 282 
F TGCTGAATGCCTCCCACG Fibroblast 
growth factor 
receptor 3  
FGFR3 
R CGTCTTCGTCATCTCCCGAG 
 57 123 
F GCACTGGCAGAAAACAACCT Interleukin 6 IL6 
R CAGGGGTGGTTATTGCATCT 
55 253 
F GAGATCAGCATTTGCATGGAACAC Mitogen-
activated 
kinase 2 
MAPK2 
R TCCGACTGCACCGAGTAATGTG 
59 323 
F CTGGAGTAGGAGCTGGTTTG Myeloid cell 
leukemia 1 
MCL1 
R GTGCTTCTCTTAACACTACAG 
55 439 
F CGAAAGGACAAGAGAAATAAGG Mitochondrial 
copy number 
MTDNA 
R CTGTAAAGTTTTAAGTTTTATGCG 
53 151 
F GAAGCCATGTTTCGAAGACCTG Mitochondrial 
single-stranded 
DNA binding  
MTSSB 
R CTGATATTCTGTGCCATGTTGTC 
57 271 
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Table 4.1: Continued 
Gene Abbreviation Forward/ 
Reverse 
Sequence (5’->3’) Annealing 
temperature 
(°C) 
Product 
size 
(bp) 
F CGGTTTATTGCAGGGAACTGAC Mitochondrial 
transcription 
termination 
factor 
MTERF 
R TGGAGGTGATCGCATCTTTC 
56  243 
F TCTCACCATCGCTCTTCTAC NADH 
dehydrogenase 
subunit 1 
ND1 
R GGTTGGTCTCTGCTAGTGTG 
56 349 
F CCGCACCAATAGGATCCTCCCGA NADH 
dehydrogenase 
subunit 6 
ND6 
R GCATGGGGGTCAGGGGTTGAG 
63 187 
F GCCACAGCCACACATAGTAT Nuclear 
respiratory 
factor 1 
NRF1 
R AAGCGCCATAGTGACTGTAG 
55 348 
F ATCCAAGGCAACAGATGAAACGGG Nuclear 
respiratory 
factor 2β 
NRF2β 
R 
TGATGACTTGCTGACCCCCTGA 
60 215 
F TTGCGCAGGTCAAACGAAAC Peroxisome 
proliferative 
activated 
receptor, 
gamma, 
coactivator 1 
alpha 
PGC1α 
R GCGCTGTCCCATGAGGTATT 
56 241 
F CACACCTAAACTCATGGCAC DNA 
polymerase 
gamma subunit 
1 
POLGA 
R GTCCACGTCGTTGTAAGGTC 
56  436 
F GTTTGCCATGAGTCCATCTAAC DNA 
polymerase 
subunit 
gamma-2 
POLGB 
R CTCTGTCAGCTGGAAAGAATC 
56 280 
F GCGGGAGAATTCTGCGGAGCC Peroxisome 
proliferator-
activated 
receptor delta 
PPARδ 
R CCCATCAGCCTCGTTGGTGCAT 
62 154 
F GAAGTGGAGGCAGCAGTGACAAG NAD-
dependent 
deacetylase 
sirtuin-3 
SIRT3 
R TGCAGGTGGCAGAGGCAAAGGTTC 
62 432 
F GTTCTCTATCAGCACAATCTAC Signal 
transducer and 
activator of 
transcription 3 
STAT3 
R CAGCTCACTCACGATGCTTC 
55 435 
F ATTGGGGTCGGGTCACTGCCTCA Mitochondrial 
transcription 
factor A 
TFAM 
R TACCTGCCACTCCGCCCTATAAGC 
63 361 
F GCCTCCGGAAAACTCAGCACTTG Mitochondrial 
transcription 
factor B1 
TFB1M 
R TTCAACCACCAGAAGTTCAGCGAC 
61 249 
F CGAAAGCATTTGCCGGCGAGG Mitochondrial 
transcription 
factor B2 
TFB2M 
R GAGCGCAACCACTTTGGCACCA 
61 273 
F GCACAAGTCCATCGTATCTTTC Progressive 
external 
opthalmoplegia 
1 
TWINKLE 
R CATACTCACTGATGAATGTCGTC 
56  197 
F GTAGTCTGGAGCTATGGTGGT X-box binding 
protein 1  
XBP1 
R TCGATCTCTGGCAGTCTGAG 
 57 283 
 
	  	   187	  
4.5. Results 
4.5.1. MtDNA copy number in multiple myeloma cells and patient tumor 
samples  
MtDNA copy numbers in clinical samples were obtained from patients with the 
confirmed diagnosis of multiple myeloma. These were compared to mtDNA 
copy number in U266 cells (Figure 4.5A). The average mtDNA copy number 
amongst all tumor samples (566.8 ± 28) revealed that there was no significant 
difference between the U266 mtDNA copy number (619.3 ± 21.5) and that from 
the tumor samples (P = 0.60) (Figure 4.5B).  
 
 
Figure 4.5. MtDNA copy number for U266 cells and patient tumor samples. (A) 
MtDNA copy numbers for all tumor samples (B) The mean mtDNA copy number 
for all tumor samples, presented against U266 cells. All data are represented by 
mean ± SEM. *** P = ≤ 0.001. 
 
4.5.2. Oxygen consumption rates in the U266 cell line. 
The respiratory capacity of U266 cells was compared with the oxygen 
consumption readings from other cancer cell lines. These included the HSR-
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GBM1 and hepatocarcinoma (HepG2) cell lines (Table 4.2). HepG2 cells were 
included as they represent a highly metabolically active cell type, which means 
that these cells are highly dependent on their mitochondrial function. The HSR-
GBM1 cells were included as it is the best characterized GBM cell line, 
expressing neural stem cell markers, such as CD133, NESTIN and 
MUSASHI1275. The HSR-GBM1 cell line would also be used in the following 
two Chapters for determining the role of mtDNA in GBM tumor biology, which 
makes it an appropriate cell line for comparison against the U266 cells. 
 
Table 4.2. Respirometry measurements on U266, HSR-GBM1 and HepG2 cells.  
 
 
U266 cells have relatively low rates of oxygen consumption (approximately 
17pmol/(s*Mil), which is almost half of that detected for hepatocarcinoma 
(HepG2) cells but not as low as for HSR-GBM1 cells (Table 4.2). HSR-GBM1 
cells were identified to have basal oxygen consumption rates of 14.86 ± 
0.57pmol/(s*Mil), which is within range of the values reported from other 
studies, namely between 10-17pmol/s*Mil 166.  
 
Comparing U266 cells to other tumor types, ovarian cancer cells have even 
higher basal rates for oxygen consumption around 42pmol/s*Mil 276. U266 cells 
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also have spare oxygen reserve capacity, since values above 1.0 for the ETC 
reserve capacity, indicate that these cells can increase their basal oxygen 
consumption rates to match increases in energy demands. Additionally, activity 
of the U266 ETC is tightly coupled to OXPHOS, but not as tightly coupled as 
HepG2 cells, since values close to 2 are representative of this feature. Altogether, 
based on the differences between the basal and maximal oxygen consumption 
rates, these respirometry results show that HepG2 cancer cells respire 
predominately via OXPHOS, whereas both the U266 and HSR-GBM1 cells 
respire primarily via glycolysis. However, there is still active OXPHOS activity 
within both U266 and HSR-GBM1 cells. 
 
4.5.3. Depletion of mtDNA in U266 cells. 
U266 cells were then depleted of their mtDNA for over 30 days (Figure 4.6A). 
From day 10 of depletion, there was a significant decline in mtDNA copy 
number, suggesting that the maximal effect of ddC was exerted by this stage of 
culture.  
 
Analysis of cell population doubling times, defined as the duration of time 
required for the complete division of a single cell277, revealed that the rate of 
proliferation in U266 cells decreased with prolonged exposure of ddC (Figure 
4.6B), whilst non-treated cells continued to proliferate at a consistent rate with a 
population doubling time of 43.16 ± 1.73 hours.  
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Figure 4.6. MtDNA depletion of U266 cells for 30 days using ddC (A) Changes 
in the pattern of mtDNA copy numbers per cell are measured during mtDNA 
depletion (black). (B) Cell population doubling times during mtDNA depletion 
(blue) of the U266 cells relative to the untreated control (red). *P = ≤ 0.05, *** 
P = ≤ 0.001. 
 
4.5.4. Expression of the mtDNA genes during depletion of U266 cells  
After observing changes to mtDNA copy number during mtDNA depletion, the 
expression of the mtDNA-encoded genes was analysed. These gene products are 
responsible for maintaining the function of the ETC.  
 
The progressive loss of mtDNA copy number induced by ddC correlated with the 
gradual decline of expression for the mtDNA-encoded genes. Amongst the genes 
assessed, there were differences in the rates at which the expression levels 
decreased. Both ND1 (Figure 4.7A) and ATP6 (Figure 4.7E) decreased their 
relative expression levels at a slower rate compared to ND6 (Figure 4.7B), CYTB 
(Figure 4.7C) and COX II (Figure 4.7D), which showed a more rapid decrease 
in their relative expression levels during the early stages of mtDNA depletion 
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(between days 0 and 3). For all genes, relative expression levels were almost 
negligible from day 21 of mtDNA depletion onwards.  
 
 Figure 4.7. Changes to the relative expression of the mtDNA-encoded genes 
during depletion. Complex I (A) ND1 and (B) ND6, Complex III (C) CYT B, 
Complex IV (D) COX II and Complex V (E) ATP6. The N15 sample (grey) 
represents a blood plasma non-tumor control for U266 cells (white). *P = ≤ 
0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
 
Comparisons between non-treated U266 cells and the blood plasma N15 sample, 
which represents the non-tumorigenic counterpart of U266 cells, showed variable 
patterns of expression for all mtDNA-encoded genes examined. Normally, one 
would expect the U266 cells to have decreased expression of OXPHOS genes. 
This is because the activity of the ETC protein complexes have been shown to be 
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down-regulated in other cancer types, such as in renal carcinoma cells when 
compared to their normal counterparts278. In the case of renal carcinoma, a 
correlation has even been determined between low OXPHOS activity and the 
stage of tumor progression279. However, gene expression results showed that 
levels of CYT B and ATP6 were both higher in the blood plasma sample than in 
U266 day 0 cells, which emphasizes differences between cancers of different 
origin.  
 
4.5.5. Expression changes to the mitochondrial transcription and replication 
genes  
The expression of the nuclear genes involved with the transcription and 
replication of mtDNA were examined during mtDNA depletion. Throughout the 
course of depletion, relative expression of the genes involved with mitochondrial 
biogenesis (PGC1α, PPARδ and SIRT3, Figures 4.8A-C) were maintained 
above levels of day 0 cells at all times. For each of these genes of mitochondrial 
biogenesis, their relative expression levels increased by at least 2 fold by day 30 
of mtDNA depletion compared to day 0 cells. PPARδ, SIRT3 and NRF1 (Figure 
4.8D) expression levels displayed a two-stage increase in relative levels during 
mtDNA depletion, which occurred from day 3 to day 14, and from day 21 to day 
30.  
 
The fall in relative PPARδ expression at day 21 of mtDNA depletion 
corresponded with the gradual decline in PGC1α expression from day 14 to 27 
of mtDNA depletion. This change in expression pattern supports the role of 
PPARδ regulating the expression of PGC1α. The gene expression profile for  
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Figure 4.8. Gene expression levels for the upstream mitochondrial regulators of 
mitochondrial biogenesis factors (A) PGC1α (B) PPARδ and (C) SIRT3; and 
those that control mitochondrial transcription (D) NRF1 and (E) NRF2β. *P = ≤ 
0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
 
SIRT3 from day 21 of mtDNA depletion revealed the opposite trend to PGC1α 
levels. It is possible that SIRT3, as a downstream target of PGC1α, could have 
up-regulated its gene expression levels to compensate for the down-regulation of 
PGC1α levels and to maintain mitochondrial biogenesis by this late stage of 
mtDNA depletion. Both NRF1 and NRF2β decreased their relative gene 
expression levels during the early stages of mtDNA depletion, which gradually 
increased above levels of day 0 cells after prolonged mtDNA depletion. All the 
mitochondrial biogenesis and nuclear respiratory factor genes demonstrated 
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higher expression levels in U266 day 0 cells compared to the N15 blood plasma 
sample.  
 
All mitochondrial transcription and replication genes experienced an up-
regulation in their expression levels by the late stages of mtDNA depletion 
(Figure 4.9). Although, the expression patterns during mtDNA depletion varied 
between genes, several displayed common trends. For TFAM, TFB1M (Figure 
4.9B) and TFB2M (Figure 4.9C) expression levels were similar from day 14 to 
day 30 of mtDNA depletion. The similarity in pattern could be due to TFAM 
directing regulating TFB1M and TFB2M during the initiation of mtDNA 
replication280. 
 
Perhaps the most important amongst all the genes analysed are the transcription 
factors TFAM, TFB1M and TFB2M (Figure 4.9C), since the expression of these 
could influence the expression of other genes examined. For example, the 
decrease in the expression levels of TFAM, TFB1M and TFB2M at day 21 of 
mtDNA depletion, could be responsible for the decrease in expression levels at 
day 21 of depletion for PGC1α (Figure 4.8A), PPARδ (Figure 4.8B), SIRT3 
(Figure 4.8C), NRF1 (Figure 4.8D), POLGB (Figure 4.9E), MTERF (Figure 
4.9G) and TWINKLE (Figure 4.9H). 
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Figure 4.9. Expression of the mitochondrial transcription and replication 
factors. Mitochondrial regulators of transcription (A) TFAM, (B) TFB1M and 
(C) TFB2M, and the mitochondrial replication genes (D) POLGA, (E) POLGB, 
(F) MTSSB, (G) MTERF and (H) TWINKLE were examined during mtDNA 
depletion in U266 cells. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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The highest fold-change increase in gene expression levels was reported for 
MTERF, which exhibited over a 6-fold increase in expression levels at day 27 of 
depletion compared to day 0 cells. POLGB had the second highest fold-change 
difference detected at day 30 of mtDNA depletion, which was 4.5 fold-higher 
than day 0 cells. Both POLGA and TFAM experienced an initial decline in 
relative gene expression at day 3 of depletion, which was followed by up-
regulation in expression levels until days 14 or 21, respectively.  
 
For a few genes including TFB1M, TFB2M, and MTSSB (Figure 4.9F), gene 
expression levels were similar at days 3 and 7 of mtDNA depletion. This could 
suggest a delay in the response of the transcriptional machinery to respond to the 
loss of mtDNA copies during depletion, since expression levels at day 3 and 7 
were comparable to day 0 cells. Despite minor changes to expression levels of 
TFB1M, POLGB and MTERF during the early stages of mtDNA depletion, by 
day 14, relative expression of these genes almost doubled to compensate for the 
minimal changes to gene expression that occurred earlier during mtDNA 
depletion.  
 
Furthermore, the gene expression profile for MTSSB showed increases to its 
relative expression levels throughout mtDNA depletion, which occurred in a 
stepwise manner (Figure 4.9F). For all the mitochondrial transcription and 
replication factors (Figure 4.9), expression levels in day 0 cells were detected at 
higher levels than for the non-tumorigenic blood plasma sample, especially for 
POLGA and TWINKLE, where expression in the plasma sample was almost 
negligible.  
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4.5.6. Expression of the genes regulating multiple myeloma tumor biology  
Tumor cells are highly reliant on energy production from glycolysis to maintain 
their ability to undergo rapid proliferation. Gene expression analysis was 
performed on selected genes associated with proliferation and apoptosis in 
multiple myeloma.  
 
For a selection of tumor genes, including XBP1 (Figure 4.10A), IL6 (Figure 
4.10B) and DAD1 (Figure 4.10G), relative gene expression did not increase 
above day 0 cells at any time during mtDNA depletion. Instead, gene levels 
remained above 50% of the gene expression levels for day 0 cells. Changes to 
gene expression patterns for the survival genes DAD1 and MCL1 could indicate 
that it was necessary for the cells to maintain expression levels of these genes 
close to that of U266 control cells, to ensure cell survival throughout mtDNA 
depletion. 
 
XBP1, DAD1, IL6 and also MCL1 (Figure 4.10D) showed that during the later 
stages of mtDNA depletion, from day 14 or 21 onwards, there was a decrease in 
the levels of expression for these genes. On the other hand, for the remaining 
genes, STAT3 (Figure 4.10C), FGFR3 (Figure 4.10E), MAPK (Figure 4.10F) 
and CASP8 (Figure 4.10H), expression levels increased during the late stages of 
mtDNA depletion. For these up-regulated genes, MAPK demonstrated the 
greatest increase with a fold change difference of at least 3 times the levels of 
day 0 cells by day 21 of mtDNA depletion. From day 21 onwards, MAPK 
expression reached a plateau where expression levels were likely to be at its 
maximal.  
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Figure 4.10. Gene expression changes to key tumorigenic genes during 
depletion. (A) XBP1 (B) IL6 (C) STAT3 and (D) MCL1 (E) FGFR3 (F) MAPK 
(G) DAD1 and (H) CASP8. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
 
	  	   199	  
For all the tumorigenic genes, the blood plasma sample exhibited lower gene 
expression levels compared to day 0 U266 cells. This observation supports the 
hypothesis that tumor cells require elevated expression levels of these genes to 
enable them to persist in the host environment. Moreover, lower expression 
levels in the blood plasma sample were expected, since non-tumor cells have 
reduced rates of proliferation compared to their tumorigenic counterparts. 
Finally, the 2-fold difference between the expression levels of CASP8 in the 
blood plasma sample compared to day 0 cells was also consistent with a study 
performed on genetically identical individuals. In this study, CASP8 expression 
was two-fold higher in the individual diagnosed with multiple myeloma, when 
compared to the healthy control281. 
 
4.5.7. ATP and lactate production during mtDNA depletion  
Next, the metabolic characteristics, in the form of ATP and lactate production in 
U266 cells, were examined in the context of mtDNA depletion. Total ATP 
production gradually increased in levels during mtDNA depletion (Figure 
4.11A). However, a temporary decline in ATP production at days 24 and 27 was 
detected, which preceded peak levels at day 30 of depletion. Total lactate 
production also increased with mtDNA depletion until day 28 (Figure 4.11B), 
after which levels declined by day 31.  
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Figure 4.11. Changes to ATP (A) and lactate (B) production during mtDNA 
depletion. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
 
4.5.8. Recovery of mtDNA copy number in the presence of glycolysis 
inhibitor.  
Next, the ability to recover mtDNA copy number in depleted U266 cells was 
examined. This was done in the presence and absence of glycolysis inhibitor, 2-
deoxyglucose (2-DG). From the respirometry results, it was previously 
determined that U266 cells primarily respire via glycolysis, even in the presence 
of some OXPHOS activity (Table 4.2). Therefore, the use of 2-DG would not 
only confirm these outcomes, but would also examine the extent to which these 
cells are reliant on glycolysis. 
 
It was identified that 7 days after mtDNA depletion, U266 cells were able to 
recover their mtDNA copy numbers above day 0 cells by day 14 of recovery 
(Figure 4.12A). However, in the presence of 2-deoxyglucose (2-DG), mtDNA 
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Figure 4.12. Recovery of mtDNA copy numbers in U266 cells after mtDNA 
depletion, cultured in the presence and absence of 2-DG. (A) 7 days of mtDNA 
depletion, (B) 14 days of mtDNA depletion. ‘R’ represents the number of days of 
mtDNA replenishment, and (G) represents the addition of 2-DG in culture. (C) 
Population doubling times during depletion in the presence and absence of 
recovery, both with and without 2-DG. ** P = ≤ 0.01; *** P = ≤ 0.001. 
C	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copy number was unable to replenish efficiently. For 14-day mtDNA depleted 
cells, recovery of mtDNA copy number was not noticeable until 14 days of 
culture in complete media (Figure 4.12B). It was not possible to analyse U266 
cells cultured in 2-DG during recovery for 14 days (Figure 4.12B), as these cells 
were undergoing significant loss of cell numbers by day 7 of recovery (Figure 
4.12C).  
 
Population doubling times of cells depleted of their mtDNA for 7 days and 
recovered in the absence of 2-DG, were able to recover proliferation rates similar 
to the non-depleted cells (Figure 4.12C). However, this was not possible for the 
same cells recovered in the presence of 2-DG, which signified that there is a 
requirement for functional glycolysis in controlling the proliferation rates of 
these cells. Furthermore, cells that underwent prolonged mtDNA depletion for 14 
days were not able to restore proliferation rates back to normal levels, even in the 
absence of 2-DG. This observation indicated the presence of irreversible damage 
at the mtDNA level induced by ddC in these cells, which not only corresponded 
to results from the copy number analysis (Figure 4.12B), but also determined 
that there was a role for mtDNA in controlling proliferation rates.  
 
In the presence of 2-DG, recovery of 14-day mtDNA depleted cells showed that 
these cells were not able to proliferate but instead underwent loss of cell 
population numbers, as negative values represented the time (in hours) required 
for the cell population to halve rather than to double. 
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4.5.9. Changes in expression to the mtDNA genes during recovery with 2-
DG.  
Since ddC appeared to exert an influence on mtDNA copy numbers, which was 
an effect dependent upon the duration of cell culture, further experiments were 
performed to determine whether the effects of ddC were reversible in the 
presence and absence of 2-DG. 
 
For 7-day mtDNA depleted cells recovered in 2-DG, there was increased 
expression of the mtDNA-encoded genes, relative to recovery without 2-DG 
(Figure 4.13). Most noticeably, expression levels increased significantly by day 
7 of recovery for all genes examined in the presence of 2-DG. This could be due 
to increased activity of the fatty acid oxidation pathway282, resulting in the 
production of acetyl-coenzyme A (acetyl-CoA) and the generation of reducing 
factors via the citric acid cycle, for use in the ETC283. The sudden requirement 
for OXPHOS activity under the influence of 2-DG, could positively regulate the 
expression of these key mtDNA genes. Together the results demonstrate the 
presence of a compensatory mechanism that acts to restore or up-regulate activity 
of the ETC following mtDNA depletion, which is enhanced following the 
inhibition of glycolysis. 
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Figure 4.13. Changes in expression to the mtDNA genes during recovery with 2-
DG, after 7 days of mtDNA depletion. Complex I genes (A) ND1 and (B) ND6, 
Complex III gene (C) CYT B, Complex IV gene (D) COX II and Complex V gene 
(E) ATP 6. ‘R’ represents the number of days of mtDNA replenishment, and (G) 
represents the addition of 2-DG in culture. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = 
≤ 0.001. 
 
In the absence of 2-DG, recovery of the mtDNA gene expression levels after 14 
days of depletion (Figure 4.14) occurred less efficiently than cells depleted for 
only 7 days (Figure 4.13). In the presence of 2-DG, changes to the relative 
expression levels of the mtDNA genes at day 7 of recovery after 14 days of 
depletion (Figure 4.14), were similar to the 7-day recovered cells that have been 
depleted for 7 days (Figure 4.13). Whereas, significant increases were observed 
to ND1 (Figure 4.14A), ND6 (Figure 4.14B) and COX II (Figure 4.14D) 
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expression levels compared to day 0 cells when undergoing recovery with 2-DG 
after prolonged (14 days) mtDNA depletion, this was not seen for ATP6 (Figure 
4.14E). While it is unlikely that the absence of ATP6 expression during this time 
could be due to defects to the transcriptional machinery, it remains possible that 
there may be defects to the ATP6 gene structure itself, which prevents the 
recovery, and therefore detection, of its gene levels. For example, ATP6 may 
undergo rapid degradation due to insufficient post-transcriptional modifications 
that would otherwise stabilize the gene for detection during real-time PCR 
analysis. 
 
Figure 4.14. Expression changes to the mtDNA genes during recovery with 2-
DG, after 14 days of mtDNA depletion. Complex I genes (A) ND1 and (B) ND6, 
Complex III gene (C) CYT B, Complex IV gene (D) COX II and Complex V gene 
(E) ATP 6. ‘R’ represents recovery in days, and (G) represents the presence of 2-
DG. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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From these results, it can be determined that overall, in the absence of glycolysis 
there is an increased need for the cell to up-regulate its transcriptional machinery 
to enhance the expression of mtDNA encoded genes. Aside from the anomalous 
result for ATP6 (Figure 4.14E), the general trends in the mtDNA gene 
expression patterns during recovery in the presence of 2-DG, represent a cellular 
attempt to switch its primary mode of metabolism from glycolysis to OXPHOS, 
most likely to maintain cell viability. Both these pathways are essential for 
energy production, and the lack of both would be detrimental to many aspects of 
cellular function and to many of the processes involved. 
 
4.5.10. Expression of the upstream mitochondrial regulators during 
recovery with 2-DG.  
Upon examining the changes in expression levels for upstream regulators 
involved with mitochondrial biogenesis, several key observations were made. 
Firstly, in the presence of 2-DG, genes PGC1α, PPARδ, NRF1 and NRF2β all 
decreased their expression levels during recovery after 7 days of mtDNA 
depletion, relative to cells recovered without 2-DG (Figure 4.15A, 4.15B, 4.15D 
and 4.15E). This suggested that the recovery of expression levels for these genes 
was more efficient in the absence of 2-DG. 
 
PGC1α was the only mitochondrial biogenesis gene whose levels remained 
above day 0 cells at all times throughout mtDNA replenishment. The changes in 
expression of SIRT3 during recovery with 2-DG was also more variable than 
recovery without the inhibitor (Figure 4.15C). The two-fold increase in SIRT3 
expression at day 3 of replenishment with 2-DG, could indicate an attempt to  
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Figure 4.15. Expression of the upstream mitochondrial regulators during 
recovery with 2-DG, after 7 days of depletion. Mitochondrial biogenesis genes  
(A) PGC1α, (B) PPARδ and (C) SIRT3. Nuclear respiratory factors (D) NRF1 
and (E) NRF2β. ‘R’ represents recovery in days, and (G) represents the presence 
of 2-DG. *P= ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
 
maintain mitochondrial biogenesis since SIRT3 mediates the effects of PGC1α. 
In the absence of inhibitor, SIRT3 expression during mtDNA replenishment was 
close to levels of 7-day mtDNA depleted cells, which can also be observed for 
both NRF1 and NRF2β at all stages of mtDNA replenishment (Figures 4.15D 
and 4.15E). 
 
A comparison of gene expression changes after 7 and 14 days of mtDNA 
depletion revealed that the mitochondrial biogenesis genes had more variable 
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changes during recovery after 14 days of depletion, which suggests that by this 
stage there could be irreversible damage to mtDNA. Cells recovered in the 
absence of 2-DG showed a decline in PPARδ (Figure 4.16B), SIRT3 (Figure 
4.16C), NRF1 (Figure 4.16D) and NRF2β (Figure 4.16E) levels below that of 
14-day mtDNA depleted cells, until day 7 of recovery. These recovered cells also 
had similar NRF1 and NRF2β expression profiles during the course of recovery. 
 
 
Figure 4.16. Expression of the upstream mitochondrial regulators during 
recovery with 2-DG, after 14 days of depletion. Mitochondrial biogenesis genes  
(A) PGC1α, (B) PPARδ and (C) SIRT3. Nuclear respiratory factors (D) NRF1 
and (E) NRF2β. ‘R’ represents recovery in days, and (G) represents the presence 
of 2-DG. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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However, cells cultured in the presence of 2-DG failed to up-regulate NRF2β 
expression by day 7 of mtDNA replenishment, whereas for NRF1, expression 
levels increased by this stage of recovery. 
 
4.5.11. Expression of the mitochondrial transcription and replication genes 
during recovery with 2-DG 
For cells recovered in the presence of 2-DG, gene expression levels of POLGB 
(Figure 4.17E), MTERF (Figure 4.17G) and TWINKLE (Figure 4.17H) were 
lower than for cells cultured in the absence of the inhibitor at all stages of 
mtDNA replenishment. For POLGB, expression in the presence of 2-DG 
remained low throughout recovery, at levels below 50% of 7-day mtDNA 
depleted cells. Expression levels of TFAM, TFB1M and TFB2M (Figures 4.17A-
C) during mtDNA recovery in the absence of 2-DG were close to 7-day mtDNA 
depleted and day 0 cells throughout recovery. This expression pattern was also 
observed for NRF1 and NRF2β (Figures 4.15D and 14.15E), both products of 
which control the transcription of TFAM, TFB1M and TFB2M.  
 
MTSSB was the only mitochondrial replication gene whose expression in the 
presence of 2-DG increased above cells recovered in the absence of 2-DG at days 
3 and 7 of recovery (Figure 4.17F). This change in MTSSB expression levels 
could indicate an attempt to increase efficiency of mitochondrial replication 
during recovery in 2-DG. However, without similar expression increases for the 
other mitochondrial replication genes, mtDNA copy number did not undergo 
efficient mtDNA replenishment as for cells cultured in the absence of glycolysis 
inhibitor (Figure 4.12A).  
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Figure 4.17. Expression of the mitochondrial transcription and replication genes 
during recovery with 2-DG, after 7 days of mtDNA depletion. Regulators of 
transcription (A) TFAM, (B) TFB1M, (C) TFB2M, and regulators of mtDNA 
replication (D) POLGA, (E) POLGB, (F) MTSSB, (G) MTERF and (H) 
TWINKLE. ‘R’ represents recovery in days, and (G) represents the presence of 
2-DG. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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Figure 4.18. Expression of the mitochondrial transcription and replication genes 
during recovery with 2-DG, after 14 days of mtDNA depletion. Regulators of 
transcription (A) TFAM, (B) TFB1M, (C) TFB2M, and regulators of mtDNA 
replication (D) POLGA, (E) POLGB, (F) MTSSB, (G) MTERF and (H) 
TWINKLE. ‘R’ represents recovery in days, and (G) represents the presence of 
2-DG. *P = ≤ 0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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Gene expression levels for 14-day mtDNA depleted cells recovered for 14 days 
in the absence of 2-DG were often double the levels detected at day 3 of recovery 
under the same culture conditions. This can be seen for NRF1, NRF2β (Figures 
4.16D-E), TFAM, TFB1M (Figures 4.18A-B) and MTSSB (Figure 4.18F). 
Occasionally, there was a greater than two- fold increase between cells recovered 
for 3 days and those recovered for 14 days in the absence of 2-DG after 14 days 
of mtDNA depletion. This was observed for TFB2M (Figure 4.18C), POLGA 
(Figure 4.18D) and TWINKLE (Figure 4.18H). 
 
During mtDNA replenishment there was a significant up-regulation in the 
expression levels of POLGA, which was suppressed in the presence of 2-DG. 
Expression levels for the supporting subunit, POLGB (Figure 4.18E), showed 
little change during the course of mtDNA replenishment for cells cultured in the 
absence of 2-DG. Furthermore, gene expression patterns for MTSSB during 
recovery in the absence of 2-DG after 14 days of mtDNA depletion, 
demonstrated an increasing trend with the duration of mtDNA replenishment 
(Figure 4.18F), which was more apparent than for cells depleted of their mDNA 
for 7 days in culture (Figure 4.17F). 
 
Cells depleted of their mtDNA for 14 days and recovered for the same length of 
time, without 2-DG, had TFAM, TFB1M and TFB2M (Figures 4.18A-C) gene 
expression profiles that were similar to NRF1 and NRF2β (Figures 4.16D-E). 
This was similar to the situation described previously for 7-day mtDNA depleted 
cells during recovery without the inhibitor, which supports the hypothesis that 
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these changes in gene expression patterns could be due to NRF1 and NRF2β 
regulating the transcription of these mitochondrial transcription factors.  
 
For most of the mitochondrial transcription and replication genes (TFB1M, 
TFB2M, POLGB and MTSSB), cells cultured in the presence of 2-DG 
demonstrated an increase in gene expression levels with the duration of mtDNA 
replenishment. A few genes, TFAM and MTERF, showed decreases in their 
expression levels during mtDNA replenishment, and others revealed no change 
during this recovery period, POLGA and TWINKLE.  
 
From these observations, it can be proposed that glycolysis plays a major role in 
the energy metabolism of U266 cells. OXPHOS is also likely to have a role in 
maintaining survival of these tumor cells. This is because inhibition of glycolysis 
during mtDNA replenishment resulted in increased levels of expression for the 
mtDNA-encoded genes, which suggests that for the survival of these tumor cells 
it is necessary to ensure sufficient OXPHOS occurs, despite the presence of 
dysfunctional glycolysis. However, overall U266 cells have a greater reliance on 
glycolysis, since cells depleted of their mtDNA for 14 days and recovered in the 
presence of 2-DG underwent a reduction in cell population numbers (Figure 
4.12C). 
 
4.5.12. Expression of the multiple myeloma tumor genes during recovery 
with 2-DG 
Recovery of mtDNA copy numbers after 7 days of mtDNA depletion in cells 
recovered in the absence of 2-DG led to early up-regulation of some genes 
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including MCL1 (Figure 4.19D) and MAPK (Figure 4.19F). Whilst these 
observations suggested that there is an immediate effect upon mtDNA 
replenishment to increase tumorigenecity of U266 cells, other genes XBP1 
(Figure 4.19A), IL6 (Figure 4.19B), STAT3 (Figure 4.19C) and FGFR3 (Figure 
4.19E) revealed up-regulation in their expression levels by the late stages of 
mtDNA replenishment.  
 
The expression profiles for IL6 and STAT3 in cells recovered in the absence of 2-
DG, shared very low expression levels until day 7 of mtDNA replenishment, 
after which there was a significant rise in their levels of gene expression. This 
effect was more pronounced for STAT3 than for IL6. For CASP8 little change in 
expression levels was observed relative to 7-day mtDNA depleted cells (Figure 
4.19H), whereas for DAD1 there was the failure to up-regulate expression levels 
throughout mtDNA replenishment (Figure 4.19G). 
 
Cells recovered in the presence of 2-DG had variable patterns of expression. 
XBP1, STAT3 and FGFR3 had low levels of expression throughout mtDNA 
replenishment, below 50% of 7-day mtDNA depleted cells. This suggests that 
suppression of glucose metabolism impaired transcription of these tumor genes. 
However, in the short-term, the tumorigenic potential of U266 cells recovered in 
the presence of 2-DG was enhanced by increased transcription of MAPK, whose 
product participates in cellular proliferation. IL6, DAD1 and CASP8 had similar 
trends in expression levels during recovery after 7 days of mtDNA depletion, 
with peak levels observed at day 7 of recovery in the presence of 2-DG.  
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Figure 4.19. Expression of the multiple myeloma tumorigenic genes during 
recovery with 2-DG, after 7 days of mtDNA depletion. (A) XBP1, (B) IL6, (C) 
STAT3, (D) MCL1, (E) FGFR3, (F) MAPK, (G) DAD1 and (H) CASP8. ‘R’ 
represents recovery in days, and (G) represents the presence of 2-DG. *P = ≤ 
0.05; ** P = ≤ 0.01; *** P = ≤ 0.001. 
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Altogether, these increases in gene expression were consistent with the 
hypothesis that inhibition of glycolysis increases tumorigenic properties of U266 
cells. Differences between XBP1 and IL6 expression profiles for cells cultured 
with 2-DG, may reflect the need to up-regulate IL6 expression in situations 
where XBP1 expression is low to compensate for the reduced stimulation from 
XBP1 on the IL6 promoter region. This could also be true for the gene 
expression changes between STAT3 and its downstream target MCL1, in cells 
recovered in the presence of the glycolysis inhibitor. 
 
Expression levels of XBP1 (Figure 4.20A), DAD1 (Figure 4.20G) and CASP8 
(Figure 4.20H) during recovery in the absence of 2-DG, after 14 days of mtDNA 
depletion, were similar to the gene expression changes observed for XBP1 during 
recovery after 7 days of mtDNA depletion (Figure 4.19A). Moreover, gene 
expression levels for IL6 during mtDNA replenishment after 14-days of mtDNA 
depletion shared the observation with 7-day mtDNA depleted cells that, in the 
presence of 2-DG, there were higher levels of IL6 compared to cells recovered in 
the absence of 2-DG. 
 
During recovery in the presence of 2-DG, expression levels of STAT3 (Figure 
4.20C), MCL1 (Figure 4.20D) and MAPK (Figure 4.20F) after 14 days of 
mtDNA depletion, was compromised more than at day 7 days of depletion 
(Figure 4.20C). Moreover, both the expression levels of MCL1 and MAPK were 
lower in cells that have been recovered in 2-DG, compared to those that were 
recovered without 2-DG at all stages of mtDNA replenishment. 
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Figure 4.20. Expression of the multiple myeloma tumorigenic genes during 
recovery with 2-DG, after 14 days of mtDNA depletion. (A) XBP1, (B) IL6, (C) 
STAT3, (D) MCL1, (E) FGFR3, (F) MAPK, (G) DAD1 and (H) CASP8. ‘R’ 
represents recovery in days, and (G) represents the presence of 2-DG. *P = ≤ 
0.05; ** P = ≤ 0.01; *** P = ≤ 0.001.  
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Altogether, 14 days of mtDNA replenishment after 14 days of depletion resulted 
in the increased ability to recover expression levels for the genes involved with 
tumor cell survival (XBP1, STAT3, MCL1, DAD1 and CASP8), and cellular 
proliferation (FGFR3 and MAPK). These observations emphasize that the 
tumorigenic characteristics of U266 cells are likely to be enhanced following 
prolonged depletion of their mtDNA (for 14 days) and 14 days of mtDNA 
recovery, when cultured in the absence of 2-DG.  
 
4.5.13. Determining the levels of apoptosis in mtDNA depleted and/or 
recovered U266 cells 
OPA1 is a nuclear-encoded mitochondrial protein that is localized to the inner 
membrane of mitochondria284. Processing of OPA1 is stimulated during 
apoptosis, reflecting the loss of the mitochondrial inner membrane potential, 
which is independent of any dysfunction to glycolysis or OXPHOS. During 
mtDNA depletion, levels of apoptosis for U266 cells increased significantly by 
day 21 of depletion (Figure 4.21), which is exemplified by greater expression of 
the shorter isoforms at positions (d) and (e).  
 
For cells recovered for 14 days after 7 days of mtDNA depletion, there was also 
an increase in the levels of apoptosis. However, this effect was more pronounced 
in cells recovered for 7 days after 14 days of mtDNA depletion, where very high 
levels of apoptosis were detected. By day 14 of recovery after 14 days of 
depletion, OPA1 processing to its shorter isoform was reduced, indicating 
reduced levels of apoptosis by this stage. Furthermore, the observation that there 
was restoration of the long OPA1 isoforms by day 14 of recovery after 14 days 
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of depletion suggests that any increases to the rates of cell proliferation (Figure 
4.12C) could be attributed to damage imposed upon the mitochondrion at this 
stage. 
 
 
Figure 4.21. Western blot analysis showing processivity of OPA1 in mtDNA 
depleted and/or recovered U266 cells. Processing of the long isoform of OPA1 
(b) into its short isoforms (d and e) is shown, with greater expression of the 
shorter isoform representing high levels of apoptosis in these cells. Lane 5 
contained insufficient protein sample and was therefore excluded from analysis. ‘ 
– ‘ represents mtDNA depletion without recovery, ‘ + ‘ represents mtDNA 
recovery for the stated number of days. Data were collected by Dr Michael 
Baker at the Bio21 Institute, Melbourne.  
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4.6. Discussion 
4.6.1. MtDNA copy number in normal and cancer cells 
Normal undifferentiated cells usually have low levels of mtDNA copy numbers, 
which expands with differentiation285. These early progenitor cells rely on 
glycolysis as their primary method for glucose metabolism, and characteristically 
have faster rates of proliferation286. During differentiation, the increase in 
mtDNA copy numbers is dependent on cell type. Highly metabolically active 
cells normally have higher requirements for metabolism via OXPHOS, thereby 
possessing higher mtDNA copy numbers than metabolically inactive cells287,288.  
 
The regulation of mtDNA copy number in tumor cells would be expected to 
follow similar patterns to normal undifferentiated cells, since cancer cells also 
undergo rapid proliferation. This is supported by others suggesting that mtDNA 
depletion is responsible for the progression of gastric carcinoma289, as well as 
increased proliferation and reduced sensitivity to apoptosis in osteosarcoma290 
and lung carcinoma cells291.   
 
Analysis of the patient tumor samples demonstrated variability in their mtDNA 
copy numbers (from 280 to 890 copies per cell). Whilst the average mtDNA 
copy number of all these tumor samples was not significantly different to those 
in U266 cells. These variations could be due to differences in the mtDNA 
variants present in these samples, since U266 cells were determined to have a 
different set of variants compared to patient tumor samples (Chapter 3).  
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4.6.2. Changes in the gene expression patterns during mtDNA depletion 
The expression of genes participating in the transcription and replication of 
mtDNA, as well as those associated with the tumor biology of multiple myeloma 
were much higher in U266 cells compared to the plasma sample. A primary 
cause of many mtDNA depletion syndromes has been thought to involve the 
impairment of nuclear-encoded factors responsible for the maintenance of 
mtDNA, rather than from mutations within the mtDNA itself292. However, in this 
situation, mtDNA depletion acts as the initial cause of metabolic stress, the 
expression of nuclear-encoded mitochondrial genes were observed to increase 
during the late stages of mtDNA depletion. This could reflect a compensatory 
response to protect against the complete loss of mtDNA. 
 
The concept of a compensatory mechanism can also be applied to the gene 
expression analyses conducted on the key tumorigenic genes for multiple 
myeloma. It was discovered that expression levels of these genes did not 
decrease below 50% of levels of U266 control cells at any point during mtDNA 
depletion, suggesting the presence of a mechanism to preserve and maintain the 
tumor phenotype of these cells. These results corresponded with others that have 
suggested increases in nuclear gene expression levels, augmentation of the tumor 
phenotype and chromosomal instability are common features in mtDNA depleted 
cells293. Moreover, increased nuclear gene expression has been reported in yeast 
petite mutants that lack mtDNA294. 
 
One of the key observations from these results included the up-regulation of 
tumor proliferation genes, FGFR3 and MAPK, in U266 cells depleted for 14 days 
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and recovered in the absence of 2-DG (Figure 4.20E-F). Despite these changes, 
these cells proliferated at a significantly slower rate, as observed from their 
population doubling times (Figure 4.12C). The evidence that the reduction in the 
cell proliferation rates for these U266 cells, depleted and recovered for 14 days 
each, are attributed specifically to the insufficient replenishment of mtDNA 
(Figure 4.12B) can be explained by the western blot analysis performed on 
OPA1, which show the presence of intact, functional mitochondria by this stage 
of recovery.  
 
Results from this Chapter was able to show that decreased expression of the 
mtDNA-encoded genes during mtDNA depletion led to decreases in the rates of 
cell proliferation, despite significant up-regulation made to the expression of the 
nuclear-encoded genes participating in the biogenesis, transcription and 
replication of mtDNA. These observations emphasise the importance of mtDNA 
copy numbers in the control of gene expression at both the mitochondrial and 
nuclear-level. 
 
4.6.3. Changes during mtDNA replenishment in the presence and absence of 
2-DG 
Although replenishment of mtDNA copy number could be assisted by the 
addition of deoxynucleoside monophosphates in culture295, for this study the 
recovery of mtDNA copies was performed by removing the influence of ddC and 
re-culturing of these cells in fresh media in the absence of ddC. This method 
allowed for the assessments of the natural rate of mtDNA replenishment after a 
period of induced stress.  
	  	   223	  
 
Cells recovered with 2-DG were not able to increase mtDNA copy numbers 
similar to those cells recovered without 2-DG. This could be due to the reduced 
availability of metabolic intermediates from the glycolysis pathway that can be 
used in the pentose phosphate pathway. Such intermediates include ribose-5-
phosphate that is required for the biosynthesis of nucleotides, which can be used 
during mtDNA replication296.  
 
The recovery of gene expression after 7 days of mtDNA depletion in the 
presence of 2-DG, led to increases in levels of the mtDNA-encoded genes, 
compared to the same cells recovered in its absence.  These changes could reflect 
an attempt to rescue mtDNA-encoded transcript levels when glycolysis is 
inhibited, thereby attempting to maintain the ability of the ETC to function. 
However, since the recovery of expression levels for the majority of 
mitochondrial biogenesis, transcription and replication genes decreased during 
recovery in the presence of 2-DG after mtDNA depletion, it is possible that the 
opposite patterns of gene expression observed between the mitochondrial and 
nuclear genes could be related.  
 
To explain the increased expression of the mtDNA-encoded genes, and the 
decreased expression of the mitochondrial biogenesis, transcription and 
replication genes during recovery with 2-DG, the effects induced by 2-DG itself 
are explored. It has been shown that in the presence of high glucose 
concentrations, there is the preferential accumulation of the transcription factor 
complex, MondoA-Mlx, in the nucleus297. This heterodimeric complex is 
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commonly known as a ‘transcriptional biosensor’ that responds to glucose flux, 
and is responsible for as much as 75% of glucose-induced transcription298. 
MondoA-Mlx is capable of shuttling between the nucleus and mitochondria299, 
and in the presence of glucose it facilitates the binding of MondoA-Mlx to the 
promoters of target genes, followed by the recruitment of transcriptional 
coactivators and finally in the activation of gene expression297. Therefore, in the 
presence of 2-DG, which would significantly lower glucose concentrations, the 
export of MondoA-Mlx from the nucleus could reflect the decrease in the 
transcription of the nuclear-encoded mitochondrial biogenesis, transcription and 
replication genes. If the nuclear export of MondoA-Mlx increases its shuttling to 
the mitochondria, this could increase the transcription of the mtDNA encoded 
genes, thereby providing a relationship between the transcription of both nuclear 
and mitochondrial genes, which is dependent on glucose concentrations.  
 
The variable patterns in the expression levels for multiple myeloma tumor 
biology genes during recovery in the presence of 2-DG, suggest that there may 
be alternative mechanisms of gene regulation for these cancer genes that is not 
related to the activities of MondoA-Mlx, but could instead be tumor-specific. 
Nonetheless, there was the up-regulation of several key cancer survival genes in 
the absence of functional glycolysis, which indicated the importance of 
glycolysis in maintaining the survival, and therefore, the tumorigenic phenotype 
of these cells.  
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4.7. Conclusion 
MtDNA plays a significant role in the tumor biology of multiple myeloma. The 
presence of sufficient copies of mtDNA is required to maintain proliferation of 
these tumor cells, a key characteristic of malignant tumors. Glycolysis was also 
determined to have an important role in the tumor biology of these cells. The 
inhibition of glycolysis during mtDNA recovery led to significant increases to 
the key survival genes IL6, DAD1 and CASP8, relative to the cells recovered in 
the absence of inhibitor, after 7 and 14 days of mtDNA depletion.  
 
These significant increases were not observed for the expression of genes 
associated with maintaining tumor cell proliferation (FGFR3 and MAPK). This 
suggests that, in the absence of glycolysis, multiple myeloma cells have reduced 
capacity to proliferate but attempt to up-regulate the expression of key survival 
genes as a defense mechanism to avoid a reduction to cell numbers. However, 
the up-regulation of these survival genes can only protect tumor cells from the 
loss of cell numbers in the short-term (7 days of mtDNA depletion), and proves 
ineffective as a defense response after prolonged mtDNA depletion, defined as a 
period of 14 days.  Glycolysis therefore predominately controls the tumorigenic 
phenotype of these cells, providing enough ATP via this cytoplasmic pathway to 
support the survival of the cancer cells, whilst being supported on some 
OXPHOS activity. It is possible that the mtDNA variants identified from Chapter 
3, may have a role in contributing towards the tumorigenic phenotype of these 
multiple myeloma cells.   
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Chapter 5: Identification of MtDNA 
Variants in Glioblastoma Multiforme 
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5.1. Introduction 
To date, a few studies have examined for the presence of variants in the nuclear 
genome that may contribute towards the progression of GBM300,301. One study in 
particular sequenced the nuclear genome of the U87MG cells, which is a cell line 
representative of grade IV glioma182. Results from this study revealed that 
sequences encoding for proteins were predominately disrupted in this cell line, 
due to large-scale chromosomal abnormalities to its genome. Combinations of 
SNPs, insertions and deletions as well as translocations were identified in this 
highly mutated cell line. However, there have been no studies that have 
investigated the potential role of mtDNA variants in the tumor biology of GBM.    
 
To address the role of mtDNA in GBM cells, analyses were performed on the 
traditional cell lines U87MG302, SF-767302 and HSR-GBM1303 cells. Often in 
primary GBM tumors, there is amplification of epidermal growth factor receptor 
(EGFR) genes304, a characteristic believed to be frequently under-represented in 
cultured GBM cells due to selection pressures that take place in vitro to eliminate 
this gene alteration305. To overcome this situation, the GBM 6 and HK301 
neurosphere cell lines were used for this investigation, since both express EGFR 
variant III (EGFRvIII). Other cell lines used in this study included the GBM L1, 
GBM L2, GBM 4, CSC-014, CSC-020, NO7-152 and BAH-1 cells, which were 
generated by Associate Professor Terrance Johns (Monash University) from 
expanded cultures of highly malignant human GBM tumors. Examining these 
cell lines derived from different GBM patients that may retain patient-specific 
characteristics in culture will enable analyses to closely represent natural 
differences in the tumor biology within each of these GBM patients.  
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The HSR-GBM1 cells were established by Vescovi et al. in 2004303. These cells 
were characterized to display traits closely resembling those of human GBM 
tumors, which include sharing their capability to migrate in vivo303. For these 
reasons, the HSR-GBM1 cells were used as the main cell line for determining 
whether mtDNA has a role in the establishment of GBM.  
 
5.2. Aims and hypothesis  
The aim of this Chapter was to sequence 12 different GBM cell lines, alongside a 
collection of patient tumor samples to determine whether GBM cells and tumor 
samples possessed the same variants, or another subset, for the establishment of 
GBM. The importance of mtDNA towards the development of GBM tumors was 
also examined.   
 
GBM cell line variants were compared with the non-tumorigenic human neural 
stem cells to ensure these GBM cell variants have not arisen as an artefact of cell 
culture. Furthermore, the GBM tumor variants were compared with normal brain 
biopsy samples to confirm that the identified variants were of tumor origin.  
 
It was hypothesized that GBM cells and tumor samples possess tumor-specific 
mtDNA variants, which would differ from those identified from the sequencing 
of multiple myeloma tumors and cells (Chapter 3). Additionally, it was 
anticipated that GBM cells and tumor samples would share a selection of 
mtDNA variants characteristic of the tumor phenotype. To determine the 
importance of mtDNA in the tumor biology of GBM, HSR-GBM1 cells were 
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depleted of their mtDNA and transplanted into BALB/c nude mice to examine 
whether the same, or different, variants arise following the replenishment of 
mtDNA copy numbers as tumor development proceeds in vivo. MtDNA variants 
that become re-established during mtDNA replenishment would likely represent 
those that are specific to GBM.  
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5.3. Methods 
The methods used are described in the following sections: 2.1.6 to 2.1.8, 2.1.9, 
2.4.1, 2.4.2, 2.6, 2.8.1, 2.8.2, 2.9.1, 2.10, 2.16 to 2.24, in addition to those below: 
 
5.3.1. HRM primers used for the screening of GBM mtDNA variants 
Primers were designed for each of the mtDNA variants identified from the Ion 
Torrent sequencing of various GBM cell lines (Table 5.1). All HRM primers 
produced a product size of between 100bp to 250bp, and all had an optimal 
annealing temperature of 55°C. 
 
Table 5.1. Primers used for GBM variant screening on the HRM: 
Variant  
Position  
(bp) 
Forward primer (5’→3’) Reverse primer (5’→3’) Product 
size (bp) 
194 TGATTCCTGCCTCATCCTATT AAGTGGCTGTGCAGACATTC 131 
302, 310 CAGGCGAACATACTTACTAAA
G 
TTAGGCTGGTGTTAGGGTTC 184 
16186, 
16218 
CCACCATGAATATTGTACGGT
A 
TGGCTTTGGAGTTGCAGTTG 147 
1386 CAAGGTGTAGCCCATGAGGT CTGTTCAACTAAGCACTCTAC 132 
1682 CACAAAGCACCCAACTTACAC GGTAAATGGTTTGGCTAAGG 116 
2130 CACAGAACCCTCTAAATCCC ACGCTTTCTTAATTGGTGGCTG 145 
5253 CTATCTCGCACCTGAAACAAG CGTAGGTAGAAGTAGAGGTTAAG 196 
5752 CAGCTAAGCACCCTAATCAAC TCTAAAGACAGGGGTTAGGC 161 
6422 CTTCTCCTTACACCTAGCAG GTAGGACTGCTGTGATTAGG 123 
6999 CTCTGAGCCCTAGGATTCAT CAGTGAATGAAGCCTCCTATG 152 
8251, 
8252 
CTCTGAAATCTGTGGAGCAAA
C 
CTAAGTTAGCTTTACAGTGGG 131 
10473 GGATTAGACTGAACCGAATTG AGTAGGGAGGATATGAGGTG 175 
10814 CCTAAACCTACTCCAATGCT AGGAAAAGGTTGGGGAACAG 186 
11361 GGCTCACTAAACATTCTACTA
C 
CTGCGGCAAGTACTATTGAC 165 
11512 CGCTGGGTCAATAGTACTTG GTTATAATTATGCCTCATAGGGATA
G 
140 
11674 CTGCCTACGACAAACAGAC GGCAGAATAGTAATGAGGATG 160 
12101 CTCACTCACCCACCACATTA CAGTTCTTGTGAGCTTTCTC 216 
13061 CAAATCAGCCCAATTAGGTC GGATTAGTGGGCTATTTTCTGCT 154 
14160 TCTTCCCACTCATCCTAACC TTAGTAGTAGTTACTGGTTGAAC 109 
14426 TCATACTCTTTCACCCACAG GGTTGTCTTTGGATATACTACAG 137 
15264, 
15267 
GAGGCCAAATATCATTCTGAG GTTGTTTGATCCCGTTTCGTG 218 
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5.3.2. Culture conditions for the human neural stem cells 
Human neural stem cells were derived from the human embryonic stem cell line 
(NIH-approved H9 (WA09); Invitrogen)). They were cultured on plates pre-
treated with 20mg/ml fibronectin, in media comprised of DMEM/F12 media 
supplemented with 2% StemPro Neural Supplement, 2mM GlutaMax (all from 
Invitrogen) and 20ng/ml bFGF and EGF (both from Millipore, Billerica, MA).   
 
5.3.3. Normal brain biopsy samples 
Healthy human brain samples were obtained from deceased patients who had 
donated their brains to the Victorian Brain Bank Network (Human research 
ethics number 09023B, Southern Health, HREC). Patient ages ranged from 48 to 
72, with the average being 59 years of age. All patient samples were absent from 
any neuropathological disorders and had no known history of neurological 
disease.  
 
5.3.4. GBM patient tumor samples 
GBM tumor samples were obtained from the Victorian Cancer BioBank (Human 
research ethics number 09023B, Southern Health, HREC). All tumor samples 
were extracted from patients with a confirmed diagnosed of grade IV GBM. 
Patient ages ranged from 34 to 80, with the average being 62 years of age.  
 
5.3.5. Xenograft tumor models 
Animal work in mice models was approved by the Animal Ethics Committee at 
Monash University (Approval number: MMCA/2011/76). HSR-GBM1 cells 
underwent mtDNA depletion with ddC in vitro for up to 50 days. Cells depleted 
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of their mtDNA to levels of 50%, 20%, 3% and 0.2% of the original mtDNA 
copy numbers were collected and re-suspended in 100µl of complete media (see 
section 2.1.6) before subcutaneous injection into both flank regions of female 
BALB/c immunodeficient nude mice (Animal Research Centre, Perth, Australia). 
All in vivo work was carried out by Dr Jacqueline Donoghue. Mice were aged 
between 4 to 6 weeks old. Extracted tumors were stored in the -80°C until further 
processing.  
	  	   233	  
5.4. Results 
5.4.1. Identification of mtDNA variants in GBM cell lines 
12 GBM cell lines were sequenced by Ion Torrent to investigate whether these 
cells shared the presence of variants, which would identify a common set of 
variants exists that are representative of GBM cell lines. A total of 13 variants 
were identified in the non-coding mtDNA region, 4 of which were previously 
unreported in the comprehensive MitoMap mutations database (2002bp, 2130bp, 
2817bp and 3168bp). The majority of variants were present in the D-loop 
hypervariable segment 1 or hypervariable segment 2 regions (Table 5.2). The 
T→C variant identified at 302bp of the D-loop region possessed the highest level 
of mutation at 77.9% within the U87MG cells. The variant at 16519bp also had 
high levels of mutation, ranging from 51.2% to 58.2% in 5 of the 12 GBM lines 
examined.  
 
Other shared variants within the D-loop region include the 310bp T→C 
substitution, present in GBM L1, GBM L2 and NO7-152 cells at similar 
frequencies but was detected at three-fold higher levels within CSC-014 cells. 
The 302bp variant was identified in 3 different GBM cell lines (GBM L1, CSC-
014 and NO7-152), but displayed distinct differences in their levels of mutation 
depending on the cell line. Several GBM cell lines (GBM L1, GBM L2, GBM 4, 
CSC-014, CSC-020 and NO7-152) shared the presence of a variant within the 
16s rRNA at 2130bp and the origin of light strand replication at 5752bp. Both 
variants were detected in all 6 GBM lines at similar levels. However, only GBM 
6 and U87MG cells shared the 3168bp variant at identical levels reported at 
3.7%. Variants observed in HSR-GBM1 cells appeared exclusive to the cell line.  
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Table 5.2. MtDNA variants identified in the non-coding region of 12 GBM cell lines.  
 
   Percentage change in variant (%)  
 Reference 
Position 
Variant HSR-
GBM1 
GBM 
L1 
GBM 
L2 
GBM 
4 
GBM 
6 
CSC 
014 
CSC 
020 
NO7 
152 
SF-767 U87MG HK301 BAH1 Gene region 
16186 C→T 4.5            
16218 C→T 16.9            
16224 T→C          77.9   
D loop - Hypervariable segment 
1, 7S DNA, membrane 
attachment site 
16519 T→C     53.7    55.8 58.2 51.2 52.9 D loop - 7S DNA, membrane 
attachment site 
194 C→T    4.1         
302 A→C  16.4    41.5  39.9     
310 T→C  5.6 5.0   17.5  6.0     
D loop - Hypervariable segment 
2, membrane attachment site 
1386 T→C 9.9            12s rRNA 
2002 * G→A     11.1        
2130 * A→G  3.9 5.5 4.0  3.6 6.3 7.4     
2817 * G→A            11.7 
3168 * C→T     3.7     3.7   
16s rRNA 
N
on
-c
od
in
g 
re
gi
on
 
5752 A→G  11.3 13.1 11.4  10.5 10.9 9.9     Origin of L-strand replication 
* Novel mtDNA variants that are not listed in the MitoMap database. 
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A further 19 variants were detected in the mtDNA coding region (Table 5.3), 12 of 
which were not previously reported in MitoMap (6999bp, 8252bp, 10473bp, 
10814bp, 12101bp, 12877bp, 13061bp, 14159bp, 14160bp, 14426bp, 15264bp and 
15267bp). The levels of mutation for these 19 coding region variants ranged from 
3.1% at position 12101bp within CSC-014 cells to 55.5% in GBM L1 cells at 
position 8252bp of the COX II gene. There were 3 variants within the coding region 
(6422bp, 8251bp and 11674bp) that caused synonymous amino acid changes. 
Amongst the 16 variants within the coding region that led to the development of 
non-synonymous amino acid changes, 5 were predicted by SNPs&GO to impair 
protein function. However, only 1 variant at 12877bp within ND5 was predicted to 
cause dysfunction with high confidence (RI value of 7). This substitution involved a 
glycine to arginine change (G181R), which was biochemically incompatible since 
glycine is a small molecule that confers flexibility to the protein structure, whereas 
arginine is a positively charged residue that can form interactions with other 
molecules, such as phosphate anions.  
 
Overall, ND4 had the highest number of mtDNA variants (n = 6), followed by both 
ND5 and ND6 (n = 3). The ND6 variant at 14160bp was shared between most of the 
cell lines (in 8 out of 12 cell lines) at relatively low levels (<10%).  
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* Novel mtDNA variants that are not listed in the MitoMap database. 
  Percentage change in variant (%)    Mutpred 
Reference 
Position 
Variant  HSR-
GBM
1 
GBM 
L1 
GBM 
L2 
GBM 
4 
GBM 
6 
CSC 
014 
CSC 
020 
NO7 
152 
SF-
767 
U87MG HK301 BAH1 Gene 
region 
Amino 
Acid 
Change 
SNPs&GO Probability of 
deleterious 
mutation 
Top 5 predicted features caused 
by the amino acid mutation 
6422 C→T 3.8            Syn (P) - -  
6999 * G→A 6.5            COX I V366M Neutral, RI 4 0.454  
8251 G→A  43.5  50.8         Syn (G) - -  
8252 * C→A  55.5  46.8         COX II P223T Neutral, RI 9 0.327  
10473 * C→G      4.3       ND4L P2A Neutral, RI 9 0.344 Loss of disorder (P = 0.0496) 
10814 * A→C  6.0  5.3   5.0 5.2     K19Q Neutral, RI 8 0.551 Loss of methylation at K19 (P 
= 0.0012) 
Loss of ubiquitination at K19 
(P = 0.0283) 
11361 T→C      6.0       M201T Neutral, RI 5 0.706  
11512 C→A  6.0  9.6  11.0 6.4 15.2     N251K Neutral, RI 4 0.495 Gain of methylation at N251 (P 
= 0.0194) 
11674 C→T    3.5         Syn (T) - -  
12101 * T→C    3.8  3.1  4.2     S448P Neutral, RI 7 0.484 Loss of helix (P = 0.0093) 
Gain of loop (P = 0.0321) 
12102 C→T    3.7    3.2     
ND4 
S448F Neutral, RI 3 0.472  
12877 * G→C         27.7    G181R Disease, RI 7 0.795  
13043 C→T          3.3   A236V Neutral, RI 3, 0.786  
13061 * C→A       4.0      
ND5 
P242Q Disease, RI 0 0.776 Loss of glycosylation at P242 
(P = 0.035) 
14159 * C→G   4.1          R172P Disease, RI 3 0.423 Loss of methylation at R172 (P 
= 0.0305) 
14160 * G→C   4.0 3.5 3.3 7.5  4.3 3.2  8.1 5.0 R172G Neutral, RI 2 0.442 Loss of methylation at R172 (P 
= 0.0305) 
14426 * C→T      8.9       
ND6 
G85E Neutral, RI 7 0.364 Loss of glycosylation at S84 (P 
= 0.0357) 
Gain of solvent accessibility (P 
= 0.0456) 
15264 * C→T 14.1            P173L Disease, RI 4 0.361  
15267 * C→G 20.5            CYT B T174S Disease, RI 3 0.866  
Table 5.3. MtDNA variants identified in the coding region of 12 GBM cell lines. MutPred predictions with a P value ≤ 0.05 are shown. 	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5.4.2. Validation of the GBM cell line variants using HRM analyses 
All GBM cell line variants identified by Ion Torrent sequencing were confirmed 
using HRM analysis (Table 5.4). The extra variants identified from HRM analyses, 
are likely to represent variants between levels of 1% and 3%, which were determined 
as the threshold levels of variant detection for the HRM and Ion Torrent, 
respectively.  
 
The similarities of each GBM cell line were compared against the variant profile for 
HSR-GBM1 cells, since these cells represented a well-established, traditional line 
that closely mimic the biological characteristics of human GBM tumors, and as a 
result, is commonly used for in vitro studies for GBM306,307. 3 cell lines (GBM 6, 
CSC-020 and NO7-152) shared over 80% of variants with HSR-GBM1 cells, 
whereas 5 (GBM L2, GBM 4, CSC-014, HK301 and BAH-1) shared above 70% of 
their variant profile with the reference cell line. The variants within U87MG cells 
had 68% similarity to the HSR-GBM1 cells. However, both GBM L1 and SF-767 
cells had variant profiles most distinct from HSR-GBM1 cells, sharing only 56% of 
variants with this cell line.   
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Table 5.4. Validation of the GBM cell line variants using HRM analyses. 
   GBM cell line samples  
 Reference 
Position 
Variant  HSR-
GBM1 
GBM 
L1 
GBM 
L2 
GBM 4 GBM 6 CSC 
014 
CSC 
020 
NO7 
152 
HK301 BAH 1 SF-767 U87MG Gene region 
16186 C→T ####           #### 
16218 C→T ####           #### 
194 C→T ####   ####  #### ####      
302 A→C  ####  ####  ####  ####   ####  
310 T→C  #### #### ####  ####  ####   ####  
D loop 
1386 T→C ####            12s rRNA 
2130 A→G  #### #### ####  #### #### ####   #### #### 16s rRNA N
on
-c
od
in
g 
re
gi
on
 
5752 A→G #### #### #### ####  #### #### ####     Origin of L-strand replication 
6422 C→T ####            
6999 G→A ####            
Cytochrome C Oxidase I 
8251 A→G  ####  ####         
8252 C→A  ####  ####         
Cytochrome C Oxidase II 
10473 C→G  #### #### ####  #### ####   ####   NADH dehydrogenase 4L 
10814 A→C  ####  ####  #### #### ####     
11361 T→C      ####       
11512 C→A  #### #### ####  #### #### ####   ####  
11674 C→T  ####  ####  ####       
12101 T→C  #### #### ####  ####  ####  #### #### #### 
12102 C→T  #### #### ####    ####  #### #### #### 
NADH dehydrogenase 4 
13061 C→A ####      ####    ####  NADH dehydrogenase 5 
14159 C→G  #### ####    ####      
14160 G→C  #### #### ####  #### #### #### #### #### ####  
14426 C→T #### ####    #### ####     #### 
NADH dehydrogenase 6 
15264 C→T #### ####    ####   ####  ####  
C
od
in
g 
re
gi
on
 
15267 C→G #### ####    ####   ####  ####  
Cytochrome B 
Similarity relative to 
HSR-GBM1 
100% 56% 72% 72% 80% 72% 80% 84% 76% 72% 56% 68%  
	   	   	   	  Variant present Variant absent Variant present (sites 
jointly analysed) 
Variant absent (sites 
jointly analysed) 
Variant presence/absence confirmed in 
both Ion Torrent and HRM analyses 
####	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5.4.3. Susceptibility of mtDNA regions to the development of mutations 
Regions of mtDNA all differ in terms of their nucleotide lengths (bp). To determine 
the susceptibility of each mtDNA region to the development of mutation, the number 
of mtDNA variants were normalised against the length of the particular mtDNA 
region within which it resides. 
  
Within the non-coding region, the 12s rRNA was determined least susceptible to the 
development of variants (score: 1.05 x 10-3), with only 1 variant identified within a 
953bp region (Table 5.5). On the contrary, the origin of light strand replication, as a 
77bp region, had the highest probability of developing mutation (score: 1.30 x 10-2), 
which was 12.38 fold greater than for the 12s rRNA region (Table 5.6). The D-loop 
was the second highest mtDNA non-coding region to be highly susceptible to 
mutation, as it had a probability score of 6.24 x 10-3, a fold change 5.95 greater than 
the 12s rRNA (Table 5.6).   
 
Although ND4 contained the highest number of variants (6) among the coding genes, 
ND6 was determined to be the region most susceptible to developing mutation 
(score: 5.73 x 10-3), whilst COX I was least susceptible (score: 1.30 x 10-3) (Table 
5.5), which was a difference of 4.41 fold (Table 5.6). CYT B and ND5 shared similar 
probability scores (1.75 x 10-3 and 1.66 x 10-3, respectively), which was a 1.06 fold 
difference. Altogether, the non-coding region had a greater chance (2.08 x 10-3) of 
developing a mutation than the coding region (1.84 x 10-3) (Table 5.5), which was a 
difference of 1.13 fold.  
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Table 5.5. Susceptibility of mtDNA regions to the development of mutations 
      Normalised data 
Reference Position Gene region Nucleotide positions for 
gene regions (bp) 
Size of gene 
region (bp) 
Number of 
variants 
Mutation rate in each 
gene region 
Mutation rate grouped for 
coding/non-coding regions 
16186, 16218,16224, 
16519...194, 302, 310 D-loop 1..576, 16024..16569 1121 7 0.00624 
1386 12s rRNA 648..1601 953 1 0.00105 
2002, 2130, 2817, 3168 16s rRNA 1671..3229 1558 4 0.00257 
5752 N
on
-c
od
in
g 
re
gi
on
 
Origin of light strand 
replication 5721..5798 77 1 0.0130 
0.00208 
6422, 6999 COX I 5904..7445 1541 2 0.00130 
8251, 8252 COX II 7586..8269 683 2 0.00293 
10473 ND4L 10470..10766 296 1 0.00338 
10814, 11361, 11512, 
11674, 12101, 12102 
ND4 10760..12137 1377 6 0.00436 
12877, 13043, 13061 ND5 12337..14148 1811 3 0.00166 
14159, 14160, 14426 ND6 14149..14673 524 3 0.00573 
15264, 15267 
C
od
in
g 
re
gi
on
 
CYT B 14747..15887 1140 2 0.00175 
0.00184 
 
Table 5.6. Fold change differences on the susceptibility of mtDNA regions to mutation. Values greater than 1 (black) indicate that 
the probability of the gene listed on the left is greater than for the gene listed across the top. Values in red inform the opposite. 
Gene region D-loop 12s rRNA 16s rRNA Origin of L-strand COX I COX II ND4L ND4 ND5 ND6 CYT B 
D loop  5.95 2.43 0.48 4.81 2.13 1.85 1.43 3.77 1.09 3.56 
12s rRNA 0.17  0.41 0.08 0.81 0.36 0.31 0.24 0.63 0.18 0.60 
16s rRNA 0.41 2.45  0.20 1.98 0.88 0.76 0.59 1.55 0.45 1.46 
Origin of L-strand 2.08 12.38 5.06  10.01 4.44 3.84 2.98 7.84 2.27 7.40 
COX I 0.21 1.24 0.51 0.10  0.44 0.38 0.30 0.78 0.23 0.74 
COX II 0.47 2.79 1.14 0.23 2.26  0.87 0.67 1.77 0.51 1.67 
ND4L 0.54 3.22 1.32 0.26 2.60 1.15  0.78 2.04 0.59 1.93 
ND4 0.70 4.15 1.70 0.34 3.36 1.49 1.29  2.63 0.76 2.48 
ND5 0.27 1.58 0.65 0.13 1.28 0.57 0.49 0.38  0.29 0.94 
ND6 0.92 5.46 2.23 0.44 4.41 1.96 1.69 1.31 3.46  3.26 
CYT B 0.28 1.67 0.68 0.14 1.35 0.60 0.52 0.40 1.06 0.31  
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5.4.4. Protein modeling of the GBM cell line variants 
Protein modeling was performed based on the bovine protein structures for COX 
I, COX II and CYT B, which have protein sequence identities to their human 
counterparts of 91%, 72% and 78.4%, respectively.  The CYT B variants at 
15264bp and 15267bp were discussed previously in section 3.4.8.1 (Figure 
3.13), which were found in the multiple myeloma tumor samples.  
 
The COX I mutations at position 366, involving a substitution from valine to 
methionine, was predicted by SNPs&GO to be a neutral mutation. Modeling of  
 
 
Figure 5.1. Modeling of the V336M COX I mutation using the bovine model. (A) 
The catalytic centre of Complex IV is shown. (B) The V366M mutation resides 
within a transmembrane helix facing towards the mitochondrial intermembrane 
space. (C) Closer observation of the V366M mutation.  
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the GBM-specific mutation identified its location on the 9th transmembrane 
helical domain, where it faces towards the intermembrane space (Figure 5.1). 
 
The amino acid change from proline to threonine at position 223 (P223T) within 
COX II represents another neutral substitution. This mutation was modeled on a 
helical segment located within the intermembrane space far from the catalytic 
core area, which supports the prediction of it being a neutral mutation (RI value 
9) (Figure 5.2). 
 
 
Figure 5.2. Modeling of the P223T COX II mutation using the bovine model. (A) 
Location of the P223T mutation (yellow). (B) Magnified image of the P223T 
mutation. 
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5.4.5. Identification of mtDNA variants in human neural stem cells 
Human neural stem cells (hNSCs) were used as a culture control to investigate 
whether the variants identified across the GBM cell lines were truly 
representative of those within GBM cells, and have not arisen as an artefact of 
culture conditions308. Sequencing of hNSCs revealed that all variants within the 
non-coding region of mtDNA resided in the D-loop region, whereas variants 
within the coding region were mostly identified in the ND5 region, with one 
residing in CYT B. The variant at position 16519bp in the D-loop had the highest 
levels of mutation at 51.3%. However, for the majority of variants the levels of 
mutation were approximately 3%, with the exception of the CYT B 15153bp 
variant at 9.4% (Table 5.7). Compared to the GBM cell lines, the hNSCs 
exhibited much lower numbers of mtDNA variants. Both cell types possessed a 
different set of mtDNA variants that were not common to one another, except for 
at position 16519bp within the D-loop region. Only two variants were previously 
unreported in MitoMap within the hNSCs, which included those at positions 
13762bp and 13985bp. 
 
Although predictions from SNPs&GO have indicated that the 13762bp T→C 
variant may impair protein function, the prediction was given a reliability index 
of 1. The second ND5 variant resulted in a synonymous amino acid change that 
would not influence protein function. The final ND5 variant identified at 
13985bp was predicted to exert a neutral effect on the overall protein structure.  
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Table 5.7. Identification of mtDNA variants in human neural stem cells  
        Mutpred 
 Reference Position Reference Variant 
Percentage 
change in 
variant (%) 
Gene region Amino acid change SNPs&GO 
Probability of 
deleterious 
mutation 
Top 5 predicted features caused by amino 
acid mutation 
16519 T C 51.3 D loop - Membrane attachment site, 7S DNA     
N
on
-
co
di
ng
 
496 C T 3.3 D loop - Hypervariable segment 3     
13762 * T C 3.2 S476P 
Disease, RI 1, 
Uniprot 
P03915 
0.392 
Gain of catalytic residue at S476 (P = 
0.0028) 
Gain of glycosylation at P477 (P = 0.068) 
Loss of helix (P = 0.1299) 
Loss of disorder (P = 0.2536) 
Gain of loop (P = 0.2754) 
13984 C T 3.6 Syn (L) -   
13985 * T C 3.6 
NADH Dehydrogenase 5: 
ND5 
 
L550P 
Neutral, RI 1, 
Uniprot 
P03915 
0.457 
Gain of loop (P = 0.0013) 
Loss of helix (P = 0.0041) 
Gain of catalytic residue at P549 (P = 
0.0244) 
Gain of glycosylation at L550 (P = 
0.0364) 
Gain of relative solvent accessibility (P = 
0.0479) 
C
od
in
g 
15153 G A 9.4 Cytochrome B: CYT B G136D 
Disease, RI 8, 
Uniprot 
P00156 
0.889 
Loss of catalytic residue at G136 (P = 
0.2619) 
Loss of sheet (P = 0.3635) 
Loss of loop (P = 0.3664) 
Loss of helix (P = 0.3949) 
Loss of MoRF binding (P = 0.4724) 
* Novel mtDNA variants that are not already listed in the MitoMap database are indicated by asterisks. 
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The CYT B variant at 15153bp was the only mtDNA variant predicted to be 
disease causing with high confidence (RI value 8). This glycine to aspartate 
substitution was located in the loop region just before the 8th transmembrane-
spanning helix structure in the bovine CYT B model (Figure 5.3). It is possible 
that this substitution was predicted to be high risk for the onset of disease, as it is 
in relatively close proximity to Heme bL (Qo site). However, due to the mutation 
being located within a flexible loop domain, it could be argued that biologically 
this variant imposes no risk to protein impairment since these regions are not 
structurally important features of the overall protein. Furthermore, this variant 
was detected at relatively low levels (less than 10%) amongst an almost 
completely wild-type mtDNA sequence, which could mask any negative effects 
caused by the presence of this variant. 
 
 
Figure 5.3. Modeling the hNSC G136D CYT B mutation using the bovine model.  
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5.4.6. Identification of mtDNA variants in normal brain biopsy samples. 
Normal brain samples were sequenced to determine the number of mtDNA 
variants present, and whether these were similar or different to those variants 
already identified in the GBM cell lines. Within the non-coding region, 2 novel 
variants were found that were not previously reported in MitoMap (2232bp and 
2647bp). The majority (81%) of non-coding region variants were identified 
within hypervariable regions 1 and 2 of the D-loop region (Table 5.8). Amongst 
the 13 samples, sample number 05-470 had the highest number of mtDNA 
variants (12) within the non-coding region, whereas the other 12 samples had 
less than 5 variants within this same region. Only the variant at 16519bp was 
shared across the normal brain samples. Overall, the levels of mutation for all 
non-coding mtDNA variants were below 10%, with the exception of a few 
samples. Sample 04-273 had an A→G change at position 16293bp, reported at 
16.1%, and sample 05-470 had a variant G→C at 2647bp, reported at 12.1% 
within the 16s rRNA region. Furthermore, 4 samples (07-104 and 07-445, 16-1 
and 22-1) had no variant in their non-coding regions. 
 
39 variants were identified across all normal brain samples that resided within 
the mtDNA-coding region (Table 5.9), 14 of which had not been previously 
reported in MitoMap (4701bp, 4878bp, 4879bp, 8497bp, 8630bp, 9526bp, 
9528bp, 9558bp, 11516bp, 11725bp, 11791bp, 12719bp, 13985bp and 14159bp). 
CYT B contained the most variants, accounting for 23% of those identified in the 
coding region. Sample 09-005 harbored the greatest number of mtDNA variants 
(11), which were present at ≤6.2%. Sample 08-012 possessed the second-highest 
number of variants (7) of which two variants were detected at 12.5% at positions  
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Table 5.8. Identification of mtDNA non-coding variants in normal brain biopsy samples  
  Percentage change in variant (%)  
Reference 
Position 
Variant 
change 
03-
965 
04-
273 
05-
470 
07-
104 
07-
445 
07-
635 
08-
012 
08-
026 
09-
005 
09-
152 
16-
1 
22-
1 
20-
1 Gene region 
16069 C→T   7.2           D loop - Membrane attachment site, Hypervariable segment 
1 
16126 T→C   5.2           D loop - Membrane attachment site, Hypervariable segment 
1, 7S DNA 
16145 G→A   4.8           D loop - Membrane attachment site, Hypervariable segment 
1, 7S DNA, termination-associated sequence 
16179 C→T         4.3     
16222 C→T   5.1           
16261 C→T   9.4           
16293 A→G  16.1            
16356 T→C         3.0     
D loop - Membrane attachment site, Hypervariable segment 
1, 7S DNA 
16519 T→C 57.5  54.5   56.0  57.6 58.3 59.4    
9 G→T   5.8           
10 T→C   5.8           
D loop - Membrane attachment site, 7S DNA 
66 G→T             3.2 
73 A→G   6.2           
D-loop - Hypervariable segment 2, membrane attachment 
site, 7S DNA 
150 C→T         4.4     
189 A→G       3.0       
D loop - Hypervariable segment 2, H-strand origin, 
Membrane attachment site, 7S DNA 
195 T→C         4.5     D loop - Hypervariable segment 2, H-strand origin, 
Membrane attachment site 
242 C→T   7.7           D loop - Hypervariable segment 2, H-strand origin, mtTF1 
binding site, Membrane attachment site 
751 A→T       3.9       12s ribosomal RNA (rRNA) 
2232 * A→T      3.0        
2647 * G→C   12.1           
3010 G→A   3.5           
16s ribosomal RNA (rRNA) 
* Novel mtDNA variants that are not already listed in the MitoMap database are indicated by asterisks. 
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Table 5.9. Identification of mtDNA coding variants in normal brain biopsy samples.  
  Percentage change in variant (%)   
Reference 
(bp) 
Variant 
change 
03-
965 
04-
273 
05-
470 
07-
104 
07-
445 
07-
635 
08-
012 
08-
026 
09-
005 
09-
152 
16-
1 
22-
1 
20-
1 
Gene region AA 
change 
4646 T→C         3.4     Syn (Y) 
4701 * A→T    4.8          N78Y 
4703 T→C    4.8          Syn (N) 
4878 * G→A         4.6     A137T 
4879 * C→G         5.0     
NADH 
Dehydrogenase 
2: ND2 
A137G 
6146 A→G         3.1     Cytochrome C 
Oxidase I: 
COX I 
Syn (W) 
8497 * A→G  12.5       4.8     ATPase 8: 
ATP8 
Syn (M) 
8630 * A→G           3.7   K35 
Stop 
8756 T→C        6.5      I77T 
8790 G→A     18.4         Syn (L) 
8994 G→A        4.7      Syn (L) 
9070 T→G         6.2     
ATPase 6: 
ATP6 
S182A 
9258 C→T     3.2         Syn (L) 
9526 * C→G  5.0    3.8        A107G 
9528 * C→A  9.9 6.4    4.8       P108T 
9558 * C→A     5.8   3.6      
Cytochrome C 
Oxidase III:  
COX III 
P118T 
10398 A→G   5.4           NADH 
Dehydrogenase 
3 
T114A 
10993 G→A   4.6           Syn (M) 
11332 C→T         3.4     Syn (A) 
11467 A→G         3.1     Syn (L) 
11516 * C→A       4.9       L253M 
11725 * A→T       3.0       Syn (T) 
11791 * C→T           11.8   
NADH 
Dehydrogenase 
4: ND4 
Syn (L) 
12719 * T→C 3.2             M128T 
12774 C→T           9.3   Syn (G) 
13984 C→T          3.7    Syn (L) 
13985 * T→C   3.1      3.1 3.7    
NADH 
Dehydrogenase 
5: ND5 
L550P 
14155 C→T          3.8    Syn (G) 
14159 * C→G       12.5       R172P 
14160 * G→C     8.1  12.5       
NADH 
Dehydrogenase 
6: ND6 R172G 
14770 C→A            8.0  N8K 
14823 * A→C     4.0         N26T 
14857 T→C       3.8       Syn (L) 
14861 * G→T       3.6       A39S 
14866 C→T         5.4     Syn (C) 
15287 T→C     26.9         F181L 
15452 C→A   3.2           L236I 
15579 * A→T      3.7        Y278F 
15693 T→C         4.9     
Cytochrome B: 
CYT B 
M316T 
* Novel mtDNA variants that are not already listed in the MitoMap database are 
indicated by asterisks. 
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14159bp and 14160bp. Sample 22-1 had only 1 variant, whereas samples, 20-1 and 
03-965 had no variant.  
 
Although many variants were identified within the mtDNA-coding region of normal 
brain samples, they appear to have arisen randomly since very few variants are 
commonly shared amongst the samples analysed (Table 5.9). At most, two variants 
at positions 9528bp (within COX III) and 13985bp (within ND5) were shared 
between 3 samples. 
 
5.4.7. Susceptibility of the mDNA regions to mutation within normal brain 
biopsy samples. 
The D-loop region was the region most susceptible to developing a mutation across 
both the non-coding and coding regions of mtDNA in normal brain samples. The 
susceptibility score was 1.52 x 10-2 (Table 5.10), which was 1.92 fold greater than 
the second most susceptible region (CYT B, score: 7.89 x 10-3) (Table 5.11). COX I 
was the least susceptible region overall to develop mtDNA variants (6.49 x 10-4). 
Comparisons between the coding and non-coding regions determined that the coding 
region had a marginally greater chance (3.78 x 10-3) than the non-coding region 
(3.37 x 10-3) of acquiring variants, namely 1.12 fold higher for the coding region. 
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Table 5.10. Susceptibility of the mtDNA regions to mutations within normal brain biopsy samples.  
 
      Normalised data 
Reference Position Gene region Nucleotide positions for gene regions (bp) 
Size of gene 
region (bp) 
Number of variants 
detected in gene 
region 
Mutation rate in 
each gene region 
Mutation rate grouped for 
coding/non-coding 
regions 
16069, 16126, 16145, 16179, 16222, 
16261, 16293, 16356, 16519…9, 10, 66, 
73, 150, 189, 195, 242 
D loop 1..576, 16024..16569 1121 17 0.0152 
751 12s rRNA 648..1601 953 1 0.00105 
2232, 2647, 3010 
N
on
-c
od
in
g 
16s rRNA 1671..3229 1558 3 0.00193 
0.00336 
4646, 4701*, 4703, 4878*, 4879* NADH dehydrogenase 2 4470..5511 1041 5 0.00480 
6146 Cytochrome C Oxidase I 5904..7445 1541 1 0.000649 
8497* ATPase 8 8366..8572 206 1 0.00485 
8630*, 8756, 8790, 8994, 9070 ATPase 6 8527..9207 680 5 0.00735 
9258, 9526*, 9528*, 9558* Cytochrome C Oxidase III 9207..9990 783 4 0.00511 
10398 NADH dehydrogenase 3 10059..10404 345 1 0.00290 
10993, 11332, 11467, 11516*, 11725*, 
11791* 
NADH 
dehydrogenase 4 10760..12137 1377 6 0.00436 
12719*, 12774, 13984, 13985* NADH dehydrogenase 5 12337..14148 1811 4 0.00221 
14155, 14159*, 14160* NADH dehydrogenase 6 14149..14673 524 3 0.00573 
14770, 14823*, 14857, 14861*, 14866, 
15287, 15452, 15579*, 15693 
C
od
in
g 
re
gi
on
 
Cytochrome B 14747..15887 1140 9 0.00789 
0.00378 
* Novel mtDNA variants that are not already listed in the MitoMap database are indicated by asterisks. 
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Table 5.11. Fold change differences on the susceptibility of mtDNA regions to mutation, for normal brain biopsy samples. Values 
greater than 1 (black) indicate that the probability of the gene listed on the left is greater than for the gene listed across the top for 
the development of variants. Values in red indicate that the gene listed on the left has a lower susceptibility for the development of 
mutations than the gene listed across the top. 
Gene 
region 
D-loop 12s 
rRNA 
16s 
rRNA 
ND2 COX I ATP8 ATP6 COX 
III 
ND3 ND4 ND5 ND6 CYT B 
D-loop  14.45 7.88 3.16 23.37 3.12 2.06 2.97 5.23 3.48 6.87 2.65 1.92 
12s rRNA 0.07  0.54 0.22 1.62 0.22 0.14 0.21 0.36 0.24 0.48 0.18 0.13 
16s rRNA 0.13 1.84  0.40 2.97 0.40 0.26 0.38 0.66 0.44 0.87 0.34 0.24 
ND2 0.32 4.58 2.49  7.40 0.99 0.65 0.94 1.66 1.10 2.17 0.84 0.61 
COX I 0.04 0.62 0.34 0.14  0.13 0.09 0.13 0.22 0.15 0.29 0.11 0.08 
ATP8 0.32 4.63 2.52 1.01 7.48  0.66 0.95 1.67 1.11 2.20 0.85 0.61 
ATP6 0.48 7.01 3.82 1.53 11.33 1.51  1.44 2.54 1.69 3.33 1.28 0.93 
COX III 0.34 4.87 2.65 1.06 7.87 1.05 0.69  1.76 1.17 2.31 0.89 0.65 
ND3 0.19 2.76 1.51 0.60 4.47 0.60 0.39 0.57  0.67 1.31 0.51 0.37 
ND4 0.29 4.15 2.26 0.91 6.71 0.90 0.59 0.85 1.50  1.97 0.76 0.55 
ND5 0.15 2.10 1.15 0.46 3.40 0.45 0.30 0.43 0.76 0.51  0.39 0.28 
ND6 0.38 5.46 2.97 1.19 8.82 1.18 0.78 1.12 1.98 1.31 2.59  0.73 
CYT B 0.52 7.52 4.10 1.64 12.17 1.63 1.07 1.55 2.72 1.81 3.57 1.38  
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5.4.8. Phylogenetic analysis on the GBM cell lines and normal brain biopsy 
samples 
Using phylogenetic analysis, it was determined that the GBM cell lines and 
normal brain samples were from comparable lineages (Figure 5.4). Since the 
normal brain biopsy samples were integrated evenly amongst the tumor cell 
lines, there was no bias in the genetic distribution of mtDNA. The mtDNA 
variants identified were therefore not from one specific population or group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Phylogenetic analysis on the GBM cell lines and normal brain 
biopsy samples. The phylogenetic tree was produced using the phylogeny 
inference package, PHYLIP.  
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5.4.9. Identification of mtDNA variants in GBM patient tumor samples 
Ion Torrent sequencing was also performed on 17 GBM patient tumor samples. 
Within the non-coding region, 5 novel variants were identified (16162bp, 707bp, 
2923bp, 7470bp and 12262bp). The D-loop region alone was found to possess 15 
variants (Table 5.12), the majority of which were discovered in a single GBM 
tumor (sample 0-8745) at high frequencies within hypervariable regions 1 and 2. 
Position 16519bp was again a common site for mutation amongst the tumor 
samples, as variants at all other non-coding sites arose exclusively within each of 
the tumors. Only the D-loop variants displayed mutation levels as high as 69.1% 
(sample 0-8745 at positions 16311bp and 195bp).  
 
Sample 0-8745 contained the most variants (13 out of 22) compared to all other 
tumor samples. For samples other than 0-8745, there were at most 2 variants 
detected within the non-coding region (samples 0-9022, 0-80243, 10-0214 and 
20-2). A few samples (0-9022, 0-7125, 0-8585 and 22-2) exhibited the absence 
of any mtDNA variant within their non-coding regions. Overall, there was a 
variable pattern for the presence of variants within the mtDNA non-coding 
region across the GBM tumor samples, which ranged from 3.1% to 69.1%.  
 
Analysis of the mtDNA coding region revealed that all variants were exclusive to 
each tumor (Table 5.13), as there was the absence of any shared variants 
amongst the 17 samples. Within the coding region, there were a total of 12 novel 
variants previously unreported in MitoMap (7428bp, 8088bp, 8447bp, 8491bp, 
8558bp, 9577bp, 9578bp, 13346bp, 14159bp, 14588bp, 15354bp and 15660bp). 
The highest level of mutation detected was 87.9% for the COX I variant at  
	  	   254	  
Table 5.12. Identification of mtDNA non-coding variants in GBM patient tumor samples. 
  Percentage change in frequency (%)  
Reference 
Position Variant 
0-8745 
(A) 
0-9022 
(B) 
0-9258 
(C) 
0-7125 
(D) 
0-9311 
(E) 
0-80680 
(F) 
0-8585 
(G) 
0-80243 
(H) 
0-85279 
(I) 
10-0214 
(J) 
0-7257 
(K) 
0-9635 
(L) 
16-2 
(M) 
22-2 
(N) 
20-2 
(O) 
9-2 
(P) 
5-2 
(Q) Gene region 
16093 T→C     67.4             
D-loop - membrane 
attachment site, 
hypervariable 
segment I 
16111 C→T 65.9                 
16162 * A→G 44.9                 
16185 C→T        3.1          
16261 C→T          3.1        
16293 A→G 69.0                 
16311 T→C 69.1                 
16319 G→A                4.5  
D-loop - membrane 
attachment site, 
hypervariable 
segment I, 7S DNA 
16519 T→C 17.5 66.5    61.7  64.9 61.7 55.8 63.1 64.3      
D-loop - membrane 
attachment site, 7S 
DNA 
66 G→T               3.1   
D-loop - 
Hypervariable 
segment 2, 
membrane 
attachment site, 7S 
DNA 
146 T→C 51.8                 
151 C→T 68.3                 
152 T→C 68.3                 
153 A→G               47.8   
195 T→C 69.1                 
D-loop - 
Hypervariable 
segment 2, H-
strand origin, 
membrane 
attachment site 
707 * C→T 7.3                 
1346 A→G                 5.5 
12s ribosomal RNA 
(rRNA) 
1646 T→C 28.9                 tRNA valine 
2648 T→C 23.4                 
2923 * G→A  12.3                
16s ribosomal RNA 
(rRNA) 
7470 * C→T             12.1     tRNA serine 1 
12262 * C→T 12.7                 tRNA serine 2 
* Novel mtDNA variants that are not already listed in the MitoMap database are indicated by asterisks.  
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position 6146bp involving an A→G substitution (Sample 0-80243). The second 
highest level of mutation was reported at 75.7% for the ND4 variant at position 
10873bp (0-9635). The lowest frequency was 3.1% for the C→G substitution at 
14159bp within ND6 (0-8745). Within the coding region, the majority of tumor 
variants gave rise to either synonymous mutations or was predicted to exert neutral 
effects on protein function (Table 5.13). This suggests that although some variants 
may have high levels of mutations, not all are capable of causing protein impairment, 
but instead could represent natural base substitutions.  
 
5.4.10. Susceptibility of the mDNA regions to mutation for GBM patient tumor 
samples. 
Although the majority of non-coding region mutations for the GBM tumor samples 
arose in the D-loop region, normalization of the number of variants to the size of the 
gene regions revealed that the tRNA serine 2 region possessed the greatest 
probability of developing a mutation (1.72 x 10-2) (Table 5.14). The tRNA serine 2 
region had a 1.17 fold greater difference (Table 5.15) than both the tRNA valine and 
tRNA serine 1 regions, which had susceptibility scores of 1.47 x 10-2 (Table 5.14). 
The 16s rRNA region was the least susceptible of all non-coding regions to mutation 
(1.28 x 10-3). For the coding regions, ATPase 8 had the highest susceptibility (9.71 x 
10-3) (Table 5.14), which was 7.48 fold greater (Table 5.15) than the least 
susceptible region, COX I (1.30 x 10-3). 
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Table 5.13. Identification of mtDNA coding variants in GBM patient tumor samples. Due to space constraints, GBM tumor samples 
are labeled according to Table 5.12, and predicted ‘neutral’ (N) and ‘disease’ (D) outcomes from SNPs&GO are shown with its 
associated reliability index in brackets. 
  Percentage change in frequency (%)    MutPred 
Reference 
Position Variant  (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) Gene region 
Amino 
acid 
change 
SNPs&GO 
Probability 
of deletrious 
mutation 
Predicted impact of the 
amino acid change on 
protein function # 
6146 A→G        87.9          Syn (W)    
7428 * G→A             17.3     
Cytochrome c 
oxidase I: COX I 
(Uniprot P00395) V509M N (9)  0.259 
Gain of disorder (P = 
0.0339) 
 
8027 G→A     7.6             A148T N (8) 0.095  
8088 * T→C                 4.2 
Cytochrome c 
oxidase II: COX II 
(Uniprot P00403) L168S D (5) 0.796 
Gain of glycosylation 
L168 (P = 0.0225) 
Loss of stability (P = 
0.0237) 
Gain of disorder (P = 
0.0265) 
8447 * A→C 4.3                 M28L N (1) 0.419 
Gain of catalytic 
residue M28 (P = 
0.001) 
Gain of methylation 
K27 (P = 0.0411) 
8491 * A→C                 48.9 
ATP synthase 8: 
ATP8  
(Uniprot P03928) 
M42I N (3) 0.261 Gain of methylation K43 (P = 0.0251) 
8558 * C→G               4.1   A11G N (2) 0.344 
Loss of stability (P = 
0.0131) 
 
8994 G→A                38.4  
ATP synthase 6: 
ATP6 
(Uniprot P00846) Syn (L)    
9557 C→T             15.2     Syn (P)    
9577 * T→A                6.5  L124Q N (4) 0.745 
Gain of disorder (P = 
0.0202) 
 
9578 * A→C                6.5  
Cytochrome c 
oxidase: COX III 
(Uniprot P00414) 
Syn (L)    
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Table 5.13. continued 
  Percentage change in frequency (%)    MutPred 
Reference 
Position Variant  (A) (B) (C) (D) (E) (F) (G) (H) (I) (J) (K) (L) (M) (N) (O) (P) (Q) Gene region 
Amino 
acid 
change 
SNPs&GO 
Probability 
of deletrious 
mutation 
Predicted impact of the 
amino acid change on 
protein function # 
9986 G→A             24.5     
Cytochrome c 
oxidase: COX III 
(Uniprot P00414) 
Syn (G)    
10873 T→C            75.7      Syn (P)    
11560 A→G  87.3                Syn (W)    
12019 C→T             14.9     Syn (T)    
12091 T→C                3.4  
ND4 
NADH 
dehydrogenase 4: 
ND4 Syn (I)    
12622 G→A             14.7     V96I N (7) 0.533  
12705 C→T               78.5   Syn (I)    
13346 * C→T             3.6     A337V D (2) 0.775  
13477 G→A        27.8          
NADH 
dehydrogenase 5: 
ND5 
(Uniprot P03915) A381T N (8) 0.447  
14155 C→T   3.6               Syn (G)    
14159 * C→G 3.1                 R172P D (3) 0.423 Loss of methylation R172 (P = 0.0305) 
14160 G→C  3.3    3.2            R172G N (2) 0.442 Loss of methylation R172 (P = 0.0305) 
14588 * C→A                 5.4 
NADH 
dehydrogenase 6: 
ND6  
(Uniprot P03923) 
G29V N (6) 0.797  
15354 * C→T             3.6     T203M N (1) 0.766  
15660 * C→T 3.9                 
Cytochrome B: 
CYT B  
(Uniprot P00156) P305L D (2) 0.703 
Gain of catalytic 
residue at P305 (P = 
0.0355) 
 
# Only the changes that were predicted significant (P < 0.05) by MutPred are listed. (*) previously unreported variants not listed in 
MitoMap.
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Table 5.14. Susceptibility of the mtDNA regions to mutation for GBM patient tumor samples. 
      Normalised data 
Reference Position Gene region Nucleotide positions for gene regions (bp) 
Size of 
gene region 
(bp) 
Number of 
variants detected 
in gene region 
Mutation rate in each 
gene region 
Mutation rate grouped for 
coding/non-coding regions 
66, 146, 151, 152, 153, 195, 
16093, 16111, 16162, 16185, 
16261, 16293, 16311, 16319, 
16519 
D-loop 16024..576 1121 15 0.0134 
707 12s rRNA 648..1601 954 2 0.00210 
1646 tRNA valine 1602..1670 68 1 0.0147 
2648, 2923 16s rRNA 1671..3229 1558 2 0.00128 
7470 tRNA serine 1 7446..7514 68 1 0.0147 
12262 
N
on
-c
od
in
g 
re
gi
on
 
tRNA serine 2 12207..12265 58 1 0.0172 
0.00353 
6146, 7428* Cytochrome C Oxidase: COXI 5904..7445 1541 2 0.00130 
8027, 8088* Cytochrome C Oxidase: COXII 7586..8269 684 2 0.00292 
8447*, 8491* ATPase 8 8366..8572 206 2 0.00971 
8558*, 8994 ATPase 6 8527..9207 680 2 0.00294 
9557, 9577*, 9578*, 9986 Cytochrome C Oxidase: COXIII 9207..9990 783 4 0.00511 
10873, 11560, 12019, 12091 NADH Dehydrogenase: ND4 10760..12137 1377 4 0.00290 
12622, 12705, 13346*, 13477 NADH dehydrogenase 5: ND5 12337..14148 1811 4 0.00221 
14155, 14159*, 14160, 14588* NADH dehydrogenase 6: ND6 14149..14673 524 4 0.00763 
15354*, 15660* 
C
od
in
g 
re
gi
on
 
Cytochrome B: CYT B 14747..15887 1140 2 0.00175 
0.00252 
* Novel mtDNA variants that are not already listed in the MitoMap database are indicated by asterisks.  
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Table 5.15. Fold change differences on the susceptibility of mtDNA regions to mutation, for GBM patient tumor samples. The 
susceptibility scores calculated for different mtDNA regions were based on Table 5.14. Values greater than 1 (black) indicate that 
the probability of the gene listed on the left is greater than for the gene listed across the top for the development of variants. Values 
in red indicate that the gene listed on the left has a lower susceptibility for the development of mutation than the gene listed across 
the top. 
Gene region D-
loop 
12s 
rRNA 
tRNA 
valine 
16s 
rRNA 
tRNA serine 
1 
tRNA serine 
2 
COX I COX II ATP8 COX III ND4 ND5 ND6 CYT B 
D-loop  6.38 0.91 10.42 0.91 0.78 10.31 4.58 1.38 2.62 4.61 6.06 1.75 7.63 
12s rRNA 0.16  0.14 1.63 0.14 0.12 1.62 0.72 0.22 0.41 0.72 0.95 0.27 1.19 
tRNA valine 1.10 7.01  11.46 1.00 0.85 11.33 5.03 1.51 2.88 5.06 6.66 1.93 8.38 
16s rRNA 0.10 0.61 0.09  0.09 0.07 0.99 0.44 0.13 0.25 0.44 0.58 0.17 0.73 
tRNA serine 
1 
1.10 7.01 1.00 11.46  0.85 11.33 5.03 1.51 2.88 5.06 6.66 1.93 8.38 
tRNA serine 
2 
1.29 8.22 1.17 13.43 1.17  13.28 5.90 1.78 3.37 5.94 7.81 2.26 9.83 
COX I 0.10 0.62 0.09 1.01 0.09 0.08  0.44 0.13 0.25 0.45 0.59 0.17 0.74 
COX II 0.22 1.39 0.20 2.28 0.20 0.17 2.25  0.30 0.57 1.01 1.32 0.38 1.67 
ATP8 0.73 4.63 0.66 7.56 0.66 0.56 7.48 3.32  1.90 3.34 4.40 1.27 5.53 
COX III 0.38 2.44 0.35 3.98 0.35 0.30 3.94 1.75 0.53  1.76 2.31 0.67 2.91 
ND4 0.22 1.39 0.20 2.26 0.20 0.17 2.24 0.99 0.30 0.57  1.32 0.38 1.66 
ND5 0.17 1.05 0.15 1.72 0.15 0.13 1.70 0.76 0.23 0.43 0.76  0.29 1.26 
ND6 0.57 3.64 0.52 5.95 0.52 0.44 5.88 2.61 0.79 1.49 2.63 3.46  4.35 
CYT B 0.13 0.84 0.12 1.37 0.12 0.10 1.35 0.60 0.18 0.34 0.60 0.79 0.23  
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5.4.11. Protein modeling of the GBM tumor sample variants. 
The 4 non-synonymous amino acid changes predicted to impair protein function 
resided within COX II, ND5, ND6 and CYT B. These represented a gain 
(R172P) or loss (P305L) of a proline residue in ND6 and CYT B, respectively. 
Protein modeling for the CYT B P305L mutation determined that it was located 
on the 16th transmembrane-spanning helix (Figure 5.5), which is distinctly 
separated from the other helical domains within CYT B. Its location could be a 
reason for the low reliability index value of 2 given to the prediction that this 
mutation may cause protein impairment. 
 
Figure 5.5. Modeling of the P305L CYT B mutation using the bovine model.  
 
Although the A337V mutation caused by the 13346bp variant does not involve a 
biochemically unfavorable amino acid substitution, the central location of the 
substitution within ND5 may contribute towards protein dysfunction. On the 
other hand, the L168S protein mutation caused by the 8088bp variant in COX II 
results not only in a biochemically incompatible substitution but also loss of a 
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conserved residue. This could explain the reliability index of 5 that was 
associated with this mutation, since leucine is more hydrophobic in nature, 
whereas serine is more hydrophilic. Based on protein modeling, the L168S 
mutation resided on a loop region immediately after the 7th beta sheet structure 
on the bovine COX II structure (Figure 5.6). If this mutation were to be located 
within the beta-sheet structure itself, it is likely that the reliability index given to 
the prediction that this mutation could cause functional impairment might 
increase.  
 
 
Figure 5.6. Modeling of the L168S COX II mutation using the bovine model.  
 
5.4.12. Comparative analyses between paired GBM tumor samples 
Several of the normal brain and GBM tumor samples represented paired samples, 
which were obtained from an individual patient who had consented to the 
surgical extraction of the GBM tumor and a small region of healthy tissue from 
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the opposite, unaffected brain hemisphere. Three pairs of samples were analysed 
to identify any patterns that may exist between the two samples (Table 5.16). 
 
Sequencing of the healthy and tumor tissues from the first individual (sample 16) 
revealed 3 variants within the normal brain sample (16-1) with the ND4 variant 
at position 11791bp exhibiting the highest level of mutation at 11.8% of all the 
variants present. On the contrary, 8 variants were identified in the tumor sample 
obtained from the same patient (sample 16-2). The highest level of mutation 
within the tumor sample was reported at 24.5% within the COX III variant 
located at 9986bp. Most of the variants within the tumor sample had higher 
levels of mutation than those found in the normal sample, except for the variants 
at positions 13346bp within ND5 and 15354bp within CYT B, both of which 
were reported at 3.6% in the tumor sample but were absent in the normal 
samples.  
 
Sequencing of the healthy and tumor tissues from the second individual (sample 
22) revealed only 1 variant within CYT B at position 14770bp in the normal 
sample (22-1) at 8%. In this case, no variants were detected within the tumor 
sample (22-2). For the third individual (sample 20), only 1 variant at 66bp was 
detected in the normal brain tissue (20-1) located within the D-loop 
hypervariable region 2 at 3.2%. In the tumor sample of this same patient, the 
same D-loop variant was present at a similar frequency of 3.1%. However, there 
was the presence of an additional 3 variants, 1 within the D-loop at position 
153bp (47.8%), another within ATP6 at 4.1% (8558bp) and finally 1 variant 
within the ND5 region at position 12705bp at 78.5%. For this third individual,
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Table 5.16. Identification of mtDNA variants in paired samples from 3 individual GBM patients. Normal brain samples are 
represented by ‘-1’ at the end of the sample number, whereas tumor samples are represented by ‘-2’.  
   Percentage change in variant (%)    Mutpred 
 Reference 
Position Variant  
16-
1 
16-
2 
22-
1 
22-
2 
20-
1 
20-
2 Gene region 
Amino Acid 
Change SNPs&GO 
Probability of 
deleterious mutation 
Predicted impact of the amino acid 
change on protein function # 
66 G→T     3.2 3.1 D loop Hypervarable Segment 2     
153 A→G      47.8 D loop H-strand origin     
N
on
-c
od
in
g 
7470 C→T  12.1     tRNA serine 1     
7428 G→A  17.3     COX I (Uniprot P00395) V509M 
Neutral RI 
9  0.259 Gain of disorder (P = 0.0339) 
8558 C→G      4.1 A11G Neutral RI 2 0.344 Loss of stability (P = 0.0131) 
8630 A→G 3.7      
ATP 6 
(Uniprot P00846) K35 Stop    
9557 C→T  15.2     Syn (P)    
9986 G→A  24.5     
COX III 
(Uniprot P00414) Syn (G)    
11791 C→T 11.8      Syn (L)    
12019 C→T  14.9     
ND4 
Syn (T)    
12622 G→A  14.7     V96I Neutral RI 7 0.533  
12705 C→T      78.5 Syn (I)    
12774 C→T 9.3      Syn (G)    
13346 C→T  3.6     
ND5 
(Uniprot P03915) 
A337V Disease RI 2 0.775  
14770 C→A   8.0    CYT B (Uniprot P00156) N8K 
Neutral RI 
1 0.446 
Gain of methylation at N8 (P = 
0.0039) 
Gain of MoRF binding (P = 0.0159) 
Gain of ubiquitination at N8 (P = 
0.0452) 
C
od
in
g 
re
gi
on
 
15354 C→T  3.6     CYT B T203M Neutral RI 1 0.766  
# Only the changes that were predicted significant (P < 0.05) by MutPred are listed.
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the presence of these extra mtDNA variants in the tumor sample arose in the key 
mtDNA regions. This is because defective ATP6 function prevents the efficient 
production of ATP and defects to ND5 are thought to be partially responsible for 
the onset of metastasis in tumors222.   
 
5.4.13. Variants in mtDNA depleted and recovered HSR-GBM1 cells 
To identify mtDNA variants that are important for GBM tumor biology, the 
traditional HSR-GBM1 cell line underwent mtDNA depletion in vitro, followed 
by recovery in vivo. This approach was used to determine whether mtDNA 
variants remained the same or differed during the establishment of a tumor from 
mtDNA depleted HSR-GBM1 cells. MtDNA depletion was performed using ddC 
so that cells contained 50% (mtDNA50), 20% (mtDNA20), 3% (mtDNA3) and 
0.2% (mtDNA0.2) of their original mtDNA content. These were then injected into 
BALB/c nude mice, together with non-depleted HSR-GBM1 cells that were used 
as a control, to generate tumors.  
 
HRM analysis was performed on the DNA from each of the tumors (Table 5.17), 
for the panel of variants identified during sequencing of the 12 GBM cell lines 
from Tables 5.2 and 5.3. 10 of the 22 tumors had 100% similarity to control 
HSR-GBM1 cells that had not undergone mtDNA depletion. These 10 tumors 
were representative of the different mtDNA depletion categories (mtDNA100, 
mtDNA50, mtDNA20, mtDNA3 and mtDNA0.2). A further 9 tumors shared 93.8% 
of variants with the HSR-GBM1 control cells (2 mtDNA100 tumors, 5 mtDNA50 
tumors, 1 mtDNA20 tumor and 1 mtDNA0.2 tumor), 2 tumors (1 mtDNA100 and 1  
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Table 5.17. Identification of mtDNA variants in depleted HSR-GBM1 that have been recovered in BALB/c nude mice, using HRM 
analysis. Variants in yellow are shared across all tumors formed, and those in orange have been acquired during tumor formation, 
which are representative of the variants identified in the other GBM cell lines that were screened. 
    Cell line Control tumor samples MtDNA depleted mice tumor samples 
 Reference Position Variant  Gene region 
HSR-
GBM1 mtDNA
100 mtDNA50 mtDNA20 mtDNA3 mtDNA0.2 
16186 C→T                        
16218 C→T                        
194 C→T                        
302 A→C                        
310 T→C 
D-loop 
                       
1386 T→C 12s rRNA                        
2130 A→G 16s rRNA                        N
on
-c
od
in
g 
re
gi
on
 
5752 A→G Origin of L-strand replication                        
6422 C→T                        
6999 G→A 
Cytochrome C Oxidase I 
                       
8251 G→A                        
8252 C→A Cytochrome C Oxidase II                        
10473 C→G NADH dehydrogenase 4L                        
10814 A→C                        
11361 T→C                        
11512 C→A                        
11674 C→T                        
12101 T→C                        
12102 C→T 
NADH dehydrogenase 4 
                       
13061 C→A NADH dehydrogenase 5                        
14159 C→G                        
14160 G→C                        
14426 C→T 
NADH dehydrogenase 6 
                       
15264 C→T                        
C
od
in
g 
re
gi
on
 
15267 C→G Cytochrome B                        
   Similarity to HSR-GBM1 (%) - 93.8 87.5 93.8 100 100 93.8 93.8 93.8 93.8 93.8 100 100 100 93.8 81.3 100 87.5 100 100 100 93.8 100 
   Gain in variants to HSR-GBM1 - 1 3 6 1 4 7 2 1 4 5 4 6 7 4 6 10 8 6 7 4 6 9 
	   	   	   	  Variant present (sites jointly analysed) Variant present  Variant absent  Variant absent (sites jointly analysed) 
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mtDNA3) shared 87.5% of variants with HSR-GBM1 cells and 1 mtDNA20 
tumor shared only 81.3%. 
 
A number of variants in the non-coding region were present in all tumors 
formed, which included 4 variants in the D-loop region at 16186bp, 16218bp, 
302bp and 310bp, and 1 variant in the 12s rRNA region at position 1386bp. 
Within the coding region, 1 COX I variant at 6999bp, 2 within ND4 at 11361bp 
and 11674bp, 2 within ND6 at 14159bp and 14160bp, and 2 within CYT B at 
positions 15264bp and 15267bp were shared by all tumor samples. Several 
variants were acquired during tumor formation (at positions 10473bp, 10814bp, 
12101bp, 12102bp, 13061bp, 14426bp). These were representative of the 
variants identified within the other GBM cell lines (Tables 5.2 and 5.3).  
 
Overall, there was an increase in the number of mtDNA variants that were 
representative of other GBM cell line variants with the duration of mtDNA 
depletion, followed by recovery in vivo (Figure 5.7). A significant gain in the 
number of variants relative to HSR-GBM1 cells was not detected until mtDNA 
copy number was depleted to 20% of the original numbers, which could indicate 
the mtDNA50 stage to possess the lowest mtDNA content that is sufficient for 
maintaining normal function of the mitochondrion. The positive correlation that 
was seen in Figure 5.7 could suggest that, with the duration of mtDNA 
depletion, there is an increasing predisposition for the GBM tumors to develop 
GBM-specific variants during re-population of mtDNA. This is likely to have 
arisen by the selection of mtDNA molecules after large-scale depletion, in order 
to drive tumor development of GBM.  
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Figure 5.7. The correlation between 
mtDNA depletion and the gain of mtDNA 
variants in HSR-GBM1 cells recovered in 
BALB/c nude mice. The number of 
variants that were acquired is relative to 
control HSR-GBM1 cells that had not 
been depleted or transplanted into mice. 
* P <0.05, ** P<0.01. 
 
5.4.14. Critical mtDNA variants required for the tumor biology of GBM. 
The GBM patient tumor samples were screened by HRM using the same panel of 
variants that were identified during Ion Torrent sequencing of the GBM cell lines 
(Tables 5.2 and 5.3). 8 variants were identified to be common in all human 
GBM tumor samples (highlighted in yellow in Table 5.18) and amongst these 
variants, few were shared with the HSR-GBM1 variants that were previously 
identified common for the establishment of a tumor in the BALB/c nude mice 
models (highlighted in yellow in Table 5.17).  
 
These shared variants between human GBM tumors and those HSR-GBM1 
tumors formed in the mice models included the D-loop variants at positions 
302bp and 310bp, the COX I variant at 6999bp and the ND4 variant at 11361bp 
(Table 5.18). The finding that these variants were common during the 
establishment of tumor formation in mice and humans, suggests that there are a 
certain set of variants that are required to initiate GBM tumor formation, with a 
small number that may initiate tumor formation in a species-dependent manner.  
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The variants that may be specific to tumor formation in mice includes the D-loop 
variants 16186bp and 16218bp, the 12s rRNA variant at 1386bp, the ND4 variant 
at 11674bp, the ND6 variants at 14159bp and 14160bp and those within CYT B at 
positions 15264bp and 15267bp. For humans, species-specific variants for tumor 
formation includes the D-loop variant 194bp, the COX I variant at 6422bp and 
the COX II variants at 8251bp and 8252bp. Variations in the tumor 
microenvironments in humans and mice may be reasons to explain for these 
differences.  
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Table 5.18. Identification of mtDNA variants in human GBM tumor samples using HRM analysis. Variants highlighted in yellow 
represent those that are shared across all tumor samples.  
   GBM tumor samples  
 Reference Position Variant  09-311 09-258 08-585 09-022 08-0243 08-0680 09-635 085-279 07-257 07-125 10-0214 08-745 09-186 Gene region 
16186 C→T              
16218 C→T              
194 C→T              
302 A→C              
310 T→C              
D-loop 
1386 T→C              12s rRNA 
2130 A→G              16s rRNA N
on
-c
od
in
g 
re
gi
on
 
5752 A→G              Origin of L-strand replication 
6422 C→T              
6999 G→A              
Cytochrome C Oxidase I 
8251 G→A              
8252 C→A              
Cytochrome C Oxidase II 
10473 C→G              NADH dehydrogenase 4L 
10814 A→C              
11361 T→C              
11512 C→A              
11674 C→T              
12101 T→C              
12102 C→T              
NADH dehydrogenase 4 
13061 C→A              NADH dehydrogenase 5 
14159 C→G #### ####  #### #### ####        
14160 G→C #### ####  #### #### ####        
14426 C→T              
NADH dehydrogenase 6 
15264 C→T              
C
od
in
g 
re
gi
on
 
15267 C→G              
Cytochrome B 
	   Variant present  	   Variant absent  	   Variant present (sites 
jointly analysed) 
	   Variant absent (sites 
jointly analysed) 
Variant presence/absence confirmed in 
both Ion Torrent and HRM analyses 
#### 
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5.4.15. Overview of the mtDNA variants identified across the cells and tissue 
samples 
Although, the number of GBM tumors analysed were not sufficient to draw reliable 
conclusions from, so far the D-loop region was determined to contain the highest 
number of mtDNA variants in the non-coding region for the GBM cell lines, tumor 
and normal brain samples (Table 5.19). However, apart from the normal brain 
biopsy samples, the D-loop region was not the region that was most susceptible to 
mutation. For the GBM cell lines, this was identified as the origin of light strand 
replication and for the GBM tumor samples, this was tRNA serine 2. Across all cells 
and tissue types, the mitochondrial rRNA regions were least susceptible to the 
development of mutation in the non-coding region of mtDNA.   
 
Table 5.19. Table showing an overview of the sequencing results from the GBM 
cells, tumors and normal brain tissue. 
  GBM cell lines GBM tumors Normal brain tissue 
Most variants D-loop 
Fewest variants 12s rRNA, Origin of L-strand replication 
tRNA valine, tRNA serine 1, 
tRNA serine 2 12s rRNA 
Most susceptible to 
mutation 
Origin of L-strand 
replication tRNA serine 2 D-loop 
N
on
-c
od
in
g 
re
gi
on
 
Least susceptible to 
mutation 12s rRNA 16s rRNA 12s rRNA 
Most variants NADH Dehydrogenase 4 
Cytochrome C Oxidase III, 
NADH Dehydrogenase 4, 
NADH Dehydrogenase 5, 
NADH Dehydrogenase 6 
Cytochrome  B 
Fewest variants NADH Dehydrogenase 4L 
Cytochrome C Oxidase I, 
Cytochrome C Oxidase II, 
ATPase 8, ATPase 6, 
Cytochrome B 
Cytochrome C 
Oxidase I, ATPase 
8,  
NADH 
Dehydrogenase 3 
Most susceptible to 
mutation NADH Dehydrogenase 6 ATPase 8 Cytochrome B 
C
od
in
g 
re
gi
on
 
Least susceptible to 
mutation Cytochrome C Oxidase I 
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Within the coding region, ND4 harbored the most number of variants within the cell 
lines, whilst ND6 was determined most susceptible to mutation within this category. 
Equal numbers of variants were identified at high levels of mutation in the COX III, 
ND4, ND5 and ND6 regions for the GBM tumors. However, the region most 
susceptible to mutation was ATPase 8 for the tumor samples. ND4 was shared as a 
region containing the most variants in both the GBM cell lines and tumor samples. 
 
The presence of high levels of mutation in the patient tumor samples could relate to 
greater compromise of the ETC to function compared to, for example, normal brain 
tissue. Within the coding region, CYT B contained the highest number of mtDNA 
variants and was the region most susceptible to mutation in normal brain tissues. 
Multiple regions (COX I, ATP8, ND3) were also identified to contain the fewest 
mtDNA variants within these normal brain biopsy samples. Despite differences 
between the GBM cell lines, tumor and normal brain biopsy samples, all were 
identified to share COX I as the mtDNA-coding region that was least susceptible to 
the development of mutation (Table 5.19). 
 
	  	   272	  
5.5. Discussion 
5.5.1. MtDNA variants in the GBM cell lines, tumors and normal brain tissue 
Many of the variants identified in the GBM cell lines and normal brain samples 
represent novel variants that have not yet been published in the MitoMap database 
for mtDNA mutations. The few that have been reported include those at positions 
1386bp, 8251bp, 11361bp, 11674bp and 12102bp within the GBM cell lines. 
However, despite being reported within the MitoMap database, none of these 
variants have so far been associated with GBM. All mtDNA variants identified 
within the GBM cell lines were absent from the normal brain tissue samples, which 
suggest that GBM cells possess a different set of mtDNA variants that could be 
responsible for its tumor phenotype. 
 
Across the GBM cell lines, GBM tumors and normal brain samples, 19 of the 22 
tRNA regions together with ND1 were revealed as mtDNA regions that were 
completely free of mutations. A possible reason for the absence of mutation within 
ND1 could be that the protein represents one of the most conserved subunits of 
Complex I, as it is involved with ubiquinone binding, one of the earliest stages of 
OXPHOS309. Consequently, if a mutation were to arise within this region, it is likely 
that protein impairment would occur. 
 
The observation that all tRNA regions within the GBM cell lines and normal brain 
samples have intact wild-type sequences suggests that these samples do not carry 
impairment to their protein translational machinery. However, variants within the 3 
tRNA regions detected in the GBM tumors (tRNA valine, tRNA serine 1 and 2) 
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could suggest dysfunction at the level of protein synthesis for these samples. 
Noticeably these tRNA variants do not include the A→G substitution at position 
8344bp310, nor the A→G substitution at 3243bp311, both of which have been 
proposed as ‘hotspot’ regions for mutations, representing the earliest discovered 
variants within the tRNA regions312. 
 
5.5.2. Reliability of the Ion Torrent sequencing results 
None of the variants identified reside within homopolymer stretches of sequence, 
which have been identified as regions particularly prone to sequencing errors when 
using the Ion Torrent. The variant at position 16218bp is located in the region 
directly before a series of T residues that reside between 16218bp and 16227bp313, 
providing evidence against it arising as a false positive variant. Furthermore, the 
polycytosine-rich region within the D-loop between positions 303bp and 309bp has 
been reported to be susceptible to an insertion of a C nucleotide, resulting in the 
length heteroplasmy at this site314. Adjacent to this region, position 310bp is thought 
to be vulnerable to damage caused by electrophiles and free radicals315, which could 
explain the detection of the high levels of mutation at positions 302bp and 310bp 
within the GBM cell lines. Also, frequent detection of the 16519bp variant within the 
D-loop across the GBM cell lines, tumor and normal samples, suggests that this 
variant is non-tumorigenic and may be present within the general population. 
 
5.5.3. The impact of GBM mtDNA variants on protein function 
Few ND5 variants located at positions 13346bp within the GBM tumor samples and 
13061bp within the GBM cell lines were predicted to impair protein function. It is 
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likely that these variants could cause dysfunction at the transcript and/or the protein 
level. Mammalian cells require a minimum of 60% transcriptional activity of ND5 to 
maintain normal function. Below this threshold, the rate of protein synthesis for ND5 
becomes insufficient to sustain the proper assembly of Complex I316.  In addition, 
protein synthesis of ND5 is also tightly coupled to the respiration rate of Complex 
I316, which suggests that mtDNA variants within ND5 may have multiple 
implications on protein function.  
 
Recently, it was hypothesized that functional Complex I is important for initiating 
the Warburg effect and in sustaining tumor growth by promoting the adaptation of 
cells to conditions of hypoxia317. Gene mutations affecting ND6 has been isolated as 
the single most important cause of defective protein function, as mutant transcripts 
of ND6 have been associated with reduced respiratory capacity in cells318. If this 
hypothesis for ND6 were true, then any variants found within the Complex I 
subunits, for example, mtDNA variants in ND2, ND4 and ND5, will likely be better 
tolerated by the protein, and will therefore not impair, or will exert minimal 
disruption, to the overall function of the Complex I319. 
 
5.5.4. MtDNA variants as initiators of GBM 
MtDNA depletion of HSR-GBM1 cells and their subsequent replenishment of copy 
number in the BALB/c immunodeficient mice models has demonstrated that de novo 
mtDNA variants are acquired during the tumor establishment of GBM. The finding 
that the novel variants acquired during mtDNA replenishment are representative of 
the variants identified from the additional GBM cell lines, suggests that clonal 
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amplification of the already existing mtDNA variants does not occur during 
replenishment in vivo. It is likely that there is a common set of mtDNA mutations 
that are characteristic of GBM, which can be targeted for the development of 
therapeutic treatments or used in the clinical setting as a diagnostic tool for GBM. 
Based on the results from Tables 5.17 and 5.18, the common set of mtDNA variants 
identified important for GBM tumor biology were determined as D-loop variants 
A→C and T→C at positions 302bp and 310bp, respectively, as well as the COX I 
variant at 6999bp (G→A) and the ND4 variant at 11361bp (T→C). 
 
5.6. Conclusion 
It remains to be determined whether mtDNA variants act as a cause of cancer or if 
they arise as a consequence of the event320. It has been proposed by some that 
unfavorable mtDNA mutations could undergo negative selection in cancer, which 
suggests that tumor establishment is dependent on wild-type mtDNA copies321. For 
example, it was suggested that lower levels of heteroplasmy could be due to negative 
selection against deleterious mutations52. However, based on the results of this 
Chapter, there is evidence to support the concept that mtDNA variants could act as 
possible initiators of GBM.  
 
Replenishment of mtDNA after cells had been depleted of their mtDNA appears to 
be essential for the establishment of a GBM tumor. The accumulation of mtDNA 
variants that occurs during this process is likely to interfere with essential processes, 
such as, protein complex assembly and the binding of factors that would result in the 
shuttling of electrons through the ETC. A positive correlation was reported between 
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the number of variants gained and the duration of mtDNA depletion for GBM cells 
recovered in BALB/c nude mice models. In a situation where there is defective 
OXPHOS, energy production would be compromised, forcing cells to utilize 
glycolysis as their primary pathway for ATP production. This is true for GBM cells, 
which respire predominately via the Warburg effect in accordance with results from 
other studies322, as well as the respirometry measurements obtained from Chapter 4 
(Table 4.2). 
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Chapter 6: The Role of MtDNA in 
Glioblastoma Multiforme 
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6.1. Introduction 
It was previously determined that U266 cells depleted of their mtDNA undergo 
changes to their expression levels for the mtDNA encoded genes, as well as 
those genes involved with mitochondrial biogenesis, transcription and replication 
(Chapter 4). In this Chapter, the HSR-GBM1 cell line was investigated to 
examine whether similar changes to gene expression levels can be induced. 
HSR-GBM1 cells were depleted in the same manner as before, using ddC. 
However, these cells were recovered in conditioned media in the absence of ddC. 
The purpose of this was to more closely mimic recovery in the tumor 
microenvironment, since cells cultured under such conditions would be 
supported by both cellular substrates and secreted factors. It has been reported 
that GBM conditioned media is abundant in supplies of secreted factors, such as 
VEGF, EGF and PDGF-AA323. Therefore, it is hoped that the recovery of the 
GBM cells in conditioned media will provide a more accurate measurement of 
gene expression changes, since it would closely represent the natural conditions 
in which these cells thrive.  
 
One study that investigated the correlation between mtDNA copy number and 
gene expression levels in GBM cells identified that mtDNA depletion increased 
the expression of key mitochondrial transcription and replication factors TFAM, 
TFB1M, TFB2M and POLG280. Additionally, it was determined that the higher 
the tumor grade of the astrocytoma, the lower the mtDNA copy number, for 
which GBM had the highest tumor grade (IV) and also the lowest mtDNA copy 
number280. This association has also been reported for other cancer types, 
including breast324 and ovarian325 cancer.  
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On the other hand, others have suggested that changes to gene expression levels 
are correlated with the metabolic characteristics of cells. This hypothesis was 
based on a study investigating levels of transcript production in isolated 
mitochondria, which demonstrated that the rate of RNA synthesis was linked 
with changes to the mitochondrial ATP levels326. Low levels of ATP were 
thought to stimulate the transcription of mtDNA genes, whereas high ATP levels 
were thought to prevent further transcription of these mtDNA genes. These 
suggestions are consistent with the previous observations in the multiple 
myeloma U266 cells, which showed a similar compensatory effect whilst 
respiring predominately via glycolysis (Chapter 4).  
 
One of the main factors that maintain the tumorigenic capacity of cancer cells is 
their failure to undergo differentiation29. Apart from increased tumor cell 
proliferation, there is also the requirement to enhance angiogenesis of the brain 
vasculature to support the growth of newly established tumor cells. Occasionally, 
brain hemorrhage and oedema arise as side effects accompanying the increased 
angiogenesis in GBM, due to poor maintenance of the intratumoral blood-brain 
barrier, which is regulated by astrocytes, a type of glial cell327,328. There is also 
diffuse infiltration of the astrocytes, as these have direct access to the blood 
vessels of the brain, encouraging metastasis329. Furthermore, their ability to 
infiltrate distal regions of the brain via migration along tracks of the white matter 
and extracellular membrane proteins of the basement membrane330,331 
complicates the possibility of treatment via curative surgical resectioning332, 
since GBM is an astrocytic glioma.  
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There has been increasing interest in the reprogramming of these GBM cells by 
differentiation to reduce the tumorigenic phenotype of these cells333,334. GBM 
cells can be differentiated into astrocytes and neurons. Both these matured cell 
types are in close communication with one another in normal individuals, as 
together they are essential for the proper development of synapses. However, 
more importantly, their modes of metabolism are believed to coupled335.  
 
According to the astrocyte-neuron lactate shuttle hypothesis, astrocytes 
preferentially metabolise glucose via glycolysis to produce lactate that is secreted 
into the extracellular space and subsequently taken up by the neighboring 
neurons. Neurons reportedly lack activity of the bi-functional enzyme 6-
phosphofructo-2-kinase/ fructose-2,6-bisphosphatase isoform 3, which is 
required for the generation of fructose 2,6-bisphosphate during glycolyis336. 
However, the secretion of lactate from the astrocytes and its subsequent uptake 
into neurons, allows for the stimulation of the citric acid cycle337. This is because 
lactate can be used as a substrate in neurons to by-pass glycolysis and, as a result, 
neurons reportedly have a greater reliance on OXPHOS as their primary 
metabolic pathway338,339.  
 
Often in clinical practice, the degree of cellular differentiation in tumor cells is 
important in defining the stage of tumor progression, which influences prognosis 
and treatment options available to the affected patient340. Gene expression 
analysis is one method that can be used to determine the stage of cancer 
progression. For example, during neuronal differentiation of human prostate 
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cancer cells induced by staurosporine, an inhibitor of protein kinases, there were 
changes to the expression levels of genes associated with cell proliferation, 
replication and malignancy341. Furthermore, expression of the MYB gene is 
thought to be responsible for maintaining human breast cancer cells in their 
undifferentiated state, which, in its absence, induces differentiation and thereby 
sensitizing cancer cells to apoptosis342.  
 
6.2. Aims and hypothesis 
The aim of this Chapter was to first identify whether the changes to gene 
expression levels during mtDNA depletion of HSR-GBM1 cells, both with and 
without recovery in conditioned media, induces similar outcomes to the U266 
cells (Chapter 4). It was hypothesized that mtDNA depletion of the HSR-GBM1 
cells would result in a compensatory response, whereby there would be an up-
regulation to, at least, the mtDNA-encoded genes. This effect has already been 
observed in the U266 cells, and has been reported in other studies326. 
Furthermore, this hypothesis is supported by the findings that mtDNA depleted 
and recovered HSR-GBM1 cells harbor greater numbers of mtDNA variants 
(Chapter 5), which is likely to impact on the expression levels of both the 
mitochondrial and nuclear-encoded genes involved with maintaining 
mitochondrial function. However, due to biological differences, variability in the 
patterns of gene expression changes during mtDNA depletion and replenishment 
was also expected between the two tumor types. 
 
Second, this Chapter also aims to determine whether there is a relationship 
between gene expression levels and the state of differentiation in GBM cells. 
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Astrocytes and neurons differentiated from HSR-GBM1 cells were used for this 
investigation. The results would indicate whether or not the tumorigenic 
characteristics of HSR-GBM1 cells were lost upon differentiation. Both 
astrocytes and neurons were analysed since evidence suggests that there is inter-
dependence in the metabolism of the two cell types. It was hypothesized that 
gene expression levels would be lower in the differentiated cells, compared to the 
non-differentiated HSR-GBM1 cells, since differentiated cells are likely to 
metabolize energy more efficiently than cancer cells.   
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6.3. Methods 
The methods used are described in the following sections: 2.1.6 to 2.1.9, 2.4.1, 
2.5.1, 2.6 to 2.8.2, 2.9.2 and 2.11. The primers used during gene expression 
analyses for the HSR-GBM1 cells were from Table 4.1 of Chapter 4. Additional 
methods are described below: 
 
6.3.1. Differentiation of HSR-GBM-1 cells into neurons and astrocytes  
Undifferentiated HSR-GBM-1 cells were harvested and mechanically dissociated 
to form a single cell suspension. 1.5 x 104 cells/cm2 were seeded onto 6-well 
plates treated beforehand with 20µg/ml poly-L-ornithine, and 10µg/ml laminin 
(both: Sigma, St Louis, MO). For differentiation into neuronal cells, plated HSR-
GBM-1 cells were grown in neural induction media consisting of 1x Neurobasal 
media, supplemented with 2mM GlutaMAX, 2% B27 supplement, 0.1mM β-
mercaptoethanol (all from Gibco), 10ng/ml Brain Derived Neurotrophic Factor 
(BDNF; Millipore), and 100µM of Adenosine 3’, 5’-cyclic monophosphate 
(cAMP; Sigma). For differentiation into astrocytes, induction media comprised 
of 1x High Glucose DMEM, supplemented with 2mM GlutaMAX, 1% N2 
supplement, 0.1mM β-mercaptoethanol and 2% FBS (all from Gibco). 
 
Media was changed every 2 days for both astrocytes and neuronal cells, and due 
to differences in their rates of proliferation, were passaged once the cultures 
reached approximately 80% confluency.   
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6.4. Results 
6.4.1. MtDNA content in HSR-GBM1 cells recovered in conditioned media 
HSR-GBM1 cells were depleted of their mtDNA and recovered in conditioned 
media. Results revealed that there was a progressive decline in the mtDNA copy 
number of HSR-GBM1 cells during mtDNA depletion to day 21 (Figure 6.1). 
After 7 days of mtDNA depletion, HSR-GBM1 cells lost over half of their total 
mtDNA copy numbers. However, the rate of decline in copy number was less 
pronounced from day 7 of mtDNA depletion onwards.  
 
  
 
 
 
 
 
 
 
Figure 6.1. MtDNA content in HSR-GBM1 cells depleted of their mtDNA and 
recovered in conditioned media. Non-depleted HSR-GBM1 cells are shown in 
white, those cells that have undergone mtDNA depletion are displayed in black 
and those that have undergone recovery after depletion are displayed in grey. 
’R14’ represents 14 days of mtDNA replenishment. * P≤0.05, **P≤0.01, 
***P≤0.001 
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After 14 days of recovery in conditioned media, following 7 days of mtDNA 
depletion, mtDNA copy number increased significantly above day 0 cells. There 
were further increases seen for cells recovered for 14 days after 14 days of 
mtDNA depletion. Noticeably, 21 days of mtDNA depletion saw an increase in 
mtDNA copy numbers after 14 days of mtDNA replenishment, which did not 
exceed levels reported for day 0 HSR-GBM1 cells. This pattern likely suggests 
that prolonged mtDNA depletion of HSR-GBM1 cells perturbs a feedback 
mechanism that prevents efficient mtDNA replenishment. To test this hypothesis, 
gene expression analyses were performed on mtDNA depleted HSR-GBM1 
cells. However, before doing so, the levels of apoptosis in the HSR-GBM1 cells 
during mtDNA depletion and recovery were determined.  
 
6.4.2. Determining the levels of apoptosis in mtDNA depleted and/or 
recovered HSR-GBM1 cells  
Western blot analysis was performed to assess OPA1 protein expression during 
the course of mtDNA depletion, both with and without recovery in conditioned 
media, for HSR-GBM1 cells. As described previously in section 4.4.11, 
processing of the OPA1 protein occurs during apoptosis, which is independent of 
dysfunction to glycolysis or OXPHOS activity.   
 
Results demonstrated that the long isoform of OPA1 was stable throughout 
mtDNA depletion, and the cells did not undergo much apoptosis, even by day 21 
of mtDNA depletion with recovery for 14 days, as indicated by the processing of 
the long OPA1 isoform to the shorter isoform (Figure 6.2). Comparing these 
outcomes to the mtDNA copy number results (Figure 6.1), show that the loss of 
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mtDNA copies up to day 21 of depletion does not itself result in apoptosis. 
Instead, it is likely that the accumulation of mtDNA variants during the 
replenishment of copy number after a period of prolonged mtDNA depletion, as 
identified from Chapter 5, could be responsible for causing apoptosis following 
the selection of mutant mtDNA copies. 
 
 
Figure 6.2. Western blot analysis for OPA1 expression in mtDNA depleted 
and/or recovered HSR-GBM1 cells. Processing of the long isoform of OPA1 (b) 
into its short isoforms (d and e) is shown, with greater expression of the shorter 
isoform representing high levels of apoptosis in these cells. Lane 3 contained an 
insufficient concentration of protein and was therefore excluded from the 
analysis. ‘ – ‘ represents mtDNA depletion without recovery, whereas ‘ + ‘ 
represents mtDNA replenishment for 14 days in HSR-GBM1 conditioned media. 
Data were collected by Dr Michael Baker at the Bio21 Institute, Melbourne.  
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6.4.3. MtDNA gene expression changes in depleted HSR-GBM1 cells 
For all mtDNA-encoded genes, there was the progressive loss of expression 
throughout mtDNA depletion (Figure 6.3).  
 
 
Figure 6.3. Expression analysis on key mtDNA genes in depleted HSR-GBM1 
cells. Complex I genes (A) ND1 and (B) ND6, Complex III gene (C) CYT B, 
Complex IV gene (D) COX II and Complex V gene (E) ATP 6. 
 
With the exception of COX II, all other mtDNA-encoded genes decreased their 
expression levels to half of that for the day 0 HSR-GBM1 cells by day 7 of 
mtDNA depletion. By day 21 of depletion, all mtDNA-encoded genes had 
negligible levels of expression. 
 
6.4.4. Expression of the upstream mitochondrial regulators  
All the key genes associated with mitochondrial biogenesis exhibited progressive 
increases to their levels of expression during mtDNA depletion of HSR-GBM1 
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cells (Figure 6.4).  PGC1α demonstrated the greatest fold increase during 
depletion, which was almost 6 times higher than at day 25 of mtDNA depletion 
when compared to day 0 HSR-GBM1 cells. For SIRT3, NRF1 and NRF2β, 
expression levels significantly decreased during the initial 7 days of mtDNA 
depletion, which preceded a subsequent rise in expression levels through to day 
25 of depletion, reaching levels that matched, or were close to levels of day 0 
cells. PPARδ was the only gene whose expression levels decreased significantly 
by day 7 of mtDNA depletion, but failed to increase to levels a third of that 
detected for day 0 cells.  
 
 
Figure 6.4. Gene expression of the upstream mitochondrial regulators in 
depleted HSR-GBM1 cells. Mitochondrial biogenesis genes  (A) PGC1α, (B) 
PPARδ and (C) SIRT3. Nuclear respiratory factors (D) NRF1 and (E) NRF2β. 
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The inability to up-regulate PPARδ levels of expression during mtDNA 
depletion could be compensated for by the significant increases in PGC1α. This 
is because PGC1α activity is regulated by PPARδ, which means that if PGC1α 
is able to self up-regulate its expression levels in the absence of sufficient PPARδ 
levels, then the changes in the expression levels of PPARδ during mtDNA 
depletion of HSR-GBM1 cells would be of lesser importance than the other 
mitochondrial biogenesis genes.  
 
6.4.5. Expression of the mitochondrial transcription and replication factors 
Generally, mtDNA depletion stimulated up-regulation of all the mitochondrial 
transcription and replication factors, with the exception of MTERF (Figure 
6.5G). During the early stages (day 7) of mtDNA depletion, all genes displayed 
significant decreases in expression levels, which preceded a rise in levels with 
prolonged mtDNA depletion. For the genes of the mitochondrial transcription 
factors TFAM, TFB1M and TFB2M (Figure 6.5A-C), there were differences in 
the rates at which the expression levels were up-regulated. For example, TFAM 
exhibited a gradual rise in expression levels from day 7 of mtDNA depletion 
onwards, whereas TFB1M and TFB2M showed minimal changes in their 
expression levels between days 14 and 21 of mtDNA depletion. For TFB1M and 
TFB2M significant increases in gene expression levels followed, which were 
apparent at day 25 of mtDNA depletion. Unlike TFB2M, TFB1M expression 
levels increased above day 0 HSR-GBM1 cells by day 25 of mtDNA depletion.  
 
The change in patterns of expression for POLGA (Figure 6.5D) were similar to 
that displayed for TFB2M. Furthermore, POLGB (Figure 6.5E) expression  
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Figure 6.5. Expression of the mitochondrial transcription and replication 
factors. Regulators of transcription (A) TFAM, (B) TFB1M, (C) TFB2M, and 
regulators of mtDNA replication (D) POLGA, (E) POLGB, (F) MTSSB, (G) 
MTERF and (H) TWINKLE. 
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patterns shared similarities with MTSSB (Figure 6.5F) during mtDNA depletion, 
since both show a transient but significant decrease in expression levels at day 21 
of mtDNA depletion. Similar to MTERF, the ability to up-regulate TWINKLE 
expression levels appeared to be compromised during mtDNA depletion (Figure 
6.5H), as TWINKLE levels reached only 50% of those reported for day 0 cells by 
day 25 of mtDNA depletion.  
 
Down-regulation of MTERF expression during mtDNA depletion ensures the up-
regulation of other mitochondrial transcription and replication factors under 
conditions of mtDNA stress, since the MTERF protein functions to terminate the 
transcription of mitochondrial genes. Together these outcomes suggest that the 
mtDNA replication factors are not damaged during the course of mtDNA 
depletion. 
 
6.4.6. Expression of the mtDNA genes during recovery of HSR-GBM1 cells  
For the mtDNA-encoded genes, only ND6 (Figure 6.6B) had significant 
increases to its expression levels above those reported for day 0 HSR-GBM1 
cells, at day 7 of recovery. Nonetheless, peak expression levels for all the 
mtDNA-encoded genes during mtDNA replenishment also occurred at this time 
(at R7). Cells recovered for 14 days exhibited a reduction in the detectable levels 
of expression for all these genes relative to day 7 mtDNA recovered cells. 
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Figure 6.6. Expression of the mtDNA genes during recovery of 7-day depleted 
HSR-GBM1 cells. Depleted cells were replenished in conditioned media. 
Complex I genes (A) ND1 and (B) ND6, Complex III gene (C) CYT B, Complex 
IV gene (D) COX II and Complex V gene (E) ATP 6. ‘R’ represents recovery in 
days. 
 
On the other hand, mtDNA depletion of HSR-GBM1 cells for 14 days followed 
by 14 days of recovery in conditioned media showed that, for all mtDNA-
encoded genes, there were significant increases to their relative gene expression 
levels when compared against the 14-day mtDNA depleted cells (Figure 6.7). 
Only ND6 (Figure 6.7B) and COX II (Figure 6.7D) were able to up-regulate 
their gene expression levels higher than those reported for day 0 HSR-GBM1 
cells.  
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Figure 6.7. Expression of the mtDNA genes during recovery of 14-day depleted 
HSR-GBM1 cells. Depleted cells were replenished in conditioned media. 
Complex I genes (A) ND1 and (B) ND6, Complex III gene (C) CYT B, Complex 
IV gene (D) COX II and Complex V gene (E) ATP 6. ‘R’ represents recovery in 
days. 
 
Overall, comparing 14-day mtDNA depleted cells with the results obtained from 
7-day mtDNA depleted cells, it can be seen that increasing the duration of 
mtDNA depletion to 14 days resulted in the enhanced efficiency of the 
mitochondrial transcription machinery to up-regulate the expression of mtDNA-
encoded genes. 
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6.4.7. Expression of the upstream mitochondrial regulators during recovery  
For all mitochondrial biogenesis and nuclear respiratory factor genes, with the 
exception of PGC1α (Figure 6.8A), there were insignificant changes to gene 
expression levels between 7-day mtDNA depleted HSR-GBM1 cells and those 
cells replenished of their mtDNA copy number for 7-days in conditioned media 
(Figures 6.8B-E).  
 
Figure 6.8. Expression of the upstream mitochondrial regulators during 
recovery of 7-day depleted HSR-GBM1 cells. Mitochondrial biogenesis genes  
(A) PGC1α, (B) PPARδ and (C) SIRT3. Nuclear respiratory factors (D) NRF1 
and (E) NRF2β. ‘R’ represents recovery in days. 
 
PPARδ was the only gene that had negligible levels of gene expression at day 7 
of mtDNA depletion, which remained the same throughout the course of mtDNA 
replenishment (Figure 6.8B). SIRT3 (Figure 6.8C), NRF1 (Figure 6.8D) and 
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NRF2β (Figure 6.8E) all had gene expression levels below 40% of day 0 HSR-
GBM1 cells, whereas PGC1α increased its transcript levels above day 0 cells at 
day 7 of mtDNA replenishment. By day 14 of recovery in conditioned media, 
PGC1α expression decreased to levels that matched day 0 HSR-GBM1 cells. 
 
After 14 days of mtDNA depletion with recovery in conditioned media, there 
were further decreases to the levels of expression for the mitochondrial 
biogenesis and the nuclear respiratory factor genes (Figure 6.9). Only NRF1 was 
able to up-regulate gene expression relative to 14-day mtDNA depleted cells, 
 
 
Figure 6.9. Expression of the upstream mitochondrial regulators during 
recovery of 14-day depleted HSR-GBM1 cells. Mitochondrial biogenesis genes  
(A) PGC1α, (B) PPARδ and (C) SIRT3. Nuclear respiratory factors (D) NRF1 
and (E) NRF2β. ‘R’ represents recovery in days. 
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although this increase was statistically insignificant (Figure 6.9E). PGC1α 
(Figure 6.9A), SIRT3 (Figure 6.9C) and NRF2β (Figure 6.9E) all had decreased 
levels of gene expression at day 14 of recovery in conditioned media relative to 
the mtDNA depleted cells. Similar to cells recovered of their mtDNA after 7 
days of mtDNA depletion, PPARδ displayed almost negligible levels of 
expression, which did not increase even after 14 days of recovery (Figure 6.8B). 
 
6.4.8. Expression of the mitochondrial transcription and replication factors 
during recovery  
TFB1M expression during recovery after 7 days of depletion was similar to the 
expression patterns for TFB2M (Figure 6.10C), POLGA (Figure 6.10D) and 
TWINKLE  (Figure 6.10H). Only POLGB (Figure 6.10E) and MTSSB (Figure 
6.10F) were up-regulated during recovery after 7 days of mtDNA depletion.  
 
After 14 days of mtDNA depletion, all mitochondrial transcription and 
replication genes, with the exception of TFAM (Figure 6.11A), had decreased 
gene expression levels after 14 days of mtDNA replenishment relative to the 14-
day mtDNA depleted cells. For the majority of these genes the decreases in the 
levels of gene expression were significant, except for POLGA (Figure 6.11D) 
and MTSSB (Figure 6.11F). Changes to the expression levels of TFAM showed 
slight but insignificant increases at day 14 of recovery in conditioned media 
compared to 14-day mtDNA depleted cells. These changes to the expression of 
the mitochondrial transcription and replication factors confirm that depletion for 
14 days prevents the efficient recovery of expression for these genes when cells 
are recovered for 14 days in conditioned media.  
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Figure 6.10. Expression of the mitochondrial transcription and replication genes 
during recovery of 7-day mtDNA depleted HSR-GBM1 cells. Regulators of 
transcription (A) TFAM, (B) TFB1M, (C) TFB2M, and regulators of mtDNA 
replication (D) POLGA, (E) POLGB, (F) MTSSB, (G) MTERF and (H) 
TWINKLE. ‘R’ represents recovery in days. 
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Figure 6.11. Expression of the mitochondrial transcription and replication genes 
during recovery of 14-day mtDNA depleted HSR-GBM1 cells. Regulators of 
transcription (A) TFAM, (B) TFB1M, (C) TFB2M, and regulators of mtDNA 
replication (D) POLGA, (E) POLGB, (F) MTSSB, (G) MTERF and (H) 
TWINKLE. ‘R’ represents recovery in days. 
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6.4.9. Changes in gene expression in differentiated astrocytes  
During the differentiation of hNSCs to astrocytes there were progressive 
increases to the expression levels of PGC1α (Figure 6.12A) and POLGA 
(Figure 6.12D), both of which are key genes for the maintenance of mtDNA. 
POLGB (Figure 6.12E) and TWINKLE (Figure 6.12F) showed early up-
regulation of expression to peak levels by day 14 of hNSC-astrocyte induced 
differentiation, whereas there was late up-regulation of TFAM (Figure 6.12C) 
expression, which peaks at day 28 of differentiation. For the expression levels of 
NRF1 (Figure 6.12B) there was a significant but transient increase during hNSC 
differentiation, which occurs at day 14 and decreases back to levels similar to 
day 0 hNSCs by day 28 of differentiation. Insignificant changes to gene 
expression levels were reported for MTSSB throughout the duration of hNSC 
differentiation (Figure 6.12G). 
 
For HSR-GBM1 cells, there were insignificant changes to the expression of 
genes PGC1α, NRF1 and TWINKLE during differentiation into astrocytes. The 
expression profiles for TFAM, POLGA, POLGB and MTSSB demonstrated that 
significant changes in gene expression did not occur until day 28 of astrocyte 
differentiation.  
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Figure 6.12. Expression analysis for the mitochondrial maintenance genes in 
astrocytes. The key genes involved with mitochondrial biogenesis, transcription 
and replication factors are shown during differentiation of the hNSCs and HSR-
GBM1 cells to astrocytes, after 14 and 28 days in astrocyte-induction media. 
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6.4.10. Expression of the mtDNA genes after differentiation into astrocytes 
and neurons 
Gene expression changes in astrocytes and neurons differentiated from HSR-
GBM1 cells were examined. The purpose of this was to determine whether there 
were differences in the gene expression levels between the two mature cell types.  
 
ND1 (Figure 6.13A) and ATP6 (Figure 6.13E) shared similar patterns of gene 
expression after 14 days of differentiation into astrocytes and neurons. For ND6 
(Figure 6.13B), CYT B (Figure 6.13C) and COX II (Figure 6.13D), expression 
levels  
 
Figure 6.13. Expression of the mtDNA genes after differentiation into astrocytes 
and neurons. HSR-GBM1 cells were differentiated for 14 days into the two cell 
types. Complex I genes (A) ND1 and (B) ND6, Complex III gene (C) CYT B, 
Complex IV gene (D) COX II and Complex V gene (E) ATP 6. 
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in the astrocytes were higher than for the undifferentiated HSR-GBM1 cells. 
However, for all mtDNA-encoded genes, expression levels in the neuronal cells 
were lower than observed in the astrocytes. 
 
6.4.11. Expression of the upstream mitochondrial regulators after 
differentiation into astrocytes and neurons 
Astrocytes and neurons shared similar patterns of expression for the 
mitochondrial biogenesis factors PGC1α, PPARδ and SIRT3 (Figure 6.14A-C). 
There were increases to the levels of PGC1α, PPARδ and SIRT3 in the astrocytes  
Figure 6.14. Expression of the upstream mitochondrial regulators after 
differentiation into astrocytes and neurons. Differentiation was performed for 14 
days on HSR-GBM1 cells cultured in induction media. Mitochondrial biogenesis 
genes (A) PGC1α, (B) PPARδ and (C) SIRT3. Nuclear respiratory factors (D) 
NRF1 and (E) NRF2β. 
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above that of undifferentiated HSR-GBM1 cells, whereas expression of these 
genes in the neuronal cells decreased as low as 50% of levels below HSR-GBM1 
cells. On the other hand, NRF1 and NRF2β (Figure 6.14D-E) both showed that 
astrocytes and neurons have reduced expression levels of these genes relative to 
undifferentiated HSR-GBM1 cells. 
 
6.4.12. Expression of the mitochondrial transcription and replication genes 
after differentiation into astrocytes and neurons  
Gene expression levels of TFB1M (Figure 6.15B), TFB2M (Figure 6.15C), 
POLGA (Figure 6.15D) and TWINKLE (Figure 6.15H) in 14-day astrocytes and 
neurons were reduced compared to undifferentiated HSR-GBM1 cells. However, 
both POLGB (Figure 6.15E) and MTSSB (Figure 6.15F) increased their 
expression levels in these differentiated cells relative to their undifferentiated 
counterpart. The up-regulation in MTSSB expression in astrocytes and neurons 
was more pronounced compared to the increases in POLGB expression relative 
to undifferentiated cells. TFAM was the only gene whose expression did not 
change following 14 days of differentiation into astrocytes and neurons (Figure 
6.15A).   
 
Gene expression changes observed in 14-day astrocytes and neurons suggest that 
there is limited replication of mtDNA in these cells, because expression of the 
key mitochondrial transcription and replication genes were reduced compared to 
undifferentiated HSR-GBM1 cells. It is likely that differentiated cells metabolise 
glucose more efficiently, and as such, OXPHOS is likely to predominate in these 
mature astrocytes and neuronal cell types for the generation of ATP. This 
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hypothesis is supported by recent data proposing that the astrocyte-neuron lactate 
shuttle is not required for OXPHOS to take place343, thereby opposing the 
traditional hypothesis that, astrocyte metabolism is closely coupled to neurons, to 
supply these cells with lactate as a substrate for stimulating OXPHOS activity. 
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Figure 6.15. Expression of the mitochondrial transcription and replication genes 
after differentiation into astrocytes and neurons. Regulators of transcription (A) 
TFAM, (B) TFB1M, (C) TFB2M, and regulators of mtDNA replication (D) 
POLGA, (E) POLGB, (F) MTSSB, (G) MTERF and (H) TWINKLE. 
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6.5. Discussion 
6.5.1. Gene expression changes in HSR-GBM1 cells recovered in conditioned 
media 
Results from day 7 and day 14 mtDNA depleted HSR-GBM1 cells recovered of 
their mtDNA copy numbers in conditioned media, suggested that prolonged 
mtDNA depletion for 14 days, was generally less effective for increasing the 
expression levels of key mitochondrial biogenesis and nuclear respiratory factor 
genes. Moreover, recovery of gene expression levels was only effective during 
short-term culture (7 days) in conditioned media after 7 days of mtDNA 
depletion.  
 
It was previously found that mtDNA depletion itself does not damage the 
mitochondrial transcription and replication factors (section 6.4.4). Therefore the 
inability to rescue gene expression levels of these factors during recovery, 
especially after day 14 of mtDNA depletion, is likely to be due to damage to a 
feedback mechanism between the mitochondria and nucleus in coordinating the 
regulation of expression for these genes during mtDNA replenishment. Whilst 
mtDNA copy number analysis (Figure 6.1) showed the up-regulation of copy 
number during recovery after 7 and 14 days of depletion, there could be a delay 
in the nuclear transcription of the mitochondrial associated genes in response to 
increases in mtDNA copy number, which further supports the hypothesis for a 
feedback mechanism.  
 
A key observation during recovery in conditioned media after 7 days of mtDNA 
depletion, was the inability of HSR-GBM1 cells to up-regulate the expression 
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levels of TFAM (Figure 6.10A), TFB1M (Figure 6.10B) and TFB2M (Figure 
6.10C), which contradicted results from another study that reported up-regulation 
in the expression of these genes during depletion280. One could interpret these 
results to indicate that recovery in conditioned media may not provide sufficient 
metabolites and factors to support the activity of the mitochondrial 
transcriptional machinery. Upon collection of the conditioned media from a 
culture of control HSR-GBM1 cells, the cells may have exhausted certain 
supplies of nutrients within the media in order for these cells to produce 
additional factors that can be secreted into the surrounding media to support its 
growth and proliferation. Without fresh supplies of certain nutrients that cannot 
be produced by the cells alone, the culture of cells in conditioned media may not 
be optimal to maintain the expression levels of genes that are important for the 
maintenance of mtDNA. 
 
Although the regulation of mitochondrial gene expression levels is thought to be 
largely dependent on the metabolic activities of cells, evidence has emerged to 
suggest that post-transcription modifications can occur independently of the 
cell’s metabolic status344. This could affect, for example, rates of transcript 
degradation, and may provide an alternative explanation for the differences 
between the recovery of gene expression levels in HSR-GBM1 and U266 cells. 
 
6.5.2. Gene expression analysis in astrocytes and neurons differentiated 
from HSR-GBM1 cells 
Within the subventricular zone of the brain, there is a population of astrocyte-like 
neural stem cells, which under abnormal regulation may give rise to GBM303,345. 
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Alternatively, de-differentiation of mature glial cells can lead to the same 
outcome, forming a GBM tumor346. These biological findings that connect 
hNSCs with HSR-GBM1 cells are the primary reasons why the hNSCs were 
used as a non-tumorigenic control when analyzing for gene expression 
differences between day 14 and day 28 astrocyte-differentiated cells (Figure 
6.12).  
 
It has been reported that, unlike astrocytes, neurons are less able to adapt to 
changes in energy metabolism. This is because inhibiting mitochondrial 
respiration in neurons using nitric oxide, induced depletion of ATP levels and led 
to cellular apoptosis347, whereas astrocytes responded to the same event by 
increasing glycolysis in an attempt to prevent decreases to ATP levels, therefore 
avoiding apoptosis347. The inability of neurons to adapt to metabolic change is 
further emphasized by their undergoing apoptosis when the rates of glycolysis348 
or glycogen synthesis are increased349. For these reasons, neuronal cells were not 
analysed for changes in gene expression levels during the course of 
differentiation from HSR-GBM1 cells. 
 
Changes in gene expression for the key factors associated with mitochondrial 
biogenesis, transcription and replication, comparing days 14 and 28 of astrocyte 
differentiation from the hNSCs and HSR-GBM1 cells (Figure 6.12) revealed 
that for most genes, except MTSSB, the hNSCs had higher gene expression levels 
compared to astrocytes differentiated from HSR-GBM1 cells. A possible 
explanation for this could be that astrocytes derived from hNSCs may develop 
certain characteristics leading towards a tumorigenic phenotype, since as 
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mentioned previously, astrocyte-like hNSCs are capable of developing into GBM 
tumor in vivo303,345.  
 
6.6. Conclusion 
MtDNA depletion of HSR-GBM1 cells shows similar results to mtDNA 
depletion of U266 cells. However, overall, HSR-GBM1 cells appear to up-
regulate gene expression levels less efficiently compared to U266 cells, which 
might be variable depending on the tumor type examined. The increase in the 
number of mtDNA variants that were gained during recovery of mtDNA 
depleted HSR-GBM1 cells may be a contributing factor towards the reduced 
ability of these cells to recover their gene expression levels as high as that 
previously observed for U266 cells. HSR-GBM1 cells also appear to have more 
stable expression of the long isoform of OPA1 compared to U266 cells, when 
undergoing mtDNA depletion, both with and without mtDNA recovery. 
 
The observation that day 14 astrocytes and neurons had reduced expression of 
the key replication genes could indicate high efficiency for glucose metabolism, 
and therefore OXPHOS is likely to predominate in these mature cell types. It has 
been suggested by other studies that cells with high levels of oxygen 
consumption have reduced ability to form tumors350-352. Therefore, lower gene 
expression levels in astrocytes derived from HSR-GBM1 cells could also reflect 
their loss of tumorigenic properties during the differentiation process. Therefore, 
mtDNA is important in the initiation of a GBM tumor. 
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Chapter 7: General discussion 
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7.1. The role of mtDNA in cancer stem cells and in tumor biology 
One of the most widely accepted concepts for explaining cancer initiation relates 
to the presence of cancer stem cells that may be responsible for sustaining tumor 
growth within a heterogenous population of tumor cells353. These cancer stem 
cells retain some of the properties of pluripotency and represent a rare population 
of cells within the tumor. Due to their high proliferative capacity, cancer stem 
cells are more likely the cause of tumor relapse after chemotherapy treatment, 
since the clonal expansion of one drug-resistant cell could give rise to the re-
establishment of a tumor354.  
 
From the results of this thesis, mtDNA has been identified to modulate the 
tumorigenic phenotypes of cancer stem cells from both multiple myeloma and 
GBM. Support for this was provided by evidence showing the acquisition of 
mtDNA variants during mtDNA replenishment (Chapters 3 and 5), as well as 
changes to the expression levels of key genes involved with its tumor biology, 
mitochondrial biogenesis, transcription and replication during mtDNA depletion 
and recovery (Chapters 4 and 6). These findings could complement the current 
cancer stem cell hypothesis, which states that a tumor arises as a single mutated 
cell that has gained a proliferative advantage to establish a tumor355, since the 
cause of the mutation could arise at the mtDNA level. 
 
However, the alternative method by which a tumor may arise could be through 
the de-differentiation of mature cell types to form undifferentiated stem cells, via 
the accumulation of genetic alterations overtime356. This was demonstrated to 
occur in intestinal epithelial cells, as a result of enhanced signaling via the NF-
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κB pathway and the increased activation of Wnt357. In terms of changes induced 
to the mitochondria during the process of cellular de-differentiation, it is likely 
that energy production within the mitochondria will change to meet the energy 
demands imposed by the cancer cells. This is because several studies have been 
able to demonstrate that mitochondria within human induced pluripotent stem 
cells (iPSCs) can alter certain properties associated with mitochondrial gene 
expression, mtDNA copy number, morphology, ATP and lactate production 
levels to match those that are characteristic of early stem cells358. This effectively 
‘reprograms’ the mitochondrion to match the metabolic demands of the cell 
type359. Either way, the ability of the mitochondria to adapt to different cellular 
conditions and energy requirements may be key to the formation of a tumor, 
including those of multiple myeloma and GBM. 
 
7.2. MtDNA variants  
MtDNA variants reported in this thesis have only included those of base 
substitutions. This is because the Ion Torrent platform is not ideal for the 
detection of small insertions and deletions (indels), consisting of 1 or 2 
nucleotides. During the variant selection procedure, many of the indels were 
detected at very low levels of less than 10, out of a genome coverage of at least 
1500 or more sequencing reads. It was likely that these had arisen as sequencing 
errors, with the majority identified as residing within homopolymer sequence 
regions, which is a known problem for the Ion Torrent sequencing platform181. 
There was also the absence of large-scale deletions from all sequencing results, 
which would have been less likely to represent false positive results. In this 
thesis, only the mtDNA variants that are likely to represent true variants are 
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included, which means that there may be additional mtDNA variants that are not 
reported, since the variant selection criteria is also quite stringent.  
 
In Chapter 3, the GC content of a gene sequence was explored as a possible 
factor that could influence mutation rates across the mtDNA. However, the GC 
content of a sequence region is not the only factor that could influence 
susceptibility of a region to mutation. It was suggested by others to contribute 
approximately 10% towards variability in the rate of substitutions across the 
human genome360. Differences in the rate at which these regions evolve could 
also be a factor.  
 
A comprehensive study reported that whilst the rate of substitution for 
synonymous amino acid changes are approximately the same for all mtDNA 
coding genes, differences are observed for non-synonymous mutations361. The 
cytochrome c oxidase region exhibited the slowest rate of substitution, whereas 
ATP8 appeared the fastest in terms of undergoing evolutionary change361. 
Moreover, the fold change for the evolutionary rate of small rRNA was reported 
to be 20 times greater in mitochondria than in the nucleus, whereas for tRNAs, 
this fold change was 100 times greater361. Therefore, the natural rates of mtDNA 
evolution are likely influence the susceptibility of a region to mtDNA mutations. 
 
7.3. Compensatory mechanisms during mtDNA depletion 
Changes to the levels of ATP production are often associated with morphological 
alterations of the mitochondria362. Depletion of mtDNA is therefore likely to 
induce a transient protective mechanism to prevent the complete loss of ATP 
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production. One possibility for mediating this effect involves the fusion of 
mitochondria, which permits the exchange of mitochondrial components to 
minimize the stresses that may be imposed upon individual mitochondrion, and 
thereby partially supporting mitochondrial function during periods of stress363.  
 
An alternative mechanism to mitochondrial fusion has been reported in plants, 
where the stress of cultivation conditions can induce the up-regulation of 
expression for the nuclear-encoded F0 subunit, which is a key component of the 
ATP synthase complex364. After its translocation into the mitochondria, ATP 
production levels increase, a situation that emphasizes the bi-directional 
communication between the nucleus and mitochondria. Other theories have 
proposed that mitochondria or mtDNA can be mobilized intercellularly via 
cytoplasmic extensions365, a concept that was developed to prove the transfer of 
plastids across plant cells via cell-wall junctions366. However, for both these 
mechanisms, whether these occur in humans currently remains elusive. 
 
7.4. The involvement of mtDNA in the initiation of GBM 
Sequencing of paired samples of GBM provide an important insight into 
understanding whether some mtDNA variants are specific to tumors or are non-
discriminative between tumor and normal tissues. From Chapter 5, the results 
demonstrated that tumor samples generally have greater numbers of mtDNA 
variants, which are also reported to have high levels of mutation. For all but one 
mtDNA variant (at 66bp, Table 5.16), the nucleotide substitutions were specific 
to either the normal or tumor tissue.  
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Earlier studies have also examined paired glioma samples. In 2001, Kirches et al. 
sequenced 17 GBM samples for comparison against their corresponding blood 
samples367. However, the level of accuracy from their sequencing method was 
not as high as other studies that utilise next generation sequencing as a primary 
approach to identifying variants. From this study, Kirches reported variants in 
only 7 of the 17 tumors analysed. Later in 2002, the same group published a 
short report to extend their analyses, sequencing 10 pairs of astrocytomas and 
their corresponding blood samples368. However, they reported the absence of any 
sequence variant present in these 10 paired samples. Moreover, in another study 
that focused on mtDNA mutations in mouse brain tumors, the absence of 
pathogenic variants across the entire mitochondrial genome was reported in both 
induced and spontaneous cases of tumor development369. Together these studies 
emphasise the importance of the sequencing techniques used for the 
identification of mtDNA variants that will provide highly accurate and 
meaningful data. 
 
A genome-wide expression screen of GBM tumor tissue and their adjacent 
normal counterparts has been performed, which demonstrated that both these 
tissue types possessed similarities as well as differences in their patterns of gene 
expression370. As anticipated, it was found that genes participating in 
angiogenesis were up-regulated in the tumor tissue, alongside genes associated 
with cell proliferation and formation of the extracellular matrix. Genes that were 
down-regulated in the tumor sample, included those that were essential for 
development of the nervous system. In adjacent normal tissue, it was discovered 
that, unexpectedly, similar to the GBM cells, there was the enhanced expression 
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of genes involved with tumor malignancy, including those participating in cell 
motility. Gene expression of tumor suppressors was also down-regulated in the 
normal tissue. These observations led to the suggestion that perhaps there is 
‘leakage’ of genes from the tumor cells that can invade the surrounding normal 
tissue. If this were true, then it remains possible for defective mitochondrial 
genes, such as those involved with mitochondrial biogenesis, transcription and 
replication to ‘leak’ and promote tumor establishment in neighboring normal 
cells. However, results from this thesis collectively support the role of mtDNA in 
the tumor biology of both GBM and multiple myeloma.  
 
7.5. The initiation of cancer from the transformation of normal cells 
The concept of gene leakage from tumor cells to normal cells counteracts the 
hypothesis that perhaps normal cells fuel tumor growth via the secretion of 
various factors. This was proposed in 2012, where a study demonstrated that the 
loss of Pten, a tumor-suppressor371, in the tumor stroma (normal cells) resulted in 
the down-regulation of microRNA, miR-320372. As a consequence, there was an 
increase in the secretion of oncogenic factors that function to enhance 
proliferation and malignancy of neighboring stromal cells. Normal cells are then 
transformed into cancer cells, thereby promoting tumor growth and 
malignancy372. 
 
Earlier theories related to the initiation of cancer from normal cells include the 
reverse Warburg effect proposed by Pavlides et al in 2009373. This hypothesis 
suggested that tumor stromal cells were encouraged to undergo transformation 
by the adjacent tumor cells, into wound-healing stromal cells, such that these 
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stromal cells will predominately utilise aerobic glycolysis (Warburg effect) for 
ATP production. The secretion of the metabolites pyruvate and lactate can then 
be taken up and used by the neighboring cancer cells during the citric acid cycle, 
and the ATP produced via OXPHOS in the cancer cells can then be used to 
further promote cellular proliferation and therefore tumor growth373. Inhibitors of 
lactate transport are thought to target these stromal cells and induce their 
apoptosis via accumulation of intracellular lactate levels373. Glycolysis inhibitors 
such as 2-DG and dichloro-acetate, which cannot be metabolized by cells, were 
also suggested as a therapeutic approach to target these transformed stromal 
cells374. 
 
7.6. The correlation between mtDNA copy number and gene expression 
levels 
During the progressive depletion of mtDNA, all factors, regardless of 
mitochondrial or nuclear origin, experienced an increase in the relative 
expression levels proportional to the duration of mtDNA depletion, up until a 
certain point. However, up-regulation of these factors does not necessarily 
correspond to increased mtDNA copy number. For example, POLG activity is 
dependent on the function of supporting factors during mtDNA replication, such 
as TWINKLE and MTSSB, both of which must precede activity of POLG to 
permit the multi-subunit complex to carry out its function of synthesizing nascent 
mtDNA strands, complementary to the mitochondrial template strand. Therefore, 
the absence of a single factor participating in mitochondrial transcription and 
replication could be rate-limiting for the processes of mtDNA transcription and 
replication. 
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Results from a protein expression study performed in HeLa cells complements 
some of the gene expression results that were reported in Chapters 4 and 6 during 
mtDNA depletion and recovery.  The protein expression study, led by Seidel-
Rogol and Shadel, identified that the key mitochondrial transcription proteins 
TFAM and mtRNA polymerase had similar expression profiles during mtDNA 
depletion and replenishment375. They reported that recovery of expression for 
both factors to day 0 levels occurred at a rate slower than the recovery of mtDNA 
copy number375. It was suggested that during mtDNA depletion, the cell attempts 
to prevent the accumulation of transcripts as a resource reserve. Under normal 
situations in the absence of mtDNA depletion, the expressions of TFAM and 
mtRNA polymerase are generally in excess of the required transcription levels. 
More specifically, 15 molecules of TFAM have been estimated to be present per 
mtDNA copy in human cells376, which is thought to be optimal for the initiation 
of transcription from the light strand promoter region377. Significant decline in 
the mtDNA transcription levels mediated by TFAM is believed to occur only 
when there is a 10-fold decrease to the TFAM/mtDNA copy number ratio378. 
Therefore, it is possible that, even during mtDNA depletion, low levels of TFAM 
may still be sufficient to support mtDNA transcription from the origin of light 
strand promoter region.  
 
7.6.1. Multiple myeloma 
For multiple myeloma cells, it was identified in Chapter 4 that recovery of 
mtDNA copy number after 7 days of mtDNA depletion, was significantly higher 
than day 0 cells at day 14 of recovery. Cells depleted for 14 days of their 
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mtDNA, were not able to effectively increase their mtDNA copy numbers even 
after 14 days of recovery, suggesting recovery was impaired after prolonged 
exposure to mtDNA depletion. TFAM expression levels by day 7 and 14 of 
mtDNA depletion already exceeded levels of day 0 cells. With the duration of 
recovery, expression of TFAM progressively increased from day 3 of mtDNA 
replenishment onwards, which did not fall below levels of day 0 cells at any 
point during the recovery process for both day 7 and 14 mtDNA depleted cells. 
Together, these observations confirm that the accumulation of TFAM expression 
is important during the recovery of copy number in multiple myeloma cells.  
 
7.6.2 GBM 
MtDNA copy number and TFAM expression levels in the HSR-GBM1 cells 
revealed different patterns of change. MtDNA copy numbers were significantly 
up-regulated relative to day 0 cells by day 14 of recovery after days 7 and 14 of 
mtDNA depletion. Both these depleted cells were unable to increase TFAM 
expression levels above day 0 cells at all stages of recovery, which contradicts 
the theory that excessive expression of TFAM must be present for mtDNA copy 
number to undergo efficient recovery. It is possible that the up-regulation of 
several other key mitochondrial transcription and replication genes is required 
for the recovery of mtDNA copy number. Alternatively, regulation at the post-
transcriptional level that controls the stability and translation of mtDNA 
transcripts may have a role in explaining the differences observed between 
multiple myeloma and GBM cells379. 
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7.7. Bi-directional communication between mitochondria and the nucleus  
One of the key observations from Chapter 4 was that, during the late stages of 
mtDNA depletion, there was up-regulation of tumor proliferation genes, such as 
FGFR3 and MAPK. These results corresponded with the reduced ability of U266 
cells to proliferate, which was also seen for cells recovered for 14 days in the 
absence of 2-DG after 14 days of mDNA depletion. Based on these findings, it is 
possible that there exists a threshold level for mtDNA copy number. Below this 
threshold level, there may be insufficient mtDNA copies to provide feedback 
signals to the nucleus (Figure 7.1). The relationship between the mitochondria 
and nucleus is likely that the nucleus produces mitochondrial biogenesis, 
transcription and replication factors to positively replicate the mtDNA. However, 
in the event where mtDNA copy number is not replenished sufficiently to be 
above the critical threshold level, which could arise from an accumulation of 
mtDNA variants during recovery, synchrony between the mitochondria and 
nucleus would be disrupted. This is because the nucleus would not receive 
enough signals that would otherwise inform of the successful replication of 
mtDNA. The nucleus would then respond by increasing the expression of 
tumorigenic genes (Figure 7.1). Ultimately, this nuclear response would promote 
a positive feedback mechanism that enhances both the malignant characteristics 
of the tumor cells, as well as further stimulation of the Warburg effect.  
 
	  	   321	  
 
 
Figure 7.1. Model of bi-directional communication between the nucleus and 
mitochondria. It was hypothesised that a feedback mechanism between the 
nucleus and the mitochondrion positively regulates cell proliferation. A 
threshold level for mtDNA copy number exists whereby, below the critical limit 
(identified at day 14 of mtDNA depletion), there would be disrupted synchrony in 
the communication between the nucleus and mitochondria. This would lead to 
the nucleus responding by increasing its expression for key tumorigenic genes, 
which would further drive both tumor development and the Warburg effect.  
 
 
Support for the Warburg effect within U266 and HSR-GBM1 cells lies in the 
observation that these cells are able to survive even during prolonged mtDNA 
depletion (Figure 4.4B, Figure 6.2), as the Warburg effect produces energy from 
the cytoplasm. However, the Warburg effect does not occur exclusively within 
these cells, as respirometry results demonstrated the presence of functional 
OXPHOS in both cell types (Table 4.2). 
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Evidence exists that can be used to support the hypothesis that there may be bi-
directional communication between the mitochondrion and the nucleus for 
maintaining cell proliferation. Some have suggested that communication between 
the two compartments is essential for controlling the expression of nuclear-
encoded proteins for example, the subunits comprising the cytochrome c oxidase 
complex380. The interactions between the two genomes are therefore important 
for ensuring the correct synthesis and assembly of the protein complexes that 
comprise the ETC, which would then allow for energy production via OXPHOS 
as well as other biological processes to take place, inclusive of cellular 
proliferation. 
 
The few studies that have investigated for molecules that interact with both the 
nucleus and the mitochondrion emerged following the discovery that peptides 
degraded from mitochondrial proteins are exported from the mitochondrion as a 
mechanism of quality control for mitochondrial proteins381,382. More than one 
peptide efflux pathway has been described in the mitochondrion383. In addition, 
several molecules have been proposed to provide interaction between the 
mitochondrion and the nucleus. Apart from MondoA-Mlx, mentioned in Chapter 
4, others include nuclear-encoded SIR2, a histone deacetylase whose function is 
dependent on the presence of NAD384, and mitochondrial protein dihydroorotate 
dehydrogenase. Dihydroorotate dehydrogenase senses the abundance of free 
nucleotides to control synthesis of DNA and RNA, with the dual role of 
detecting the ratio of ubiquinone/ubiquinol and NADH levels since it catalyses 
the oxidation of dihydroorotate to orotate via ubiquinone, required for the de 
novo synthesis of pyrimidines in the mitochondrion385. 
 
	  	   323	  
7.8. Further evidence to support the role of mtDNA in the tumor biology of 
GBM 
Recently, a study by Dickinson et al. have published evidence to support the 
hypothesis that mtDNA are crucial initiators of GBM, as discussed in Chapter 6. 
MtDNA copy number in GBM cell lines, HSR-GBM1, GBM L1 and GBM L2 
were examined during differentiation into astrocytes386. Compared to hNSCs, the 
GBM cells were found not to effectively increase their mtDNA copy number 
after 28 days of differentiation into astrocytes. Alongside this, respirometry 
results demonstrated that oxygen consumption rates were higher in hNSC-
derived astrocytes than astrocytes differentiated from HSR-GBM1 cells. 
Undifferentiated HSR-GBM1 cells also had higher lactate production, which 
declined with the duration of differentiation when compared with hNSCs386. On 
the other hand, ATP production during differentiation was greater in hNSCs than 
for HSR-GBM1 cells. These observations together demonstrated the importance 
of mtDNA copy number in the tumor biology of GBM (Figure 7.1). 
 
Furthermore, mtDNA depletion and recovery of HSR-GBM1 cells in BALB/c 
nude mice, demonstrated an inverse correlation between the rate of tumor growth 
and the extent of mtDNA depletion386. Reduced tumor growth during recovery 
after mtDNA depletion could be related to the acquisition of other GBM variants 
during mtDNA replenishment, as described in Chapter 5. It is also likely that 
mtDNA copy number could be responsible for the changes to gene expression 
patterns identified in Chapter 6, since depletion of GBM cells using ddC did not 
disrupt mitochondrial integrity, as shown by stable expression of the OPA-1 
	  	   324	  
mitochondrial protein386. These findings strongly support the concept that 
mtDNA acts as initiators of GBM tumor establishment. 
 
7.9. Summary  
Overall, the conclusions from this study are:  
[1] The abnormal accumulation of mtDNA variants in cancer cells can result in 
the formation of dysfunctional protein complexes that comprise the ETC, 
especially if non-synonymous amino acid mutations translate as polypeptides 
that disrupt critical regions of the protein complex (Figure 7.2; 1). Conserved 
regions of the protein complex are more likely to carry greater deleterious 
effects.  
 
[2] Impaired protein function of the ETC complexes leads to disruption in the 
sequential transfer of electrons, and therefore the inability to generate an 
electrochemical gradient that could otherwise be used to produce ATP molecules 
via ATP synthase (Complex V) (Figure 7.2; 2). This causes the cancer cell to 
respire predominately via glycolysis. 
 
[3] Overtime, glycolytic cancer cells establish low mtDNA copy numbers, which 
correlate with tumor grade (Figure 7.2; 3). This is likely to occur, as mtDNA 
encodes genes essential for OXPHOS function, and due to the reduced demand 
for OXPHOS in predominately glycolytic cells, there would be a reduced need 
for efficient mtDNA replication. During the decline of mtDNA copy number, 
there may also be the acquisition of further mtDNA variants.  
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[4] The presence of low mtDNA copy number increases the expression levels of 
nuclear-encoded genes associated with mitochondrial biogenesis, transcription 
and replication as a compensatory effect (Figure 7.2; 4). The inability of 
mtDNA to expand its copy number in response to the increased expression of 
these genes, which could arise as a consequence of the accumulation of mtDNA 
variants, results in the increase in the expression of tumorigenic genes from the 
nucleus. This occurs due to disruption in the synchrony between the 
mitochondria and nuclear compartments. The up-regulation in the expression of 
tumor biology genes would positively enhance tumor cell malignancy and further 
promote the Warburg effect and thus cellular proliferation rather than 
differentiation. 
 
 
In conclusion, mtDNA variants and mtDNA copy number act together in 
controlling the tumor biology of multiple myeloma and GBM cells. This arises as 
cells are forced to generate energy through aerobic glycolysis, which promotes 
proliferation of naïve cells rather than the differentiation of naïve cells into 
mature, differentiated cells.  
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Figure 7.2. Proposed model for the role of mtDNA in the tumor biology of multiple 
myeloma and GBM cells. The mitochondrion is positioned as the central organelle 
(orange) and the nucleus is shown in blue. The two biochemical pathways for energy 
production are presented within the boxes. [1] Mutant mtDNA copies in the 
mitochondrion arise as a consequence of the abnormal accumulation of mtDNA variants 
in cancer cells. [2] The presence of mutant mtDNA disrupts the function of proteins that 
comprise the ETC, which leads to defective OXPHOS in these cancer cells. [3] Since 
glycolysis predominates as the primary method for ATP generation, there is a reduced 
need for these cancer cells to efficiently replicate their mtDNA, resulting in a decline in 
mtDNA copy number and possibly the acquisition of further mtDNA variants. [4] The 
presence of low mtDNA copy number increases the expression levels of nuclear-encoded 
mitochondrial genes that assist in the biogenesis, transcription and replication of 
mtDNA. However, the failure of mtDNA to respond to the increased expression of these 
genes causes disruption to the synchrony between the nucleus and mitochondria. This 
promotes tumor malignancy by the up-regulation of key tumorigenic genes, which 
enhances the Warburg effect and increases cell proliferation. 
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7.10. Further work 
To further confirm that mtDNA is essential for tumor establishment, it would be 
beneficial to perform functional studies using immunodeficient mice models. 
MtDNA depleted HSR-GBM1 cells have already been examined for mtDNA 
variants during tumor formation in BALB/c nude mice. However, it is important 
to do this work with multiple myeloma cells, as no in vivo experiments have yet 
been done on these cells. This is especially important, as there is currently no 
effective method to mimic the bone marrow microenvironment using in vitro 
techniques. Furthermore, the microenvironment of the bone marrow, where 
multiple myeloma cells are naturally found, consists of various interacting cells 
that are capable of secreting factors to promote the survival and proliferation of 
multiple myeloma cells.  
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i. Further information on sequence quality from the Ion Torrent 
To describe in detail the quality of the sequencing results obtained from the Ion 
Torrent, the data from one of the patient multiple myeloma samples  (sample 
S219, sequenced in Table 3.6) was included as a representative example.  
 
Quality reports on the raw sequencing data 
All sequencing runs performed using the Ion Torrent were automatically 
analysed by the pre-installed Ion Torrent Suite Software. The quality reports that 
were produced at the end of each run provide information on the loading density 
of the Ion chip, in the form of a heat map. This provides an indication of how 
many of the microwells on the Ion chip were successfully occupied by the Ion 
Sphere Particles (ISPs), and their distributions across the Ion chip. Quantitative 
data was also provided to inform the user of how successful the emulsion PCR 
was in amplifying the DNA template on these ISPs.  
 
Using the S219 myeloma sample as an example, typically there was an even 
loading of the ISPs across the Ion chip (Figure A1). The proportion of 
microwells containing an ISP, was usually above 60%, and of these ISPs the 
proportion of ‘live ISPs’ were generally always above 80%, since template-
positive ISPs were enriched for prior to the sequencing reaction (section 
2.18.10). The percentage of live ISPs is therefore representative of the 
enrichment efficiency, and is measured by the presence of a key sequence 
‘TCAG’ attached to the ends of successfully amplified DNA template, located on 
the 3’ adaptor itself. Further information on these template-positive ISPs was 
also provided to inform users of the final percentage of library reads that were 
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included in the sequencing output (FASTQ) file. The filtering process to produce 
the final percentage of acceptable library reads was automated on the Ion Torrent 
Suite Software, and was based on the exclusion of low quality DNA templates, 
which yielded low sequencing signal or polyclonal reads.  
 
Figure A1: Quality report on the raw sequencing data obtained from the Ion 
Torrent Suite Software. 
 
Any sequencing runs that reported uneven loading of the microwells on the Ion 
chip, or even unsatisfactory statistics on, for example, the percentage of live 
ISPs, were re-run on the Ion Torrent.  
 
Sequence analysis before and after trimming  
As mentioned in Section 2.19, all raw sequencing reads from the Ion Torrent 
were subjected to filtering using the CLC Genomics Workbench software. The 
purpose of this was to select for reads above a Phred quality score of 15 and to 
discard short reads below a length of 15bp. All sequences were also trimmed on 
each end by 1bp to prevent reporting nucleotides that may be ambiguous. An 
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example showing changes to the distribution of read lengths before and after 
quality-based trimming is shown in Figure A2a, with the typical distribution of 
Phred scores before trimming shown in Figure A2b. Quantitative data to support 
Figure A2a are presented in Table (i). 
 
       
Figure A2: (a) Read length distribution for the S219 multiple myeloma sample, 
before and after trimming. (b) Distribution of the Phred quality scores before 
trimming. Images taken from CLC Genomics Workbench analysis software. 
(b)	  
(a)	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Table (i): Detailed sequencing results before and after trimming (sample S219) 
Trim Input reads No trim Trimmed Nothing left 
or Discarded 
Trim on quality 68,916 26,444 42,462 10 
Ambiguity trim 68,906 68,906 0 0 
Trim ends 68,906 0 68,863 43 
Filter on length 68,863 66,088 0 2,775 
 
Values from Table (i) demonstrated that by applying analysis parameters that 
filter the raw sequencing data based on their Phred quality scores, low quality 
reads were discarded to improve the reliability and accuracy of the data prior to 
SNP analysis. From the example above, which is representative of the trimming 
outcomes from other samples, approximately a third of all reads (26,444) already 
met the quality criteria for read inclusion. Results also showed that the data 
retrieved did not yield any ambiguous nucleotides, indicating precision in the 
sequencing chemistry used by the Ion Torrent, which relies on the detection of 
pH changes in the microwells of the Ion chip. Finally, it can be seen that in total, 
2,775 reads were completely discarded upon filtering reads of less than 15bp.  
 
Overall, the profile of read length distribution after trimming shows little change 
compared to the profile of read length distributions before trimming (Figure 
A2a). The exception is that there are a greater number of shorter reads (between 
15bp and 100bp) accompanied with a slight fall in the number of longer reads 
(from 140bp to 200bp) after the trimming process. 
 
Sequence analysis of the mapped data 
All trimmed reads were mapped to the human mitochondrial Cambridge 
Reference Sequence (NC_012920.1). Using the myeloma S219 data as a 
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representative sample, almost all (95.12%) of the trimmed reads were 
successfully aligned to the reference genome (Figure A3a). Those that were not 
mapped (4.88%) represented the proportion of trimmed reads that did not share 
at least 80% identity with the reference sequence (Figure A3b), which was part 
of the inclusion criteria for reads as detailed in section 2.19.  
              
               
Figure A3: Distribution of trimmed read lengths for the S219 sample (a) 
successfully mapped or (b) not mapped to the human mitochondrial reference 
sequence. 
(a)	  
(b)	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Analysis on data coverage 
To illustrate the levels of sequence coverage obtained after mapping the trimmed 
reads to the human mitochondrial reference sequence, a section of the mapped 
alignment for the S219 multiple myeloma sample was analysed (Figure A4). 
 
 
Figure A4: Sequence coverage analysis using the myeloma S219 mapped 
alignment. (a) A 1kbp section of the S219 mtDNA that spans nucleotide positions 
2600bp-3600bp. Green lines represent the forward reads, and the red lines 
symbolize the reverse strand reads. Coverage of the data is shown at the top of 
the image, and a region of low coverage is highlighted in a red box. (b) 
Magnified view of the region highlighted in the red box from panel A.  
(a)	  
(b)	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For much of the mtDNA sequence, coverage remains consistent (around 600x) 
for the S219 sample (Figure A4a). However, there were also a few regions of 
low coverage (approximately 100x) (Figure A4b). Examining this particular 
region further, it was found that the mtDNA region of low coverage spanned 
approximately 54bp and comprised of a low (33.3%) GC content. Based on this 
observation, the relationship between GC content and sequence coverage was 
investigated to determine if there was a correlation between the two variables.   
 
Firstly, the sequence reads were analysed for their GC composition (Figure A5). 
Results revealed that the majority of reads had a GC content of between 45-50%. 
 
Figure A5: Examining the relationship between the percentage numbers of 
sequence reads carrying a particular GC composition (%), using the S219 
myeloma data as an example. 
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From analysing the influence of GC content to sequence coverage, it was 
determined that coverage levels were variable especially in sequence regions 
where the percentage GC content was 46% (Figure A6). This corresponded with 
the ‘peak’ seen from Figure A5, which meant that coverage was variable for 
most of the sequence reads and that there was the absence of a strong correlation 
between the two factors. This observation was also true for many other Ion 
Torrent DNA samples.  
 
 
Figure A6: Examining the relationship between sequence coverage and the 
percentage GC content in the S219 myeloma sample.  
 
Finally, investigating the levels of coverage in the S219 sample revealed that 
there was no bias in the coverage levels (of up to 650x) for most positions across 
the entire mtDNA sequence (Figure A7). High levels of coverage (over 650x) 
occurred less frequently across the mtDNA, which meant that for the majority of 
	  	   361	  
nucleotide positions on the mtDNA there is an almost equal chance of the 
sequence coverage ranging from 60x to 650x. 
 
 
Figure A7: Overall profile for sequence coverage across the mtDNA of the S219 
myeloma sample. 
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ii. Chemical composition of laboratory reagents 
 
Formulations of laboratory chemicals are listed below, where details have been 
available. 
 
Cell culture 
 
Dulbecco’s Modified Eagle Medium (DMEM), high glucose  
Amino acids: 
0.4mM Glycine 
0.398mM L-Arginine hydrochloride 
0.201mM L-Cystine 2HCl 
4mM L-Glutamine 
0.2mM L-Histidine hydrochloride-H2O 
0.802mM L-Isoleucine 
0.802mM L-Leucine 
0.798mM L-lysine hydrochloride 
0.201mM L-Methionine 
0.4mM L-Phenylalanine 
0.4mM L-Serine 
0.798mM L-Threonine 
0.0784mM L-Tryptophan 
0.398mM L-Tyrosine disodium salt dihydrate 
0.803mM L-Valine 
Vitamins: 
0.0286mM Choline chloride 
0.00839mM D-Calcium pantothenate 
0.00907mM Folic Acid 
0.0328mM Niacinamide 
0.0196mM Pyridoxine hydrochloride 
0.00106mM Riboflavin 
0.0119mM Thiamine hydrochloride 
0.04mM i-Inositol 
Inorganic Salts: 
1.8mM Calcium Chloride (CaCl2) (anhydrate) 
0.000248mM Ferric Nitrate (Fe(NO3)3”9H2O) 
 0.814mM Magnesium Sulfate (MgSO4) (anhydrate) 
5.33mM Potassium Chloride (KCl) 
44.05mM Sodium Bicarbonate (NaHCO3) 
110.34mM Sodium Chloride (NaCl) 
0.906mM Sodium Phosphate monobasic (NaH2PO4-H2O) 
Other Components: 
25mM D-Glucose (Dextrose) 
0.0399mM Phenol Red 
 
Dulbecco’s Phosphate Buffered Saline (PBS), no calcium, no magnesium 
Inorganic Salts: 
2.67mM Potassium Chloride (KCl) 
1.47mM Potassium Phosphate monobasic (KH2PO4) 
137.93mM Sodium Chloride (NaCl) 
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8.06mM Sodium Phosphate dibasic (Na2HPO4-7H2O) 
 
RPMI 1640 media 
Amino Acids: 
0.133mM Glycine 
1.15mM L-Arginine 
0.379mM L-Asparagine 
0.15mM L-Aspartic Acid 
0.208mM L-Cystine 2HCl 
0.136mM L-Glutamic Acid 
0.0968mM L-Histidine 
0.153mM L-Hydroxyproline 
0.382mM L-Isoleucine 
0.382mM L-leucine 
0.219mM L-Lysine hydrochloride 
0.101mM L-Methionine 
0.0909mM L-Phenylalanine 
0.174mM L-Proline 
0.286mM L-Serine 
0.168mM L-Threonine 
0.0245mM L-Tryptophan 
0.111mM L-Tyrosine disodium salt dihydrate 
0.171mM L-Valine 
Vitamins 
0.00082mM Biotin 
0.0214mM Choline chloride 
0.000524mM D-Calcium pantothenate 
0.00227mM Folic Acid 
0.0082mM Niacinamide 
0.0073mM Para-Aminobenzoic Acid 
0.00485mM Pyridoxine hydrochloride 
0.000532mM Riboflavin 
0.00297mM Thiamine hydrochloride 
0.0000037mM Vitamin B12 
0.194mM i-Inositol 
Inorganic Salts 
0.424mM Calcium nitrate (Ca(NO3)2 4H2O) 
0.407mM Madnesium Sulfate (MgSO4) (anhyd.) 
5.33mM Potassium Chloride (KCl) 
23.81mM Sodium Bicarbonate (NaHCO3) 
103.45mM Sodium Chloride (NaCl) 
5.63mM Sodium Phosphate dibasic (Na2HPO4) anhydrous 
Other Components 
11.11mM D-Glucose (Dextrose) 
0.00326mM Glutathione (reduced) 
0.0133mM Phenol Red 
 
DMEM/F12 
Amino Acids 
0.25mM Glycine 
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0.05mM L-Alanine 
0.699mM L-Arginine hydrochloride 
0.05mM L-Asparagine-H2O 
0.05mM L-Aspartic Acid 
0.0998mM L-Cysteine hydrochloride-H2O 
0.1mM L-Cystine 2HCl 
0.05mM L-Glutamic Acid 
2.5mM L-Glutamine 
0.15mM L-Histidine hydrochloride-H2O 
0.416mM L-Isoleucine 
0.451mM L-Leucine 
0.499mM L-Lysine hydrochloride 
0.116mM L-Methionine 
0.215mM L-Phenylalanine 
0.15mM L-Proline 
0.25mM L-Serine 
0.449mM L-Threonine 
0.0442mM L-Tryptophan 
0.214mM L-Tyrosine disodium salt dihydrate 
0.452mM L-Valine 
Vitamins 
0.0000143mM Biotin 
0.0641mM Choline chloride 
0.0047mM D-Calcium pantothenate 
0.00601mM Folic Acid 
0.0166mM Niacinamide 
0.00971mM Pyridoxine hydrochloride 
0.000582mM Riboflavin 
0.00644mM Thiamine hydrochloride 
0.000502mM Vitamin B12 
0.07mM i-Inositol 
Inorganic Salts 
1.05mM Calcium Chloride (CaCl2) (anhyd.) 
0.0000052mM Cupric sulfate (CuSO4-5H2O) 
0.000124mM Ferric Nitrate (Fe(NO3)3”9H2O) 
0.0015mM Ferric Sulfate (FeSO4-7H2O) 
0.301mM Magnesium Chloride (anhydrous) 
0.407mM Magnesium Sulfate (MgSO4) (anhyd) 
4.16mM Potassium Chloride (KCl) 
29.02mM Sodium Bicarbonate (NaHCO3) 
120.61mM Sodium Chloride (NaCl) 
0.5mM Sodium Phosphate dibasic (Na2HPO4) anhydrous 
0.453mM Sodium Phosphate monobasic (NaH2PO4-H2O) 
0.0015mM Zinc sulfate (ZnSO4-7H2O) 
Other components 
17.51mM D-Glucose (Dextrose) 
0.015mM Hypoxanthine Na 
0.00015mM Linoleic Acid 
0.00051mM Lipoic Acid 
0.0215mM Phenol Red 
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0.000503mM Putrescine 2HCl 
0.5mM Sodium pyruvate 
0.00151mM Thymidine 
 
TrypLE Express (1X), no phenol red 
Inorganic Salts: 
2.67mM Potassium Chloride (KCl) 
1.47mM Potassium Phosphate monobasic (KH2PO4) 
137.93mM Sodium Chloride (NaCl) 
8.06mM Sodium Phosphate dibasic (Na2HPO47H2O) 
Other Components: 
1.1mM ethylenediamine tetraacetic acid (EDTA) 
(concentration of recombinant protease undisclosed by manufacturer) 
 
 
DNA extraction 
 
Buffer AE 
10mM Tris-HCl 
0.5mM EDTA 
pH 9.0 
 
 
Gel extraction and PCR purification 
 
Buffer QG 
5.5M guanidine thiocyanate (GuSCN) 
20mM Tris-HCl, pH 6.6 
 
Buffer PB 
5.5M guanidine hydrochloride (GuHCl) 
20mM Tris-HCl, pH 6.6 
 
Buffer PE 
20mM NaCl 
2mM Tris-HCl, pH 7.5 
80% ethanol 
 
Buffer EB 
10mM Tris-HCl, pH 8.5 
 
 
Plasmid extraction 
 
Buffer P1 
50mM Tris-HCl, pH 8.0 
10mM EDTA 
50µg/ml RNase A 
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Buffer P2 
0.2M NaCl  
1% SDS 
 
Buffer P3 
4M guanidine hydrochloride (Gu HCl) 
0.5M potassium acetate, pH 4.2 
 
Buffer PB 
5.5M guanidine hydrochloride (GuHCl) 
20mM Tris-HCl, pH 6.6 
 
Buffer PE 
As before 
 
Buffer EB 
10mM Tris-HCl, pH 8.5 
  
 
Reverse transcriptase PCR 
 
RiboSafe RNase inhibitor 
Storage buffer 
20mM HEPES-KOH (pH 7.6) 
50mM KCl 
8mM DTT 
0.1mM EDTA 
50% glycerol 
stabilizer (details not disclosed) 
 
Bioscript 
Storage buffer 
25mM Tris-HCl (pH 7.9) 
100mM NaCl 
1mM EDTA 
5mM DTT 
Stabilizer (details not disclosed) 
50% glycerol 
 
 
PCR 
 
Reaction buffer 
160mM (NH4)2SO4 
670mM Tris-HCl, pH 8.8 
0.1% Tween-20 
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Gel electrophoresis 
 
6X Loading Dye 
10mM Tris-hydrochloric acid (HCl) (pH 7.6), 
0.03% bromophenol blue, 
0.03% xylene cyanol FF 
60% glycerol  
60mM EDTA 
 
50X TAE Buffer 
2M Tris-acetate 
50mM EDTA 
pH 8.0  
 
1X TAE Buffer 
1X TAE buffer was made from the stock solution of 50X TAE, diluting 1 part of 
the 50X TAE buffer with 49 parts of deionized water.  
 
Final concentration of the 1X TAE buffer solution: 
40mM Tris acetate 
1mM EDTA 
 
 
Long PCR 
 
Platinum Taq DNA Polymerase High Fidelity Storage Buffer 
20mM Tris-HCl (pH 8.0) 
0.1mM EDTA 
1mM Dithiothreitol (DTT) 
stabilizers (specifics not disclosed by Invitrogen) 
50% (v/v) glycerol 
 
10X High Fidelity PCR Buffer 
600mM Tris-SO4 (pH 8.9) 
180mM Ammonium Sulfate 
 
 
Real time PCR 
 
Sensimix SYBR  
SYBR Green I dye 
dNTPs 
stabilizers  
enhancers (exact details not disclosed) 
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Respirometry (Oxygraph) 
 
10x Hank’s Balanced Salt Solution (HBSS) 
Inorganic Salts 
1.26mM Calcium Chloride (CaCl2) (anhydrous) 
0.493mM Magnesium Chloride (MgCl2-6H2O) 
0.407mM Magnesium Sulfate (MgSO4-7H2O) 
5.33mM Potassium Chloride (KCl) 
0.441mM Potassium Phosphate monobasic (KH2PO4) 
4.17mM Sodium Bicarbonate (NaHCO3) 
137.93mM Sodium Chloride (NaCl) 
0.338mM Sodium Phosphate dibasic (Na2HPO4) anhydrous 
Other components 
5.56mM D-Glucose (Dextrose) 
 
 
DNA cloning 
 
pCR2.1, linearized 
25ng/µL in 10mM Tris-HCl 
1mM EDTA, pH 8 
 
10X Ligation Buffer 
60mM Tris-HCl, pH 7.5 
60mM MgCl2 
50mM NaCl 
1mg/ml bovine serum albumin 
70mM beta (β)-mercaptoethanol 
1mM ATP 
20mM dithiothreitol 
10mM spermidine 
 
S.O.C Medium  
2% Tryptone  
0.5% Yeast Extract  
10mM NaCl  
2.5mM KCl 
10mM MgCl2  
10mM MgSO4  
20mM glucose (dextrose) 
 
5-bromo-4-chloro-3-indolyl β-D-galactopyranoside (X-GAL) solution 
40mg/ml X-GAL dissolved in N, N-dimethylformamide (DMF) 
 
Luria-Bertani (LB) agar plates 
1.0% Tryptone  
0.5% Yeast Extract  
1.0% NaCl  
15g/L Agarose (pH. 7.0) 
100µg/ml ampicillin 
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Luria-Bertani Broth  
1.0% Tryptone  
0.5% Yeast Extract  
1.0% NaCl 
100µg/ml ampicillin, pH 7.0 
 
 
Capillary Sequencing 
 
5x BDT buffer 
400mM Tris 
10mM MgCl2, pH 9.0 
 
Next Generation Sequencing 
 
E-Gel 
0.1 to 0.3ug/ml ethidium bromide 
0.055% proclin (preservative) 
 
Platinum PCR SuperMix High Fidelity 
22 U/ml complexed recombinant Taq DNA polymerase 
Pyrococcus species GB-D thermostable polymerase 
Platinum Taq Antibody 
66mM Tris-SO4 (pH 8.9) 
19.8mM (NH4)2SO4 
2.4mM MgSO4 
220uM dNTPs 
stabilizers 
 
Melt-Off Solution 
125mM NaOH  
0.1% Tween 20 
 
1x TEX 
10mM Tris 
1mM EDTA 
0.01% Triton X-100, pH 8 
 
1x SSPE  
150mM Sodium Chloride 
10mM Sodium Phosphate 
1mM Na2EDTA 
 
Buffer TE 
10mM Tris-HCl  
1mM EDTA.Na2  
pH 8.0 
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Low TE Buffer 
10mM Tris-HCl 
0.1mM EDTA 
pH 8.0 
 
Dynabeads MyOne Strepavidin C1 beads 
Dynabeads are supplied in PBS, pH 7.4 
0.01% Tween-20 
0.02% NaN2 (preservative) 
stored at 4°C 
 
 
Western blot 
 
4X Loading Dye 
200mM Tris-Cl pH 6.8 
0.4M DTT 
8% SDS 
40% glycerol 
stored in -20C 
 
1X Transfer Buffer 
20% methanol 
47.8mM Tris 
38.6mM Glycine 
0.03% SDS 
 
1X SDS Running Buffer 
24.7mM Tris 
58.6mM Glycine 
0.2% SDS 
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